Artificial Intelligence in Oncology Drug Discovery and Development by Cassidy, John W. & Taylor, Belle
Artificial Intelligence in 
Oncology Drug Discovery 
and Development
Edited by John W. Cassidy and Belle Taylor
Edited by John W. Cassidy and Belle Taylor
There exists a profound conflict at the heart of oncology drug development. The 
efficiency of the drug development process is falling, leading to higher costs per 
approved drug, at the same time personalised medicine is limiting the target market 
of each new medicine. Even as the global economic burden of cancer increases, the 
current paradigm in drug development is unsustainable. In this book, we discuss 
the development of techniques in machine learning for improving the efficiency of 
oncology drug development and delivering cost-effective precision treatment. We 
consider how to structure data for drug repurposing and target identification, how to 
improve clinical trials and how patients may view artificial intelligence.
Published in London, UK 
©  2020 IntechOpen 
©  Sashkinw / iStock
ISBN 978-1-78984-689-8
A







Artificial Intelligence in 
Oncology Drug Discovery 
and Development
Edited by John W. Cassidy and Belle Taylor
Published in London, United Kingdom

Supporting open minds since 2005
Artificial Intelligence in Oncology Drug Discovery and Development
http://dx.doi.org/10.5772/intechopen.88376
Edited by John W. Cassidy and Belle Taylor
Contributors
Dominic Magirr, Jacob Bradley, Roberta Dousa, Ayaka Shinozaki, John Cassidy, Kristofer Linton-Reid, 
Steve Gardner, Sayoni Das, Krystyna Taylor
© The Editor(s) and the Author(s) 2020
The rights of the editor(s) and the author(s) have been asserted in accordance with the Copyright, 
Designs and Patents Act 1988. All rights to the book as a whole are reserved by INTECHOPEN LIMITED. 
The book as a whole (compilation) cannot be reproduced, distributed or used for commercial or 
non-commercial purposes without INTECHOPEN LIMITED’s written permission. Enquiries concerning 
the use of the book should be directed to INTECHOPEN LIMITED rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons 
Attribution - NonCommercial 4.0 International which permits use, distribution and reproduction 
of the individual chapters for non-commercial purposes, provided the original author(s) and source 
publication are appropriately acknowledged. More details and guidelines concerning content reuse 
and adaptation can be found at http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not 
necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of 
information contained in the published chapters. The publisher assumes no responsibility for any 
damage or injury to persons or property arising out of the use of any materials, instructions, methods 
or ideas contained in the book.
First published in London, United Kingdom, 2020 by IntechOpen
IntechOpen is the global imprint of INTECHOPEN LIMITED, registered in England and Wales, 
registration number: 11086078, 5 Princes Gate Court, London, SW7 2QJ, United Kingdom
Printed in Croatia
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
Additional hard and PDF copies can be obtained from orders@intechopen.com
Artificial Intelligence in Oncology Drug Discovery and Development




eBook (PDF) ISBN 978-1-78985-898-3
An electronic version of this book is freely available, thanks to the support of libraries working with 
Knowledge Unlatched. KU is a collaborative initiative designed to make high quality books Open Access 
for the public good. More information about the initiative and links to the Open Access version can be 
found at www.knowledgeunlatched.org
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
5,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books









IN D E X E D

Meet the editors
John Cassidy completed his PhD at the University of Cambridge, 
where his research focused on understanding and modelling 
the causes of tumour heterogeneity and how tumour evolution 
could impact clinical practice. In 2015, he founded CCG.ai to 
continue this mission and to apply advances in machine learning 
to the discovery of tumour biomarkers. In 2017, he was included 
on the prestigious Forbes 30 Under 30, and in 2020 was elected a 
fellow of the Royal Society of Biology. Dr. Cassidy sits on multiple advisory coun-
cils and boards both in the United Kingdom and internationally. He has published 
papers in journals such as Cell and Cancer Research and has helped raise more than 
£20m in grant funding for cancer research projects. 
Belle Taylor is a communications and engagement professional, 
currently based at the University of Edinburgh. A chemist by 
training, she has a First Class Chemistry MSci from University 
College London (UCL), where she also undertook her PhD. As a 
science communicator, she regularly speaks at and chairs events 
across the country. She is also co-host of the science comedy 




AI in Drug Development 1
Chapter 1 3




Applications of Machine Learning in Drug Discovery I: Target Discovery 
and Small Molecule Drug Design












Drug Repurposing and Clinical Trials 81
Chapter 5 83
Applications of Machine Learning in Drug Discovery II: Biomarker 
Discovery, Patient Stratification and Pharmacoeconomics
by John W. Cassidy
Chapter 6 101





AI in Drug Development 1
Chapter 1 3




Applications of Machine Learning in Drug Discovery I: Target Discovery 
and Small Molecule Drug Design












Drug Repurposing and Clinical Trials 81
Chapter 5 83
Applications of Machine Learning in Drug Discovery II: Biomarker 
Discovery, Patient Stratification and Pharmacoeconomics
by John W. Cassidy
Chapter 6 101




AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing  
and Combination Therapies




Toward the Clinic: Understanding Patient Perspectives on AI  
and Data-Sharing for AI-Driven Oncology Drug Development
by Roberta Dousa
Preface
Cancer remains one of the leading causes of morbidity and mortality worldwide. 
In 2020, we will have an estimated 15 million new diagnoses and 12 million new 
cancer-related deaths [1]. As we move further into the decades ahead, an increasing 
proportion of this global challenge will be shouldered by developing nations. This 
is part of a larger epidemiological shift as chronic, non-communicable disease—
associated with diet, tobacco, alcohol, lack of exercise, and industrial exposures—is 
added to morbidities attributable to infectious disease in the world’s emerging 
economies [2].
The cancer therapeutic market was estimated to reach $98.9 billion USD in 2018, 
with a compounded annual growth rate of 7.7%. The cost of individual cancer drugs 
is similarly rising at a rate well above inflation. Ipilimumab, for example, was priced 
at $120,000 on launch, despite providing an overall survival benefit of just four 
months. More generally, if we correct for inflation and increased survival benefit, 
the average cost of new cancer therapies increased $8,500 per year from 1995 to 
2013 [3]. If we continue along this path of yearly incremental price increases in new 
therapies, whilst not seeing associated health benefits, public opinion may begin to 
further question the moral standing of the pharmaceuticals industry [4]. Moreover, 
will it really be sustainable to treat a worldwide increase in the incidence of cancer 
with more and more expensive drugs?
It is not simply a case of capping the price of essential medicines, or even seizing 
the means of production. Indeed, drug discovery and development are long and 
arduous processes; recent figures point to 10 years and $2 billion USD to take a new 
chemical agent from discovery through to market. Moreover, though an approved 
blockbuster drug can be lucrative for the controlling pharmaceutical company, new 
therapeutic agents suffer from a 90% attrition during development, making the 
chances of success in the drug development process low.
Nor is it as easy as developing better drugs. As our understanding of the impor-
tance of tumour heterogeneity and evolution continues to improve, it is becoming 
increasingly evident that new strategies may be needed to continue our fight against 
cancer [5, 6]. New therapeutic agents, such as immunotherapies, new strategies 
such as combination therapy and new ways of testing drugs such as adaptive clinical 
trials are all appropriate for tumour biology, but many orders of magnitude more 
expensive than standard chemotherapy.
Efficiency of drug discovery and development together with clinical testing and 
delivery of new medicines must improve by orders of magnitude if we are to keep 
pace with a growing understanding of tumour biology and a growing incidence 
of disease in the developing world. Thankfully, computational techniques such as 
machine learning (ML) and artificial intelligence (AI) have re-emerged in the last 
several years as powerful sets of tools for unlocking value from large datasets. ML 
has shown great promise in improving efficiencies across numerous industries with 
high-quality, vast, datasets. In an age of increasing access to highly curated rich 
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trends shown in drug discovery and development. As biology in general and cancer 
research in particular become ever richer in data, there is a great deal of promise for 
ML in changing the cancer drug development landscape [7].
This book explores the role of AI and ML in improving the efficiency in drug 
discovery and development. In general, the contents should be accessible cross-
disciplinarily to both cancer biologists and computer scientists, though we do zoom 
in to focus on some specific technical challenges, for example, in the structuring of 
genomic data (Chapter 3) and the interpretation of clinical trials (Chapter 6). As 
a particularly unique feature of this book, Chapter 8 deals with patients’ perspec-
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Introduction: An Overview of AI 




Artificial intelligence (AI) has been termed the machine for the fourth industrial 
revolution. One of the main challenges in drug discovery and development is the 
time and costs required to sustain the drug development pipeline. It is estimated 
to cost over 2.6 billion USD and take over a decade to develop cancer therapeutics. 
This is primarily due to the high numbers of candidate drugs failing at late drug 
development stages. Many sizable pharmaceutical and biotech companies have 
made considerable investments in AI. This is primarily due to recent advancements 
in AI, which have displayed the possibility of rapid low-cost drug discovery and 
development. This overview provides a general introduction to AI in drug discov-
ery and development. This chapter will describe the conventional oncology drug 
discovery pipeline and its associated challenges. Fundamental AI concepts are also 
introduced, alongside historical and modern advancements within AI and drug 
discovery and development. Lastly, the future potential and challenges of AI in 
oncology are discussed.
Keywords: oncology, AI, drug discovery, drug development
1. Introduction
Artificial intelligence (AI) has been termed the machine for the fourth industrial 
revolution. AI is anticipated to transform every industry. In drug discovery and 
development, the key challenges are the time and costs required to sustain the drug 
development pipeline. It is estimated to cost over 2.6 billion USD and take over 
a decade to develop an oncology therapeutic [1]. These soaring costs are mostly 
a result of money invested in the 90% of candidate therapies that fail at the late 
stages of drug development, between phase 1 trials and regulatory approval [2]. AI 
is projected to be the foundation for an era of quicker, cheaper, and more efficient 
drug discovery and development.
Recent advancements in AI are displaying the possibility of rapid low-cost 
drug discovery and development. The term AI broadly describes the ability of a 
machine to perform tasks commonly associated with intelligent beings. Another 
term, machine learning (ML), is a subset of AI involving machines using data to 
artificially think for themselves. The main difference between ML and AI is that 
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a decade to develop an oncology therapeutic [1]. These soaring costs are mostly 
a result of money invested in the 90% of candidate therapies that fail at the late 
stages of drug development, between phase 1 trials and regulatory approval [2]. AI 
is projected to be the foundation for an era of quicker, cheaper, and more efficient 
drug discovery and development.
Recent advancements in AI are displaying the possibility of rapid low-cost 
drug discovery and development. The term AI broadly describes the ability of a 
machine to perform tasks commonly associated with intelligent beings. Another 
term, machine learning (ML), is a subset of AI involving machines using data to 
artificially think for themselves. The main difference between ML and AI is that 
ML is the direct application and involves the combination and analysis of complex, 
disparate data sets.
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Within the pharmaceutical industry, experts agree that AI will revolutionize and 
change how drugs are discovered. There are many components, directly and indi-
rectly, related to the drug discovery and development that AI can enhance. These 
include but are not limited to: the use of AI in tumour classification [3], computer-
aided organic synthesis [4], compound discovery [5], assay development, and 
biomarker and target discovery [6–8]. In general, AI aims to automate and optimize 
slow processes to substantially speed up the R&D drug discovery process.
Several pharmaceutical, biotech, and software companies are also making 
every effort to integrate AI with drug discovery and development. In 2016, Pfizer 
partnered with IBM Watson Health, an AI platform, to enhance their search for 
immuno-oncology treatments. Sanofi paired with Dundee university spin-out 
Exscientia, to discover metabolic-disease therapies. In 2009, Roche acquired 
Genentech for $46.8 billion, providing a foundation for Roche’s biotechnology 
division, which is not integrating AI. Genentech is now collaborating with GNS 
Healthcare platform to use machine learning to find and validate potential new 
drug candidates. Recently, Genentech displayed the capacity of AI to diagnose 
diabetic macular degeneration.
Even large traditional tech companies are investing in drug development. 
Alphabet’s subsidiary DeepMind developed an AI platform, AlphaFold, that pre-
dicted protein 3D structures based upon genomic data; their prediction was better 
than over 90 other companies including Novartis, and Pfizer, in the 13th Critical 
Assessment of Structure Prediction. DeepMind’s success with AlphaFold is display-
ing how non-healthcare companies can also contribute to and improve the drug 
discovery and development pipeline. These investments are forming a clear vision 
that AI will play an important role in future drug discovery and development.
In this overview, we start with introducing key components of conventional 
oncology drug discovery, and associated shortfalls. Following this, fundamental AI 
concepts are introduced, alongside historical and modern advancements within AI 
and drug discovery and development. Lastly, the future potential and challenges of 
AI in oncology are introduced.
2. Conventional oncology drug discovery and development
The conventional drug discovery and development pipeline has five key com-
ponents: target identification, lead discovery, preclinical development, clinical 
development, and regulatory approval (Figure 1). A drug discovery program 
initiates after researching the inhibition or activation of a protein or pathway and 
explaining the potential therapeutic effect. This leads to the selection of a biological 
target, often requiring extensive validation prior to the lead drug discovery phase. 
This phase involves the search for a viable drug-like small molecule or biological 
Figure 1. 
Five key components of drug discovery and development: target identification, lead discovery, preclinical 
development, clinical development, and regulatory approval.
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therapy, termed a development candidate. The drug candidate will progress into 
preclinical development, and if successful into clinical development.
2.1  Drug discovery and development pipeline: target identification and 
validation
Biological target identification and validation is a fundamental step in drug 
discovery. A biological target is a broad term, used to describe a variety of entities 
including proteins, metabolites, and genes. A biological target must have a clear 
effect, meet clinical and therapeutic needs, as well as industry needs. Above all, a 
biological target must be ‘druggable’. The term ‘druggable’ refers to a target that can 
be bound by a small molecule or larger biologic and elicit a response.
2.1.1 Target identification
A variety of methods exist to identify biological targets. This includes gene 
expression, proteomics and genomics analysis, and phenotypic screening.
The analysis of mRNA/protein expression is often employed to elucidate expres-
sion to disease relationships if changes in expression levels are correlated with 
exacerbation or progression. At the genetic level, targets are identified by determin-
ing if there is an association between genetic polymorphism and disease occur-
rence or progression. For example, one of the most well-studied genetic-disease 
associations is that of N-acetyltransferase 2 (NAT2) with bladder and colon cancer. 
N-acetyltransferase 1 (NAT1) and NAT2 are precursors of enzymes that mediate the 
transformation of two types of carcinogens, aromatic and heterocyclic amines. The 
NAT2 rapid acetylator phenotype and the slowest NAT2 acetylator phenotype are 
associated with colon and bladder cancer respectively [9, 10].
Phenotypic screening is another method for target identification. This can take 
a variety of forms. Generally, compounds are screened in cellular or animal disease 
models to identify a compound that leads to the desired change in phenotype. 
Kurosawa and colleagues [11] screened for overexpressed carcinoma antigens by 
isolating human monoclonal antibodies that bind to the surface of tumour cells. In 
this study, clones were screened with immunostaining. Clones that displayed strong 
staining with the malignant cells were selected. Subsequently, 21 distinct antigens 
were derived via mass spectroscopy. Several immunotherapies may be capable of 
binding to these 21 antigen targets, possibly leading to a new clinical therapy.
Target identification may involve one or a combination of the previously men-
tioned methods.
2.1.2 Target validation
While identifying a target typically requires one method, the following target 
validation requires a variety of methods. A multi-validation approach increases 
confidence in the biological target and subsequent drug candidate’s success.
There are a variety of target validation methods that may be implemented, 
although validation almost always requires target expression in the disease-relevant 
cells or tissues. A typical primary validation protocol is to measure the expression of 
protein and/or mRNA in clinical samples, with immunohistochemistry and in situ 
hybridization.
Generally, in vivo studies are often a pivotal factor in the decision to proceed 
with drug development; these usually involve protein inhibition/gene knock-out/
knock-in studies. Transgenic animal models are particularly useful as they facilitate 
phenotypic observations. These animal models often yield insights into potential 
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therapeutic side effects. Transgenic models traditionally gene edits whereby an ani-
mal would lack or obtain a certain gene(s) for its entire life. An example is the P2X7 
knockout mouse model, which lacks an inflammatory and neuropathic response. 
These knockout mice revealed their respective mechanism of action, as their cells 
did not release the mature pro-inflammatory cytokine IL-1beta from cells, despite 
IL-1 beta expression remaining constant. Contrary to gene knockout models, are 
gene knock-ins models. In gene knock-ins, genes not originally in the mouse are 
inserted, and subsequent disease protein is synthesized. These transgenic animals 
usually have a different phenotype to a knockout and may mimic more closely what 
happens during disease and treatment.
Another in vivo technique used for target identification is antisense oligonucle-
otide-based models. Antisense oligonucleotides mimic RNA and complement the 
target mRNA molecule [12]. Bound antisense oligonucleotide prevents ribosomal 
translation of mRNA to protein. Honore and colleagues created an antisense oligo-
nucleotide that inhibited translation of the rat P2X3 receptor [13]. When rat models 
were dosed with P2X3 antisense, they displayed anti-hyperalgesic activity. Once 
administration of the antisense oligonucleonucleotides was discontinued, receptor 
function and algesic responses returned. Unlike transgenic model, the antisense 
oligonucleotide effect is reversible [14].
While there are many viable target validation methods, two modern technolo-
gies can enable tissue specific validation: clustered regularly interspaced short 
palindromic repeats (CRISPR), and CRISPR-related techniques, and organs 
on a chip.
The CRISPR-Cas9 and related approaches provide multiple advancements 
compared to the transgenic model; these include the ability to overcome embryonic 
lethality and avoid resistance mechanisms. In brief, CRISPR-Cas9 works by distrib-
uting the Cas9 nuclease into the cell. Synthetic guide RNA then guides the nuclease 
to the desired cut location, facilitating the addition or removal of genes in vivo [15]. 
An example of CRISPR-Cas 9 target validation is with the elucidation of the mecha-
nism of action behind tumour suppressor, p53, reactivating compounds. Employing 
CRISPR-Cas9-based target validation in lung and colorectal cancer displayed that 
the anti-proliferate activity of nutlin is dependent on functional p53. However, 
using traditional models, the mechanism and therapeutic response to p53-reactivat-
ing compounds is lost via compound-specific resistance mechanisms [16].
Another emerging technology that will facilitate improved target validation is 
organs-on-chips. These are multi-channel 3-D microfluidic cell culture chips that 
mimic the functionality and physiology of entire organs. This technology yields the 
potential to quickly assess the efficacy and human response to target mediation. 
Song and colleagues used a vasculature system chip model to assess the relationship 
between vascular endothelium and the metastatic behavior of circulating tumour 
cells. This study suggested that the inhibition of CXCL12-CXCR4 binding on endo-
thelial cells may be a valid target in the prevention of metastasis [17]. Importantly, 
organs-on-chips technologies may provide novel insights to target identification 
and validation studies.
Overall, there are many means to validate targets; all strategies have a common 
aim: to evaluate the target’s cellular function prior to full investment into the target, 
and drug candidate screening.
2.2 Drug discovery and development pipeline: lead discovery
Once the biological targets have been identified and validated, the next fun-
damental step is the lead discovery phase. This comprises of three components, in 
order: hit identification, hit-to-lead phase, and lead optimization.
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2.2.1 Drug discovery and development pipeline: hit identification
It is during this phase that drug compound screening assays are developed, and 
subsequent ‘hit’ compounds derived. The term ‘hit’ compound is used in a range 
of terminologies; in this overview we refer to it as a compound that obtains the 
desired screening effect, which has been validated upon retesting. Various screen-
ing approaches exist to identify hit molecules. In this overview, we will describe 
the most common screening strategies: high throughput screening, Focused based 
screening, and fragment screening.
High throughput screening utilizes an entire compound library and assesses the 
activity of each compound on the biological target. This typically involves large 
semi-automated cell-based assays. A candidate hit compound typically requires 
further assays to confirm its mechanism of action [18].
Focused based screening, also termed knowledge-based screening, selects com-
pounds from a library based on existing information about the target, stemming 
from literature or patents, which suggest compounds likely to yield the desired 
target activity [19].
Fragment screening uses small-molecular weight compound libraries and 
screens these compounds at high concentrations. Small fragments that bind to 
the target are often scaled with chemical alterations to increase their binding 
affinity [20].
2.2.2 Hit-to-lead phase and lead optimization
The aim of this intermediate phase is to develop a compound(s) with enhanced 
properties, with pharmacokinetics suitable for one or many different in vivo 
models. This step regularly involves a series of structure-active-relationship (SAR) 
investigations for each hit compound, in an attempt to measure the activity and 
selectivity of each compound.
The goal of the final lead discovery phase is to obtain compounds with optimal 
structural, metabolic, and pharmacokinetic properties. This often involves further 
applications of various in vitro and in vivo screens.
2.3 Drug discovery and development pipeline: preclinical
Once a lead candidate is identified, further elucidation of its structure, meta-
bolic, and pharmacokinetic properties may be required. The typical preclinical 
development stage is comprised of various components, typically used with 
animal models: (1) The first preclinical experiments revolve around dose design; 
a safe dose must be identified with estimated human measurements. (2) Second, 
the pharmacodynamics of a compound is required; the mechanism of action that 
causes the clinical response, with respect to doses, must be determined. (3) Third, 
pharmacokinetics properties of the drug candidate are required. This includes 
absorption, distribution, metabolism, excretion, and potential drug-drug interac-
tions. The aim of preclinical studies is to obtain enough information to determine 
a safe dose for the first human study. On average, one in 5000 preclinical devel-
opment candidate drugs make it through preclinical development and become 
regulatory approved [21].
2.4 Drug discovery and development pipeline: clinical development
The clinical development/clinical trial stage comprised of three main stages and 
one post-market surveillance stage.
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The phase 1 clinical studies are carried out in a small number of healthy volun-
teers. The aim of this stage is to distinguish a therapy’s metabolic and pharmacologi-
cal effects, as well as the side effect response to varying dosages. The main aim of 
phase 1 is to determine a therapy’s safety profile.
Stemming from the data collected during phase 1, phase 2 studies also termed 
‘therapeutic exploratory’ trials involve investigations on several diseased individu-
als. This phase aims to further determine the effectiveness of the drug with respect 
to disease or condition. Side effects and risks are further distinguished. Phase 2 
studies are controlled, usually conducted on a few hundred patients.
The phase 3 studies are a much larger drug assessment of the drug’s efficacy, 
safety, and evaluate the overall benefit-risk relationship of the drug. This phase 
may also yield enough data to estimate the results of a general population, as they 
include several hundred to several thousand people.
Once the drug is approved, there is a fourth phase, known as post-marketing 
surveillance. These are observational studies, whereby the goal is to define and 
ensure the safety profile of the drug on a larger population scale.
2.5 Drug discovery and development pipeline: challenges and overview
There are three main reasons why drugs fail: the first is that they simply do 
not work, second is that they are unsafe for clinical use, and the third reason of 
drug failure is due to poor clinical trial structure. The cost of a candidate soars the 
further it gets in the drug development pipeline.
The primary source of trial failure is a drug’s lack of efficacy. Hwang and 
colleagues investigated 640 phase 3 trials, of which 54% failed. Over 50% of these 
failures were due to a lack of efficacy [22]. There are a variety of reasons why a drug 
may enter phase 3 trials and yet lack efficacy. This may also include the propaga-
tion of error due to flawed target validation, a poor study design, or simply having 
an insufficient number of patient trials resulting in weak statistical power and an 
inability to reject the null hypothesis.
The infamous, poly ADP ribose polymerase (PARP) inhibitor, Olaparib failed 
its first trial for ovarian cancer due to a lack of trial structure. In the initial trial, 
in individuals with the BRCA mutation and platinum-sensitive recurrent ovarian 
cancer, Olaparib delayed the time to recurrence to 11.2 months from 4.3 months. 
However, the median time to death was 34.9 months in the treatment group and 
31.9 months in the control group (p = 0.19) [23]. In 2014, Olaparib was approved 
by the FDA for women with recurrent ovarian cancer who have the germline BRCA 
mutation and had previously received three or more lines of chemotherapy. This 
approval was based on a study by Kaufman and colleagues [24], which displayed 
a response rate > 30% with Olaparib monotherapy in patients who had previously 
received three or more lines of chemotherapy.
Clinical trials also fail with respect to safety. In Hwang and colleagues’ study, out of 
the initial 640 compounds, 17% of them failed due to safety [22]. Drug safety is a key 
factor in every stage of the candidate drug development; however, challenges may only 
present at larger populations [25]. One reason for failure due to safety is due to ill report-
ing of safety concerns. Generally, a patient’s safety concerns may not align with that of 
the administering physician. It is logical to assume people will be more likely to report 
an adverse event that is of concern to them. It is important that at each step within the 
drug development pipeline safety is a primary consideration. The cost of determining a 
safety issue propagates with progression through each drug development stage.
One of the most impactful drug candidate failures was with sulphanilamide. 
This drug was popular in the 1930s and sold in both a bolus and elixir form. 
However, important safety tests had not been conducted for the elixir form, 
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although at the time this testing was not required. Unfortunately, after being 
treated with the elixir form, over 100 people died due to diethylene glycol poisoning 
[26]. This led to the implementation of two important acts: The Food, Drug and 
Cosmetic Act and Drugs and Cosmetics Act.
3. The potential of AI
AI has been utilized in drug discovery since the early 1960s. However, in 2016 
many large pharmaceutical companies started investing in AI by partnering 
with AI startups or academic groups or initiating their own internal AI R&D 
programs. This has resulted in an enormous number of new publications within 
the field that cover the entire drug discovery and development pipeline. This has 
included the implementation of deep learning models to predict the properties 
of small molecules from transcriptomics data [27] to the identification of novel 
drug targets [28]. AI has integrated into almost every area of drug discovery and 
development.
The primary aim of drug discovery and development combined with AI remains 
to facilitate the development of the best drugs and bring them to the clinic to fulfill 
unmet medical needs.
AI and machine learning has a lot of potential. For those new to the field, AI limita-
tions seem endless, regardless of the input information. AI has a range of applications. 
It can be successful at creating an image of a cat from a model trained on images of 
cats or can enable a car to drive automatically without making a single mistake, or a 
drug that can be designed to treat a disease safely and efficaciously. However, AI will 
not succeed with every challenge; it is simply a tool that may drive new technologies, 
and enhanced understanding. In drug discovery and development, AI is not one entity 
that can design a drug from start to finish, but many different AIs which enhance our 
understanding throughout the drug discovery and development process.
3.1 Fundamental AI concepts
While many computational approaches can fit the broad definition of AI, two 
fields are currently popular: machine learning and its subfield deep learning. In 
layman’s terms, the key difference with deep learning is that it uses multiple layers, 
each employing different calculations on the initial data. In order to understand 
their capacities, a few fundamental concepts must be understood.
Broadly, there are two different types of machine learning to understand. 
Supervised learning is when a model is trained using labeled data sets to predict 
a certain outcome. An example of this is the quantitative structure–activity rela-
tionship (QSAR) approach. This is used to predict a chemical’s property, such as 
solubility and bioactivity [29]. The other approach is unsupervised learning, as the 
name suggests, it does not depend upon training with labeled data to find relation-
ships with data. Examples include the use of hierarchical clustering, algorithms and 
principal components analysis to analyze and group large molecular libraries into 
smaller sub-groups of similar compounds.
With supervised machine learning, there are two types: classification and 
regression. Classification models are used when the problem is categorical, as in 
the predicted output is a limited set of values. Regression models are used when the 
problem involves predicting a numeric value within a range.
There are a variety of different types of machine learning models, such as 
random forests, autoencoders, and convolutional neural networks. Each of the 
subsequent chapters will describe specific models as required.
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3.2 Examples of AI implementations in drug discovery and development
A vast number of AI and drug discovery papers are published every day, cover-
ing various aspects of the entire drug discovery and development pipeline. Drug 
discovery and development-based AI technologies range from the identification 
and validation of drug targets, drug repurposing, identification of new compounds, 
and improving the R&D efficiency. There are a number of potential contributions 
AI can make to reduce inefficiencies in the conventional drug development and 
discovery pipeline.
Target identification and validation have been enhanced by AI. This is made 
possible by genomics, with biochemical and histopathological information. The IBM 
Watson identified five novel RNA-binding proteins as potential targets linked to the 
pathogenesis of amyotrophic lateral sclerosis, which currently has no known cure [30].
One huge opportunity for AI in drug discovery is with drug repurposing. As an 
example, Donner and colleagues [31] used a transcriptomics data set and derived 
a new measurement of compound functionality, based on gene expression. This 
measurement allowed the identification of compounds that shared biological tar-
gets, despite being structurally different, revealing previously unknown functional 
associations between compounds.
An AI platform that can predict a candidate’s mechanism of action and in vivo 
safety would cut wasted costs dramatically. There are several examples of compa-
nies with this goal. This includes DeeoTox and ProCTOR, both of which aim to pre-
dict the toxicity of new compounds [32, 33]. The performance of these AI platforms 
is expected to increase as larger robust data sets on the toxicity of compounds are 
made available.
As of 2019, one important study was the discovery of a drug within 21 days. 
Deep learning enabled the identification of potent DDR1 kinase inhibitors within 
21 days. Out of the four compounds discovered, one lead candidate has displayed 
ideal pharmacokinetics in mice [34].
Overall, it is clear AI may yield increases in drug discovery efficiency through 
various strategies.
3.3 Current challenges in AI
AI has shown promise in drug discovery and development. However, it is not 
without its challenges. There are many challenges faced by AI in medical research 
such as lack of data, lack of interoperability, and the curse of dimensionality.
The lack of data is a recurring problem throughout every industry wanting to 
implement AI. The minimum number of samples in a traditional biological study is 
five, for it to be valid. However, most machine learning algorithms must be trained 
on hundreds, or thousands, of data points/samples, in order to perform well. 
Furthermore, obtaining labeled data can be a challenge, as this often requires some 
form of manual input. Fortunately, large databases, such as The Cancer Genome 
Atlas program (TCGA), are aggregating and open-sourcing vast amounts of robust 
data from multiple institutions. However, on some occasions, large databases that 
include the requested data may not exist. One such strategy to combat this is data 
augmentation. Data augmentation is the process of creating artificial data from real 
data. There are a variety of data augmentation approaches; ultimately they increase 
the data available for training models, without collecting new data.
Another challenge faced by machine learning is the lack of interpretability. The 
term ‘black box model’ is often used when it is difficult to explain how a model 
makes certain predictions and performs. This is more likely an occurrence with deep 
learning, as each layer adds complexity to the model explaining each layer’s outputs 
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can become exponentially complex and the number of layers increases. However, a 
variety of tools are being developed in order to elucidate further explainability such 
as LIME (Local Interpretable Model-Agnostic Explanations) and SHAP (Shapley 
Additive Explanations). LIME adopts a local linear approximation of the model’s 
behavior, whereas SHAP employs a game theory-based approach to explain the 
model output. Both LIME and SHAP, and other similar strategies, are projected to 
become common practice in machine learning and are going to be necessary to get 
more AI technologies to the clinic [35].
A recurring issue with artificial intelligence in medical data is known as the 
curse of dimensionality. This is when the data sets used have a small number of 
samples and many features. This is a common occurrence in medical omics data 
sets, as they typically yield thousands of features and less than 100 samples; thus 
the available data become sparse. This problem may be addressed with a variety of 
dimensionality reduction techniques.
Overall, there are a series of challenges that will need to be addressed for AI to 
reach its optimal capacity. In this passage, we have only described a few challenges. 
However, they are being addressed with advancements in complementary data 
science approaches and tools, such as the creation of large data repositories, tools to 
increase explainability, and the creation of feature reduction techniques.
4. Concluding remarks
Taking a drug from idea to the clinic is a long diverse process, costing over 
2.6 billion dollars, and take over a decade to develop a cancer therapeutic. This is 
primarily due to high numbers of candidate drugs failing at late drug development 
stages. Advancements in AI are continually displaying the possibility of rapid low-
cost drug discovery and development. As we make our way through the 2020s, it is 
evident the drug discovery and development will be permanently shaped by AI.
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safety would cut wasted costs dramatically. There are several examples of compa-
nies with this goal. This includes DeeoTox and ProCTOR, both of which aim to pre-
dict the toxicity of new compounds [32, 33]. The performance of these AI platforms 
is expected to increase as larger robust data sets on the toxicity of compounds are 
made available.
As of 2019, one important study was the discovery of a drug within 21 days. 
Deep learning enabled the identification of potent DDR1 kinase inhibitors within 
21 days. Out of the four compounds discovered, one lead candidate has displayed 
ideal pharmacokinetics in mice [34].
Overall, it is clear AI may yield increases in drug discovery efficiency through 
various strategies.
3.3 Current challenges in AI
AI has shown promise in drug discovery and development. However, it is not 
without its challenges. There are many challenges faced by AI in medical research 
such as lack of data, lack of interoperability, and the curse of dimensionality.
The lack of data is a recurring problem throughout every industry wanting to 
implement AI. The minimum number of samples in a traditional biological study is 
five, for it to be valid. However, most machine learning algorithms must be trained 
on hundreds, or thousands, of data points/samples, in order to perform well. 
Furthermore, obtaining labeled data can be a challenge, as this often requires some 
form of manual input. Fortunately, large databases, such as The Cancer Genome 
Atlas program (TCGA), are aggregating and open-sourcing vast amounts of robust 
data from multiple institutions. However, on some occasions, large databases that 
include the requested data may not exist. One such strategy to combat this is data 
augmentation. Data augmentation is the process of creating artificial data from real 
data. There are a variety of data augmentation approaches; ultimately they increase 
the data available for training models, without collecting new data.
Another challenge faced by machine learning is the lack of interpretability. The 
term ‘black box model’ is often used when it is difficult to explain how a model 
makes certain predictions and performs. This is more likely an occurrence with deep 
learning, as each layer adds complexity to the model explaining each layer’s outputs 
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can become exponentially complex and the number of layers increases. However, a 
variety of tools are being developed in order to elucidate further explainability such 
as LIME (Local Interpretable Model-Agnostic Explanations) and SHAP (Shapley 
Additive Explanations). LIME adopts a local linear approximation of the model’s 
behavior, whereas SHAP employs a game theory-based approach to explain the 
model output. Both LIME and SHAP, and other similar strategies, are projected to 
become common practice in machine learning and are going to be necessary to get 
more AI technologies to the clinic [35].
A recurring issue with artificial intelligence in medical data is known as the 
curse of dimensionality. This is when the data sets used have a small number of 
samples and many features. This is a common occurrence in medical omics data 
sets, as they typically yield thousands of features and less than 100 samples; thus 
the available data become sparse. This problem may be addressed with a variety of 
dimensionality reduction techniques.
Overall, there are a series of challenges that will need to be addressed for AI to 
reach its optimal capacity. In this passage, we have only described a few challenges. 
However, they are being addressed with advancements in complementary data 
science approaches and tools, such as the creation of large data repositories, tools to 
increase explainability, and the creation of feature reduction techniques.
4. Concluding remarks
Taking a drug from idea to the clinic is a long diverse process, costing over 
2.6 billion dollars, and take over a decade to develop a cancer therapeutic. This is 
primarily due to high numbers of candidate drugs failing at late drug development 
stages. Advancements in AI are continually displaying the possibility of rapid low-
cost drug discovery and development. As we make our way through the 2020s, it is 
evident the drug discovery and development will be permanently shaped by AI.
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Drug discovery and development are long and arduous processes; recent figures 
point to 10 years and $2 billion USD to take a new chemical agent from discovery 
through to market. Moreover, though an approved blockbuster drug can be lucrative 
for the controlling pharmaceutical company, new therapeutic agents suffer from 
a 90% attrition during development, making the chances of success in the drug 
development process relatively low. Machine learning (ML) has re-emerged in the 
last several years as a powerful set of tools for unlocking value from large datasets. 
ML has shown great promise in improving efficiencies across numerous industries 
with high quality, vast, datasets. In an age of increasing access to highly curated 
rich sources of biological data, ML shows promise in reversing some of the negative 
trends shown in drug discovery and development. In this first part of our analysis 
of the application of ML to the drug discovery and development process, we discuss 
recent advances in the use of computational techniques in drug target discovery 
and lead molecule optimisation. We focus our analysis on oncology, though make 
reference to the wider field of human health and disease.
Keywords: cancer, machine learning, drug discovery, computational biology
1. Introduction
Cancer is, first and foremost, a disease of the genome. Specific changes in the 
DNA of an otherwise normal cell, caused by environmental mutagens or as a result 
of a defective DNA repair mechanisms, result in inherited base-pair changes in the 
genome of daughter cells [1]. Such mutations can be benign (i.e. ‘passenger muta-
tions’) or can directly contribute to malignant transformation of the cell (i.e. ‘driver 
mutations’) [2, 3]. Over the past few decades, advances in our understanding of these 
basic principles have led to unprecedented clarity in the genomic drivers of tumour 
development. Projects such as The Cancer Genome Atlas [4] and International 
Cancer Genome Consortium [5] have sequenced thousands of cancers and systemati-
cally classified common mutations into driver or passenger categories. Concurrently, 
advances in our understanding of the context of these mutations, for example 
through the advent of high throughput methylome sequencing [6] and the numer-
ous studies on the functional consequences of a mutation for cell signalling [1], have 
helped us design therapeutic strategies to halt tumour progression.
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Drug discovery and development are long and arduous processes; recent figures 
point to 10 years and $2 billion USD to take a new chemical agent from discovery 
through to market. Moreover, though an approved blockbuster drug can be lucrative 
for the controlling pharmaceutical company, new therapeutic agents suffer from 
a 90% attrition during development, making the chances of success in the drug 
development process relatively low. Machine learning (ML) has re-emerged in the 
last several years as a powerful set of tools for unlocking value from large datasets. 
ML has shown great promise in improving efficiencies across numerous industries 
with high quality, vast, datasets. In an age of increasing access to highly curated 
rich sources of biological data, ML shows promise in reversing some of the negative 
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1. Introduction
Cancer is, first and foremost, a disease of the genome. Specific changes in the 
DNA of an otherwise normal cell, caused by environmental mutagens or as a result 
of a defective DNA repair mechanisms, result in inherited base-pair changes in the 
genome of daughter cells [1]. Such mutations can be benign (i.e. ‘passenger muta-
tions’) or can directly contribute to malignant transformation of the cell (i.e. ‘driver 
mutations’) [2, 3]. Over the past few decades, advances in our understanding of these 
basic principles have led to unprecedented clarity in the genomic drivers of tumour 
development. Projects such as The Cancer Genome Atlas [4] and International 
Cancer Genome Consortium [5] have sequenced thousands of cancers and systemati-
cally classified common mutations into driver or passenger categories. Concurrently, 
advances in our understanding of the context of these mutations, for example 
through the advent of high throughput methylome sequencing [6] and the numer-
ous studies on the functional consequences of a mutation for cell signalling [1], have 
helped us design therapeutic strategies to halt tumour progression.
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Specifically, whereas some of the earliest cancer drugs were serendipitously 
discovered and functioned through the inhibition of cell division on an organism-
wide scale, increasingly, new molecular agents are designed to specifically inhibit 
the function of single molecular targets driving tumour growth [7]. The first of 
these molecularly targeted drugs for cancer were developed in the 1970s and 1980s. 
These ‘targeted therapies’ have many notable success stories, such as Gleevec (for 
BCR-ABL positive leukaemia), Herceptin (for Erbb2 amplified breast cancer) and 
Tamoxifen (for ER positive breast cancer) [1, 8–10]. As we enter the 2020s, the 
oncology pharmaceutical industry is now producing >60 new molecularly targeted 
cancer therapies per year.
Although each of these targeted therapies has the potential to generate billions 
of dollars in revenue for their parent pharmaceutical company, typically there is a 
90% attrition rate between Phase I clinical trials and market approval; additionally, 
each drug may cost $2.6 billion USD to go from target identification to approval 
[11, 12]. Interestingly, the difference between a so-called blockbuster drug (one 
generating >$1 billion a year in gross revenues) and a market failure, is arguably 
almost entirely based on patient cohort selection. An interesting case study comes 
from Olaparib, the first in a class of poly ADP ribose polymerase (PARP) inhibitors 
developed by KuDOS Therapeutics after initial work from the Stephen Jackson, 
amongst others, and ultimately taken through clinical trials by AstraZeneca. 
Olaparib activates a ‘synthetic lethality’ pathway in Brca1/2 mutant breast cancers 
by biasing DNA-damaged cells toward double strand breaks rather than mismatch 
repair pathways [13]. Brca1/2 mutations are common in triple negative breast cancer 
(TNBC) and the initial clinical trials sought to leverage the efficacy of Olaparib 
in Brca1/2 mutant TNBCs to show increased overall survival in all TNBCs. These 
initial trials failed, primarily because patient stratification was sub-optimal. The 
use of ML in improving patient stratification through the identification of complex 
biomarkers of clinical response will be discussed in depth in the latter part of this 
series: Applications of Machine Learning in Drug Discovery II: Biomarker Discovery, 
Patient Stratification and Pharmacoeconomics.
Like the above Olaparib example, and the preceding examples of success in 
targeted therapy more generally, the pre-emanant strategy in drug discovery is 
first to establish a causal relationship between a gene, mutation, or pathway and 
pathophysiological features of a disease [14]. Although other strategies, such as 
phenotypic screening [12], have witnessed a resurgence in popularity recently, this 
rational target discovery is still heavily relied upon in drug discovery programs the 
world over. Typically, once a target has been identified and its causal role in disease 
progression confirmed through, for example gene perturbation studies, a molecule 
is sought to perturb the targets function (or abnormal function) whilst having 
minimal effect on other proteins [15]. These molecules can be rationally designed 
if the three-dimensional structure of the target protein is known, we can screen 
a large library of small molecules with drug-like properties, or we can use a tech-
nique such as phage display to identify monoclonal antibody species with specific 
inhibitory function.
Complicating matters somewhat, perturbation of a molecular target can be 
inhibitory (i.e. antagonist), excitatory (i.e. agonist), excitatory of a secondary 
downstream pathway (i.e. biased agonist) or be inhibitory of the basal effects of 
target activity (i.e. inverse agonist). Moreover, small molecules may bind to protein 
clefts with known activity or function (e.g. an ATP-binding pocket) or secondary 
allosteric sites of unknown function in the protein or even its surroundings.
There are therefore at least three stages in early drug development which could 
be advanced by computational approaches such as ML: (1) target identification 
from literature data mining, (2) structure-based design of drugs intended to 
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perturb a target, and (3) optimisation of screening protocols for small molecule 
or biologic inhibitors. In this chapter, we will provide a basic primer to ML before 
discussing methods for, and examples of, the use of ML-based techniques in target 
identification and structure-based drug design.
2. Machine learning—a primer
Fundamentally, ML is the design and deployment of statistical models used to 
parse large datasets, learn from underlying patterns present in the data and apply 
those learnings to make predictions about future data [16]. This differs fundamen-
tally from many rule-based algorithms in that the predictive power of the model 
is improved when exposed to more data, rather than necessarily when any expert 
understanding is improved. The strength of ML is to solve problems for which large, 
well annotated, datasets exist but for where the underlying connection between 
variables in the dataset is unknown. For these reasons, the application of ML to the 
field of modern biology is extremely well suited.
A core objective of any ML model is to generalise from experience, i.e. to accu-
rately predict some aspect of an unseen dataset after training on a prior dataset. 
Before selecting a model to use in a particular situation, we must have methods for 
determining its performance. To assess our model, we must be cognisant of the 
required parameter tuning and the overall separation of signal from noise [16]. As 
we cannot sample all possible futures, and because training sets are, by definition, 
finite, we typically must express performance in terms of probabilistic bounds. 
Numerous probabilistic evaluation metrics are commonly used by the field for 
drawing comparisons between models, for example classification accuracy, kappa, 
area under the curve (AUC), logarithmic loss and confusion matrix the F1 score 
[14, 17, 18]. Additionally, the available of gold standard datasets are invaluable for 
testing new model performance.
In optimising for model performance, we must also be cognisant of overfitting 
to the data, which occurs when a model attempts to include and account for dataset 
noise in the hypothesis, which can significantly impact model generalisation. 
Formally, the complexity of a model’s hypothesis should match that of the function 
underlying the dataset. Underfitting occurs when the hypothesis is less complex 
that the underlying function, and overfitting occurs when the hypothesis is too 
complex.
In practice, there are a number of technical methods for dealing with overfitting. 
For example, we can hold back part of the training dataset to use as a validation 
dataset. This process can be automated and randomised for each new model build, 
so long as each model is trained on one subset of the data and tested on another, 
unseen, subset. We can also account for fit in our model design, for example by add-
ing ‘penalties’ to model performance for each new parameter is incorporated into 
the model. This process is known as regularisation and forces models to generalise 
without overfitting to the data, examples in practice include Ridge, LASSO and 
elastic nets [16, 19, 20].
Of course, there are many different models which we can train on a single 
dataset, we can avoid brute force sensitivity and specificity optimisation by 
understanding some of the philosophy underlying different model architectures. 
Broadly, we can define ML models as being either supervised or unsupervised, 
named for the datasets for which the methods work. In supervised learning, the 
model is a mathematical relationship between variables found in a dataset with 
known input and output variables (for example drug treatment and patient out-
come) [15, 21]. We then ask the model to predict future outputs for unseen inputs. 
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The most well-known example of supervised learning is a linear regression between 
two known variables; however, models can be significantly more complicated. 
Unsupervised learning, on the other hand, finds patterns hidden within input 
data and builds clusters based on intrinsic structures or relationships between 
data points. Of course, there is a great deal of nuance between supervised (with 
completely labelled training data) and unsupervised (without any labelled training 
data). Indeed, combining the two model types on the same dataset (semi-super-
vised learning) is increasingly employed in the field [21].
ML models themselves are numerous and varied; and our goal here is not to 
present a comprehensive library of models. However, because of their increasing 
popularity in the field, artificial neural networks (ANNs) deserve special mention. 
ANNs belong to their own subset of ML methods known as Deep Learning [22–24]. 
Deep Learning models are inspired by biological neural networks in that they are 
comprised of many connected nodes (‘neurons’), with each connection transmit-
ting ‘signal’ between nodes, like a synapse. Typically, this signal is a number, and 
each neuron performs some non-linear function of the sum of its inputs. As the 
network completes several attempts at ‘learning’ a task, the mathematical weight-
ing of each nodal connection is determined based on that node’s contribution to a 
successful outcome [24]. In this way, the ANN is thought to resemble the function 
of biological synapse restructuring during a learning task. Unlike a biological brain, 
neurons in the ANN are arranged in layers, with each layer performing a specific 
task or data transformation. ANNs and Deep Learning in general have been suc-
cessful in a variety of tasks, from computer vision and mobile advertising to cancer 
variant detection and patient outcome prediction [17, 23, 25].
3. ML for target identification
Aside from purely phenotypic screening approaches, the typical target discov-
ery process begins with target identification and prioritisation. As discussed, this 
requires identification of a target with a causal link with some aspect of a patho-
physiology and a plausible framework for believing that modulation of this target 
will result in modulation of the disease itself [14, 15]. Though proof of a successful 
therapeutic strategy will come first from in vivo drug response studies and ulti-
mately through showing efficacy in a randomised clinical trial, there is no doubt 
that target identification is a crucial step in this path.
The first full DNA genome to be sequenced was that of a bacteriophage, com-
pleted in 1977 [26]. This catalysed a multinational effort to sequence the human 
genome, which was completed by 2001 at a cost of >$1 billion [27]. Around this 
same time, commercial sequencers had begun to become available and what has 
become known as Next Generation Sequencing (NGS) began to be carried out in labs 
across the world. What has followed is the age of big biological data. As the price of 
sequencing continues to fall, we have seen projects such as The Cancer Genome Atlas 
[4] that publish thousands of genomes. Recently, this has been extended to national 
scale projects such as the UK’s 100,000 Genome Project [28] and the beginning of an 
age of incorporating genomics into the regular clinical workflow for cancer patients, 
pioneered by the likes of Memorial Sloan Kettering with their Integrated Mutation 
Profiling of Actionable Cancer Targets (IMPACT) study [29]. Alongside this surge 
in genomics, we have seen unprecedented development of other high-throughput 
technologies in cancer research, from RNA-sequencing to methylome sequencing 
and imaging-based proteomics [1].
Cumulatively, these efforts have transformed biology from a functional low-
throughput pursuit to one which is increasingly rich in data. The ability to mine 
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these datasets in target discovery efforts has been democratised through an increas-
ing willingness amongst researchers to share data. However, finding meaningful 
patterns in such multi-dimensional data requires statistical models of sufficient 
complexity to yield meaningful results. Such tasks are perfectly suited for ML-based 
techniques.
Perhaps the richest untapped resource in new therapeutic target discovery is the 
scientific literature itself, representing countless years of experimental data from 
groups around the world. However, these largely unstructured data present several 
challenges. Recent advances in the field of natural language processing (NLP) 
have gone some way to resolving these issues. For example, Kim and colleagues 
developed an NLP-based tool for disease-gene relationship building from unstruc-
tured Medline abstracts [30]. Biological events between genes and disease types 
are extracted and these associations are ranked based on the strength of evidence 
sentences using a Bayesian classifier. This tool, named DigSee, identified associa-
tions between 13,054 genes and 4494 disease types, which the authors claim is more 
than any manually curated database currently available. Although difficult to verify 
the associations, the authors further showed that these relationships were at least 
comparable to those inferred from such manually curated databases [30].
ML can also be useful in the prediction of unseen biology. For example, Costa 
and colleagues built a computational model to predict morbid genes (i.e. those 
where mutations could cause hereditary human disease) and druggable genes 
(i.e. those coding for proteins able to be modulated by small molecules to elicit a 
phenotypic effect) on a genome wide scale [31]. Such efforts have the potential to 
reduce laborious experimental procedures and identify early likelihood of a puta-
tive molecular target to be causally associated with disease. The authors trained a 
decision tree-based meta-classifier on databases of protein–protein, metabolic and 
transcriptional interactions, as well as tissue expression and subcellular localization 
for known morbid or druggable genes. Although the meta-classifier had question-
able results, correctly recovering just 65% of known morbid genes (precision 
66%) and 78% of known druggable genes (precision 75%), the authors were able 
to inspect the decision tree and uncover rules for morbidity and druggability [31]. 
Parameters such as membrane localisation (for druggability) and regulation by 
multiple transcription factors (for morbidity), suggesting that the model was cor-
rectly identifying biological traits.
A more common approach is to focus on a specific disease or therapeutic area. 
For example, Jeon and colleagues built a support vector machine (SVM) classifier 
that integrated a variety of genomic and systematic datasets to classify proteins 
based on their likelihood to bind a small molecule drug and prioritised targets 
specific for breast, pancreatic and ovarian cancer [32]. Like Costa et al., the clas-
sifier developed appears to have uncovered biological rational from a data-driven 
perspective; Key classification features were gene essentiality, mRNA expression, 
DNA copy number, mutation occurrence and protein-protein interaction network 
topology [31, 32]. The authors then designed therapeutic strategies and validated 
their targets using proliferation-based assays in cancer cell line models with either 
synthetic peptides or small molecule inhibitors. In total, the authors found 122 
putative tumour-type-agnostic targets, 69 of which overlapped with known cancer 
targets, together with 266 specific to breast, 462 to pancreatic and 355 to ovarian 
cancer [32].
Although many diseases are known to be monogenic, many more are associ-
ated with dysregulation of complicated multi-genomic signalling pathways [11]. 
Designing a therapeutic strategy in this case can be aided by taking a systems 
biology approach. Ament and colleagues followed such rational when they recon-
structed a transcription factor regulatory network associated with pre-symptomatic 
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Huntington’s disease [33]. This genome scale model carried information on the 
target genes of a total of 718 distinct transcription factors associated with mouse 
models of the disease. The authors selected a regression model with LASSO regu-
larisation to avoid overfit and discovered a total of 48 differentially expressed 
TF-target gene modules associated with age- and CAG repeat length-dependent 
gene expression changes in Htt CAG knock-in mouse striatum [20, 34]. Of these, 13 
were further validated in human samples and the authors experimentally validated 
one based on the transcription factor SMAD3.
Taking the concept of target identification in complicated disease states further, 
Mamoshina and colleagues took advantage of advances in the discovery of bio-
markers of in muscle tissues to find druggable targets underpinning the molecular 
basis of human ageing [35]. The authors constructed an SVM-based model with 
linear kernel and deep feature selection to identify gene expression signatures 
associated with ageing. The model’s performance was evaluated on gene expression 
samples from the Gene expression Genotype-Tissue Expression (GTEx) project 
and achieved an accuracy of 0.80 when predicting the binned age, highlighting the 
importance of external gold-standard datasets in model tuning [36]. Importantly, 
the model confirmed several established mechanisms of human skeletal muscle 
ageing, including neurotransmitter recycling, IGFR and PI3K-Akt-mTOR signal-
ling and dysregulation of cytosolic Ca2+ homeostasis, giving a biological basis for 
the model’s effectiveness [35]. Moreover, the model generated a set of targets with 
druggable properties, suggesting future therapeutic intervention may be possible.
4. ML for optimisation of high throughput screens
Once a target with causal relation to a disease phenotype of interest has been 
identified, the next step is typically to identify and optimise a suitable chemi-
cal entity to perturb the normal or pathogenic activity of said target. Until very 
recently, by far the most common approach to identify such candidate molecules 
was through a high throughput screen (HTS). Typically, a suitable reporter system 
would be designed, exposed to a pharmaceutical company’s vast compound librar-
ies and any reporter changes reported. For example, in the task of identifying 
antagonists for the β2 adrenoceptor, researchers may design a radioligand binding 
assay whereby a library of new chemical agents are assayed for their ability to 
interfere with radiolabelled fenoterol (an agonist) and radiolabelled alprenolol 
(an antagonist) binding. Characteristics of their binding (e.g. KD as a measure of 
affinity) correspond to changes in surface plasmon resonance (SPR) detected at the 
receptor [37], allowing researchers to select a variety of candidate molecules into 
the lead optimisation phase.
An alternative use of HTS techniques, which is becoming ever more important, 
is phenotypic screening. Here, researchers look for a specific phenotypic change 
induced by one of the thousands of screened chemicals against a process or cell type 
of interest. In the most simplistic sense, we could be screening for cell death in a 
heterogenous cell population [12], but more complicated indicators (such as fluo-
rescence activated by signalling pathways) are in use in drug discovery processes 
across the industry [38]. As our understanding of tumour biology grows, research-
ers are increasingly favouring drug screens which preserve some degree of tumour 
heterogeneity, thus complicated phenotypic screens are growing in importance in 
drug discovery [1].
Advanced imaging is a popular technique for identification of complex phe-
notypes and perturbations, and can be greatly enhanced by the use of advanced 
ML-based analytics. Broadly, we can think of imaging-based screens as composing 
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of two camps. In the first, typically called high-content or phenotypic screening, we 
focus on pre-defined phenotypes and the candidate drugs which modulate it. For 
example, identification of compounds which modulate the subcellular localisation 
of specific pre-defined intracellular signalling molecules with a role in disease [39].
Alternatively, we may stain multiple subcellular structures with multiplexed 
fluorescent dyes or antibodies and expose cells to genetic, pathogenic or chemical 
perturbing agents and categorise their response. Such investigatory screens are 
highly amenable to automated image acquisition and analysis through machine 
learning. In order to profile phenotypes of cells in an unbiased manner, computer 
vision can be used to extract multivariant feature vectors of cellular morphology 
(size, shape, texture) as well as staining intensity. After cellular segmentation, 
feature sets of cells or groups of cells can then be stratified to find relation-
ships between thousands of different perturbations which can give insights 
into mechanisms or action of drugs or help researchers piece together pathway 
information [40, 41].
In one study, Perlman and colleagues made multidimensional measurements of 
individual cell states for a variety of perturbations. The authors were able to build 
a multidimensional classifier to group small molecules with similar mechanism 
of action [42]. This technique has similarly been applied to correlate phenotypic 
response with chemical structure similarity by Young and colleagues [43]. In this 
study, researchers explored ‘factor analysis’ for large data reduction whilst retaining 
relevant biological information, then clustered their identified features into seven 
phenotypic categories containing compounds of similar mechanism of action and 
chemical structures. These techniques can be built upon to build annotated libraries 
of pharmacologically active small molecules and model their potential off-target 
affects in silico [44].
Moreover, the use of mechanisms of action association studies in high content 
imaging and HTS opens up drug repurposing and new target identification. For 
example, Breinig and colleagues used high-content screening and image analysis 
to measure effects of >1200 pharmacologically active compounds on complex 
phenotypes in isogenic cancer cell lines which had been genetically modified in 
key oncogenic signalling pathways [41]. The cell lines were exposed to a library of 
~200 known drugs and phenotypic response recorded by high content imaging. The 
resource was published as the Pharmacogenetic Phenome Compendium (PGPC), to 
enable researchers to explore drug mechanisms of action, detect potential off-target 
effects, and generate hypotheses on drug combinations. The resource was validated 
by confirming that tyrphostin (EGFR inhibitor) has off-target activity on the 
proteasome [41].
5. ML for structure-based drug design
As discussed previously, after suitable target identification, a new therapeutic 
program relies on the discovery and development of one, or several, lead molecules 
which can perturb the targets normal structure [14]. Though traditionally these 
lead compounds were invariably small molecules, modern biology and particularly 
modern oncology relies on novel drug modalities. To modulate the function of a 
receptor molecule such as the adrenoreceptor (a G-protein coupled receptor) we 
require a molecule which resembles the structure of the natural ligand (in this 
case noradrenalin), but with some small functional changes [45]. However, many 
appealing drug targets have no such ligand binding domain (for example PARP), 
may activate in the absence of ligand [e.g. the epidermal growth factor receptor 
(EGFR)], may have no known ligand (e.g. HER2) or may bind many natural ligands 
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Huntington’s disease [33]. This genome scale model carried information on the 
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of interest. In the most simplistic sense, we could be screening for cell death in a 
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focus on pre-defined phenotypes and the candidate drugs which modulate it. For 
example, identification of compounds which modulate the subcellular localisation 
of specific pre-defined intracellular signalling molecules with a role in disease [39].
Alternatively, we may stain multiple subcellular structures with multiplexed 
fluorescent dyes or antibodies and expose cells to genetic, pathogenic or chemical 
perturbing agents and categorise their response. Such investigatory screens are 
highly amenable to automated image acquisition and analysis through machine 
learning. In order to profile phenotypes of cells in an unbiased manner, computer 
vision can be used to extract multivariant feature vectors of cellular morphology 
(size, shape, texture) as well as staining intensity. After cellular segmentation, 
feature sets of cells or groups of cells can then be stratified to find relation-
ships between thousands of different perturbations which can give insights 
into mechanisms or action of drugs or help researchers piece together pathway 
information [40, 41].
In one study, Perlman and colleagues made multidimensional measurements of 
individual cell states for a variety of perturbations. The authors were able to build 
a multidimensional classifier to group small molecules with similar mechanism 
of action [42]. This technique has similarly been applied to correlate phenotypic 
response with chemical structure similarity by Young and colleagues [43]. In this 
study, researchers explored ‘factor analysis’ for large data reduction whilst retaining 
relevant biological information, then clustered their identified features into seven 
phenotypic categories containing compounds of similar mechanism of action and 
chemical structures. These techniques can be built upon to build annotated libraries 
of pharmacologically active small molecules and model their potential off-target 
affects in silico [44].
Moreover, the use of mechanisms of action association studies in high content 
imaging and HTS opens up drug repurposing and new target identification. For 
example, Breinig and colleagues used high-content screening and image analysis 
to measure effects of >1200 pharmacologically active compounds on complex 
phenotypes in isogenic cancer cell lines which had been genetically modified in 
key oncogenic signalling pathways [41]. The cell lines were exposed to a library of 
~200 known drugs and phenotypic response recorded by high content imaging. The 
resource was published as the Pharmacogenetic Phenome Compendium (PGPC), to 
enable researchers to explore drug mechanisms of action, detect potential off-target 
effects, and generate hypotheses on drug combinations. The resource was validated 
by confirming that tyrphostin (EGFR inhibitor) has off-target activity on the 
proteasome [41].
5. ML for structure-based drug design
As discussed previously, after suitable target identification, a new therapeutic 
program relies on the discovery and development of one, or several, lead molecules 
which can perturb the targets normal structure [14]. Though traditionally these 
lead compounds were invariably small molecules, modern biology and particularly 
modern oncology relies on novel drug modalities. To modulate the function of a 
receptor molecule such as the adrenoreceptor (a G-protein coupled receptor) we 
require a molecule which resembles the structure of the natural ligand (in this 
case noradrenalin), but with some small functional changes [45]. However, many 
appealing drug targets have no such ligand binding domain (for example PARP), 
may activate in the absence of ligand [e.g. the epidermal growth factor receptor 
(EGFR)], may have no known ligand (e.g. HER2) or may bind many natural ligands 
Artificial Intelligence in Oncology Drug Discovery and Development
24
(e.g. CXCR2) and thus any small molecule inhibitor could have cross-reactivity 
with other receptors [9, 13, 46–49]. These limitations have led to a multitude of 
drug targeting strategies, broadly described as ‘biologics’. In cancer these include, 
humanised monoclonal antibodies, chimeric receptors, bi-specific antibodies, 
oncolytic viruses, and even engineered T-Cells, to name but a few [9, 38, 50–52]. 
Notwithstanding these advances, there are still a multitude of small molecule drugs 
developed each year.
Structure-based drug design (SBDD) typically begins with resolution of the 
three-dimensional structure of the target protein [53]. Traditionally, this process 
was the exclusive domain of experimental structural biology, through labour 
intensive tools such as nuclear magnetic resonance (NMR), X-ray crystallography, 
and cryo-electron microscopy [54]. However, modern computational techniques 
have opened up the possibility of in silico protein structure modelling [22]. Amongst 
such techniques, homology modelling, which begins with the known structure 
of a protein with >40% homology to the target, is often seen as the most reliable. 
Validation of a homology modelled structure is typically carried out by considering 
stereochemical properties in, for example, a Ramachandran plot [22]. Next, poten-
tial binding sites are modelled by considering interaction energy across the length 
of the folded protein when exposed to charged functional groups. Stable conforma-
tions are predicted with, for example, Q-SiteFinder, an energy-based method for 
binding site prediction [55]. Amino acid residues associated with putative binding 
sites can then be annotated for function.
Extensive virtual and experimental high-throughput screens (HTS) are then 
carried out against the synthesised or computationally modelled target protein 
with large compound libraries of drug like structures [53]. Candidates, or ‘hits’, 
in SBDD have stable free energies on docking with binding clefts on the target 
protein [56]. Alternatively, de novo drug design may be employed if the binding 
pocket is of sufficient resolution [57]. Hits then have their structures optimised 
against a set of ideal pharmacodynamic, pharmacokinetic and toxicological crite-
ria. These processes are highly amenable to augmentation by ML based techniques.
For example, many studies have attempted to implement ANNs to ligand-based 
virtual screens, to varying levels of success. One such implementation of a multi-
task deep ANN was released by Ramsundar and colleagues as an open source tool 
known as DeepChem [58]. In general, multitask models outperform standard ANNs 
by synthesising information from many distinct sources. DeepChem itself powers 
ligand screening for commercial drug discovery with a simple python scripts to 
construct, fit, and evaluate sophisticated models [58]. The authors aimed to over-
come barriers associated with software accessibility amongst the drug discovery 
industry. Moreover, their validation results demonstrated that multitask ANNs were 
robust and showed substantial improvements over more traditional techniques such 
as random forests. To help in benchmarking, a large library of 700,000 compounds 
and their binding data was collated by Wu and colleagues, and integrated into 
DeepChem [59].
When combining multitask ANNs, Markov state models and one-shot learn-
ing to reduce the data requirement of making meaningful predictions in a new 
experimental setup, we can identify previously unknown mechanisms of ligand 
receptor interaction [60]. For example, Farimani and colleagues performed 
extensive molecular dynamic simulation and analysis to find selective allosteric 
binding sites for the μ-opioid receptor, an important G-protein coupled receptor 
(GPCR) in analgesia [61]. Discovering novel allosteric sites is particularly relevant 
in analgesia and GPCR biology as new therapeutic agents could allow receptor 
modulation or fine-tuning without competing for receptor occupancy of the 
natural ligand.
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ANNs can also be used to predict pharmacokinetic drug properties. In a compe-
tition sponsored by Merck, Sharp & Dohme, ANNs outperformed random forests 
and other ML methods in 13 of 15 assay-based classification tasks to predict absorp-
tion, distribution, metabolism and excretion (ADME) parameters of drug like 
molecules [62]. A multitask ANN also won the Tox21 dataset challenge of compu-
tational toxicity prediction of 12,000 compounds in 12 high-throughput toxicity 
assays. This ANN, developed by Mayer et al., and named DeepTox, normalises 
chemical structures computes chemical descriptors to train an ANN to predict the 
nuclear toxicity [63].
In addition to virtual screening and optimisation of lead compounds, we can 
use ML-based techniques to enhance de novo drug design by generating completely 
novel chemical entities. For example, Kadurin and colleagues combined varia-
tional autoencoders with generalised adversarial networks (GANs) to computer 
design highly selective and novel anticancer agents [64]. GANs are particularly 
interesting in de novo drug design; they function by training two ANNs (the 
generator and the discriminator) simultaneously with different and opposing 
objective functions. The GAN must compete in a zero-sum game to create a single 
best molecular structure [64]. A key preceding step is to use variational autoen-
coders to map chemical structures from known databases in latent space, the latent 
vector then transforms the molecular structure into a simplified molecular-input 
line-entry system (SMILES) string.
6. ML for drug repurposing
As discussed previously, the development of new drugs is a long and arduous 
process, often costing >$2 billion and taking 10 years. Even in phase III trials, drugs 
can fail because of some unforeseen side effect or off target affect. Interestingly, this 
very property opens up a shortcut for drug development. Over the last several years 
there has been substantial interest in repurposing existing drugs for new indica-
tions. This can be hypothesis driven, where we learn new features of a diseases 
pathology which make us confident that an existing inhibitor could be useful, or 
data driven, where researchers and companies use structure activity relationships 
to find serendipitous matches between known disease targets and already approved 
(or close to approval) drugs.
Various approaches underpinned by ML have been used to predict potential 
repurposing positions for drugs. For example, multiple studies have used natural 
language processing to make sense of text mined from electronic health records, 
clinical trial data and drug side-effect labels [15]. Correlation between drug 
molecules and clinicopathological symptoms, expression profiles or target pathway 
modulation can then be uncovered using a variety of ML techniques. In one study, 
for example, Zhao and So built drug-specific expression maps from transcriptomic 
changes collected from three cell lines exposed to a variety of compounds [65]. 
This method is powerful as the underlying mechanism of action of the drug need 
not be known. The authors could then apply a variety of ML models including deep 
neural networks, SVMs, elastic nets and gradient boosted machines to identify 
repositioning opportunities. However, the authors relied on cancer cell lines in this 
study, despite focussing on neurological conditions, we should be careful when 
extrapolating studies with inappropriate model systems [11].
Many academic and commercial groups have turned to a technique known as 
signature reversion (also known as connectivity mapping) in repurposing studies. 
Here, gene expression measurements by proteomics or transcriptomics are taken 
for various pathological phenotypes and built into, for example, graph networks 
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binding site prediction [55]. Amino acid residues associated with putative binding 
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ria. These processes are highly amenable to augmentation by ML based techniques.
For example, many studies have attempted to implement ANNs to ligand-based 
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known as DeepChem [58]. In general, multitask models outperform standard ANNs 
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come barriers associated with software accessibility amongst the drug discovery 
industry. Moreover, their validation results demonstrated that multitask ANNs were 
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ing to reduce the data requirement of making meaningful predictions in a new 
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modulation or fine-tuning without competing for receptor occupancy of the 
natural ligand.
25
Applications of Machine Learning in Drug Discovery I: Target Discovery and Small Molecule…
DOI: http://dx.doi.org/10.5772/intechopen.93159
ANNs can also be used to predict pharmacokinetic drug properties. In a compe-
tition sponsored by Merck, Sharp & Dohme, ANNs outperformed random forests 
and other ML methods in 13 of 15 assay-based classification tasks to predict absorp-
tion, distribution, metabolism and excretion (ADME) parameters of drug like 
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assays. This ANN, developed by Mayer et al., and named DeepTox, normalises 
chemical structures computes chemical descriptors to train an ANN to predict the 
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there has been substantial interest in repurposing existing drugs for new indica-
tions. This can be hypothesis driven, where we learn new features of a diseases 
pathology which make us confident that an existing inhibitor could be useful, or 
data driven, where researchers and companies use structure activity relationships 
to find serendipitous matches between known disease targets and already approved 
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Various approaches underpinned by ML have been used to predict potential 
repurposing positions for drugs. For example, multiple studies have used natural 
language processing to make sense of text mined from electronic health records, 
clinical trial data and drug side-effect labels [15]. Correlation between drug 
molecules and clinicopathological symptoms, expression profiles or target pathway 
modulation can then be uncovered using a variety of ML techniques. In one study, 
for example, Zhao and So built drug-specific expression maps from transcriptomic 
changes collected from three cell lines exposed to a variety of compounds [65]. 
This method is powerful as the underlying mechanism of action of the drug need 
not be known. The authors could then apply a variety of ML models including deep 
neural networks, SVMs, elastic nets and gradient boosted machines to identify 
repositioning opportunities. However, the authors relied on cancer cell lines in this 
study, despite focussing on neurological conditions, we should be careful when 
extrapolating studies with inappropriate model systems [11].
Many academic and commercial groups have turned to a technique known as 
signature reversion (also known as connectivity mapping) in repurposing studies. 
Here, gene expression measurements by proteomics or transcriptomics are taken 
for various pathological phenotypes and built into, for example, graph networks 
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of genewise expression changes. The objective is then to identify drugs which 
revert the genewise expression networks toward baseline. Driven by the desire to 
increase the drug development process for all concerned, researchers have been 
forthcoming in submitting such maps to open large-scale perturbation databases, 
such as Connectivity Map (CMap) or Library of Integrated Network-based Cellular 
Signatures (LINCS). Such databases have provided significant opportunities for 
computational pharmacogenomics and drug design [66].
It is worth noting that the majority of drug repurposing studies rely on an 
assumption that drugs with a similar chemical structure will behave in a similar 
fashion. This misconception has led to significant societal detriment in the past, for 
example in the thalidomide disaster. Thalidomide exists as two chiral forms (same 
chemical composition but having mirrored structures), one can be used to treat 
morning sickness; the other has teratogen effects.
7. Conclusion
ML is a powerful technique for identifying hidden patterns in complex datas-
ets. Although based on standard statistical methods, recent advances in available 
compute power have led to a resurgence of the field. Deep Learning, in particular, 
has seen a profound resurgence in popularity and has the potential to revolutionise 
multiple fields of human endeavour. As we increasingly move into an age of large 
medical datasets, from clinical studies to massive cell line -omics databases, there 
is clearly an opportunity for application of machine learning to biology. Amongst 
biological problems, there is a pressing need for increased efficiency of the drug 
discovery process, particularly in high mortality and morbidity problems like 
oncology. For these reasons, we have seen significant steps toward the application 
of ML to cancer drug discovery over the past several years. In this chapter, we have 
discussed some of these efforts, including the use of ML for target identification 
and in structure-based drug design. Additionally, we have provided a primer to 
ML in an effort to familiarise biologists to the field. In the second part of our work, 
addressed in the second part of our analysis (Applications of Machine Learning in 
Drug Discovery II: Biomarker Discovery and Patient Stratification), we extend the 
analysis of uses of ML in the drug discovery process to the clinical arena. First, we 
will discuss the use of ML in biomarker discovery, before moving to clinical trial 
optimisation and post market treatment effectiveness monitoring.
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of genewise expression changes. The objective is then to identify drugs which 
revert the genewise expression networks toward baseline. Driven by the desire to 
increase the drug development process for all concerned, researchers have been 
forthcoming in submitting such maps to open large-scale perturbation databases, 
such as Connectivity Map (CMap) or Library of Integrated Network-based Cellular 
Signatures (LINCS). Such databases have provided significant opportunities for 
computational pharmacogenomics and drug design [66].
It is worth noting that the majority of drug repurposing studies rely on an 
assumption that drugs with a similar chemical structure will behave in a similar 
fashion. This misconception has led to significant societal detriment in the past, for 
example in the thalidomide disaster. Thalidomide exists as two chiral forms (same 
chemical composition but having mirrored structures), one can be used to treat 
morning sickness; the other has teratogen effects.
7. Conclusion
ML is a powerful technique for identifying hidden patterns in complex datas-
ets. Although based on standard statistical methods, recent advances in available 
compute power have led to a resurgence of the field. Deep Learning, in particular, 
has seen a profound resurgence in popularity and has the potential to revolutionise 
multiple fields of human endeavour. As we increasingly move into an age of large 
medical datasets, from clinical studies to massive cell line -omics databases, there 
is clearly an opportunity for application of machine learning to biology. Amongst 
biological problems, there is a pressing need for increased efficiency of the drug 
discovery process, particularly in high mortality and morbidity problems like 
oncology. For these reasons, we have seen significant steps toward the application 
of ML to cancer drug discovery over the past several years. In this chapter, we have 
discussed some of these efforts, including the use of ML for target identification 
and in structure-based drug design. Additionally, we have provided a primer to 
ML in an effort to familiarise biologists to the field. In the second part of our work, 
addressed in the second part of our analysis (Applications of Machine Learning in 
Drug Discovery II: Biomarker Discovery and Patient Stratification), we extend the 
analysis of uses of ML in the drug discovery process to the clinical arena. First, we 
will discuss the use of ML in biomarker discovery, before moving to clinical trial 
optimisation and post market treatment effectiveness monitoring.
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Computational analysis of genomic data has transformed research and clinical
practice in oncology. Machine learning and AI advancements hold promise for
answering theoretical and practical questions. While the modern researcher has
access to a catalogue of tools from disciplines such as natural language processing
and image recognition, before browsing for our favourite off-the-shelf technique it
is worth asking a sequence of questions. What sort of data are we dealing with in
cancer genomics? Do we have enough of it to be successful without designing into
our models what we already know about its structure? If our methods do work, will
we understand why? Are our tools robust enough to be applied in clinical practice?
If so, are the technologies upon which they rely economically viable? While we will
not answer all of these questions, we will provide language with which to discuss
them. Understanding how much information we can expect to extract from data is
a statistical question.
Keywords: dimensionality, sparsity, high-dimensional statistics, cancer genomics,
biomarkers, learning theory
1. Introduction
This chapter should be equally approachable to those with a background in
machine learning/statistics and those with a more biological background. Beginning
with a contextualisation of cancer genomics as the starting point for drug and
biomarker discovery, we will attempt to convince the reader that statistical theory
serves as the backbone and language of modern developments in machine learning.
In order to facilitate those with less experience in biology, we will provide a very
brief introduction to the types of data encountered in sequencing-based studies and
the opportunities and problems they present. After providing some terminology
and useful concepts from high-dimensional statistics, we will discuss how these
concepts arise naturally in the context of cancer genomics, with some illustrative
examples of how different techniques may be employed in translational scientific
research. We will conclude by providing sketches of some modern developments
and a description of the transition from what can loosely be termed statistical
learning to what nowadays is referred to as machine learning.
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1.1 Cancer genomics in drug discovery
Since the success of the Human Genome Project [1], sequencing technologies
have improved at an exponential rate, both in terms of cost per megabase
sequenced and the number of individuals who have had some portion of their
genome sequenced (although the cost remains higher in practice than often
reported) [2]. This has introduced an invaluable new resource for biomedical
research in general. For the study of cancer, a disease of the genome, the ability to
rapidly and cheaply sequence normal and tumour-derived DNA has transformed
basic research, birthing the field of cancer genomics. This is beginning to impact
frontline clinical oncology [3]. Whole genome sequencing is not yet standard of care
for the generic cancer patient, but access to in-depth genetic data is becoming more
common. Initiatives such as the 10,000/100,000 Genomes Projects [4] and The
Cancer Genome Atlas [5] have given researchers access to large clinical datasets
with a variety of accompanying omics data.
Understanding the genomic landscape of cancer genomes is critical to the drug
discovery pipeline [6], particularly in pre-clinical identification of targets and bio-
markers. Knowledge of the location and associated products of oncogenes (genes in
which mutation can cause a cell to become cancerous) can allow for intelligent
selection of druggable sites and identification of tumour suppressor genes (genes
that under normal circumstances prevent uncontrolled cell division) gives options
for therapies which may replace patients’ defective cell cycle control mechanisms.
Alongside new drugs, it is becoming increasingly common for therapies to be
offered alongisde genomic biomarkers, which may stratify patients who are more
likely to benefit from the treatment [7, 8].
These new sources and types of data allow researchers a greatly expanded
toolbox with which to investigate the causes and development of cancer, but also
present a unique set of challenges. The number of covaraiates in omics datasets
causes a variety of theoretical and practical problems for classical statistical analysis,
a problem often referred to as the curse of dimensionality [9].
1.2 Statistical learning and machine learning
Informally, the field of high-dimensional statistics attempts to address theoreti-
cal and computational problems associated with datasets in which the number of
covariates (in our case this may refer to chromosomal locations or genes) is com-
parable to or greater than the number of samples available. In these settings results
such as the central limit theorem that rely on divergence of the sample size inde-
pendent of the dimensionality are often not of much use [10]. This is often the case
in cancer genomics.
Recent decades have seen much excitement around the application of machine
learning methods to a wide variety of high-dimensional problems. Particular pro-
gress has been made in automated image recognition and natural language
processing (NLP). This progress has come via the development of specialised tech-
niques to exploit the structure inherent in each data type (e.g. convolutional neural
networks for image recognition [11] and word embedding for NLP [12]), but also
from a vastly increased pool of data on which to train models. These data resources
have typically been collected online, where there exists an abundance of labelled
and unlabelled images and pieces of text.
It is hoped that similar strides forward can be anticipated in biology, but it is
important to acknowledge the current gap in data availability between cancer
genomics and the other machine learning disciplines mentioned above. In the next
section we will discuss typical types of biological data encountered in cancer
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genomics (including sequencing-based omics technologics that may not strictly be
genomics, such as gene expression profiling), their dimensionality and typical
availability. While efforts to deploy machine learning architectures are certainly
producing results in some cases [13, 14], an important takeaway is that in many
cases, we are not yet in a situation where the data-heavy deep learning approaches
that have revolutionised image recognition will be applicable to cancer genomics
problems.
That is not to say that we cannot do anything! In fact, it is often instructive to try
and make headway in situations where a ‘data-heavy, structure-light’ approach is
unsuitable, and these sorts of investigations can have a profound impact on the
design of more sophisticated models [15]. As a final point, readers approaching
without a significant backlog of machine learning expertise will find that an under-
standing of statistical terminology will aid comprehension of the machine learning
literature which has them as its basis.
2. Omics and biological data
2.1 DNA sequencing
Cancer genomics is underpinned by the ability to sequence DNA cheaply and
quickly. DNA is organised into chromosomes, along each of which many genes are
arranged, with further non-coding regions interspersed in-between. The funda-
mental units of DNA are nucleotide bases, of which there are four varieties (labelled
C, G, T and A). These are organised in groups of length three called codons, which
code for the production amino acids. Codons are arranged in sequences such that
their amino acids when joined in chain form proteins—the products of genes.
The aim of sequencing is to read, base by base, the information content of DNA.
This was originally done by Sanger sequencing, a procedure to infer the base
composition of a piece of DNA one base at a time. High-throughput sequencing
automates this process via the following workflow:
1.DNA is isolated from a sample and amplified (replicated many times) to
ensure good signal.
2.Purified DNA is broken into many pieces of manageable length.
3.These short strands are sequenced individually and simultaneously by an
automated process similar to Sanger sequencing.
4.These short sequences are matched to a reference human genome to identify
where the DNA in the original sample differed from that reference.
2.1.1 Tumour/normal variants
In cancer, some subset of cells accumulate mutations, via random misreplication
of DNA during cell division or exposure to some external mutagen (e.g. cigarette
smoke, UV light). Tumour cells therefore contain DNA with a different sequence to
that of the patients’ typical sequence. To understand this two samples are collected,
one from the tumour and one from normal tissue, and both are sequenced. The
sequences are compared and this produces a list of locations at which mutations
have occured: these mutations can have a variety of types (replacements, insertions,
etc.) and can have vastly differing functional implications.
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In simplest setting, we could express a tumour’s mutational profile as a vector,
with each component corresponding to whether the tumour-derived and normal
sequences match at that point. How long would this vector be? The human genome
contains approximately 3� 109 base locations. This is the dimensionality (which we
will refer to later on as p) of naively presented genomic data. We often like to
compare the dimensionality of a dataset with the number of samples (which we will
later call n) to which we can expect to have access. In this case, unless we have
access to tumour profiling for more than a third of all humans on the planet, we can
never hope that these numbers will be comparable. We could make a small gain by
listing all codons in the genome, labelling a component as one if the codon has been
functionally altered by mutations and zero otherwise. Here though we would still
have p ¼ 109.
We could simplify our data further. Decades of biological research has focused
on cataloguing the locations of genes across the genome. We might consider as
covariates each of the (approximately 2� 104) genes, and represent each sample as
a vector where each component refers to (a) whether or not the gene contained a
functional mutation; (b) how many such mutations were present; or (c) some other
representation of the severity of collective mutations presents in the gene, drawing
upon known biology. It is important to appreciate the trade-off we have made here:
we have imposed an external notion of structure onto our data and in return have
greatly reduced the dimensionality (by five orders of magnitude), but in exchange
have lost resolution and thus potential information. This gain/sacrifice will be
reflected when we choose to make even further structural assumptions in order to
construct sensible models.
2.1.2 Heterogeneity and depth
Another important concern for those dealing with cancer genome data is that
tumours are often highly heterogeneous. Different sub-populations of cells have
different mutation profiles, which fit into an evolutionary hierarchy within the
tumour’s history. The importance of understanding the role of heterogeneity is
beginning to be appreciated in a clinical context, and this has implications for the
type of data that are used. In the context of the high-throughput sequencing pipe-
line, the relevant quantity is depth: identifying not just one but a variety of tumour
sequences at a genomic locus along with the proportion in which they occur means
thinking very hard about how best to express that data.
2.2 Gene expression
It is often not just the sequence of a gene which it relevant in a tumour, but the
level of gene expression. The way that this is most often estimated is via the
proxy of RNA transcript abundance: RNA is a similar molecule to DNA that is
produced during the process of DNA being ‘read’, and acts as a messenger for
sequences that should be converted to protein. Abundances of different RNA
transcripts can be measured using procedures based on DNA sequencing. This
will in general give data with the same dimensionality as gene-based mutation
data, but is of a different type. Measured values are continuous to represent
concentrations of gene products, rather than discrete ‘mutated/not mutated’
values. This has implications as to the sort of structural assumptions we can make
about the data that we observe, and the models that will be best suited to
capitalise on that structure.
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3. Dimensionality and structure in statistical learning theory
Now familiar with the most relevant biological concepts, we turn to the
mathematical theory of high-dimensional statistics, which has experienced a surge
of interest in the last two decades. This is the language with which we will be
attempting to interrogate issues of inference and prediction in cancer genomics.
Informally, we may think of high-dimensional statistics to be concerned with the
realm in which the dimensionality of our input data, p, is comparable to or greater
than the number of training samples nwe have available. In this regime the classical
asymptotic theory of statistics, which generally relies on an assumption of fixed
dimension and considers limiting behaviour as n ! ∞, may fail to apply. Classical
results such as the law of large numbers and central limit theorem are not
applicable.
3.1 What is high-dimensional statistics?





, … , xn, yn
  
. We model each of these pairs as being drawn from a
joint probability distribution PX�Y , which gives the probability of observing any
combination of observation x and label y. For now we make no assumptions about
the nature of the yi labels: they may be continuous values (regression), discrete
values (classification) or more complicated objects such as is the case in survival
analysis. We assume that xi ∈X ⊂p for each 1≤ i≤ n, so that our observed values
are vectors of length p and each element is a real number (possibly restricted to
some subset such as the positive reals—this is what X specifies). We refer to p as the
dimension and n as the sample size of our data. We wish to fit some modelM to the
data. This could be in order to make some inference about the parameters of the
distribution PX�Y , which will hopefuly shed light on the effect of each of the
covariates contained in an observation x. Alternatively, we might be trying to
predict future values of y from unlabelled observations as accurately as possible.
These two aims are often distinguished by the umbrella terms statistical inference
and statistical learning.
In many statistical models we have a vector β of parameters with at least the
same dimension as our data (β∈q, q≥ p). In generalised linear models (GLMs)
the likelihood of an observation y depends upon the data xi solely via the inner
product xTi β, so that each component of β corresponds to the relative importance of
its associated covariate. Classically, we would attempt to to estimate the parameter
β via our observation through a procedure such as likelihood maximisation. How-
ever, it is clear in this context that if p is comparable to or larger than n then we
have very little chance of accurately inferring the parameter vector β. For example,
we canot expect to simultaneously learn about the effect of 20 covariates if we only
have 10 observations: we say here that the model is unidentifiable.
High-dimensional statistics attempts to gauge what we can do in regimes such as
these. One is approach is to assume the data has some low-dimensional structure.
This means that we can embed our data in a lower dimensional space such that the
smaller representation of our data contains all or most of the necessary information
about the joint distribution PX�Y . We will discuss some common structural
assumptions. The simplest and most interpretable is sparsity.
Definition 3.1. (Sparsity): ‘Relatively few covariates are important’.
Given a vector β∈p parameterising a model, we say β is k-sparse, for k≤ p, if at
most k elements of β are non-zero, that is
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We can say a model M parameterised by a vector β is k-sparse if the vector β is
k-sparse.
Sparsity is a useful assumption to make for a variety of reasons. We are reducing
the number of parameters that we must estimate—for a k-sparse model, we need
only estimate k parameters. Before we do so we need to decide which k parameters




choices) our parameter belongs. In practice this is not a huge issue—some powerful
theory from the field of convex optimisation allows for efficient training of sparse
models (see the LASSO estimator below). Finally, sparse models are interpretable.
A small number of covariates selected for importance can be useful in hypothesis
refinement.
3.1.1 Sparse data vs. sparse models
It is worth at this point drawing a distinction between two phenomena in
statistics and data science both referred to as ‘sparsity’, both of which are exhibited
in cancer genomics. The first is sparse data, in which almost all observed data points
have the same value (typically zero). Mutation data displays this trait—the rate at
which mutations occur in the genome varies widely across and within cancer types,
but rarely exceeds 100 Mut/Mb, that is one mutation per 104 nucleotide base pairs
[16]. This sparsity is exploited in the way that tumour/normal DNA data is stored,
in file formats such as VCF (variant called format) and MAF (mutation annotated
format). Many programming languages and data science packages have data struc-
tures optimised for sparse data, and it is also often possible to optimise learning and
algorithms for sparse data. However, here we will focus on sparse models. These are
models where it is assumed that only a small subspace of the covariate space is
relevant, via assumptions such as the one described above.
This notion that there is some sparse representation of data but that it may not
translate directly to a subset of our covariates motivates the more general principle
of Sufficient Dimension Reduction (SDR). Sparsity restricts our attention to some
small subspace of the covariate space p. More generally, we may insist on some
important smaller subspace, but one that does not depending on a specific repre-
sentation of our data x. The definition of SDR is somewhat more technical, so those
without mathematical background may find it easier to skip.
Definition 3.2. (Sufficient Dimension Reduction): ‘Some small representation
of our data contains all the important information’.
Given X,Yð Þ drawn from probability distribution PX�Y , we say there exists a
sufficient dimension reduction of size d ∗ if there exists some function S : p ! d ∗
with d ∗ < p such that Y is conditionally independent of X given S Xð Þ, that is,
Y⊥⊥X ∣ S Xð Þ
For an observation x, the image S Xð Þ is a d ∗ -dimensional representation of x. As
a special case we have linear sufficient dimensional reduction if the function S is a
linear projection A ∗ : p ! d ∗ .
Picking apart this definition, conditional independence means that Y only
depends on X through some low-dimensional image. Note that, in contrast to
sparsity, we have not made reference to a linear model parameter β. In fact, in the
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context of a generalised linear model where Y depends on X only through some
function of βTX, we can simply take S Xð Þ ¼ A ∗X ¼ βT and see that Y admits a
sufficient dimensionality condition with d ∗ = 1. SDR, therefore, is a helpful notion
in settings in which we need to apply a non-linear model structure. Methods based
on finding sufficient dimension reduction projections by searching through spaces
of projections [17] in combination with non-linear base classifiers are beginning to
show promise in a variety of domains including the analysis of high-dimensional
medical data [18].
3.1.2 Techniques in high-dimensional statistics: Selection and regularisation
It is all very well imposing assumptions of low-dimensional structure onto our
data. How can we now exploit this to produce models that reflect the structural
assumptions we have made? One answer is regularisation. Regularisation refers to
some penalisation process being applied to the parameters of our model. The intuition
is that, given some model parameter β of size greater than or equal to the dimension p
of our data, and thus of comparable magnitude to our number of samples, we have
enough degrees of freedom when fitting the model that we can be guaranteed to
produce almost perfect training set results without having done anything more than
memorise our data. Therefore we must place restrictions on our parameter, and the
trick is to do this as part of the model fitting process by combining a regularisation
term to the loss function of our learning procedure (ideally in such a way as to
preserve what is known as loss convexity, which allows efficient model fitting).
Regularisation is applied in practice across a whole range of model types, but is
easiest to understand in the context of linear regression, so in the discussion that
follows we will restrict ourselves to this setting.
In linear regression we have a model Mβ, parameterised by β, given by
Mβ : Yi ¼ XTi β þ ε, (1)
for some noise ε. We are saying that Y can be approximated by a linear combi-
nation of the components of X, with the relative weightings of each component
given by the components of β. The loss of our model (a measure of how inaccurately
it is predicting across all our data) is given by
L Mβ




Yi � XTi β
� �2
: (2)
In general we choose β to minimise this loss for an optimal model, but suppose
we wish to find an optimal k-sparse model, that is one for which β is k-sparse.
Rather than minimising over all possible choices of β, we are minimising the loss
over all values of β that are also k-sparse:
min




Here we face a computational difficulty: we have to separately check each subset
of covariates of size k and minimise on that set of possible parameters, then
compare them all to find the best. What we do to circumvent this is include a
penalisation term for β, which encourages sparsity alongside the loss function in our
optimisation. An obvious choice would be the L0 ‘norm’, βj j0, which counts non-
zero coefficients. In practice this is not computationally feasible (to be technical, the
problem is non-convex and so NP-hard), so instead we use the the L1 norm βj j1
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We can say a model M parameterised by a vector β is k-sparse if the vector β is
k-sparse.
Sparsity is a useful assumption to make for a variety of reasons. We are reducing
the number of parameters that we must estimate—for a k-sparse model, we need
only estimate k parameters. Before we do so we need to decide which k parameters
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j¼1∣β j∣. While this does not explicitly encode sparsity, it turns out that in
practice it does produce sparse solutions. This process of replacing a non-convex
problem with an easier one is in general called convex relaxation.
Technique 3.1. (Regularisation for Sparsity: L1/LASSO): Given the setup
above, L1 regularised estimation (known in the case of linear regression as the






� �þ λ βj j1
( )
where λ is a positive number chosen to specify how strongly we want to encour-
age sparsity: different values of λ will produce different k s in the ouput. A
particularly attractive feature of the LASSO selector is that it acts simultaneously as
a variable selection and model fitting procedure.
To take stock, we have begun with an assumption that some small subset of our
covariates are important in predicting the response Y. This assumption might have
come from necessity due to data availability, from knowledge of the biological
system we are modelling, or from both. We will discuss these possibilities in more
depth in the next chapter. We have taken a simple model, and altered it to express
this structure, and have done so in a way that is computationally feasible.
The specific form of the regularisation we employ can have very subtle effects
on the traits it encourages in models, which should motivate us to be very careful
when translating the biological knowledge we want to express into our learning
systems. For example, adding an identical regularisation term but replacing the L1




) does not produce sparse models, but rather
models that do not contain large coefficients. The corresponding structural
assumption for this is slightly more technical (we can assert a multivariate Gaussian
prior on the parameter space for β). This can be applied in a wide variety of high-
dimensional situations, often alongside other forms of regularisation, as a combat-
ant to over-fitting (typically via cross-validation).
Technique 3.2. (Regularisation for Dimension: L2/Ridge Regression): L2
regularised estimation (known as ridge regression in the linear setting [19]) selects






� �þ λ βj j2
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where again λ is a positive value that can be selected by cross-validation to
reduce overfitting.
Figure 1.
An example of a high-dimensional workflow, where high dimensionality is addressed via the imposition of
model structure, in this case sparsity. This is translated into a computationally tractable extension of standard
regression model fitting via an L1 penalty. Dimension-induced overfitting is simultaneously managed via L2
regularisation. If sparsity is a reasonable structural assumption, that is few covariates have genuine impact, L2
regularisation should have a relatively small impact.
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Figure 1 describes the workflow of modelling high-dimensional data. The data
dimensionality, as discussed in the previous chapter, is the underlying problem, which
we address with structural assumptions informed from a mixture of external knowl-
edge and practicality, which are then transformed into a feasible computational prob-
lem. Intuition around the biological and also statistical context are applied at each step.
For those unsatisfied with the abstract nature of the discussion above, we now
attempt to provide more concrete examples.
4. Cancer genomics questions in the language of high-dimensional
statistics
4.1 Biomarker/driver gene identification
We have discussed some of the terminology associated with high-dimensional
statistics. We can now express some cancer genomics questions in the same language.
We have data with a very high dimensionality p: bases, codons or genes (p≈3 109,
1 109 and 2 104 respectively) and we would like to predict some outcome, be it a
survival value, biomarker signature or other phenotype. Due to the resources and
time required to perform whole genome or exome sequencing we often face restric-
tions in the number of samples at our disposal. The popular Cancer Genome Atlas
resource [5], for example, contains sequencing data for around 20,000 tumour/
normal matched samples. Even if all of these samples were relevant to our study, and
we were trying to predict some phenotype Y using gene-level data, we would be
working in the p≈n regime. If we were using codon or nucleotide level information,
we would be well into the p> > n regime. In the following we will assume we are
working with some gene-level covariates, and investigate what sort of structural
assumptions we may wish to make in order to fit tractable and robust models.
4.2 Sparsity by assumption: driver genes
Driver genes in the simplest sense are genes that, when mutated, will elevate risk
of the development, progression or adaptation of a tumour [20]. They may be
grouped roughly into oncogenes and tumour suppressors: oncogenes admit muta-
tions giving some selective advantage to a cancer cell, while tumour suppressors in
their standard form protect against aberrant cell growth or apoptosis evasion. Iden-
tifying driver genes (or driver sites within genes) among the extensive backdrop
mutation in tumours is notoriously difficult. Selection pressures produce subtle and
often non-obvious patterns of mutation density between neutral and non-neutral
genes as well as distinct signatures for oncogenes and tumour suppressors [21].
Neglecting these difficulties for now, suppose we wish to infer some phenotype Y
(again for simplicity we assume that this is continuous and single-valued). We do
not have nearly enough data to fully explore the dependence of Y on all genes
simultaneously—we have to assume that there are relatively few relevant features/
driver genes. This is exactly a sparsity assumption—a regularisation method such as
LASSO might be helpful. The advantages of this are twofold. We have identified a
set of genes of interest, which might form the basis for some targeted prognostic
panel, while simultaneously inferring a predictive structure on top of this list of
genes. The added interpretability of our model given by assuming a structural
restraint is useful when verifying our results in the lab. We have produced a
manageable set of interesting genes that can be investigated on a more detailed
individual basis.
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4.3 Sparsity by necessity: gene panels for genome-wide biomarkers
Another justification for selecting some small set of genes/genomic loci to
include in an investigative panel is that the cost and time to perform sequencing
depends (approximately linearly) on the size of the subsection of the genome to be
sequenced, and the depth at which it is sequenced. This means that in many
practical or clinical environments, cost is a major factor. While the cost of whole
genome sequencing has decreased at an impressive rate, it is far from being stan-
dard of care for cancer patients. It is therefore important that gene-panel style
biomarkers are as small as possible, while maintaining enough accuracy that clini-
cians feel confident in acting upon predictions. This is a particular issue for genome-
wide biomarkers, which have gained popularity in recent years, for example in
cancer immunotherapy. Examples include tumour mutation burden [22] and indel
burden [23], which report density of somatic mutation across the entire cancer
genome. In this case all regions of the genome are relevant to greater or lesser extent
(Figure 2)—the optimal panel for prediction would be the entire genome (or
exome, depending on the specific biomarker). However, certain genes may be
particularly relevant, for example by taking an active role in DNA repair mecha-
nisms. When estimating such biomarkers, we therefore want to offset the positive
predictive contributions of individual genes/loci against the added cost burden
given by inclusion in the panel. Analyses of the impact of panel size on predictive
power in theoretical and practical settings are becoming more common [24].
Suppose we have some set G of genes, where g refers to an individual gene with
coding sequence of length ng. Now let P⊂G refer to a gene panel comprising a set of
genes, and MP be a model trained on some data with covariates included according
to the gene panel P. Then we might wish to solve the optimisation problem
Figure 2.
For an additive, genome-wide biomarker such as TMB (tumour mutational burden), all genomic loci are
significantly correlated with TMB (unlike in typical GWAS studies). How do we choose a subset that is not
prohibitively large but can reliably estimate the marker via some predictive model?
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min
P⊂G
L MPð Þf g such that ∣P∣ ≤L, (4)
where L Mð Þ is the loss of the model M, ∣P∣ ¼ Pg∈Png is the total length of the
gene panel P and L is some prescribed maximum panel length. Note the similarity
with the LASSO setup described in Section 3.1. In the case of a linear model we can
similarly reformulate the problem in terms of the parameter β, and solve the
analogous problem.
Technique 4.1. (Weighted L1 Regularisation/LASSO): Here we select β satisfy-












where we have again swapped the panel length bound L for the regularisation
parameter λ. Since all the ng values are positive, this is still a convex optimisation
problem and thus can be solved efficiency as in the standard case. Choice of λ is less
likely to be chosen via cross-fitting, as smaller values of λ will always improve predic-
tive power. Instead λ will be chosen to control the size of the resulting gene panel.
4.3.1 Distinguishing causative mutations
It should again be noted that these are illustrations of how high-dimensional
model construction is done. In reality many more subtleties may have to be taken
into account. In the above a key caveat requiring understanding is the role of
selective pressure in cancer-relevant genes [25], and how this affects the mutation
rate in different sections of the genome [26]. One way this can be investigated is by
looking at the relative predictive power of synonymous and non-synonymous
mutations for genome-wide mutation burden [27]. The gold standard for identify-
ing causative relationships between genotype and phenotype, however, remains
with functional validation studies.
4.4 Survival prediction
No review of statistical learning in cancer genomics would be complete without
a mention of survival prediction. Survival prediction is useful in a variety of situa-
tions, far beyond direct prognostic application. Hazard regression models based on
genomic data have been useful in identifying therapeutic resistance [28] or general
prognosis [29, 30] factors, which are of great interest to those developing drugs or
attempting to understand which patients can expect to benefit from them.
Regularisation-based techniques are perfectly adaptable to proportional-hazards
style models [31], to which end there has much literature beyond what we have
scope to discuss in this chapter.
5. Modern techniques in high-dimensional statistics and dimensionality
reduction
We conclude with some examples from recent literature of techniques related to
dimensionality reduction in modelling genomic data. The examples have been cho-
sen to demonstrate the structure/regularisation workflow discussed in this chapter,
and are small a set of examples rather than (anywhere near) an exhaustive list.
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5.1 Regularised graphical models
In the regression examples discussed previously, the parameters of interest have
represented the weighted effect of observed covariates on a label. In supervised and
unsupervised cases, we are also often interesting in looking at how closely related
different covariates are, through estimating the correlation matrix of the observa-
tion variable X. If we have an observation of dimensionality p, then the covariance
matrix will be of size p2, so problems of estimation from small n are even more
confounded!
Two forms of regularisation are popular, often used in tandem. The first is a
sparsity penalty applied to all matrix entries [32]. What does this correspond to
structurally? It means that that most pairs of covariates are independent (or at least
uncorrelated). This is a very relevant notion in network analysis, where variables
are thought to affect each other in a way that can be described by some graphical
structure. Sparsity of matrix elements then corresponds to sparsity of the graph
describing the network. It is also not uncommon to sparsely penalise precision,
defined by the components of the inverse covariance matrix [33].
Alternately (or in addition), we may wish to limit the number of distinct patterns
of correlation, so that all covariates display a correlation profile that is made up of a
combination of a relatively small set of base signatures. This structure may be fitted
for by imposing rank-based regularisation [34, 35]. For those wanting a greater
appreciation of the theory, the way this is imposed is another good example of
convex penalty relaxation (as was achieved by switching from the L0 to L1 norm in
sparsity regularisation), where here the nuclear norm is used as the convex relaxa-
tion of matrix rank.
5.2 Localised sparsity assumptions
We have made an extensive discussion of sparse models in this chapter. We
might wonder if there are any generalisations to the assumption that relatively few
of our covariates are important throughout all of our samples. One such generalisa-
tion would be that for some subsets of our samples sparsity assumptions hold, but
that the important covariates may differ from subset to subset within our data. In a
localised sparsity setting, we are often given some knowledge of the organisational
structure of data, either in a discrete way through a prior partition of the samples or
network structure, or in a continuous way through a measure of distance between
samples (which may come directly from the input data). We can then fit linear
models that are regularised towards sparsity, but where variable selection is allowed
to vary between samples, and allowed to vary more between samples that are more
distant. This has been applied to the prediction of drug toxicity based on differential
gene expression data [36].
5.3 Variational autoencoders
For our final example we consider a notion of dimensionality reduction that is
more general and that has been studied extensively in the machine learning litera-
ture. This nicely elucidates the grey border between statistical and machine learn-
ing, and the difficulties and opportunities available to biological research by
embracing the latter.
Variational autoencoders (VAEs) are a class of neural networks with a variety of
architectures and sizes, but whose premise centres around producing an encoding/
decoding framework between high-dimensional data and a lower dimensional
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representation [37]. VAEs have an ‘hourglass’ shape: input data is fed into the
network, and information is propagated through layers of progressively smaller size
until a bottleneck is reached. The central layer will have some small number of
latent nodes. Subsequent layers increase in size, reaching an output of dimension
matching the input. VAEs are trained to reproduce the inputs with which they are
trained as accurately as possible. We can then view the central latent nodes as an
encoding of our input data [38]. This might (a) contain some insightful information
and (b) be useful as lower dimensional input data for training other models.
In the context of cancer genomics [39], VAEs pose two challenges, illustrative of
those that machine learning procedures in general must overcome to be useful in a
basic research or clinical setting. Firstly, they are highly parameterised compared to
the types of model discussed so far. We have discussed at length the balance
between data availability and model size, and the significant extra effort necessary
to extract information when information is scarce. One of the advantages of deep
learning procedures is their versatility and lack of dependence on prior knowledge
and assumptions of structure. The cost is that they are very data intensive, prohib-
itively so in some cases. Secondly, while a VAE’s latent nodes may be informative
within a network, there is no necessary guarantee that they will be interpretable by
a human, nor that biologically relevant features will have been neatly allocated to a
single node. Strategies to ‘untangle’ VAEs are necessary to make biologically rele-
vant predictions [40].
6. Conclusions
The dimensionality of data in genomics is a sticking point that at its full potency
is more debilitating than in any other research discipline [9]. Even at the current
pace of increase of the availability of sequencing data, it will be a long time away (if
ever) that the most powerful and general machine learning techniques will be at our
disposal without recourse to the vast wealth of biological knowledge we as a species
have accumulated. To properly use that knowledge, we need researchers who are
able to speak the language of both camps. It is not sufficient that researchers in
cancer genomics provide data and questions to researchers in machine learning, nor
that machine learning researchers communicate back the output of their methods.
Instead, methods need to be crafted bespokely by those who understand what
features of cancer data are relevant, how those features manifest themselves and
how to exploit them in a mathematically consistent way.
This entire workflow is quite easy to follow when the sort of structure we are
insisting upon in our models is very simple. Even when a structural assumption can
be motivated in a single sentence (see Definition 3.1), and a model is simple (such as
in linear regression), a good design of learning procedure might not be immediately
obvious. It can likely, however, be given a fairly ground-up description within a
single book chapter. When the structural assumptions we really want to incorporate
might well extend as far as our current appreciation of the mutational processes
affecting tumours across heterogenuous cell populations, chromosomes, genes and
codons, and the models we want to fit are similarly at the cutting edge of computa-
tional research, then the position of an interdisciplinary researcher may well require
far more legwork to maintain.
As motivation for the above legwork, it should go without saying that cancer
genomics in the machine learning age has potential to do a great deal of good in the
long term. Yet uncovering a deeper understanding of how cancer works is not the
only worthwhile goal. Designing procedures that can work now to be more effec-
tive, sometimes crossing a threshold between non-pracitcality and practicality (in
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some part of the world), can have a more immediate benefit. In the clinic, the time
scale and cost of data collection are not abstract mathematical problems, so design-
ing a test that works with less data can be just as enabling as uncovering a new
paradigm of cancer progression.
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Chapter 4
Electronic Medical Records and




Electronic medical records (EMRs) were primarily introduced as a digital health
tool in hospitals to improve patient care, but over the past decade, research works
have implemented EMR data in clinical trials and omics studies to increase transla-
tional potential in drug development. EMRs could help discover phenotype-
genotype associations, enhance clinical trial protocols, automate adverse drug event
detection and prevention, and accelerate precision medicine research. Although
feasible, data mining in EMRs still faces challenges. Existing machine learning tools
may help overcome these bottlenecks in EMR mining to unlock new approaches in
drug development. This chapter will explore the role of EMRs in drug development
while evaluating the viability and bottlenecks of their uses in data mining. This will
include discussions on EMR usage in drug development while highlighting success-
ful outcomes in oncology and exploring ML tools to complement and enhance EMR
as a widely accepted drug-research source, a section on current clinical applications
of EMRs, and a conclusion to summarize and imagine what a future drug research
pipeline from EMR to patient treatment may look like.
Keywords: drug research and development, machine learning, AI, electronic
medical records, EMR, EHR, NLP, deep learning, big data, data analysis,
data-mining
1. Introduction
Advances in Artificial Intelligence methods have skyrocketed in the past decade,
especially in the medical space where the impact of healthcare reaches individuals
across a broad spectrum of communities. In particular, machine learning (ML)
researchers have gained access to a large quantity of high quality medical data,
aggregated by health providers as a result of implementing hospital management
systems. A crucial element of these management systems is electronic medical
records (EMRs), which are rich in valuable real world data on patient, clinical and
genomic data. An EMR is a digitized record of a medical occurrence documented
either during or after an encounter by a medical professional in a medical environ-
ment. For example, the results of a blood test administered at a hospital may be part
of an EMR. Clinical notes taken by the doctor in a routine check-up at a local clinic are
also included in the EMR. EMRs can come in the form of structured data such as drug
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researchers have gained access to a large quantity of high quality medical data,
aggregated by health providers as a result of implementing hospital management
systems. A crucial element of these management systems is electronic medical
records (EMRs), which are rich in valuable real world data on patient, clinical and
genomic data. An EMR is a digitized record of a medical occurrence documented
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ment. For example, the results of a blood test administered at a hospital may be part
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orders, medications, laboratory tests and diagnosis codes or unstructured data such as
text-based clinical progress notes, radiology reports and pathology findings [1].
When EMRs are amalgamated to create a longitudinal overview of a specific
patient, this larger unit of digitized records is called an electronic health record
(EHR). Since EHRs contain historical data, they are used to track the health pro-
gression of patients over time. Although in some sources, the terms EMR and EHR
are used interchangeably, or are sometimes referred to as the electronic patient
record, for simplicity the above definitions are used here. Another digital record is
the personal health record, which is the electronic medical data that the individual
may choose to provide to the medical institutions or health providers, however
issues of personal choice in volunteering data are beyond the scope of this chapter,
so we do not consider the personal health record here.
Today, providers produce EMRs with the hope to provide a centralized source of
medical data, which helps increase care coordination. With a standardized EMR
system, if an individual decides to switch health providers, the medical data can
seamlessly transfer to the new institutions. Furthermore, centralized medical data
reduces duplication of records and identifies missing patient data, which reduces
valuable time spent in clinical care. Compared to the traditional paperwork, EMRs
significantly decreases disease identification time, making healthcare more time
efficient and cost effective [2, 3]. In this sense, the EMRs improve quality of care.
In reality, there are issues in introducing EMRs into healthcare provider systems
such as implementation and workflow disruptions. Implementation requires
funding, necessary staff, and up to date digital technology. Institutions and geo-
graphic regions with ample resources will benefit from this implementation. How-
ever, for many smaller scale practices, implementation is not financially viable. For
regions where institutions do not have access to technology that enables the pro-
duction, storage and sharing of EMRs, this concept does not make sense. Further-
more, workflow is disrupted when clinicians and other medical professionals must
alter their workflow in order to complete these documents. EMRs are notoriously
unpopular in the medical community as it burdens professionals to constantly type
on their computer instead of caring for their patients. Burdened professionals do
not see the long term benefits and the reality in medical environments is that EMRs
are primarily used for financial and administrative purposes. For example, although
there are no global standards to what may be included in an EHR, it must always
have billing codes, which are used for administrative purposes such as reimburse-
ment or auditing reasons.
Despite these institutional challenges, EMRs are gaining traction in the biomed-
ical space because there is potential to extract important biomedical conclusions
from EMRs. As of December 2019, there are just under 2.1 million papers published
on electronic medical records in drug development and research within google
scholar [4]. Because EMRs are untapped and vast in quantity, researchers are
particularly focused on testing ML methods on EMRs. EMRs also provide resources
to carry out clinical trials at a lower cost and with reduced duration in terms of
efficiency gained from automation and having better data sources. With a manual
approach to identify and extract high value data, drug research on EMRs are not
scalable and are extremely costly to employ domain experts for data extraction. The
push for medical document digitization in conjunction with recent development in
ML methods, such as natural language processing (NLP) that allows for machines to
mimic human comprehension of written text, has allowed the outsourcing of these
research tasks to machines and further facilitate drug research.
In the context of ML methods, EMRs pose problems such as how EMRs do not
have a standardized formatting, how minorities could be underrepresented, and
how EMRs contain human errors. Today in the healthcare space, EMRs exist in
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abundance but were not originally created with a large scale data-mining vision [5].
Rather, providers replaced paper-work with electronic records to keep up with the
technological pace of the 21st century. Such digitization of the traditional paper-
work was done on an ad-hoc basis and many healthcare institutions independently
regulate EMRs to create a highly heterogeneous data set [6, 7]. This heterogeneity
makes data pre-processing for ML methods time consuming and financially costly if
domain experts are required for this task. Another difficulty stems from the issue of
institutions and geographic regions not having access to technology or financial
resources to implement EMRs. The lack of EMRs in particular communities means
those individuals are not electronically visible. In this sense, EMRs will not be able
to sample certain populations in the world. These underrepresented populations
will not have as much benefit from the biomedical success of EMRs as those
represented in the sample populations, increasing the inequality of medical care.
Lastly, basic human error in the EMRs will affect analysis performed on these data
sets, if they are not corrected. In addition, the EMRs come from different institu-
tions, which may enter their data differently. Without a standardized requirement
for EMRs, some parts will be missing core information and the operation is not
scalable.
1.1 Chapter overview
This introduction started with a brief discussion of what an EMR is and how
we define it in the absence of international unifying standards. This chapter will
now move on to an overview of how machine learning techniques, applied to
EMRs, are influencing three key areas of biomedical research and drug discovery:
(1) phenotype-genotype associations, (2) clinical trials, and (3) pharmacovigilance.
Firstly, we assess the impact of EMRs on making accurate phenotype-genotype
associations, where physical traits are linked to specific locus in the genome. We
then look at EMRs in the context of clinical drug trials and pharmacovigilance,
which together amount to the tracking of a drug’s efficacy and adverse side-effects
both before and after it is licensed and used. Finally, a number of different case
studies are looked at in detail, and we present a vision of how integrated EMRs and
ML-driven EMR drug research could be implemented in the future.
2. EMRs and phenotype-genotype association research
Phenotype-genotype association is the correspondence between a person’s
genetic makeup—their genotype, and the observable characteristics or pathologies
that are a product of their genetics interacting with the environment—their pheno-
type. In the medical space, researchers study phenotype-genotype associations
because variations in the human genome affect how a person exhibits phenotypic
traits, so to understand phenotype-genotype relations is to have biological insight
into disease mechanisms. Furthermore, phenotype-genotype associations are
important in drug discovery because phenotype targets are used to identify viable
drug targets within the human genome and are needed to understand the chemistry
of a potential drug within the human biology. Understanding phenotype-genotype
associations has useful downstream applications in many fields including disease
categorization, phenotype discovery, pharmacogenomics, drug–drug interaction
(DDI), and adverse drug event (ADE) detection, and genome-wide and phenome-
wide association studies [8].
Phenotype-genotype association research owes its foundation to the genome-
wide association studies (GWAS) studies that were driven by the potential of
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gression of patients over time. Although in some sources, the terms EMR and EHR
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the personal health record, which is the electronic medical data that the individual
may choose to provide to the medical institutions or health providers, however
issues of personal choice in volunteering data are beyond the scope of this chapter,
so we do not consider the personal health record here.
Today, providers produce EMRs with the hope to provide a centralized source of
medical data, which helps increase care coordination. With a standardized EMR
system, if an individual decides to switch health providers, the medical data can
seamlessly transfer to the new institutions. Furthermore, centralized medical data
reduces duplication of records and identifies missing patient data, which reduces
valuable time spent in clinical care. Compared to the traditional paperwork, EMRs
significantly decreases disease identification time, making healthcare more time
efficient and cost effective [2, 3]. In this sense, the EMRs improve quality of care.
In reality, there are issues in introducing EMRs into healthcare provider systems
such as implementation and workflow disruptions. Implementation requires
funding, necessary staff, and up to date digital technology. Institutions and geo-
graphic regions with ample resources will benefit from this implementation. How-
ever, for many smaller scale practices, implementation is not financially viable. For
regions where institutions do not have access to technology that enables the pro-
duction, storage and sharing of EMRs, this concept does not make sense. Further-
more, workflow is disrupted when clinicians and other medical professionals must
alter their workflow in order to complete these documents. EMRs are notoriously
unpopular in the medical community as it burdens professionals to constantly type
on their computer instead of caring for their patients. Burdened professionals do
not see the long term benefits and the reality in medical environments is that EMRs
are primarily used for financial and administrative purposes. For example, although
there are no global standards to what may be included in an EHR, it must always
have billing codes, which are used for administrative purposes such as reimburse-
ment or auditing reasons.
Despite these institutional challenges, EMRs are gaining traction in the biomed-
ical space because there is potential to extract important biomedical conclusions
from EMRs. As of December 2019, there are just under 2.1 million papers published
on electronic medical records in drug development and research within google
scholar [4]. Because EMRs are untapped and vast in quantity, researchers are
particularly focused on testing ML methods on EMRs. EMRs also provide resources
to carry out clinical trials at a lower cost and with reduced duration in terms of
efficiency gained from automation and having better data sources. With a manual
approach to identify and extract high value data, drug research on EMRs are not
scalable and are extremely costly to employ domain experts for data extraction. The
push for medical document digitization in conjunction with recent development in
ML methods, such as natural language processing (NLP) that allows for machines to
mimic human comprehension of written text, has allowed the outsourcing of these
research tasks to machines and further facilitate drug research.
In the context of ML methods, EMRs pose problems such as how EMRs do not
have a standardized formatting, how minorities could be underrepresented, and
how EMRs contain human errors. Today in the healthcare space, EMRs exist in
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abundance but were not originally created with a large scale data-mining vision [5].
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work was done on an ad-hoc basis and many healthcare institutions independently
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institutions and geographic regions not having access to technology or financial
resources to implement EMRs. The lack of EMRs in particular communities means
those individuals are not electronically visible. In this sense, EMRs will not be able
to sample certain populations in the world. These underrepresented populations
will not have as much benefit from the biomedical success of EMRs as those
represented in the sample populations, increasing the inequality of medical care.
Lastly, basic human error in the EMRs will affect analysis performed on these data
sets, if they are not corrected. In addition, the EMRs come from different institu-
tions, which may enter their data differently. Without a standardized requirement
for EMRs, some parts will be missing core information and the operation is not
scalable.
1.1 Chapter overview
This introduction started with a brief discussion of what an EMR is and how
we define it in the absence of international unifying standards. This chapter will
now move on to an overview of how machine learning techniques, applied to
EMRs, are influencing three key areas of biomedical research and drug discovery:
(1) phenotype-genotype associations, (2) clinical trials, and (3) pharmacovigilance.
Firstly, we assess the impact of EMRs on making accurate phenotype-genotype
associations, where physical traits are linked to specific locus in the genome. We
then look at EMRs in the context of clinical drug trials and pharmacovigilance,
which together amount to the tracking of a drug’s efficacy and adverse side-effects
both before and after it is licensed and used. Finally, a number of different case
studies are looked at in detail, and we present a vision of how integrated EMRs and
ML-driven EMR drug research could be implemented in the future.
2. EMRs and phenotype-genotype association research
Phenotype-genotype association is the correspondence between a person’s
genetic makeup—their genotype, and the observable characteristics or pathologies
that are a product of their genetics interacting with the environment—their pheno-
type. In the medical space, researchers study phenotype-genotype associations
because variations in the human genome affect how a person exhibits phenotypic
traits, so to understand phenotype-genotype relations is to have biological insight
into disease mechanisms. Furthermore, phenotype-genotype associations are
important in drug discovery because phenotype targets are used to identify viable
drug targets within the human genome and are needed to understand the chemistry
of a potential drug within the human biology. Understanding phenotype-genotype
associations has useful downstream applications in many fields including disease
categorization, phenotype discovery, pharmacogenomics, drug–drug interaction
(DDI), and adverse drug event (ADE) detection, and genome-wide and phenome-
wide association studies [8].
Phenotype-genotype association research owes its foundation to the genome-
wide association studies (GWAS) studies that were driven by the potential of
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genetic variations modulating disease risks, expression and progression. Although
the GWAS studies accumulated vast amount of genetic data, a remaining challenge
is translating genetic markers to its associated phenotype [9, 10]. A high-
throughput solution to such challenge is to harness phenotype data embedded in
EMRs.
In a medical provider setting, clinical professionals observe phenotypes on a
daily basis to diagnose diseases because phenotypic traits are manifestations of an
individual’s genome interacting with the environment. Such diagnosis is recorded
extensively in EMRs, making them rich in phenotype-related data. Following the
human genome project and the following development in sequencing whole
genomes, EMRs can now feasibly link an individual’s genome as part of their
medical data.
However, linking genomic data to EHRs is not common in clinical practice. This
is due to the combination of clinics offloading new sequencing technology to bioin-
formatics laboratories and the lack of infrastructure for integrating the processed
genomic data into EHRs [11]. Unlike most clinical laboratory tests, genomic testing
requires data curation during the bioinformatics pipelines. Therefore, when labora-
tories send genomic tests back to the original provider, the format or structure of
that data may not be directly compatible with the local EHR system [12]. In 2016,
laboratories were still physically mailing or faxing genomic reports in PDFs, which
is a format that is extremely difficult for machines to read and interpret [12]. This
clinical hurdle aside, in biomedical research this genomic inclusion in EHRs shows
potential in secondary use as raw data from which to draw medically meaningful
results [2, 12, 13]. Assuming that the EMR has adequate phenomic and genomic data
on an individual, algorithms can translate raw data in EMRs to phenotype data,
which in turn can be associated with the genomic data.
This section will focus on studies that cover phenotype-genotype research using
EMRs that aims to advance drug research, with particular attention to the machine
learning methods used in these cases. In a broad sense, this phenotype-genotype
application of EMRs to drug research has two major tasks. First is to identify
phenotypes contained in EMRs and second is to extract the phenotype to genotype
associations.
One of the validated processes to identify phenotypic traits from EMRs is the use
of standardized codes. Standardized codes have been designed for specific medical
needs and are heavily used in the structured documentation in EMRs. When com-
posing EMR’s, medical professionals use an internationally standardized set of codes
for reporting disease and health conditions called the International Classification of
Disease (ICD) developed by the World Health Organization (WHO). For example,
the ICD code may be a procedure code that indicates what medical procedures a
patient has received during hospitalization or a disease code that specifies a clini-
cian’s diagnosis. Although standardized, the recorded ICD relies on a consistent
interpretation of the ICD criteria for accuracy and relevancy, which will inevitably
vary between clinicians, departments and institutions. However, researchers cir-
cumvent the larger issue of heterogenous EMR data types, which might range from
character strings in clinical notes to matrices of pixels in radiology images, by
focusing on these codes that are a standardized part of EHRs.
In the context of AI, using standardized codes is advantageous because they
vastly reduce the set of possible inputs to any given machine learning algorithm.
In practical terms, the data requires little pre-processing, since the codes already
contain accurate and rich medical information described by domain experts. Com-
putation becomes scalable as less pre-processing means less manual work involved,
which is a necessity when extracting phenotypic data. Inevitably, there are a multi-
tude of competing standards. As mentioned earlier, the ICD is consistently updated
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in order to internationally keep track of morbidity and mortality statistics with its
eleventh version being adopted and replacing previous revisions starting 1 January
2022 [14]. In addition to the ICD, the US government has designed the ICD Clinical
Modification (ICD-CM), which is based upon ICD but tailored to the US healthcare
market. The Clinical Classification Software for ICD-CM, developed by the US
Agency for Healthcare Research and Quality, is a further development to the ICD-
CM that regroups codes into clinically relevant categories. New standards do not
have to be based upon existing ones, however. Phecodes is a standard specifically
designed for biomedical research and to facilitate phenome-wide association stud-
ies, first published in 2010 [15, 16]. In 2017, these different sets of standardized
EMR codes (ICD, ICD-CM, phecodes) were compared based on their ability to
create correctly pair single nucleotide polymorphism (SNP), which is a nucleotide
level genetic variation, to the corresponding phenotype, and it was found that the
phecodes performed markedly better than the ICD based standards [15, 17]. It is
perhaps not surprising that the phecodes performed best. Phecodes were developed
for research purposes, whereas ICD and related standards are more focused on
record keeping and streamlining the financial aspect of healthcare. These results
illustrate how common EMR codes used in hospitals are not well designed for ML
purposes. Although these codes are a convenient aspect within the context of
diverse data from EMRs, care must be taken when designing algorithms, which
repurpose the codes for phenotype extraction.
EMRs often contain a mixture of standardized codes and free-text. To improve
upon methods that only consider codes, machine learning tools, largely based upon
NLPs, have been developed to collect more phenotypic data from data sources
beyond standardized codes such as textual clinical notes, textual discharge summa-
ries and radiology reports [1, 18–21]. Liao et al. developed a multimodal automated
phenotyping (MAP) algorithm to leverage both ICD codes and EMR textual narra-
tives based on the Unified Medical Language System [18]. MAP is multimodal
because it can extract entities such as ICDs, medical NLP concepts and healthcare
utilization information related to a certain phenotype from both codes and free text.
Using MAP, Liao et al. analyzed those entities by different latent mixture models to
predict whether a patient had a certain phenotypic feature. Liao et al. ran the
algorithm through a validation dataset that contained labelled data with one of 16
unique phenotypes to show that MAP can extract relevant and phenotype-specific
entities at comparable accuracy to those identified by a manual approach (AUC-
MAP = 0.943, AUC-manual = 0.941). Another example of successful high through-
put method to extract phenotypes from EMRs is PheNorm, which harnesses stan-
dardized codes as training labels and does not require domain experts to label the
training set, making the model highly scalable and cost effective for phenotype
research [19]. In the face of the ML hype, it is naive to say that ML methods are
superior and domain experts will become superfluous in the future. For example,
Coquet et al. demonstrated the use of NLP methods and a Convolutional Neural
Network (CNN) method to create word embeddings in clinical notes to automate
clinical phenotyping of prostate cancer patients [20]. In this particular case, the
phenotyping accuracy of CNN model (F-measure = 0.918) surpassed that of the
rule-based model (F-measure = 0.897) [20] and the authors concluded that the
mixture of both models can lead to even better precision and accuracy. These
statistics in which the CNN model, which is a class of deep neural networks,
outperformed the rule-based model, an example of human driven modelling where
domain knowledge is needed, is indicative of the potential in ML methods but
human expertise is still needed to attain even higher accuracy and precision.
The next stage after phenotype extraction is to create phenotype-genotype asso-
ciations. In addition to the development of higher quality and more available
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genetic variations modulating disease risks, expression and progression. Although
the GWAS studies accumulated vast amount of genetic data, a remaining challenge
is translating genetic markers to its associated phenotype [9, 10]. A high-
throughput solution to such challenge is to harness phenotype data embedded in
EMRs.
In a medical provider setting, clinical professionals observe phenotypes on a
daily basis to diagnose diseases because phenotypic traits are manifestations of an
individual’s genome interacting with the environment. Such diagnosis is recorded
extensively in EMRs, making them rich in phenotype-related data. Following the
human genome project and the following development in sequencing whole
genomes, EMRs can now feasibly link an individual’s genome as part of their
medical data.
However, linking genomic data to EHRs is not common in clinical practice. This
is due to the combination of clinics offloading new sequencing technology to bioin-
formatics laboratories and the lack of infrastructure for integrating the processed
genomic data into EHRs [11]. Unlike most clinical laboratory tests, genomic testing
requires data curation during the bioinformatics pipelines. Therefore, when labora-
tories send genomic tests back to the original provider, the format or structure of
that data may not be directly compatible with the local EHR system [12]. In 2016,
laboratories were still physically mailing or faxing genomic reports in PDFs, which
is a format that is extremely difficult for machines to read and interpret [12]. This
clinical hurdle aside, in biomedical research this genomic inclusion in EHRs shows
potential in secondary use as raw data from which to draw medically meaningful
results [2, 12, 13]. Assuming that the EMR has adequate phenomic and genomic data
on an individual, algorithms can translate raw data in EMRs to phenotype data,
which in turn can be associated with the genomic data.
This section will focus on studies that cover phenotype-genotype research using
EMRs that aims to advance drug research, with particular attention to the machine
learning methods used in these cases. In a broad sense, this phenotype-genotype
application of EMRs to drug research has two major tasks. First is to identify
phenotypes contained in EMRs and second is to extract the phenotype to genotype
associations.
One of the validated processes to identify phenotypic traits from EMRs is the use
of standardized codes. Standardized codes have been designed for specific medical
needs and are heavily used in the structured documentation in EMRs. When com-
posing EMR’s, medical professionals use an internationally standardized set of codes
for reporting disease and health conditions called the International Classification of
Disease (ICD) developed by the World Health Organization (WHO). For example,
the ICD code may be a procedure code that indicates what medical procedures a
patient has received during hospitalization or a disease code that specifies a clini-
cian’s diagnosis. Although standardized, the recorded ICD relies on a consistent
interpretation of the ICD criteria for accuracy and relevancy, which will inevitably
vary between clinicians, departments and institutions. However, researchers cir-
cumvent the larger issue of heterogenous EMR data types, which might range from
character strings in clinical notes to matrices of pixels in radiology images, by
focusing on these codes that are a standardized part of EHRs.
In the context of AI, using standardized codes is advantageous because they
vastly reduce the set of possible inputs to any given machine learning algorithm.
In practical terms, the data requires little pre-processing, since the codes already
contain accurate and rich medical information described by domain experts. Com-
putation becomes scalable as less pre-processing means less manual work involved,
which is a necessity when extracting phenotypic data. Inevitably, there are a multi-
tude of competing standards. As mentioned earlier, the ICD is consistently updated
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in order to internationally keep track of morbidity and mortality statistics with its
eleventh version being adopted and replacing previous revisions starting 1 January
2022 [14]. In addition to the ICD, the US government has designed the ICD Clinical
Modification (ICD-CM), which is based upon ICD but tailored to the US healthcare
market. The Clinical Classification Software for ICD-CM, developed by the US
Agency for Healthcare Research and Quality, is a further development to the ICD-
CM that regroups codes into clinically relevant categories. New standards do not
have to be based upon existing ones, however. Phecodes is a standard specifically
designed for biomedical research and to facilitate phenome-wide association stud-
ies, first published in 2010 [15, 16]. In 2017, these different sets of standardized
EMR codes (ICD, ICD-CM, phecodes) were compared based on their ability to
create correctly pair single nucleotide polymorphism (SNP), which is a nucleotide
level genetic variation, to the corresponding phenotype, and it was found that the
phecodes performed markedly better than the ICD based standards [15, 17]. It is
perhaps not surprising that the phecodes performed best. Phecodes were developed
for research purposes, whereas ICD and related standards are more focused on
record keeping and streamlining the financial aspect of healthcare. These results
illustrate how common EMR codes used in hospitals are not well designed for ML
purposes. Although these codes are a convenient aspect within the context of
diverse data from EMRs, care must be taken when designing algorithms, which
repurpose the codes for phenotype extraction.
EMRs often contain a mixture of standardized codes and free-text. To improve
upon methods that only consider codes, machine learning tools, largely based upon
NLPs, have been developed to collect more phenotypic data from data sources
beyond standardized codes such as textual clinical notes, textual discharge summa-
ries and radiology reports [1, 18–21]. Liao et al. developed a multimodal automated
phenotyping (MAP) algorithm to leverage both ICD codes and EMR textual narra-
tives based on the Unified Medical Language System [18]. MAP is multimodal
because it can extract entities such as ICDs, medical NLP concepts and healthcare
utilization information related to a certain phenotype from both codes and free text.
Using MAP, Liao et al. analyzed those entities by different latent mixture models to
predict whether a patient had a certain phenotypic feature. Liao et al. ran the
algorithm through a validation dataset that contained labelled data with one of 16
unique phenotypes to show that MAP can extract relevant and phenotype-specific
entities at comparable accuracy to those identified by a manual approach (AUC-
MAP = 0.943, AUC-manual = 0.941). Another example of successful high through-
put method to extract phenotypes from EMRs is PheNorm, which harnesses stan-
dardized codes as training labels and does not require domain experts to label the
training set, making the model highly scalable and cost effective for phenotype
research [19]. In the face of the ML hype, it is naive to say that ML methods are
superior and domain experts will become superfluous in the future. For example,
Coquet et al. demonstrated the use of NLP methods and a Convolutional Neural
Network (CNN) method to create word embeddings in clinical notes to automate
clinical phenotyping of prostate cancer patients [20]. In this particular case, the
phenotyping accuracy of CNN model (F-measure = 0.918) surpassed that of the
rule-based model (F-measure = 0.897) [20] and the authors concluded that the
mixture of both models can lead to even better precision and accuracy. These
statistics in which the CNN model, which is a class of deep neural networks,
outperformed the rule-based model, an example of human driven modelling where
domain knowledge is needed, is indicative of the potential in ML methods but
human expertise is still needed to attain even higher accuracy and precision.
The next stage after phenotype extraction is to create phenotype-genotype asso-
ciations. In addition to the development of higher quality and more available
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electronic medical records, EHRs can now be matched with biopsies stored in
biobanks through patient-specific identifiers making it possible to study genetic and
phenotypic data alongside clinical findings. Earlier studies focused on using statis-
tical methods, such as the proof of concept study done by Denny et al. to develop a
method to scan phenomic data for genetic associations using ICD billing codes [16].
Subsequent studies have shown the viability of using ML algorithms to understand
phenotype-genotype associations using EMR sources with most of the papers
published in the past year [22, 23]. Recently, deep learning gained popularity as an
accurate framework at identifying phenotype-genotype associations [24].
Boudellioua et al. takes a deep neural network and developed an OpenSource
phenotype-based tool called DeepPVP, which prioritizes potential causative vari-
ants from whole genome sequence data [25]. As another example, Zeng et al. used
Bayesian network learning to extract epistatic interactions, which are gene-to-gene
interactions that change exhibited phenotypic traits, that effect breast cancer
patient survival on 1981 EHRs taken from the METABRIC dataset [26]. Their model
learned SNP associations that effect breast cancer patient survival that agreed with
domain knowledge from breast cancer oncologists [26]. Furthermore, unsupervised
learning has also been recognized as a great tool to discover new phenotypes [27].
Stark et al. studied the unsupervised extraction of phenotypes from cancer clinical
notes to use in association studies and reported success in finding new phenotype-
genotype association hypothesis that are not published but plausible from a biolog-
ical perspective [27]. Positive results form many recent studies demonstrates how
deep learning shows promise in phenotype-genotype association extraction.
Such high performing machine learning on big data to create phenotype-
genotype associations give hope to the future of personalized medicine, which is
healthcare tailored to different variations in a genotypes. More basic biomedical
research on phenotype-genotype associations opens possibilities for selecting best
treatments and for studying drugs that come back with negative or adverse results.
However, getting to such advanced levels of drug research is still on the horizon as
there are still more challenges in finding phenotype-genotype associations.
As mentioned before, one of the major problems is that EMRs generally suffers
from the difficulty in identification and correction of missing or mistaken data. In
many cases, ML methods require large datasets and when EHRs are amalgamated
from multiple sources, a high number of varying kinds of errors are carried over to
the data set and therefore propagate through to the algorithms. Due to the high
throughput of data in ML methods, there is a need for an automatic correction
filter, or a complete work around the missing data. One solution to missing EMR
data is to identify the missing phenotype data and correct it using a combination of
bioinformatics and genomic data [28, 29]. Even with sparse numbers of high quality
phenotypic or genotypic data, there has been studies that have successfully
extracted phenotype-genotype information from EMR using semi-supervised, bulk
phenotyping framework, and NLP-based machine learning techniques [24, 30, 31].
Another method to tackle missing data is to use a machine learning model to
completely encompass the missing data as part of the training set and therefore
accept the sparsity as part of the valid data [32]. Another solution is to acknowledge
the missing data as a variable in the modelling of the algorithm and quantify its
predicted effects on the final results and conclusion [33].
In summary, EMRs are a vital source of information in basic biomedical science,
specifically for phenotype-genotype associations, and there is a trend to test ML
methods on this untapped and vast data set to overcome the challenges EMRs face
during data mining. The advantage of EMRs is that it can be mined for phenotypes
and linked to genomic data. The section discussed different types of standardized
codes used in EMRs, which are easy to pre-process for ML frameworks. Codes such
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as ICDs, ICD-CM, and phecodes showed that they can successfully and conve-
niently identify phenotypes. However, standard codes used by providers were not
intended for data-mining purposes and therefore see performance issues when they
are used outside their primary objective, to identify phenotypes. To harness EMR
data beyond codes, studies look at a mixture of ICDs and free text. In the context of
phenotype identification, this blend of data sources showed high performance
especially when using ML methods in conjunction with more rule-based methods
that require domain expertise. Furthermore, this section discussed the strong via-
bility of ML methods for phenotype-genotype association identification, with a
trend toward using deep learning frameworks. EMR applications through ML
methods still face the problem of missing or erroneous data, which may affect the
subsequent biomedical conclusions. Further work is being done to combat the
shortcomings discussed and overall, EMRs have proven to be a promising data
source for phenotype-genotype related research.
3. EMR use in clinical trials
Clinical research informatics has emerged in the last 5–6 years as a new field of
biomedical translational research, which revolves around using informatics
methods to collect, store, process and analyze real-world clinical data to further
biomedical research purposes. With the increasing availability of such electronic
data and the development of analysis tools, EMRs can help decrease the cost and
time of clinical trials by automating patient recruitment, extend randomized control
trials and enhance retrospective cohort studies.
Clinical trials are a crucial stage in drug development to test for drug safety and
efficacy. These trials are time consuming, labor intensive and costly to operate, and
a significant bottleneck for many trials is insufficient patient enrollment [34].
However, by harnessing the data contained within EMRs, clinical trials can become
more efficient by automating recruitment and having a more extensive view of
medical data compared to the traditional manual search. Successful examples have
shown that EMR mining for potential recruitment are more cost efficient and less
time consuming than traditional methods [35, 36]. As a quantitative example, a
study done in the US studied 31 EHR-driven analysis on drug-to-genome interac-
tions and concluded that EHRs helped decrease the trial cost by 72% per subject and
reduced the duration of the studies [13].
It is also possible to repurpose systems that already exist within a clinical setting
to improve trial recruitment. A study conducted by Devoe et al. repurposed an
already existing Best Practice Alert (BPA) system, which was originally intended to
improve patient care by automating basic keyword searches on patient EHRs, to
recruit potential trial participants for a COPD study [37, 38]. Devoe et al. directly
compared the cost effectiveness of the BPA-driven screening to that of the tradi-
tionally manual method, namely the EMR Reporting Workbench method where
clinicians customize a query through a platform in order to pull data from the EHR
database, and concluded that BPA was four times faster at screening all patients and
ultimately lead to a projected 442.5 h reduction over the course of the study.
A particularly interesting case of a commercial EMR product developed for
research purposes used in a clinical setting is a platform called InSite. This Software
as a Service platform was developed out of the Electronic Health Record for Clinical
Research (EHR4CR) project (completed Spring 2016), which aimed to create a
secure, robust and scalable platform used around Europe to create a network of safe
and security-compliant real world data, which can be reuse to further clinical
research [39]. International research groups and medical providers from multiple
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electronic medical records, EHRs can now be matched with biopsies stored in
biobanks through patient-specific identifiers making it possible to study genetic and
phenotypic data alongside clinical findings. Earlier studies focused on using statis-
tical methods, such as the proof of concept study done by Denny et al. to develop a
method to scan phenomic data for genetic associations using ICD billing codes [16].
Subsequent studies have shown the viability of using ML algorithms to understand
phenotype-genotype associations using EMR sources with most of the papers
published in the past year [22, 23]. Recently, deep learning gained popularity as an
accurate framework at identifying phenotype-genotype associations [24].
Boudellioua et al. takes a deep neural network and developed an OpenSource
phenotype-based tool called DeepPVP, which prioritizes potential causative vari-
ants from whole genome sequence data [25]. As another example, Zeng et al. used
Bayesian network learning to extract epistatic interactions, which are gene-to-gene
interactions that change exhibited phenotypic traits, that effect breast cancer
patient survival on 1981 EHRs taken from the METABRIC dataset [26]. Their model
learned SNP associations that effect breast cancer patient survival that agreed with
domain knowledge from breast cancer oncologists [26]. Furthermore, unsupervised
learning has also been recognized as a great tool to discover new phenotypes [27].
Stark et al. studied the unsupervised extraction of phenotypes from cancer clinical
notes to use in association studies and reported success in finding new phenotype-
genotype association hypothesis that are not published but plausible from a biolog-
ical perspective [27]. Positive results form many recent studies demonstrates how
deep learning shows promise in phenotype-genotype association extraction.
Such high performing machine learning on big data to create phenotype-
genotype associations give hope to the future of personalized medicine, which is
healthcare tailored to different variations in a genotypes. More basic biomedical
research on phenotype-genotype associations opens possibilities for selecting best
treatments and for studying drugs that come back with negative or adverse results.
However, getting to such advanced levels of drug research is still on the horizon as
there are still more challenges in finding phenotype-genotype associations.
As mentioned before, one of the major problems is that EMRs generally suffers
from the difficulty in identification and correction of missing or mistaken data. In
many cases, ML methods require large datasets and when EHRs are amalgamated
from multiple sources, a high number of varying kinds of errors are carried over to
the data set and therefore propagate through to the algorithms. Due to the high
throughput of data in ML methods, there is a need for an automatic correction
filter, or a complete work around the missing data. One solution to missing EMR
data is to identify the missing phenotype data and correct it using a combination of
bioinformatics and genomic data [28, 29]. Even with sparse numbers of high quality
phenotypic or genotypic data, there has been studies that have successfully
extracted phenotype-genotype information from EMR using semi-supervised, bulk
phenotyping framework, and NLP-based machine learning techniques [24, 30, 31].
Another method to tackle missing data is to use a machine learning model to
completely encompass the missing data as part of the training set and therefore
accept the sparsity as part of the valid data [32]. Another solution is to acknowledge
the missing data as a variable in the modelling of the algorithm and quantify its
predicted effects on the final results and conclusion [33].
In summary, EMRs are a vital source of information in basic biomedical science,
specifically for phenotype-genotype associations, and there is a trend to test ML
methods on this untapped and vast data set to overcome the challenges EMRs face
during data mining. The advantage of EMRs is that it can be mined for phenotypes
and linked to genomic data. The section discussed different types of standardized
codes used in EMRs, which are easy to pre-process for ML frameworks. Codes such
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as ICDs, ICD-CM, and phecodes showed that they can successfully and conve-
niently identify phenotypes. However, standard codes used by providers were not
intended for data-mining purposes and therefore see performance issues when they
are used outside their primary objective, to identify phenotypes. To harness EMR
data beyond codes, studies look at a mixture of ICDs and free text. In the context of
phenotype identification, this blend of data sources showed high performance
especially when using ML methods in conjunction with more rule-based methods
that require domain expertise. Furthermore, this section discussed the strong via-
bility of ML methods for phenotype-genotype association identification, with a
trend toward using deep learning frameworks. EMR applications through ML
methods still face the problem of missing or erroneous data, which may affect the
subsequent biomedical conclusions. Further work is being done to combat the
shortcomings discussed and overall, EMRs have proven to be a promising data
source for phenotype-genotype related research.
3. EMR use in clinical trials
Clinical research informatics has emerged in the last 5–6 years as a new field of
biomedical translational research, which revolves around using informatics
methods to collect, store, process and analyze real-world clinical data to further
biomedical research purposes. With the increasing availability of such electronic
data and the development of analysis tools, EMRs can help decrease the cost and
time of clinical trials by automating patient recruitment, extend randomized control
trials and enhance retrospective cohort studies.
Clinical trials are a crucial stage in drug development to test for drug safety and
efficacy. These trials are time consuming, labor intensive and costly to operate, and
a significant bottleneck for many trials is insufficient patient enrollment [34].
However, by harnessing the data contained within EMRs, clinical trials can become
more efficient by automating recruitment and having a more extensive view of
medical data compared to the traditional manual search. Successful examples have
shown that EMR mining for potential recruitment are more cost efficient and less
time consuming than traditional methods [35, 36]. As a quantitative example, a
study done in the US studied 31 EHR-driven analysis on drug-to-genome interac-
tions and concluded that EHRs helped decrease the trial cost by 72% per subject and
reduced the duration of the studies [13].
It is also possible to repurpose systems that already exist within a clinical setting
to improve trial recruitment. A study conducted by Devoe et al. repurposed an
already existing Best Practice Alert (BPA) system, which was originally intended to
improve patient care by automating basic keyword searches on patient EHRs, to
recruit potential trial participants for a COPD study [37, 38]. Devoe et al. directly
compared the cost effectiveness of the BPA-driven screening to that of the tradi-
tionally manual method, namely the EMR Reporting Workbench method where
clinicians customize a query through a platform in order to pull data from the EHR
database, and concluded that BPA was four times faster at screening all patients and
ultimately lead to a projected 442.5 h reduction over the course of the study.
A particularly interesting case of a commercial EMR product developed for
research purposes used in a clinical setting is a platform called InSite. This Software
as a Service platform was developed out of the Electronic Health Record for Clinical
Research (EHR4CR) project (completed Spring 2016), which aimed to create a
secure, robust and scalable platform used around Europe to create a network of safe
and security-compliant real world data, which can be reuse to further clinical
research [39]. International research groups and medical providers from multiple
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countries developed this platform and intended for researchers to interact with
hospital-based EHRs. A study by Claerhout et al. studied the feasibility of using
InSite as a tool to estimate numbers of eligible participants for clinical trials at 24
European hospitals [40]. They studied the inclusion and exclusion (I/E) criteria of
protocols from 23 trials across diverse therapeutic areas, including ABP 980 and
trastuzumab for early breast cancer, a combination of cediranib and chemotherapy
in relapsed ovarian, fallopian tube or epithelial cancer, and selumetinib in combi-
nation with docetaxel for metastatic lung cancer. These clinical trials were spon-
sored by various pharmaceutical companies 1 to represent key I/E criterion using
terms included in the standard medical coding systems 2 [40]. It was found that a
median of 55% of the I/E criteria can be translated to InSite queries using the
standard medical coding systems to correctly identify potential trial patients. This
result is promising as it shows the feasibility of translating the complex protocol
criteria into machine-readable queries via an already existing platform.
This success of patient identification is attributed to how well defined the disease
parameters are in the I/E criterion and whether its clinical concepts exactly match a
query that the InSite platform can digest. Unfortunately, these queries do not contain
easily accessible nor standardized temporal information on disease development such
as the rapid progression of a tumor size or the timing at which an operation was carried
out. This lack of temporal resolution led to the lowest formalization rate (38%) in
patients with metastatic melanoma, revealing the difficulty of acquiring temporal
information on tumor staging and genetic testing [40]. A possible next step to this
study is to harness NLP to the unstructured EMR data and to resolve the temporal
issue in order to increase performance in patient recruitment. Overall, this study
showed the potential for this commercialized platform for optimizing recruitment by
hospitals. Beyond the feasibility of estimating the number of potential trial patients,
this platform is advantageous because InSite offers a convenient and efficient way for
researchers can access real-time clinical data by extracting relevant EMRs without
disrupting healthcare providers with new technological implementations.
It has been shown that NLP [34] is able to reduce the amount of manual-driven
patient identification required. Once the number of patients eligible for a clinical
trial is estimated, the next step is to carry out patient screening on each individual.
There are three methods that can carry out these checks. Meystre et al. harnessed
NLP to directly compare clinical trial screen accuracy between machine learning,
rule-based and cosine-similarity based methods and reported the highest accuracy
(micro-averaged recall 90.9%) and precision (89.7%) for the machine learning
method [34]. In such automations, the usage of NLP and harnessing machine
learning is key to fully automating cohort selections using EHRs, and there are
research done to further those tools, which is illustrated with the emergence of
CREATE [41] and SemEHR, which is an open source semantic search and analysis
tool for EMRs [42]. Such automations revolutionize clinical trial processes by cut-
ting down administrative work by an order of magnitude. To deal with the ever
increasing amount of EMR data made available, case studies have also shown that
unsupervised ML methods may be used to identify disease cohort selection with
high accuracy compared to the traditional and manual methods [43].
In some cases, EMRs can allow for more diversity in clinical trials and provide
data collection on individuals that are traditionally underrepresented, such as racial
minorities, children, rural communities or pregnant women [35, 44, 45]. However,
1 Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, F-Hoffman La Roche, Janssen, Sanofi.
2 Diagnosis: ICD-10CM, procedures: ICD-PCS, medication: ATC, laboratory: LOINC, clinical findings:
SNOMED and anatomic pathology/oncology ICD-O-3.
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there are also studies that published poor performance of information retrieval
through EMR and ML [46]. There are high expectations for a new wave of ML tools
to revolutionize medicine but researchers must be vigilant for unexpected biases
arising from ML models trained on skewed or bad data.
For an example of bias in EMR driven selection of patients for trial, we look at
the work of Aroda et al. They compared EMR-driven recruitment for type 2 diabe-
tes patient across multiple health centers in the US to that of the traditional manual
method [47]. Although Aroda et al. reported that the EMR-based recruitment had
higher numbers of patients screening, better performance and improved randomi-
zations, they also noticed an association with fewer women and racial minorities
recruited. EMR and electronic-driven recruitment may cause bias in the type of
cohorts identified, as electronically visible individuals are more likely to be identi-
fied and then consent to trials. A skew in this electronic visibility allow only certain
cohort groups to be identified and studied in a clinical trial [48].
These biases arising from ML models are a significant aspect of drug research as
they may cause inadvertent negative effects when these technologies are brought to
market and into the medical centers. This may be the case of poor data sets or a poor
selection of algorithms. In the real world, catch-all algorithms that work in acade-
mia sometimes fail and sometimes there is just not enough data for the data-hungry
machine learning methods. Since manual methods do not suffer due to lack of scale
when ML-based and data-driven research fail when they cannot access big data, the
rise of ML driven processes will not make manual ones totally obsolete.
Another potential for EMR is to extend short, cost-limited trials by electronically
monitoring the cohort after the trial is over. This creates a long term follow up
without the cost associated with a traditional, extended clinical trial. There has been
a successful case in testing novel probiotics to carry out a 5 year follow up, which
would have been too expensive in traditional methods and retention rate increased
due to this electronic method [49]. Furthermore, EMR data may be used in clinical
trials beyond just a follow-up. There is interest in using EMRs as a primary data
source or as a feasibility assessment tool in observational clinical trials, comparative
effectiveness studies and randomized clinical trials [50]. In addition, data can be
used to carry out retrospective cohort studies or population based cohort studies.
Kibbelaar et al. proposed a method to combine data from population-based regis-
tries with detailed EHR to conduct an observational study and reported on a case
study in an hemato-oncology randomized registry trial [51].
These implementations are dependent on the patient’s consent to partake in the
trials and there are studies that investigate the process and ethics of such consent
[52]. Beskow et al. identified patient informed consent as a bottleneck in using EHR
for randomized clinical trials. A study has also identified gaps in ethical responsi-
bility in clinical studies carried out [53]. Furthermore, compliance to security and
privacy regulations is a critical challenge as clinically produced EMRs proliferate
through cloud platforms, mobile devices and commercialized technology. Whilst
security and data protection are of paramount importance when dealing with
EMRs, a discussion of the methods currently in use is beyond the scope of this
chapter. The reader is directed to Refs. [54–56], in which the current technologies
and methods used for security measures on EMRs are reviewed.
To conclude, using data within EMRs can help decrease the cost and time of
clinical trials. First, the section discussed successful examples of EMR mining for
potential recruitment in clinical trials, which included using systems that already
exist in clinical settings, such as BPA and InSite, and tools that employ ML methods.
An advantage with the use of ML methods in clinical trials is the increase in
diversity in trial patients but there is still an issue with the bias that cause inequality
in patient selection. Ultimately, the quality of the ML approach depends on the
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countries developed this platform and intended for researchers to interact with
hospital-based EHRs. A study by Claerhout et al. studied the feasibility of using
InSite as a tool to estimate numbers of eligible participants for clinical trials at 24
European hospitals [40]. They studied the inclusion and exclusion (I/E) criteria of
protocols from 23 trials across diverse therapeutic areas, including ABP 980 and
trastuzumab for early breast cancer, a combination of cediranib and chemotherapy
in relapsed ovarian, fallopian tube or epithelial cancer, and selumetinib in combi-
nation with docetaxel for metastatic lung cancer. These clinical trials were spon-
sored by various pharmaceutical companies 1 to represent key I/E criterion using
terms included in the standard medical coding systems 2 [40]. It was found that a
median of 55% of the I/E criteria can be translated to InSite queries using the
standard medical coding systems to correctly identify potential trial patients. This
result is promising as it shows the feasibility of translating the complex protocol
criteria into machine-readable queries via an already existing platform.
This success of patient identification is attributed to how well defined the disease
parameters are in the I/E criterion and whether its clinical concepts exactly match a
query that the InSite platform can digest. Unfortunately, these queries do not contain
easily accessible nor standardized temporal information on disease development such
as the rapid progression of a tumor size or the timing at which an operation was carried
out. This lack of temporal resolution led to the lowest formalization rate (38%) in
patients with metastatic melanoma, revealing the difficulty of acquiring temporal
information on tumor staging and genetic testing [40]. A possible next step to this
study is to harness NLP to the unstructured EMR data and to resolve the temporal
issue in order to increase performance in patient recruitment. Overall, this study
showed the potential for this commercialized platform for optimizing recruitment by
hospitals. Beyond the feasibility of estimating the number of potential trial patients,
this platform is advantageous because InSite offers a convenient and efficient way for
researchers can access real-time clinical data by extracting relevant EMRs without
disrupting healthcare providers with new technological implementations.
It has been shown that NLP [34] is able to reduce the amount of manual-driven
patient identification required. Once the number of patients eligible for a clinical
trial is estimated, the next step is to carry out patient screening on each individual.
There are three methods that can carry out these checks. Meystre et al. harnessed
NLP to directly compare clinical trial screen accuracy between machine learning,
rule-based and cosine-similarity based methods and reported the highest accuracy
(micro-averaged recall 90.9%) and precision (89.7%) for the machine learning
method [34]. In such automations, the usage of NLP and harnessing machine
learning is key to fully automating cohort selections using EHRs, and there are
research done to further those tools, which is illustrated with the emergence of
CREATE [41] and SemEHR, which is an open source semantic search and analysis
tool for EMRs [42]. Such automations revolutionize clinical trial processes by cut-
ting down administrative work by an order of magnitude. To deal with the ever
increasing amount of EMR data made available, case studies have also shown that
unsupervised ML methods may be used to identify disease cohort selection with
high accuracy compared to the traditional and manual methods [43].
In some cases, EMRs can allow for more diversity in clinical trials and provide
data collection on individuals that are traditionally underrepresented, such as racial
minorities, children, rural communities or pregnant women [35, 44, 45]. However,
1 Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, F-Hoffman La Roche, Janssen, Sanofi.
2 Diagnosis: ICD-10CM, procedures: ICD-PCS, medication: ATC, laboratory: LOINC, clinical findings:
SNOMED and anatomic pathology/oncology ICD-O-3.
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there are also studies that published poor performance of information retrieval
through EMR and ML [46]. There are high expectations for a new wave of ML tools
to revolutionize medicine but researchers must be vigilant for unexpected biases
arising from ML models trained on skewed or bad data.
For an example of bias in EMR driven selection of patients for trial, we look at
the work of Aroda et al. They compared EMR-driven recruitment for type 2 diabe-
tes patient across multiple health centers in the US to that of the traditional manual
method [47]. Although Aroda et al. reported that the EMR-based recruitment had
higher numbers of patients screening, better performance and improved randomi-
zations, they also noticed an association with fewer women and racial minorities
recruited. EMR and electronic-driven recruitment may cause bias in the type of
cohorts identified, as electronically visible individuals are more likely to be identi-
fied and then consent to trials. A skew in this electronic visibility allow only certain
cohort groups to be identified and studied in a clinical trial [48].
These biases arising from ML models are a significant aspect of drug research as
they may cause inadvertent negative effects when these technologies are brought to
market and into the medical centers. This may be the case of poor data sets or a poor
selection of algorithms. In the real world, catch-all algorithms that work in acade-
mia sometimes fail and sometimes there is just not enough data for the data-hungry
machine learning methods. Since manual methods do not suffer due to lack of scale
when ML-based and data-driven research fail when they cannot access big data, the
rise of ML driven processes will not make manual ones totally obsolete.
Another potential for EMR is to extend short, cost-limited trials by electronically
monitoring the cohort after the trial is over. This creates a long term follow up
without the cost associated with a traditional, extended clinical trial. There has been
a successful case in testing novel probiotics to carry out a 5 year follow up, which
would have been too expensive in traditional methods and retention rate increased
due to this electronic method [49]. Furthermore, EMR data may be used in clinical
trials beyond just a follow-up. There is interest in using EMRs as a primary data
source or as a feasibility assessment tool in observational clinical trials, comparative
effectiveness studies and randomized clinical trials [50]. In addition, data can be
used to carry out retrospective cohort studies or population based cohort studies.
Kibbelaar et al. proposed a method to combine data from population-based regis-
tries with detailed EHR to conduct an observational study and reported on a case
study in an hemato-oncology randomized registry trial [51].
These implementations are dependent on the patient’s consent to partake in the
trials and there are studies that investigate the process and ethics of such consent
[52]. Beskow et al. identified patient informed consent as a bottleneck in using EHR
for randomized clinical trials. A study has also identified gaps in ethical responsi-
bility in clinical studies carried out [53]. Furthermore, compliance to security and
privacy regulations is a critical challenge as clinically produced EMRs proliferate
through cloud platforms, mobile devices and commercialized technology. Whilst
security and data protection are of paramount importance when dealing with
EMRs, a discussion of the methods currently in use is beyond the scope of this
chapter. The reader is directed to Refs. [54–56], in which the current technologies
and methods used for security measures on EMRs are reviewed.
To conclude, using data within EMRs can help decrease the cost and time of
clinical trials. First, the section discussed successful examples of EMR mining for
potential recruitment in clinical trials, which included using systems that already
exist in clinical settings, such as BPA and InSite, and tools that employ ML methods.
An advantage with the use of ML methods in clinical trials is the increase in
diversity in trial patients but there is still an issue with the bias that cause inequality
in patient selection. Ultimately, the quality of the ML approach depends on the
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quality of the training data. Therefore, with access to excellent data, EMRs can be
used to extend short, financially limited trials or used as a primary data source to
carry out aspects of data-driven clinical trials. Whilst ML methods are showing
strong performance in enhancing clinical trials, big challenges remain before the
data-driven method replaces the current clinical methodology.
4. EMR use in pharmacovalidation and data mining
However thoroughly a new drug is trialed and tested before it enters the market,
it is possible that there are unknown adverse drug events (ADEs, colloquially
known as side-effects) that manifest on time scales or in ways that cannot be seen in
a clinical trial. Currently, adverse side effects of pharmaceutical products are a
significant source for morbidity and are a significant healthcare cost in many coun-
tries [57, 58]. Therefore, it is vital that pharmaceutical companies undertake
pharmacovigilance, in which they continually track the effects of their drugs after
the drugs deployment. This means that clinical data on post-market drug effects has
a high value to pharmaceutical companies [59]. Post-market surveillance of drugs to
detect, evaluate and prevent ADEs with licensed drugs released in the market is
called pharmacovigilance and is imperative for decreasing negative drug incidents.
Traditionally, medical professionals with domain knowledge would manually
identify ADEs through sources such as clinical trials, health reports, published
medical literature, observational literature and social media [60], which is time
consuming and costly. Therefore, automatically mining these electronic narratives
are an efficient way to identify negative events in the real world setting. Luckily,
real world data on pharmaceutical products and their effects are richly logged in
patient EHRs. To successfully mine the vast quantity of dense data in the EHRs for
drug events, specifically ADEs, studies have focused on the narrative aspect of EMR
and have successfully extracted ADE from both structured [61, 62] and unstruc-
tured [63–65] texts.
This focus on EHR narratives stems from studies that have shown that disease
classification codes, such as ICD, used in EMRs do not encompass the symptoms,
disease status and severity needed for ADE sensitivity and therefore are not appro-
priate in drug event mining [66–68]. Therefore it is necessary to extract more
detailed information from the written text in EMRs, which is achieved using NLP
algorithms. This is a two staged computational task. Firstly, the algorithm must
perform accurate name entity recognition (NER) to identify diseases, drugs, and
negative events in the text, and then it must quantify associations between those
entities, to build a concept of what had occurred [69, 70].
Since 2012, significant developments in statistical analysis, machine-learning
methods and heterogeneous data integration have allowed for automated ADE
detection and offer tools for a novel, automated pharmacovigilance analytics [71].
Some statistical methods such as the odds ratio has been used by Leeper et al. and
Banda et al. to create algorithms designed for extracting drug–ADE associations
from EHRs [72, 73]. However, due to the need to define hypothesis using domain
knowledge, experts in the field were necessary and this suggests a limitation that
these statistical frameworks will not necessarily benefit from having more access to
EHR resources because the core predictors depend on a priori knowledge, which is
static within the algorithm. This means that there is currently still a manual element
required in the process, which limits the scalability of this approach.
Some of the early EMR-narrative studies focused on keyword and phrase driven
identification of general ADE. For example, there are semantic searches specializing
in certain disease targets such as the work done by Ferrajolo et al. who looked at
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drug related acute liver injury [74, 75] and Pathak et al. who mined for DDI between
cardiovascular and gastroenterology pharmaceutical products [76, 77]. Although
these disease specific searches may increase ADE detection in a certain medical
domain, this tailored approach is not scalable or translatable to other diseases. In
terms of identifying general ADEs without a target disease, Honigman et al. devel-
oped a search method using the Micromedex M2 D2 (Micromedex, Denver, Colo-
rado) medical data dictionary to semantically associate drugs and drug classes to
their negative effects and successfully showed the viability of keyword searches on
EMRs [78, 79]. Chazard et al. went a step further to demonstrate searches on a
variety of data structures such as drug administration records, laboratory results,
and other clinical records to successfully detect general ADEs within free texts
[80, 81]. These previous methods successfully identified general ADEs, but key-
word driven searches are now considered simplistic and not scalable, but the suc-
cess of even that method shows that there is great promise for modern techniques.
A further development to keyword-based semantics is a more symbolic rule-based
search that looks for semantic patterns around drug and ADE entities. These symbolic
rule-based searches allow for more information on dosage and non-standard termi-
nologies to be identified during queries and are more capable of general ADE recog-
nition [82–85]. With the rise of semantic research in the medical space, biomedical
NER and NLP has been developed to aid clinical semantic searches and there are
several open sources available, which have been adapted for ADE identification such
as MedLEE [86], MetaMap [87], cTAKES [88, 89], MedEx [90], and GATE [91]. Of
those, MedLEE and MetaMap are two of the most widely used, particularly in the
pharmacovigilance space, where researchers extract Unified Medical Language Sys-
tem (UMLS) concepts from texts using NLP based approaches. Studies have shown
the adaptability of these already available NLP systems. Banerjee et al. used grammar
rules to extract all noun entities and then used MetaMap to semantically identify the
type of entity found. This study found that medications are easily found as entities,
but the model had difficulty in extracting symptoms from laboratory test results as
they vary in length and word choices [92]. In adapting these NLP systems, each study
hit limitations of each source and in particular these tools are not very capable in
temporal resolution, which makes it difficult to distinguish drugs that cause ADEs
from those products that indicate the presence of an ADE.
This shortcoming in temporal resolution has pushed for another wave of studies.
In understanding the use of medication and mentions of diseases, the context
surrounding these entities will determine whether the drug was or was not used at a
time before or after an adverse incident. Some studies have created time stamps on
event entities and medication administration in order to exclude situations where
the adverse symptom was an already existing condition at drug administration, the
ADE was due to another drug, the drug did not cause the ADE and is mentioned as a
negative association, or the pharmaceutical product was given as treatment to the
ADE [84, 93, 94]. Although time resolution on ADE events increase the accuracy of
adverse incident detection, the vagueness and implicit tendency in the human
language to describe temporal events remain as bottlenecks [95].
A great example to illustrate a collaborative ML research on clinical EMRs is the
MADE1.0 challenge carried out in the US. This ML challenge illuminated the popu-
larity and effectiveness of deep neural networking learning in identifying negative
drug incidents, as these models counted for most submissions to the competition.
4.1 MADE1.0 challenge: pharmacovigilance on cancer patient EMRs
In the US, death due to a drug incidence is one of the top six causes of death with
around 2–5% of hospitalized patients suffering from ADEs; in each case an adverse
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quality of the training data. Therefore, with access to excellent data, EMRs can be
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Some statistical methods such as the odds ratio has been used by Leeper et al. and
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tem (UMLS) concepts from texts using NLP based approaches. Studies have shown
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rules to extract all noun entities and then used MetaMap to semantically identify the
type of entity found. This study found that medications are easily found as entities,
but the model had difficulty in extracting symptoms from laboratory test results as
they vary in length and word choices [92]. In adapting these NLP systems, each study
hit limitations of each source and in particular these tools are not very capable in
temporal resolution, which makes it difficult to distinguish drugs that cause ADEs
from those products that indicate the presence of an ADE.
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In understanding the use of medication and mentions of diseases, the context
surrounding these entities will determine whether the drug was or was not used at a
time before or after an adverse incident. Some studies have created time stamps on
event entities and medication administration in order to exclude situations where
the adverse symptom was an already existing condition at drug administration, the
ADE was due to another drug, the drug did not cause the ADE and is mentioned as a
negative association, or the pharmaceutical product was given as treatment to the
ADE [84, 93, 94]. Although time resolution on ADE events increase the accuracy of
adverse incident detection, the vagueness and implicit tendency in the human
language to describe temporal events remain as bottlenecks [95].
A great example to illustrate a collaborative ML research on clinical EMRs is the
MADE1.0 challenge carried out in the US. This ML challenge illuminated the popu-
larity and effectiveness of deep neural networking learning in identifying negative
drug incidents, as these models counted for most submissions to the competition.
4.1 MADE1.0 challenge: pharmacovigilance on cancer patient EMRs
In the US, death due to a drug incidence is one of the top six causes of death with
around 2–5% of hospitalized patients suffering from ADEs; in each case an adverse
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event can increase healthcare cost by more than $3200 [96]. Traditionally, ADE-
based pharmacovigilance is done by domain experts reading information on causal-
ity of drugs on incidents and temporal data on these events buried in the clinical
narrative. However, this manual method is not scalable and very costly. To tackle
the significant health and financial strain caused by ADEs, US research institutions
participated in a machine learning challenge to develop methods automate real-time
drug safety surveillance.
In 2018, University of Massachusetts (UMass) hosted a public NLP challenge to
detect Medication and Adverse Drug Events from Electronic Health Records
(MADE1.0). UMass provided 1092 longitudinal EHR notes, which were
anonymized from 21 cancer patients from the University of Massachusetts Memo-
rial Hospital. This EHR resource was rich with information on diseases, symptoms,
indications, medications and relationships between these entities. Three main tasks
were defined in this challenge: (1) named entity recognition (NER), which extracts
drug medications, their attributes (dosage, drug administration, duration, etc.),
disease indications, ADEs and severity, (2) relation identification (RI), which cre-
ates associations between entities, namely drug-indication, drug-ADE, and
medication-attribute relations, and (3) the joint task that assess the NLP model’s
ability to perform both NER and RI. More detailed information on the challenge can
be found at [96]. Jagannatha et al. reported that out of the 11 participating teams the
highest F1 scores in each category was 0.8290 in NER, 0.8684 in RI, and 0.6170 in
NER + RI, where the F1 score is the weighted mean of precision and recall with
ranges from 0 (worst) up to 1 (best) [97].
Within NER task models, the main task can be distilled down to tokenizing
sentences, so the tokens can then be labelled as specified entities. One common
framework for NER is the hidden Markov model (HMM), in which the system is
assumed to be the product of an unknown Markov process, which can then be
statistically modelled. Conditional random fields (CRFs) are related to HMMs,
however they differ in that, unlike HMMs, they are discriminative and classify
labels by drawing decision boundaries. Unlike HMM, CRF does not have strict
independence assumptions, which makes the model more flexible but highly com-
plex at the training stage, meaning that retraining is more involved than that of the
HMM [98]. The other main class of model is the neural network, including
convolutional neural networks (CNN) and recurrent neural networks (RNN). Long
short-term memory (LSTM) is an RNN architecture in common use for NER pur-
poses. It is designed for classifications and predictions on time series data, in which
events may occur with significant and unknown time lags in the sequence [99].
Teams involved in the MADE1.0 challenge used pre-trained embeddings to prepare
the RNNs or as feature inputs into CRF training [97]. Within NER task models in
this challenge, conditional random fields (CRF) and long short-term memory
(LSTM) were among the most frequently used frameworks [97].
In the NER category, team WPI-Wunnava scored the highest scores with
F1 = 0.8290 [97]. Wunnava et al. created a system called the Dual-Level Embed-
dings for Adverse Drug Event Detection (DLADE) to tailor to the NER task [100].
In the challenge, the NER task is limited to certain standard resources like NLTK,
Stanford NLP, and cTakes for the text pre-processing for fairness of the participants
with varying accessibility to resources. In particular, DLADE used training data and
word embeddings provided by the challenge organizer as part of the publicly
released resources. Wunnava et al. developed the system with a rule-based
tokenizer, which first tokenized sentences, and then entities within sentences,
where entities may be multiple words. The system then uses a combination of
bi-LSTM, a model that examines the text sequence in the forward and reverse
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direction to extract contextual representation, for the initial two layers responsible
for the character embedding and the word embedding but employed a linear-chain
CRF for the output layer [100]. Wunnava et al. concluded that their dual-level
character and word embedding method was a better approach compared to the
simple word-embeddings by showing a statistically significant (p < 0.05 and
p < 0.01) improvement in F1-score over multiple entities (ADE, drug, dose,
duration, etc.) [100]. However, many challenges remain when identifying
multi-worded entities, unknown abbreviations, ambiguous differentiation between
entities such as indication vs. ADE, and uses of colloquial or non-medical jargon.
In both the RI and NER-RI tasks, the process can be simplified to a classification
problem, where entity pairs are in a certain class of relationships. Research teams
used a variety of approaches to the RI tasks. As well as neural network methods,
they also used random forest classifiers, in which an ensemble of decision trees is
used and the aggregate score from the committee of decision trees decides the
output class. Support vector machines (SVM) were another popular tool; they are
optimizing algorithms that maximize the margin between the support vectors
(input data) and the decision hyperplane [101].
In the RI category, team UofUtah-Patterson score the highest scores with
F1 = 0.8684 [97]. Chapman et al. treated the RI task as a two-step supervised
classification problem and employed random forest models implemented on scikit-
learn to identify true relations between entities and to class the type of relation of
the identified pair [102]. Their source code for their models submitted to the
MADE1.0 challenge can be found on their github page [103] and details on the
model architecture is authored at [104].
In the NER + RI category, team IBMResearch-dandala obtained the highest
integrated task score (F1 = 0.6170) by harnessing bidirectional long short-term
memory (BiLSTM) and CRF neural network for medical entity recognition, and a
combined BiLSTM and attention network for relation extraction [97]. Dandala et al.
reported that NER was achieved at high accuracy (F = 0.83) and RI measured an F
score of 0.87 achieved by adding joint modelling techniques and using external
resources as extra data inputs [105]. However high the individual F score, the
overall integrated task only reached 0.6170, which suggests the need for domain
knowledge to increase accuracy in ADE detection.
The MADE1.0 challenge highlights the potential for developing pharmacov-
alidation based on ML methods with very high performance in categories such as
NER and RI, which are crucial in automated ADE extraction from EMRs. At the
time of completion of the MADE1.0 challenge, Jagannatha et al. suggested two
broad approaches to further improve the challenge’s outcomes [97]. First, to work
on designing methods that include external knowledge and unlabeled text, which
suggests the potential for unsupervised learning. The second point was to increase
efforts in higher volume, labelled corpus to train the models on, but this does not
solve the issue of algorithms failing to adapt to the messy, real world EHRs, an
inevitable encounter in commercial use. Not only did this challenge show success in
developing ML-based pharmacovigilance but also demonstrated the power of
collaboration and influenced other groups to further ADE research.
4.2 Further ML works and trends on pharmacovigilance
After the MADE1.0 challenge, an even further increase of available EHR
resources has pushed researchers to develop robust ML methods, which are inher-
ently data hungry and are predisposed to the vast amount of information provided
by clinical texts. There is a study that builds on the MADE1.0 challenge and shows
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however they differ in that, unlike HMMs, they are discriminative and classify
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plex at the training stage, meaning that retraining is more involved than that of the
HMM [98]. The other main class of model is the neural network, including
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poses. It is designed for classifications and predictions on time series data, in which
events may occur with significant and unknown time lags in the sequence [99].
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the RNNs or as feature inputs into CRF training [97]. Within NER task models in
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(LSTM) were among the most frequently used frameworks [97].
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combined BiLSTM and attention network for relation extraction [97]. Dandala et al.
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time of completion of the MADE1.0 challenge, Jagannatha et al. suggested two
broad approaches to further improve the challenge’s outcomes [97]. First, to work
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efforts in higher volume, labelled corpus to train the models on, but this does not
solve the issue of algorithms failing to adapt to the messy, real world EHRs, an
inevitable encounter in commercial use. Not only did this challenge show success in
developing ML-based pharmacovigilance but also demonstrated the power of
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After the MADE1.0 challenge, an even further increase of available EHR
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the potential for deep learning models on EHR to extract ADE measures to help
with pharmacovigilance. To try to solve the issue of under-reporting within the
FDA Adverse Event Reporting System, Li et al. employed deep learning models
and multi-task learning (MLT), in particular, hard parameter sharing, parameter
regularization, and task relation learning, for ADE detection [106]. They used the
MADE 1.0 challenge corpus, 1089 high-quality EMRs from oncology patients, for
training and validation of their model. A BiLSTM conditional random field network
was used for entity recognition and a BiLSTM-Attention network for entity relation
extraction. Li et al. reported that the deep learning produced a F1 = 0.65 for the
NER + RI task and this score was further improved through the hard parameter
sharing MLT method to F1 = 0.67, whereas the other two MLTs did not improve
performance. This study successfully built upon the findings from MADE1.0
and further improved the performance of the NER + RI task to show potential in
this area.
Some ML trends that extract medically actionable results are the popularity of
CRFs, SVMs, and random forest models. CRFs and SVMs may be used on languages
beyond English. For example, Aramaki et al. studied Japanese clinical records and
found that ADE were found in 7.7% of EHRs, out of which 59% can be automatically
extracted [107]. They used CRFs and SVMs to determine whether a detected drug
and adverse event pair was an ADE, which gave a 0.411 precision and 0.917 recall.
In contrast, random forest models have been popular due to its reliable performance
and explainability of the classifications when compared with other “black-box”
models such as SVMs. Studies by Henriksson et al. andWang et al. has used random
forests for classification of entities and identify ADEs [108, 109]. Explainability of
models is an often undervalued aspect of ML, but is valuable in the medical space.
Overall, despite the many challenges, data-driven pharmacovigilance has advanced
at an incredible pace owing to the mixture of funded challenges and developing ML
methods and shows much promise to improve healthcare.
5. Drug repurposing
It is worth mentioning that EMR data can be mined for drug repurposing indi-
cations. The idea behind drug repurposing is to see whether existing, licensed drugs
may have therapeutic benefits for conditions other than what they were designed
for. Data-driven analysis is evidently key in this regard as it can detect drug
response signals. Drug repurposing is different from the traditional drug discovery
because data-driven analysis lacks a hypothesis for the indication intended to be
treated or for the targeted biology. In other words, studies examine machine learn-
ing methods to see whether data-centric analysis can help create new hypothesis,
which may either be a completely random and biologically impossible statement or
a novel signal worthy of scientific investigation. Since drug repurposing only needs
medical data and analytics, it is a cheap and quick alternative to the traditional drug
discovery stages, which require basic research, pre-clinical research, clinical trials,
and finally the review and approval of the pharmacogenomic product. The potential
of drug repurposing is highly anticipated as this method requires big data and an
increasing amount of digitized medical records such as EHRs are made available.
It is a particularity popular topic in recent years as data-hungry machine learning
tools develop and high-throughput server less machines are made cheaper and
more accessible through cloud computing services such as AWS, Google Cloud
Platform, and Microsoft Azure, to name a few. For a more in-depth discussion of
oncology drug repurposing using data from EMRs, the reader is directed to Refs.
[110–112].
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6. Case studies in different countries
6.1 Oncology precision medicine in the US and Japan
Another anticipated but still young area is the possibility of precision medicine
using individual genomic data. Cancer is an accumulation of genetic alternations
within the cell and, oncogenetic or cancer-developing genes are called driver genes.
Identifying driver genes within the genome and delivering the optimal treatment to
such cancer-related targets is known as precision medicine. However, there is a vast
amount of data within even a single individual’s genome and finding variants
becomes the key challenge in order to pinpoint the best pharmacological treatment
for an individual based on their genetic background. Harnessing the combination of
data from already existing genomic variant databases and historic clinical data from
EMRs, researchers aim to find such cancer-related variations and driver genes. In a
few countries, studies revolving around the interaction between the genome and
cancer treatment drugs have gained much attention.
In the US, the NCI-MATCH trials, a phase II precision medicine cancer trial
initiated in 2015, showed negative results in precision medicine and concluded that
the genomic data did not correlate with any significant results in drug variation [113].
This low statistical significance is not surprising from a data mining perspective as
numbers of patients accrued for each of the +40 arms within this study were very
small, ranging from 4 to 70 people [114]. Furthermore, the majority of the recruited
patients (62.5%) had rare tumors that were not the four most common cancers
(breast, colorectal, non-small cell lung, and prostate) [115]. This diversity in cancer
types may have introduced confounding factors that affected the statistics of the trial.
In Japan, starting 2018, the Japanese Ministry of Welfare and Labor is sponsor-
ing a panel trial on partial genomic testing for oncogenetic variation. This partial
genomic testing aims to reveal the best and optimal cancer drug treatment on the
individual based on their genetic variations. In 2019, 11 Cancer Genomic Core
hospitals and central medical institutions were selected to start collecting genomic
data and clinical data in preparation for a nation-wide genomic panel trial [116].
Under the funding of the country’s National Health Insurance, it strives to predict
cancer patient treatment responses based on their partial genome data.
There is a complex interplay between intricate biological systems and the NCI-
MATCH trial illustrates that precision medicine methods need much more devel-
opment before they can pin point a certain genomic sequences to the onset of
cancer. Some have voiced pessimistic views that this precision medicine task is not
feasible and overly-costly at this point in time [117]. However, precision medicine is
in the horizon. With more data samples, similar research can yield more insight into
precision medicine.
In the future, individual whole genome data may be regular practice to include
as part of EHRs in order to help deliver the optimal cancer treatment. Currently,
there is a bottleneck where there are not enough types of commercialized cancer
drug against which to test the genomic variation and to find which treatment works
best on an individual. As all aspects of EMR-driven research converge, more med-
ical data will be collected, stored and published. This will lead to already available
commercial drugs undergoing more comprehensive pharmacovigilance and real-
world data will effectively drive new drug research. Therefore, it is likely that more
types of cancer pharmacology products will become available. Furthermore, the
efforts in using ML to mine EMRs may lead to AI predicting cancer patient disease
trajectories. The trend toward using NLP to extract relevant information from
unstructured EMRs and harnessing deep learning could help reproduce drug-
related clinical decision making carried out by medical professionals [110, 111].
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6. Case studies in different countries
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6.2 Open sourced resources using EMRs in the UK
In England, there are trusts and clinical commissioning groups who oversee how
providers such as hospitals and clinics use their resources. A problematic bottle-
necks are that different trusts use different EMR platforms, which have little
national standardization and do not allow for interprovider access, which especially
cause problems when patients switch trust domains.
A remedy to this lack of standardization is the use of open sourced, publicly
available resources including de-identified EMR data. Evident from the data-
hungry nature of ML methods and their demonstrated need in scalable phenotype-
genotype association research, publicly available EMRs play a crucial role in the
advancement of this field. Some notable open sourced data sources and tools
include the UK Biobank, where 50,000 individuals (aged 40–69) were recruited
from England, Wales, Scotland [118]. The biobank includes detailed phenotype and
genotype data, lifestyle surveys, pathophysiological data and imaging data on each
individual [118]. Once a centralized, open-sourced EMR data is made available, the
next step is the development of platforms that interact with said resource.
The CArdiovascular disease research using LInked Bespoke studies and
Electronic health Records (CALIBRE) portal offers freely available software that
provides tools and algorithms, which is research ready and have already extracted
variables extracted from various EMRs. Phenotype algorithms contained in CALI-
BRE, which employs data from the UK Biobank, are rule based and use phenotype
validations like etiological, which use external published evidence to support the
algorithm; prognostic, which evaluate the event’s similarity to already existing
scientific knowledge; case-note review, which compares the positive predictive
value (PPV) and the negative predictive value (NPV) against a gold standard like a
clinician’s notes; cross-EHR-source concordance, which checks the consistency in
findings across other EHRs; genetic, which double checks whether there is consis-
tency in genetic associations and external populations, which validates by compar-
ing results to similar studies done in different countries [119]. These phenotype
validations, and standardized validation systems in general, are crucial in charac-
terizing ML algorithms since variations in training data can alter outputs even when
the ML method does not change. As open source data proliferates, freely available
validation methods may grow in a parallel manner.
In addition, openEHR is also a platform that pools industry specifications, clin-
ical models and software that are intended for data science solutions in the
healthcare space. OpenEHR was founded in 2003 by an international non-profit
organization and maintained by individuals around the world [120]. In 2017, the
UK became the first country to introduce infrastructure from openEHR into the
main healthcare system to streamline phenotype data collection and vendor-neutral
clinical data storage from all the trusts participating in the 100,000 genome project
[121]. Newly coordinated pipelines of additional EHR data such as those from the
NHS will increase the through-put in openEHR, which in turn develops the best
tools to handle big data, which then completes the circle by promoting the use of an
ever increasing amount of medical data. This data-driven vision, in which an open
community encourages cooperation by open access and pools existing knowledge
around EMR-driven healthcare, will certainly accelerate the evolution of ML
methods.
6.3 EHR databases in Estonia
Estonia is one of the world-leading countries in terms of the nationwide system-
atization of digital medical documentation and the high quality of EHRs. By the end
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of 2014, Estonia had centralized EHR access via a single portal, where over 99% of
the population could view their own medical records [122]. This is a remarkable
statistic but more notably, Estonia’s EHR vision had already been initiated in 2007
when the Estonian Genome Center of the University of Tartu established the foun-
dations of the Estonian biobank, which includes 52,000 participants worth of
genomic and health data representing about 5% of the adult population of Estonia
[123, 124]. Seven years later, the Estonian biobank was linked to the Estonian
National Health Information System (ENHIS), which included 44,000 inpatient
and 212,000 outpatient medical summaries, EHRs and digital prescriptions from all
medical service providers [124]. Since the merge, the databases have been updated
through periodic additions of EHRs. By 2016, Estonia was ranked within the top
three countries to have the best capability of effectively deploying, operating,
maintaining and supporting statistical and medical research using EHRs by the
HCQI Survey of Electronic Health Record System Development and Use [125]. This
extensive data collection was made possible by the national electronic identification
card (ID-card) as this chipped ID-card was made compulsory and became part of
the national infrastructure [126]. As result of these efforts, Estonian EHR databases
are highly valuable sources for researching EHR-driven methods.
An ADE study using Estonian EHR databases by Tasa et al. demonstrates the
database’s ability to conduct high impact, translational research. The whole-genome
sequencing (WGS) data of +2200 Estonian Biobank participants and the EHRs of
the sequenced individuals were taken from Health Insurance Fund Treatment Bills,
Tartu University Hospital and North Estonia Medical Center databases [127]. EHRs
were mined using ICD codes to find ADE occurrences and a mixture of the ICD and
manual verification methods was used to identify associations between genetic
polymorphisms and ADEs [127]. Associations between genetic variations and drug
responses are vital in advancing personalized drug treatment, which is also referred
to as pharmacogenomics. Important genes within the study of pharmacogenomics
are called pharmacogenes. The study reported 29.1  106 novel variants. To priori-
ties genetic analysis, Tasa et al. compiled 1314 loss-of-function, missense, and
putative high-impact variants in promoter regions of 64 pharmacogenes [127]. They
reported that 80.3% of the variants were rare (MAF < 1%), and this high propor-
tion suggests that gene variation is crucial in understanding pharmacogenomics
[127]. Next, the study combined EHRs to the genetic data to extract 1187 partici-
pants with potential ADEs. As a validation, Tasa et al. replicated pharmacogenetic
associations between the CYP2D6*6 allele and tramadol related ADEs (p = 0.035;
odds ratio [OR] = 2.67) and between the same allele and amitriptyline induced
ADEs (p = 0.02; OR = 6.0) [127]. In addition, they replicated four more validated
pharmacogenetic associations and discovered nine independent, new gene associa-
tions with ADEs in a group of individuals divided by drug prescriptions. Notably,
they identified a new association between CTNNA3 and myositis for oxicam-
treated participants. This study demonstrated the viability of layering EHR and
WGS data at a population-based scale in order to advance pharmacogenomic.
Beyond the scope of this study, identifying pharmacogenomic associations relies
more and more on big-data driven projects that looks for genetic variants in differ-
ent communities and highlights variants that can be medically targeted to advance
healthcare [128–130].
In summary, Estonia’s world-leading efforts to integrate EHRs as a method to
feedback data to basic research is a possible future of data-driven healthcare medi-
cine, which focuses on digitization with a vision for translational biomedical
research. Estonia created a data-mining driven database, in which different aspects
of the EHRs are linked an ID-card. Although different implementations will be
necessary to replicate Estonia’s rich and accessible EHR database, Estonia sets a
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precedent to the rest of the world and demonstrates the positive biomedical impli-
cations of such well-organized databases of rich EHR sources.
7. Conclusion
In the past decade, EMRs have become a vital data source in advancing
healthcare. In the context of AI, EMRs are highly attractive because there is a vast
quantity of rich and variable data types which cannot be processed manually. In the
context of biomedical research, EMRs have exciting potential for impactful medical
applications, but only if actionable biomedical conclusions can be accurately
extracted. In the clinical context, EMRs were introduced to replace the traditional
paperwork but were not intended for data-mining research; they were never
intended to perform anything that paper documents were not designed to do.
Having been introduced in a time before the phrase “machine learning”, digitiza-
tion of medical records has far surpassed the imagined benefits of this transition.
Envisioned as a direct replacement of paper records, EMR history has been fraught
with difficulties: implementation costs, workflow disruptions and cyber-attacks to
name a few. Harnessing EMRs for research purposes marks a milestone in transla-
tional biomedical medicine. It is the intersection of basic science, data-driven
methods and clinical research where healthcare is transformed: every hospital visit
improving human knowledge of diseases one EMR at a time.
The chapter started with a discussion of the EMRs definition, given that they
have been introduced with little regard to compatibility with other existing EMR
systems. There are many issues that hospitals can encounter when transitioning
from paper records to electronic, however, efficiency gains from digitizing records
are significant even without the use of big data. To exemplify what can be achieved
by applying ML techniques to the data contained in EMRs, three key biomedical
research areas were considered: phenotype-genotype association, clinical trials for
new drug and pharmacovigilance studies.
Adopting high throughput data strategies into clinical drug trials can reduce the
inefficiencies that often plague such trials. EMR mining using already existing
systems can improve trial recruitment, but care must be taken to reduce potential
bias in patient selection. Additionally, EMRs can be employed to continue data
collection after the trial formally ends, a great benefit for financially limited trials,
or they can even be treated as a primary data source as long as the data is considered
to be of satisfactory standard.
After a drug undergoes clinical trials and is approved for market launch, phar-
maceutical companies are encouraged to continue drug surveillance to detect, eval-
uate and prevent adverse drug events, which create medical and financial burdens.
Such surveillance can be cheaply and efficiently done by continually mining EHR
narratives. In the context of ADE detection, keyword searches are considered to be
too simplistic and to lack scalability. Despite this, they still show some success in
small scale studies, serving as a proof of concept that harnessing EHRs with more
advanced processes could greatly benefit pharmagovigilance. However, NLP
based-approaches performed much better than keyword-based methods and an
excellent case study on NLP-driven pharmacovigilance is the MADE1.0 challenge.
By bringing together multiple institutions, the challenge succeeded in developing
high performing ML methods, including frequent usage of CRFs and LSTM,
for the NER and RI tasks. This initiative promoted further works to create even
more robust ML methods to extract ADEs from oncology EMRs and reflects the
overall trend in the pharmacovigilance space toward CRF, SVM and random forest
models.
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With this vital context on how ML methods are used to analyze the data within
EMRs, some selected international case studies on EHR-driven research were
presented. Firstly, on the outlook of oncology precision medicine: NCI-MATCH
trials in the US concluded that no drug response is correlated with genomic data,
whilst preparation for partial genomic testing for oncology drugs is underway in
Japan. Despite negative results nation-wide initiatives may spur on the collective
development of drug research. Secondly, UK-based open source resources for EHR
manipulation, were discussed, both large consolidated datasets and freely available
tools, algorithms and platforms. This vision for open sourced resources is a valuable
digital environment in which to pool technical knowledge, especially because of the
translational and multi-disciplinary dimension of extracting medically meaningful
conclusions from EHRs. Thirdly, the EHR databases set up in Estonia were
reviewed, which are both nationally extensive and high quality. This set up the
groundwork to deploy a population-based WGS and EHR combinatory study con-
ducive to pharmacogenetic advances. Estonia’s databases demonstrate the power of
harnessing data from EHR for the progress of healthcare.
In contrast to the recent advancement and current interest in clinically-applied
deep learning, there is still no definitive evidence of a model with predictive per-
formance that is similar to a human physician [131]. As of 2020, there is no imme-
diate vision in which AI can fully automate drug research pipelines or
independently diagnose and provide subsequent health care procedures making
researchers and clinicians obsolete. As we have seen, however, there is ample
evidence that EMRs will increasingly play a vital role in all aspects of the drug
research arc from fundamental science and clinical trials to post-market surveil-
lance.
Conflict of interest
The author declares no conflict of interest.
Abbreviations
EMR electronic medical record
EHR electronic health record
NHS National Health Services
ML machine learning
DDI drug–drug interaction
ADE adverse drug event
ICD International Classification of Disease
WHO World Health Organization
ICD-CM ICD Clinical Modification
SNP single nucleotide polymorphism
CNN convolutional neural network
I/E criteria inclusion and exclusion criteria
NLP natural language processing
HMM hidden Markov model
CRF conditional random fields
RNN recurrent neural networks
LSTM long short-term memory
BiLSTM bidirectional long short-term memory
NER named entity recognition
69
Electronic Medical Records and Machine Learning in Approaches to Drug Development
DOI: http://dx.doi.org/10.5772/intechopen.92613
precedent to the rest of the world and demonstrates the positive biomedical impli-
cations of such well-organized databases of rich EHR sources.
7. Conclusion
In the past decade, EMRs have become a vital data source in advancing
healthcare. In the context of AI, EMRs are highly attractive because there is a vast
quantity of rich and variable data types which cannot be processed manually. In the
context of biomedical research, EMRs have exciting potential for impactful medical
applications, but only if actionable biomedical conclusions can be accurately
extracted. In the clinical context, EMRs were introduced to replace the traditional
paperwork but were not intended for data-mining research; they were never
intended to perform anything that paper documents were not designed to do.
Having been introduced in a time before the phrase “machine learning”, digitiza-
tion of medical records has far surpassed the imagined benefits of this transition.
Envisioned as a direct replacement of paper records, EMR history has been fraught
with difficulties: implementation costs, workflow disruptions and cyber-attacks to
name a few. Harnessing EMRs for research purposes marks a milestone in transla-
tional biomedical medicine. It is the intersection of basic science, data-driven
methods and clinical research where healthcare is transformed: every hospital visit
improving human knowledge of diseases one EMR at a time.
The chapter started with a discussion of the EMRs definition, given that they
have been introduced with little regard to compatibility with other existing EMR
systems. There are many issues that hospitals can encounter when transitioning
from paper records to electronic, however, efficiency gains from digitizing records
are significant even without the use of big data. To exemplify what can be achieved
by applying ML techniques to the data contained in EMRs, three key biomedical
research areas were considered: phenotype-genotype association, clinical trials for
new drug and pharmacovigilance studies.
Adopting high throughput data strategies into clinical drug trials can reduce the
inefficiencies that often plague such trials. EMR mining using already existing
systems can improve trial recruitment, but care must be taken to reduce potential
bias in patient selection. Additionally, EMRs can be employed to continue data
collection after the trial formally ends, a great benefit for financially limited trials,
or they can even be treated as a primary data source as long as the data is considered
to be of satisfactory standard.
After a drug undergoes clinical trials and is approved for market launch, phar-
maceutical companies are encouraged to continue drug surveillance to detect, eval-
uate and prevent adverse drug events, which create medical and financial burdens.
Such surveillance can be cheaply and efficiently done by continually mining EHR
narratives. In the context of ADE detection, keyword searches are considered to be
too simplistic and to lack scalability. Despite this, they still show some success in
small scale studies, serving as a proof of concept that harnessing EHRs with more
advanced processes could greatly benefit pharmagovigilance. However, NLP
based-approaches performed much better than keyword-based methods and an
excellent case study on NLP-driven pharmacovigilance is the MADE1.0 challenge.
By bringing together multiple institutions, the challenge succeeded in developing
high performing ML methods, including frequent usage of CRFs and LSTM,
for the NER and RI tasks. This initiative promoted further works to create even
more robust ML methods to extract ADEs from oncology EMRs and reflects the
overall trend in the pharmacovigilance space toward CRF, SVM and random forest
models.
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With this vital context on how ML methods are used to analyze the data within
EMRs, some selected international case studies on EHR-driven research were
presented. Firstly, on the outlook of oncology precision medicine: NCI-MATCH
trials in the US concluded that no drug response is correlated with genomic data,
whilst preparation for partial genomic testing for oncology drugs is underway in
Japan. Despite negative results nation-wide initiatives may spur on the collective
development of drug research. Secondly, UK-based open source resources for EHR
manipulation, were discussed, both large consolidated datasets and freely available
tools, algorithms and platforms. This vision for open sourced resources is a valuable
digital environment in which to pool technical knowledge, especially because of the
translational and multi-disciplinary dimension of extracting medically meaningful
conclusions from EHRs. Thirdly, the EHR databases set up in Estonia were
reviewed, which are both nationally extensive and high quality. This set up the
groundwork to deploy a population-based WGS and EHR combinatory study con-
ducive to pharmacogenetic advances. Estonia’s databases demonstrate the power of
harnessing data from EHR for the progress of healthcare.
In contrast to the recent advancement and current interest in clinically-applied
deep learning, there is still no definitive evidence of a model with predictive per-
formance that is similar to a human physician [131]. As of 2020, there is no imme-
diate vision in which AI can fully automate drug research pipelines or
independently diagnose and provide subsequent health care procedures making
researchers and clinicians obsolete. As we have seen, however, there is ample
evidence that EMRs will increasingly play a vital role in all aspects of the drug
research arc from fundamental science and clinical trials to post-market surveil-
lance.
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Cancer remains a leading cause of morbidity and mortality around the 
world. Despite significant advances in our understanding of the pathology of 
the disease, and the substantial public and private investment into treatment 
development, late-stage patients often exhaust therapeutic options. Indeed, in the 
US alone, there were >1.7 million new cancer diagnoses and >600,000 cancer-
associated deaths in 2019. As biology in general and cancer research in particular 
become ever richer in data, we explore the role of machine learning (ML) in 
changing the cancer drug development landscape. In the first part of this analy-
sis, we focussed on ML for target identification and drug design. We discussed 
the growing need for ML-based analysis as we enter an age of clinical -omic 
data and provided a primer to ML-based techniques for the non-statistician/
mathematician. In this chapter, we will explore the problem of tumour hetero-
geneity together with the role of ML in the discovery and development of cancer 
biomarkers and for clinical trial design. We end with a brief consideration of the 
economics of personalised cancer treatment.
Keywords: machine learning, biomarker discovery, oncology
1. Introduction
The cancer therapeutic market was estimated to reach $98.9 billion USD in 
2018, with a compounded annual growth rate of 7.7%. The cost of individual cancer 
drugs is similarly rising at a rate well above inflation. Ipilimumab, for example, was 
priced at $120,000 on launch, despite providing an overall survival benefit of just 
4 months. More generally, if we correct for inflation and increased survival benefit, 
the average cost of new cancer therapies increased at $8500 per year from 1995 to 
2013 [1]. If we continue along this path of yearly incremental price increases in new 
therapies approved, while not seeing associated health benefits, public opinion may 
begin to further question the moral standing of the pharmaceuticals industry [2].
However, there exists a profound conflict at the heart of the pharmaceutical 
industry. The efficiency of the drug development process is falling, leading to 
higher costs to be recovered per approved drug. At the same time, research into 
the biological underpinnings of disease are making it clear that pathologies once 
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However, there exists a profound conflict at the heart of the pharmaceutical 
industry. The efficiency of the drug development process is falling, leading to 
higher costs to be recovered per approved drug. At the same time, research into 
the biological underpinnings of disease are making it clear that pathologies once 
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thought of as a single disease are incredibly heterogeneous in nature [3]. In such 
cases, personalised medicine may be the best method for treating diseases like 
cancer, which could shrink the available markets for each individual drug.
Cancer has been known to be heterogeneous since experimental pathologists 
began to study tumour in detail at the turn of the nineteenth century. First, dif-
ferences in cellular morphology were described [4], followed by surface marker 
expression [5] and later growth rates [6] and response to therapy [7]. Recently, high 
throughput profiling of DNA, RNA and protein expression in human cancers has 
helped uncover the true scale of this diversity [8]. For example, early work in breast 
cancer enabled stratification of patients based on the presence of oestrogen receptor 
alpha (ERα), which led to the successful targeting of tamoxifen for ERα-positive 
(ERα+) patients [9]. More recent work has enabled comprehensive stratification of 
breast and other cancers [8, 10]. In breast cancer, a 50-gene signature (PAM50) can 
now be used to stratify patients into four intrinsic subtypes (luminal A, luminal B, 
HER2-enriched and basal-like) with distinct clinical outcomes [11, 12]. Taking this 
stratification effort further, researchers at the University of Cambridge integrated 
copy number (CN) data with transcriptomics to uncover 11 distinct Integrative 
Clusters of breast cancer [10].
Patient stratification improves the taxonomy of cancer, which is the initial step 
towards better understanding of the drivers of tumour growth and consequently 
towards improved precision medicines [13]. However, as our appreciation of strati-
fication and heterogeneity increases, the challenge for pharmaceutical companies is 
to develop an economic model that enables them to provide personalised treatment 
to patients at a sustainable cost.
In practice, the efficiency of the drug development process has been dropping for 
a number of years. The average time for taking a new therapeutic to market is often 
stated as 10 years; however, in reality this often ranges from 3 to 20 years [14]. If we 
consider the average cost of developing a new drug, in 2014 the Tufts Center for the 
Study of Drug Development estimated this at $2.6 billion [14]. A large proportion of 
this cost is associated with a 90% attrition rate in Phase I–Phase III trials; $2.6 billion 
covers the nine failures for every one approved drug. However, on an individual 
pharmaceutical company basis, the picture can get even worse. AstraZeneca has 
recently spent an average of $11 billion per registered drug [15]. Considering (1) high 
upfront costs, (2) high risk of overspending and failure and (3) the possibility of very 
long development time frames, pharmaceutical companies must price in the cost of 
capital to their calculation of drug price. $11bn spent over 20 years, when that money 
could have been generating 10% annual returns in a stock market index, means that 
it is not uncommon for pharmaceutical companies to wish to generate many tens of 
billions of dollars in lifetime drug sales.
Thankfully, we are entering a world of big data biology and techniques like 
machine learning (ML) can help us increase efficiency in the drug discovery and 
development process. In the first part of our analysis, Applications of Machine 
Learning in Drug Discover I: Target Discovery and Small Molecule Drug Design, we 
discussed how molecular target identification and small molecule lead optimisation 
can be improved though computational techniques. However, early development 
accounts for a relatively small proportion of the total costs associated with drug 
development. Phase III trials alone, for example, on average cost over $100 million 
[16]. If we are to improve efficacy in drug development, we must improve late-stage 
clinical trials and stratification of patients post market approval.
In this chapter, we discuss how ML is allowing high personalisation of treatment 
strategies.
First, we consider the causes of tumour heterogeneity, its genomic underpin-
nings and the latest research into patient stratification. Next, we consider the 
85
Applications of Machine Learning in Drug Discovery II: Biomarker Discovery, Patient…
DOI: http://dx.doi.org/10.5772/intechopen.93160
discovery of predictive biomarkers for patient stratification in clinical trials and 
post market approval. Thankfully, the same techniques we use to improve trials 
can also be used to fulfil precision oncology and deliver better patient outcome. 
As the number of drugs increases, we may also be able to use repurposing and 
repositioning to make up for lost revenues from personalisation and increase 
profitability of old drugs. Lastly, we discuss computational pathology as one of 
the most obvious early uses of ML in cancer diagnosis. We end with a forward-
looking discussion of the future of precision oncology and what this means for the 
pharmaceutical industry.
2. The causes and consequences of tumour heterogeneity
Cancer is a disease of the genome [13, 17]. Through the normal course of ageing, 
cells acquire somatic mutations as a consequence of intrinsic processes or the expo-
sure to exogenous mutagens. These changes in the cellular DNA can directly influ-
ence the structure and function of transcribed proteins, and, in some cases, confer 
a survival advantage (‘fitness’), on the cell. Peter Nowell postulated in 1976 that 
heterogeneous fitness in a niche could lead to Darwinian competition and selection 
among clones [18], and that successive clonal expansion was the origin of a tumour. 
This theory was supported by early evidence that genetic aberrations were the cause 
of a tumour’s phenotypic traits [19] and more recent genomics research [8, 20].
It is now accepted that tumours harbour various layers of genomic complexity 
and the resultant heterogeneity can have profound effects on disease progression. 
Moreover, genomic instability, which fuels the diversity essential for any Darwinian 
process is intertwined with both the development and maintenance of tumour 
heterogeneity, and the clinical consequences thereof [21, 22]. Indeed, both inter- 
and intratumour heterogeneity can be explained by the genomic instability inherent 
to a tumour’s biology and the sequential acquisition of driver mutations. Though 
changes in a tumour’s microenvironment (e.g. increase in inflammation or immune 
cell infiltrate) or epigenetic regulation (e.g. MLH1 promotor methylation in micro-
satellite unstable CRC) are undoubtedly required to transform a clonal expansion of 
benign cells into a malignancy [17, 23].
Interestingly, a series of studies over the last couple of years from the Sanger 
Institute have shed new light onto the clonal origins of human cancers. First, in 
2013, it was shown by Alexandrov and colleagues that distinct mutational processes 
(e.g. exposure to tobacco smoke and exposure to ultraviolet light) led to distinct 
mutational signatures in human cancer [24]. Next, Martincorena and colleagues 
showed that outwardly normal human skin not only had traces of these mutational 
signatures but in some cases harboured daughter cells of past clonal expansion 
events [25]. This was later corroborated in other tissues including the oesophagus 
[26]. It was not until 2020, when a study by Colom et al. [27] was published that 
we had any insight into what differentiated these clonal populations from bona 
fide premalignant clones. In an elegant study, the authors showed that when an 
expanding mutant clone occupied the same niche as one of similar ‘fitness’, each 
clone’s proliferative advantage decreases, and the niche reverts towards balanced 
proliferation and differentiation that characterises normal tissue homeostasis [27]. 
Such studies highlight how far we have come in our understanding of the causes 
of tumour heterogeneity since Peter Nowell’s seminal work in 1976 [18], and how 
much we may still have to learn.
Tumour heterogeneity has a very real clinical consequence: chemotherapy and 
targeted agents do not have uniform efficacy. This holds across malignancies of 
different subtype and even between cells of the same tumour [28]. As mentioned, 
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for example, breast cancers can be clinically stratified based on heterogeneity in the 
presence of hormone receptors (ERα/PR) and HER2, the presence of which define 
treatment recommendation.
As the cost of DNA sequencing and other high throughput profiling technologies 
continues to drop, our taxonomy of cancer is becoming ever more nuanced [29]. 
Early genomic classifications based on single parameters have evolved into complex 
integrative methodologies designed to capture heterogeneity across multiple levels, 
such as the 11 Integrative Clusters of breast cancer defined by Curtis et al. [10]. 
Indeed, as multi-parameter stratification improves, we are beginning to stratify 
both breast [30] and colorectal cancers [31] based on immune infiltrates and immu-
nogenomic signatures. Such classification will have a direct influence on our use of 
novel immunotherapies [32].
A second clinical consequence of tumour heterogeneity is in the development of 
resistance to targeted therapies [33]. Typically, this results from the outgrowth of 
specific pre-existing populations within a tumour rather than from de novo evolu-
tion [3, 34]. It therefore stands to reason that the higher the more pronounced the 
clonal heterogeneity in a tumour, the wider the pool from which drug-resistant 
clones may evolve [3]. There exists a fine balance within a tumour between waves of 
clonal expansion by hyper-fit cells, and the maintenance of subclones from which 
resistance can develop. Such an association between tumour heterogeneity and drug 
resistance has been noted in ovarian [35] and oesophageal [21] cancers.
Evolution occurs when spatial or temporal selective pressure is applied to popu-
lations with differential fitness, which is itself underwritten by heritable features. 
Drug treatment induces evolution of clonal populations within a tumour, which can 
provide a niche into which resistant clones can grow. Counterintuitively, however, 
anti-cancer therapies do not necessarily lead to a reduction in overall clonal diver-
sity or tumour genomic heterogeneity [36]. For example, in a study of 47 breast 
cancer patients, strong changes in cellular phenotype were seen before and after 
chemotherapy, with no corresponding changes in genetic diversity, implying that a 
shift in the epigenomic landscape had resulted from exposure to chemotherapeutic 
selective pressures [37]. In addition, several studies have identified the role of 
transient epigenetic states in the resistance to cancer therapy. For example, Sharma 
et al. consistently detected a subpopulation of cells with >100-fold reduced erlotinib 
sensitivity across a panel of eight cancer cell lines [38]. The authors found that this 
drug-tolerant phenotype was transiently acquired and lost by individual cells within 
the population in a process linked to IGF-1 signalling and histone demethylase-
mediated chromatin remodelling [38].
Genomic instability is the driving force of tumour heterogeneity. Although 
intratumour heterogeneity is linked with poor patient outcome, genomic instabil-
ity is only associated with poor prognosis to a point. A recent study examined 
1000 treatment-naïve tumours and found that the total number of genomic clones 
had significant association with overall survival [39]. However, the authors note 
that high clone number was only indicative of survival up to a maximum clonal 
diversity of four. Indeed, a diversity of more than four subclones was associated 
with longer overall survival [39, 40]. The authors used a 10% cell frequency cut 
off in their studies, yet, they are rare clonal populations which are thought to have 
evolved most recently [41] and may be more associated with resistance to targeted 
therapy [42–44]. This could go some way to explaining the apparent discrepancy 
seen between this, and other studies.
Hence, both intra- and intertumour heterogeneity have profound clinical conse-
quences in terms of differential response to therapy, development of drug resistance 
and disease progression. Beyond stratified medicine, a better understanding of 
the causes and consequences of clonal heterogeneity within a tumour will allow a 
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deeper understanding of the emergence of drug resistance. New analysis tools such 
as the REVOLVER package could empower researchers to stratify patient groups 
based on the basis of how their tumour evolved [45, 46] and perhaps allow predic-
tion of a tumour’s evolutionary trajectory and a corresponding therapeutic strategy. 
Moreover, a greater understanding of genomic instability and its contribution to 
treatment resistance, and sensitivity, is needed.
3. Predictive biomarkers for personalised cancer care
As discussed, late-stage clinical trials are one of the most expensive, in terms 
of resource spending and time, in the total drug development lifecycle. Although 
many predictive models are mentioned in the literature, few have been validated 
in clinical trials. Various limitations around model performance, validation and 
dataset availability are currently limiting translation [47].
As one of the key clinical endpoints, drug sensitivity or efficacy would be one of 
the most important metrics to predict from preclinical data in order to improve the 
clinical success rate of drugs. In terms of real-world evidence, a handful of groups 
have now published case studies where biomarkers derived from ML-driven predic-
tive modelling have played a central role in the discovery and development of new 
therapeutic agents [48–50].
In one such case study, Li and colleagues built drug sensitivity models from 
cancer cell lines treated with erlotinib [an EGFR protein kinase inhibitor approved 
for NSCLC patients with activating mutations: exon 19 deletion (del19) or exon 21 
(L858R) substitution] and sorafenib (a non-specific kinase inhibitor approved for 
advanced renal cell carcinoma) [48, 51]. Models were then used to stratify patients 
in the BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung 
Cancer Elimination) clinical trial [48, 52], with identified biomarkers backwards 
justified with knowledge of the mechanism of action of each kinase inhibitor drug. 
Crucially, combining biomarker-driven adaptive trials such as BATTLE with basket 
trials (tissue of origin agnostic), we can move towards truly data-driven person-
alised oncology. Indeed, the FDA approved pembrolizumab [a programmed cell 
death 1 (PD1) inhibitor] in 2017 for tumours of a specific genetic background rather 
than site of origin [53]. This is the first instance of a cross-indication approval based 
solely on a genetic biomarker and highlights the need for further study in drug 
repurposing and data-driven biomarker discovery for the future of genomic cancer 
medicine.
To address some barriers to model translation into clinical practice, several 
community efforts have been attempted to help evaluate and standardise ML-based 
models. For example, the FDA launched a validation initiative for benchmarking 
ML models for predicting clinical endpoint from RNA expression data [54]. In this 
Microarray Quality Control II (MAQC II) initiative, teams were tasked with gener-
ating predictive models for several clinical endpoints in a multiple myeloma dataset. 
The most effective method used a univariant Cox regression model to identify a 
gene signature associated with individuals at high risk of low overall survival [55]. 
Though the authors note that arbitrary cut offs in overall survival may have limited 
effectiveness (24 months was the cut off for high risk, despite overall survival being 
a continuous variable suited to Cox modelling). A similar approach can be taken 
with breast cancer gene expression data to predict overall survival as a continuous 
variable [46]. Interestingly, the multiple myeloma prognostic biomarker developed 
was later independently validated by several groups [56–58].
The NCI-DREAM challenge was a similar community-driven effort to provide 
standardised datasets for benchmarking ML models [59]. In this case, models were 
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for example, breast cancers can be clinically stratified based on heterogeneity in the 
presence of hormone receptors (ERα/PR) and HER2, the presence of which define 
treatment recommendation.
As the cost of DNA sequencing and other high throughput profiling technologies 
continues to drop, our taxonomy of cancer is becoming ever more nuanced [29]. 
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such as the 11 Integrative Clusters of breast cancer defined by Curtis et al. [10]. 
Indeed, as multi-parameter stratification improves, we are beginning to stratify 
both breast [30] and colorectal cancers [31] based on immune infiltrates and immu-
nogenomic signatures. Such classification will have a direct influence on our use of 
novel immunotherapies [32].
A second clinical consequence of tumour heterogeneity is in the development of 
resistance to targeted therapies [33]. Typically, this results from the outgrowth of 
specific pre-existing populations within a tumour rather than from de novo evolu-
tion [3, 34]. It therefore stands to reason that the higher the more pronounced the 
clonal heterogeneity in a tumour, the wider the pool from which drug-resistant 
clones may evolve [3]. There exists a fine balance within a tumour between waves of 
clonal expansion by hyper-fit cells, and the maintenance of subclones from which 
resistance can develop. Such an association between tumour heterogeneity and drug 
resistance has been noted in ovarian [35] and oesophageal [21] cancers.
Evolution occurs when spatial or temporal selective pressure is applied to popu-
lations with differential fitness, which is itself underwritten by heritable features. 
Drug treatment induces evolution of clonal populations within a tumour, which can 
provide a niche into which resistant clones can grow. Counterintuitively, however, 
anti-cancer therapies do not necessarily lead to a reduction in overall clonal diver-
sity or tumour genomic heterogeneity [36]. For example, in a study of 47 breast 
cancer patients, strong changes in cellular phenotype were seen before and after 
chemotherapy, with no corresponding changes in genetic diversity, implying that a 
shift in the epigenomic landscape had resulted from exposure to chemotherapeutic 
selective pressures [37]. In addition, several studies have identified the role of 
transient epigenetic states in the resistance to cancer therapy. For example, Sharma 
et al. consistently detected a subpopulation of cells with >100-fold reduced erlotinib 
sensitivity across a panel of eight cancer cell lines [38]. The authors found that this 
drug-tolerant phenotype was transiently acquired and lost by individual cells within 
the population in a process linked to IGF-1 signalling and histone demethylase-
mediated chromatin remodelling [38].
Genomic instability is the driving force of tumour heterogeneity. Although 
intratumour heterogeneity is linked with poor patient outcome, genomic instabil-
ity is only associated with poor prognosis to a point. A recent study examined 
1000 treatment-naïve tumours and found that the total number of genomic clones 
had significant association with overall survival [39]. However, the authors note 
that high clone number was only indicative of survival up to a maximum clonal 
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with longer overall survival [39, 40]. The authors used a 10% cell frequency cut 
off in their studies, yet, they are rare clonal populations which are thought to have 
evolved most recently [41] and may be more associated with resistance to targeted 
therapy [42–44]. This could go some way to explaining the apparent discrepancy 
seen between this, and other studies.
Hence, both intra- and intertumour heterogeneity have profound clinical conse-
quences in terms of differential response to therapy, development of drug resistance 
and disease progression. Beyond stratified medicine, a better understanding of 
the causes and consequences of clonal heterogeneity within a tumour will allow a 
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deeper understanding of the emergence of drug resistance. New analysis tools such 
as the REVOLVER package could empower researchers to stratify patient groups 
based on the basis of how their tumour evolved [45, 46] and perhaps allow predic-
tion of a tumour’s evolutionary trajectory and a corresponding therapeutic strategy. 
Moreover, a greater understanding of genomic instability and its contribution to 
treatment resistance, and sensitivity, is needed.
3. Predictive biomarkers for personalised cancer care
As discussed, late-stage clinical trials are one of the most expensive, in terms 
of resource spending and time, in the total drug development lifecycle. Although 
many predictive models are mentioned in the literature, few have been validated 
in clinical trials. Various limitations around model performance, validation and 
dataset availability are currently limiting translation [47].
As one of the key clinical endpoints, drug sensitivity or efficacy would be one of 
the most important metrics to predict from preclinical data in order to improve the 
clinical success rate of drugs. In terms of real-world evidence, a handful of groups 
have now published case studies where biomarkers derived from ML-driven predic-
tive modelling have played a central role in the discovery and development of new 
therapeutic agents [48–50].
In one such case study, Li and colleagues built drug sensitivity models from 
cancer cell lines treated with erlotinib [an EGFR protein kinase inhibitor approved 
for NSCLC patients with activating mutations: exon 19 deletion (del19) or exon 21 
(L858R) substitution] and sorafenib (a non-specific kinase inhibitor approved for 
advanced renal cell carcinoma) [48, 51]. Models were then used to stratify patients 
in the BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung 
Cancer Elimination) clinical trial [48, 52], with identified biomarkers backwards 
justified with knowledge of the mechanism of action of each kinase inhibitor drug. 
Crucially, combining biomarker-driven adaptive trials such as BATTLE with basket 
trials (tissue of origin agnostic), we can move towards truly data-driven person-
alised oncology. Indeed, the FDA approved pembrolizumab [a programmed cell 
death 1 (PD1) inhibitor] in 2017 for tumours of a specific genetic background rather 
than site of origin [53]. This is the first instance of a cross-indication approval based 
solely on a genetic biomarker and highlights the need for further study in drug 
repurposing and data-driven biomarker discovery for the future of genomic cancer 
medicine.
To address some barriers to model translation into clinical practice, several 
community efforts have been attempted to help evaluate and standardise ML-based 
models. For example, the FDA launched a validation initiative for benchmarking 
ML models for predicting clinical endpoint from RNA expression data [54]. In this 
Microarray Quality Control II (MAQC II) initiative, teams were tasked with gener-
ating predictive models for several clinical endpoints in a multiple myeloma dataset. 
The most effective method used a univariant Cox regression model to identify a 
gene signature associated with individuals at high risk of low overall survival [55]. 
Though the authors note that arbitrary cut offs in overall survival may have limited 
effectiveness (24 months was the cut off for high risk, despite overall survival being 
a continuous variable suited to Cox modelling). A similar approach can be taken 
with breast cancer gene expression data to predict overall survival as a continuous 
variable [46]. Interestingly, the multiple myeloma prognostic biomarker developed 
was later independently validated by several groups [56–58].
The NCI-DREAM challenge was a similar community-driven effort to provide 
standardised datasets for benchmarking ML models [59]. In this case, models were 
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trained on a dataset consisting of RNA expression profiles, mutation data (from 
SNP array), protein array data, exome sequencing and DNA methylation, from 
35 breast cancer cell lines treated with 31 anti-cancer drugs. The models then had 
to predict outcome from a blinded dataset of 18 cell lines with the same 31 drugs. 
The best performing models were invariably regression based: such as the kernel 
method, nonlinear regression, regression trees, sparse linear regression, partial 
least squares regression, principal component regression and ensemble methods 
[59]. The dataset continues to be used to benchmark a variety of models such a 
random forest ensemble frameworks [60], group factor analyses [61] and other 
approaches [62, 63].
Our group has approached the problem of data availability by combining 
datasets from multiple sources (DNA, RNA; patients, cell lines) using variational 
autoencoders (VAE) optimised to compress somatic mutations while maintain-
ing signal [64]. We trained our models on somatic profiles from 8062 Pan-Cancer 
patients from The Cancer Genome Atlas and 989 cell lines from the COSMIC cell 
line project and compared two different neural network architectures for the VAE: 
multilayer perceptron (MLP) and bidirectional LSTM. We found that the size of the 
latent space did not have a significant effect on the VAE learning ability and showed 
that the model maintained representations of 64 dimensions and held the same 
predictive power as the original 8298-dimension vector, through prediction of drug 
response [64].
Stratification of cancer patients into molecular subgroups in an effort to predict 
drug sensitivity is a common practice. As discussed previously, one such method 
integrated copy number, gene expression and mutational data from >2000 breast 
cancers in order to define 11 ‘Integrative Subtypes’ [10]. In a later study from the 
same authors, a biobank of breast cancer xenografts (PDX models) was established 
and high throughput combinatorial drug screens were performed on xenograft-
derived tumour cells [65, 66]. The authors observed differential sensitivity between 
PDX models of different integrative clusters and even observed drugs with similar 
molecular mechanisms of action to cluster together [67]. However, in general the 
reproducibility and clinical relevance of unsupervised clustering is poor. This is 
thought to be attributable to the routine analysis of small cohorts consisting of 
fewer than 100 patients, together with the use of biased traditional consensus 
clustering techniques. In our study, we combined multiple RNA expression data-
sets and developed a robust Monte-Carlo Consensus Clustering program, called 
PDACNet. We identified six biologically novel subtypes that were reproducible 
across datasets [67].
ML-based predictive biomarkers have also seen recent advances outside of the 
oncology space. Leveraging the rich UK biobank dataset, for example, Paré and 
colleagues were able to explain 46.9% of overall polygenetic variance for height 
and 32.7% for body mass index (BMI) through the building of gradient boosted 
regression trees based on SNP arrays [68]. Expanding this beyond SNP arrays, 
Khera and colleagues built ML-driven polygenic risk score to identify individuals 
with greater than threefold increased risk for coronary artery disease (80% of the 
population were found to be genetically predisposed), atrial fibrillation (6.1%), 
type 2 diabetes (3.5%), inflammatory bowel disease (3.2%) and breast cancer 
(2.5%) [69].
Building from polygenic risk scores to multi-omic profiling, Tasaki and col-
leagues studied clinical remission in rheumatoid arthritis patients by longitudinal 
monitoring of the drug response at multi-omics levels in the peripheral blood of 
patients [70]. This high dimensional phenotyping, coupled with ML-led analysis, 
enabled the authors to uncover signatures independently associated with resistance 
to treatment and with no known associated with previously discovered disease 
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severity indexes. This technique could be expanded to a quantitative measure of 
molecular remission useful in a clinical setting.
Perhaps among the most exciting use of ML in driving our understanding of 
human pathophysiology is in the building of in silico experimental models in which 
researchers may perturb regulatory networks at will and illicit real (but simulated) 
biological responses. Towards this goal, Way and Greene built a VAE model trained 
on over 10,000 tumours across 33 different cancer types from The Cancer Genome 
Atlas (TCGA) named ‘Tybalt’ [71]. The authors showed Tybalt could capture 
biologically relevant features and model cancer gene expression under perturba-
tion. Though a lot of future work is needed, such system-based approaches could 
1 day aid in prediction of specific activated expression patterns that resulted from 
genetic changes or perturbation by therapeutics. Combined with discussed survival 
and outcome-based predictive models, we could then model treatment response to 
myriad theoretical combination therapies in silico.
Though the discussed examples of ML-led biomarker discovery are promising, 
there are several key barriers to adoption that still require work. End clinical users, 
for example, cite interpretability of the classifier as a critical barrier for clinical 
adoption. We must also validate our models in the context of multi-site, multi-
institutional datasets to demonstrate their generalisability.
4. Adaptive clinical trials
As stated, the most capital and time-intensive part of brining a new medicine 
to market is arguably the late-stage clinical trial. Phase III studies, for example, can 
run over multiple years and across multiple clinical centres and cost upwards of 
$100 million. As advanced statistical techniques gain traction, and as our under-
standing of biomarkers of response improves, we could see dramatic overhaul in the 
way clinical trials are carried out.
One set of designs of particular interest to this chapter are the adaptive clinical 
trials. Adaptive designs utilise results accumulating through the course of a trial 
to modify the trial’s course in accordance with pre-specified rules. Pre-specified 
changes to the trial design may include refining the sample size, abandoning treat-
ments or doses, changing the ratio of patients in each arm (e.g. placebo arm), focus-
sing recruitment efforts in patients most likely to benefit or stopping the entire trial 
early either successfully or due to a lack of efficacy [72]. In this way, adaptive trials 
can be more capital and time efficient, more informative and more ethically accept-
able than those of a traditional fixed design.
As adaptive trials could theoretically rely on sequential decision-making, they 
could be particularly well suited to ML-based efficiency gains. Indeed, there is 
a class of algorithms inspired by clinical trials themselves, known as Multi-Arm 
Bandit (MAB) algorithms [73]. MABs are useful when a fixed and limited set of 
resources must be allocated between alternative (competing) choices in a way that 
maximises total reward, even though the reward for each choice is not immediately 
known to the MAB. Thus, MABs can find a set of choices to maximise reward with 
incomplete information through reinforcement learning. Given the fixed nature of 
a classical clinical trial, in which groups patients are given treatments sequentially 
one after another, MAB algorithms could be natural candidates to help guide 
further phases of drug testing [47, 74].
As the simplest form of a MAB system, we can consider a Phase III clinical 
study to comprise K treatment arms, each with an unknown probability of success 
(p1, p2, … pK) and a reward (Xt) equal to 1 if treatment succeeds and 0 if treatment 
fails. The choice of treatment for the tth patient depends on each of the previously 
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and high throughput combinatorial drug screens were performed on xenograft-
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and 32.7% for body mass index (BMI) through the building of gradient boosted 
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severity indexes. This technique could be expanded to a quantitative measure of 
molecular remission useful in a clinical setting.
Perhaps among the most exciting use of ML in driving our understanding of 
human pathophysiology is in the building of in silico experimental models in which 
researchers may perturb regulatory networks at will and illicit real (but simulated) 
biological responses. Towards this goal, Way and Greene built a VAE model trained 
on over 10,000 tumours across 33 different cancer types from The Cancer Genome 
Atlas (TCGA) named ‘Tybalt’ [71]. The authors showed Tybalt could capture 
biologically relevant features and model cancer gene expression under perturba-
tion. Though a lot of future work is needed, such system-based approaches could 
1 day aid in prediction of specific activated expression patterns that resulted from 
genetic changes or perturbation by therapeutics. Combined with discussed survival 
and outcome-based predictive models, we could then model treatment response to 
myriad theoretical combination therapies in silico.
Though the discussed examples of ML-led biomarker discovery are promising, 
there are several key barriers to adoption that still require work. End clinical users, 
for example, cite interpretability of the classifier as a critical barrier for clinical 
adoption. We must also validate our models in the context of multi-site, multi-
institutional datasets to demonstrate their generalisability.
4. Adaptive clinical trials
As stated, the most capital and time-intensive part of brining a new medicine 
to market is arguably the late-stage clinical trial. Phase III studies, for example, can 
run over multiple years and across multiple clinical centres and cost upwards of 
$100 million. As advanced statistical techniques gain traction, and as our under-
standing of biomarkers of response improves, we could see dramatic overhaul in the 
way clinical trials are carried out.
One set of designs of particular interest to this chapter are the adaptive clinical 
trials. Adaptive designs utilise results accumulating through the course of a trial 
to modify the trial’s course in accordance with pre-specified rules. Pre-specified 
changes to the trial design may include refining the sample size, abandoning treat-
ments or doses, changing the ratio of patients in each arm (e.g. placebo arm), focus-
sing recruitment efforts in patients most likely to benefit or stopping the entire trial 
early either successfully or due to a lack of efficacy [72]. In this way, adaptive trials 
can be more capital and time efficient, more informative and more ethically accept-
able than those of a traditional fixed design.
As adaptive trials could theoretically rely on sequential decision-making, they 
could be particularly well suited to ML-based efficiency gains. Indeed, there is 
a class of algorithms inspired by clinical trials themselves, known as Multi-Arm 
Bandit (MAB) algorithms [73]. MABs are useful when a fixed and limited set of 
resources must be allocated between alternative (competing) choices in a way that 
maximises total reward, even though the reward for each choice is not immediately 
known to the MAB. Thus, MABs can find a set of choices to maximise reward with 
incomplete information through reinforcement learning. Given the fixed nature of 
a classical clinical trial, in which groups patients are given treatments sequentially 
one after another, MAB algorithms could be natural candidates to help guide 
further phases of drug testing [47, 74].
As the simplest form of a MAB system, we can consider a Phase III clinical 
study to comprise K treatment arms, each with an unknown probability of success 
(p1, p2, … pK) and a reward (Xt) equal to 1 if treatment succeeds and 0 if treatment 
fails. The choice of treatment for the tth patient depends on each of the previously 
Artificial Intelligence in Oncology Drug Discovery and Development
90
given treatments and their observed outcomes. The trial’s data-driven adaptiv-
ity could therefore allow statistical power for each arm to be reached with fewer 
patients by incorporating automatic interim analysis in the treatment decision. 
Theoretically, such a trial would be resource efficient across all parameters (time, 
economic, minimise side effects, maximise patient life) [74].
Despite the theoretical promise of adaptive trials, clinical uptake has been slow. 
This could be due to statistical requirements for traditional trials, for example 
balancing prognostic covariates in each arm [74], or could be due to practical dif-
ficulties such as the significant delay in feedback on treatment effectiveness [75]. It 
is for this reason that we can look forward to the maturation of technologies such as 
the real-time monitoring of treatment effectiveness pioneered by companies such 
as Cambridge Cancer Genomics.
5. Balancing the economics and promise of personalised oncology
Even as our understanding of the heterogeneity in cancer makes it ever more a 
part of the need for personalised treatment strategies, and as our computational 
tools begin to make this possible, a significant barrier to adoption is becoming 
apparent: the cost of personalised medicine in oncology is increasing [76]. There 
exists a profound conflict at the heart of precision oncology between the varied and 
contrasting priorities of the pharmaceutical industry, local and national govern-
ments, international medical community, and patients, which needs to be reviewed 
and balanced. Even as the stated aims of each stakeholder align, individual incen-
tive sets around target patient populations, the need to increase revenues and 
offset inefficiencies and the need to personalise treatment plans must be aligned if 
precision oncology is to become truly widespread.
It is no secret that the financial burden of cancer to the global economy is 
significant, perhaps more surprising is the personal economic costs. In the UK, 
where healthcare is free at the point of use, a cancer diagnosis results in a net loss 
to an individual of >£570, and in the US, a diagnosis increases the likelihood of 
bankruptcy by 250% [76]. Aside from direct costs associated with health insur-
ance deductibles and co-pays (e.g. in the US) and ancillary spending (e.g. in the 
UK), cancer is among the most expensive diseases to manage across the healthcare 
ecosystem. In particular, the last decade or so has seen a substantial increase in the 
direct costs of cancer medicine. At the turn of the twenty-first century, the average 
annual cost of a new anti-cancer therapy was a little under $10,000, by 2016 this 
had risen to $100,000 for the same treatment duration [77]. Proponents of the 
pharmaceutical industry would point out that treatment modalities have increased 
in complexity significantly in the same period; however, there is little evidence that 
improvements in patient outcomes have kept pace with the increase in costs.
Indeed, when viewed in terms of Quality Adjusted Life Years (QALYs), the incre-
mental gain from new treatment modalities such as targeted and antibody therapies 
launched between 1999 and 2011 is 0.25 QALYs [78]. To put this in context, the 
average cost per QALY in the UK across all treatments is £13,000 and the threshold 
for approving treatments not intended for oncology by the National Institute for 
Clinical Excellence (NICE) is £20,000–£30,000. Moreover, beyond the cost of the 
drug itself, new treatment modalities are also associated with ancillary costs, for 
example, in companion diagnostics, development costs, and relevant associated 
technology. Personalised oncology is often seen as a saving grace in terms of making 
the high-quality cancer care sustainable. However, it is vital to understand the cost 
drivers in the current management of cancer and how these may change in a world 
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of widespread personalised treatment in order to improve or maintain value for 
money in the future of cancer care.
Fundamentally, in order to bias the QALY calculation in favour of cost-
effectiveness, we must either (1) improve targeting of drugs to only those patients 
who receive clinical benefit or (2) ensure that efficiency of the drug development 
process increases, to avoid fixed R&D costs being spread over a smaller patient 
population. Therefore, if precision oncology has the potential of improving the 
efficacy of drug targeting, we must look to cost-saving efficiencies in the drug 
development process.
Clearly, a key driver of the increasing cost of cancer care is the reduction in R&D 
efficiency in pharmaceuticals companies; indeed, this is ingrained in our collective 
understanding of the industry that has even been dubbed ‘Eroom’s Law’ [79]. It 
has long been argued that all the ‘low hanging fruit’ (i.e. all the easy targets) has 
long since been ‘picked’. However, this assumption belittles the fact that of the $2.6 
billion it costs to develop a new drug, a large proportion of this cost is associated 
with a 90% attrition rate in Phase II–Phase III trials [14]. Nevertheless, there is a 
real danger that the majority of recurrently mutated targets in cancer, for example 
EGFR, have already been targeted and any new therapies can only hope to pro-
vide incremental benefit beyond what has already been done. Thankfully, as new 
avenues of biology are explored, such as immune disruption by tumours, or new 
targeting modalities are discovered, new targets become available.
A potential avenue for improving the efficiency of drug development comes 
from considering manufacturing practices. The past two decades have seen a shift 
from small molecules to larger and more complicated biotherapies such as monoclo-
nal antibodies. The manufacturing methods of biotherapies are considerably more 
complicated and expensive than traditional small molecule therapies, which could 
in part account for the increasing cost of the end product. However, the efficiency 
of manufacture of biopharmaceuticals has increased dramatically over the same 
period: with typical yields increasing from 1 to 2.5 g/l during the period 2001–2014 
[80]. The complexity of manufacture also creates an additional barrier to entry for 
new drug manufacturers. There is a real concern that identical production process 
will not equate to identical products, this could protect against generic manufactur-
ers entering the market as soon as the initial patient protection has lapsed. Indeed, 
regulators have introduced regulatory processes for so-called biosimilars much 
costlier and more involved than for generics for small molecules.
An alternative explanation for the rising cost of cancer drugs, and one that is 
perpetuated by the media, is based entirely on market forces: that is the cost of can-
cer drugs increases because that is what the market is willing to tolerate. Proponents 
point to Orphan Drugs developed in the early 2000s. Initially priced in excess of 
$100,000 a year, the initial price was protested but inevitably paid. In terms of 
economic theory, this was a signal to the market of price elasticity and the willing-
ness to pay more for health [1]. Though comprised of well-meaning individuals, 
pharmaceutical companies are corporations with a legal obligation to maximise 
value for their shareholders. A slightly more palatable theory simply points to the 
reimbursement period: cancer is an acutely managed disease, treated for 6 months 
before the patient either recovers or, sadly, passes away. Unlike with chronic 
medications, therefore, the entire R&D costs of that drug must be paid back over a 
relatively short period of treatment time. This, of course, raises the effective price.
Clearly the balance of incentives in healthcare is a complicated problem. The 
danger is that precision oncology has the potential to increase some of these compli-
cations. If we are to see widespread adoption of more personalised medicine, then 
care must be taken to address inefficiencies in the pharmaceutical development 
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average cost per QALY in the UK across all treatments is £13,000 and the threshold 
for approving treatments not intended for oncology by the National Institute for 
Clinical Excellence (NICE) is £20,000–£30,000. Moreover, beyond the cost of the 
drug itself, new treatment modalities are also associated with ancillary costs, for 
example, in companion diagnostics, development costs, and relevant associated 
technology. Personalised oncology is often seen as a saving grace in terms of making 
the high-quality cancer care sustainable. However, it is vital to understand the cost 
drivers in the current management of cancer and how these may change in a world 
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of widespread personalised treatment in order to improve or maintain value for 
money in the future of cancer care.
Fundamentally, in order to bias the QALY calculation in favour of cost-
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population. Therefore, if precision oncology has the potential of improving the 
efficacy of drug targeting, we must look to cost-saving efficiencies in the drug 
development process.
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understanding of the industry that has even been dubbed ‘Eroom’s Law’ [79]. It 
has long been argued that all the ‘low hanging fruit’ (i.e. all the easy targets) has 
long since been ‘picked’. However, this assumption belittles the fact that of the $2.6 
billion it costs to develop a new drug, a large proportion of this cost is associated 
with a 90% attrition rate in Phase II–Phase III trials [14]. Nevertheless, there is a 
real danger that the majority of recurrently mutated targets in cancer, for example 
EGFR, have already been targeted and any new therapies can only hope to pro-
vide incremental benefit beyond what has already been done. Thankfully, as new 
avenues of biology are explored, such as immune disruption by tumours, or new 
targeting modalities are discovered, new targets become available.
A potential avenue for improving the efficiency of drug development comes 
from considering manufacturing practices. The past two decades have seen a shift 
from small molecules to larger and more complicated biotherapies such as monoclo-
nal antibodies. The manufacturing methods of biotherapies are considerably more 
complicated and expensive than traditional small molecule therapies, which could 
in part account for the increasing cost of the end product. However, the efficiency 
of manufacture of biopharmaceuticals has increased dramatically over the same 
period: with typical yields increasing from 1 to 2.5 g/l during the period 2001–2014 
[80]. The complexity of manufacture also creates an additional barrier to entry for 
new drug manufacturers. There is a real concern that identical production process 
will not equate to identical products, this could protect against generic manufactur-
ers entering the market as soon as the initial patient protection has lapsed. Indeed, 
regulators have introduced regulatory processes for so-called biosimilars much 
costlier and more involved than for generics for small molecules.
An alternative explanation for the rising cost of cancer drugs, and one that is 
perpetuated by the media, is based entirely on market forces: that is the cost of can-
cer drugs increases because that is what the market is willing to tolerate. Proponents 
point to Orphan Drugs developed in the early 2000s. Initially priced in excess of 
$100,000 a year, the initial price was protested but inevitably paid. In terms of 
economic theory, this was a signal to the market of price elasticity and the willing-
ness to pay more for health [1]. Though comprised of well-meaning individuals, 
pharmaceutical companies are corporations with a legal obligation to maximise 
value for their shareholders. A slightly more palatable theory simply points to the 
reimbursement period: cancer is an acutely managed disease, treated for 6 months 
before the patient either recovers or, sadly, passes away. Unlike with chronic 
medications, therefore, the entire R&D costs of that drug must be paid back over a 
relatively short period of treatment time. This, of course, raises the effective price.
Clearly the balance of incentives in healthcare is a complicated problem. The 
danger is that precision oncology has the potential to increase some of these compli-
cations. If we are to see widespread adoption of more personalised medicine, then 
care must be taken to address inefficiencies in the pharmaceutical development 
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process. Otherwise, governments and patients may be left with an unpalatable bill 
for marginally improved health outcomes.
6. Summary
The estimated global incidence of all cancer types in 2015 was 17.5 million [81]. 
Fourteen per cent of all deaths in 2005 were due to cancer, which increased to 16% 
in 2015 [82]. In combating cancer, we have created a global industry of research 
institutes, pharmaceutical companies and specialist hospitals. This industry is 
currently failing to keep up with the rising global cancer burden and suffers from 
unprecedented inefficiencies. To solve this problem, we must incorporate technolo-
gies such as ML into the clinical care pathway. It is our opinion that investment 
should be focussed on the development of predictive biomarkers for treatment 
outcome, which take account of tumour heterogeneity and evolution. If we are to 
beat cancer, we should begin to look at it as a highly heterogeneous and dynamic 
disease that requires a more sophisticated treatment paradigm. In particular, we 
must be cognisant of tumour evolution and develop biomarkers suitable for the 
growing field of adaptive oncology.
Tumour evolution has been a key conceptual framework in cancer biology since 
it was first put forth by Peter Nowell in 1976 [18]. The theory postulates that cancers 
arise from a single cell that has a selective advantage over its neighbours and that 
cancer can be understood based on the evolutionary principles of selection and 
adaptation originating from this ancestral cell. Over time, cells within the tumour 
continue to adapt and bestow on the tumour whole, specific traits described as 
the Hallmarks of Cancer [22, 83]. These ideas have been developed using many of 
the concepts first established in evolutionary biology [84, 85], considering cancer 
as a disease of multicellular organisms in constant balance between Darwinian 
selection acting on the level of a single cell and the need for coordination between 
multiple cells for the good of the organism [86, 87]. From this perspective, cancers 
occur when an individual cell behaves in an autonomous manner, escaping from the 
mechanisms in place to coordinate cell behaviour [88].
The classic model of carcinogenesis describes multiple, successive clonal 
expansions driven by the accumulation of genomic changes or ‘mutations’ that are 
preferentially selected by the tumour environment [89]. However, it is important 
to note that natural selection acts on phenotypes rather than genotypes. Indeed, 
selection can be transient, favouring a specific phenotype in response to fluctuating 
changes in microenvironment. Indeed, recent work has uncovered monogenetic 
clonal expansion of phenotypic clones responsible for tamoxifen resistance in breast 
cancer [90] and chemotherapeutic resistance in CRC PDX models [91, 92].
More broadly, tumour evolution and resultant heterogeneity have been linked 
to several clinically important facets of cancer [10, 93], but are currently under-
served in terms of clinical translation. ML and the age of big biological data give 
us the necessary power to address this problem, and the clinical and the financial 
need is now.
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Chapter 6
Efficacy Evaluation in the Era of




Patient stratification and the use of real-world evidence in regulatory decision-
making are two key areas where algorithms are having an impact on drug develop-
ment. The two are linked: increased patient stratification makes it harder to recruit
patients into randomized-controlled trials, increasing the pressure on drug devel-
opers to find alternative sources of evidence for showing efficacy. In addition to
real-world evidence, we are also seeing the emergence of more efficient ‘master
protocol trials’, where multiple targeted agents can be evaluated simultaneously.
In this chapter, I will review these developments and investigate the limitations for
AI in terms of demonstrating the efficacy of novel targeted agents.
Keywords: drug development, precision medicine, statistics
1. Introduction
The use of algorithms to find patterns and make predictions from multiple data
sources—here referred to as artificial intelligence (AI)—is having an increasingly
large impact on clinical drug development.
Algorithms can be applied to combined clinical and genetic data sets to stratify
patient populations into subgroups, based on shared characteristics or similar prog-
nostic profiles [1–2]. This would appear to make sense, since the majority of new
drugs approved by the US FDA in recent years have been targeted towards specific
genetic aberrations [3–4]. If we increase our search, we will find more genetic
aberrations, more drug targets, and more potentially efficacious drugs. However,
this approach also presents severe challenges in the clinical stages of drug develop-
ment, as the size, complexity and duration of studies increases.
One way to react to increased cost and duration is to improve the operational
efficiency of clinical trials. The last decade has seen the emergence of ‘master
protocol trials’, which allow several substudies to be conducted simultaneously,
reducing the rate of screen failures [5]. In addition, there is increasing enthusiasm
for augmenting (possibly even replacing) randomized-controlled trials (RCTs) with
external and real-world data, where it is claimed that further use of algorithms can
protect us from the biases that this approach would otherwise impose [1].
The purpose of this article is three-fold. Firstly, to explain how precision medi-
cine presents challenges to traditional drug development, quantifying the effect of
disease stratification on trial recruitment. Secondly, to describe how master
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The purpose of this article is three-fold. Firstly, to explain how precision medi-
cine presents challenges to traditional drug development, quantifying the effect of
disease stratification on trial recruitment. Secondly, to describe how master
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protocol studies have emerged in response to these challenges. Finally, to explore
whether it is possible for single-arm studies with ‘synthetic control arms’ to provide
the same standard of evidence as a randomized controlled trial, thus reducing
drug development timelines.
2. Disease stratification
Consider a patient population that can be stratified according to the value of a
diagnostic test. The ‘target’ population consists of patients who test positive. The
‘non-target’ population consists of patients who do not test positive. Suppose that
a new treatment is expected to be more effective in the target population than in the
non-target population. Let θþ and let θ� denote the treatment effect sizes in target
and non-target populations, and γ denote the prevalence of the target group. Three
things that we would like to demonstrate are:
1.Treatment benefit in the full population, γθþ þ 1� γð Þθ� >0.
2.Treatment benefit in the target population, θþ >0.
3.Greater benefit in the target population than in the non-target population,
θþ > θ�.
Which of these is easiest to demonstrate, and which most difficult? To answer
this, we compare the standardised statistics, Z, that we would use to test the
corresponding null hypotheses. For most commonly-used clinical-trial endpoints,
the test statistic ends up looking like







where θ is the treatment effect size and I is the statistical information, which is
typically proportional to the sample size [6, 7]. The power of a test is the probability
that Z > k, for a threshold k, where k is chosen to ensure a given false-positive rate.
The larger the expected value of Z, the higher the power. Therefore two trials (‘A’
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We can use (2) to assess the relative difficulty of our three goals, firstly for the
full population versus the interaction (1. versus 3.), and then for the full population
versus the target population (1. versus 2.).
2.1 Full population versus interaction
It is shown in the appendix that a test of the interaction null hypothesis, θþ ¼ θ�,
with total sample sizeNint, will have the same power as the test for the full population
null hypothesis, γθþ þ 1� γð Þθ� ¼ 0, with sample size N, provided that
θþ � θ�ð Þ
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For example, when θ�=θþ ¼ 0:5, for a prevalence of 50%, the ratio of sample
sizes is Nint=N ¼ 9. For a prevalence of 5%, Nint=N ≈ 23. This shows how difficult it
is to provide compelling evidence for treatment-biomarker interactions, and why
drug development is still focussed on demonstrating average treatment effects. It is
also explains why post-hoc data-driven subgroup identification following a clinical
trial is often a bad idea. See Gelman [8] for further discussion.
2.2 Full population versus target population
A test for the full population null hypothesis with sample size N will have the
same power as a test for the target population null hypothesis, θþ ¼ 0, with sample
size NT, provided that

















In (5), we have expressed the relative sample size, NT=N, as a function of the
relative efficacy, θ�=θþ [9]. This relationship is drawn in solid lines in Figure 1 for
two potential prevalences (50% and 5%) when θ�=θþ is between 0.5 and 1. For a
prevalence of 50%, the targeted strategy requires up to 40% fewer patients than the
non-targeted strategy. For a prevalence of 5%, a 70% reduction is possible. Note,
however, that this is the relative number of patients enrolled. What about the
Figure 1.
Relative sample size when testing efficacy in the target population compared to the full population (NT=N),
shown in solid lines. The dashed lines show the relative number of patients screened ( NT=γð Þ=N).
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number of patients screened? In the full population the minimum number screened
is N, whereas in the targeted population it is Nt divided by γ. The ratio, Nt=γð Þ=N, is
drawn in dashed lines in Figure 1. For the 50% prevalence case, there is a maximum
2-fold increase in the number screened for the targeted compared to the non-
targeted trial. But for the 5% prevalence case, there is somewhere between a six-fold
and a twenty-fold increase.
2.3 Situations where θ� ≪ θþ
The conclusion from Figure 1 is that population stratification is only likely to be
useful if there exists a potential treatment where the treatment effect is consider-
ably higher (e.g. at least two-fold) in the target subgroup than in the rest of the
population. Marginal increases in efficacy are not enough in practice. The targeted
approach would require a prohibitively large number of patients to be screened,
compared to a trial in the full population which would have the same statistical
power. Marginal increases are also difficult to establish empirically, as shown in
Section 2.1. It follows that successful implementation of precision-medicine drug
development is restricted to situations where there is strong biological and pre-
clinical evidence for expecting θ� ≪ θþ. Such cases certainly do exist, and the
targeted trial is the only sensible approach here. Nevertheless, one still needs to
screen a very high number of patients. This is expensive for the sponsor. It is also
disheartening for patients who do not meet the eligibility criteria.
3. Master protocol trials
The high screen failure rate of precision-medicine trials can be mitigated to some
extent by merging multiple sub-studies into a single ‘master protocol’. The last
decade has seen the emergence of the labels ‘basket’ and ‘umbrella’ to describe these
complex studies. As a rule of thumb, a basket tends to refer to studies involving the
same drug in multiple diseases, whereas umbrella is used when multiple experi-
mental treatments are studied in the same disease. However, as reported by Janiaud
and colleagues [10], these terms have not been applied consistently. Their system-
atic review of master protocol trials in oncology found 30 ‘basket’ trials and 27
‘umbrella’ trials in a time period of 2006–2018, but with most studies starting after
2015. They explain that some basket trials are mistakenly labeled as umbrella trials,
and vice-versa, but there are also trials that contain elements of both and thus
become difficult to describe using current language.
Stallard and colleagues [11] propose a refined classification which replaces
ambiguous labels with a more precise visual description, as shown in Figure 2. In
each of the six designs, a small square is representative of a cohort of patients. On
the left hand side are the basket-type designs, where there is only one new treat-
ment (T) targeting a particular mutation (M), but this mutation occurs across
diseases (D1,D2, … ). In the middle are the umbrella-type designs, where there are
multiple treatments (T1,T2, … ) targeting particular mutations (M1,M2, … ), all
within the same overall disease (D). The designs on the right hand side combine the
features of the basket-type and umbrella-type designs. They allow for multiple
disease types within each of the separate treatment-mutation combinations. Note,
however, that it is always the mutation that is driving the choice of treatment,
rather than the disease type. In all of the designs, for each T-M-D sub-study, it is
possible to use a single-arm design (Figure 2a), or compare with a concurrent
control arm (Figure 2b).
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3.1 Example 1: Vemurafenib in cancers (not melanoma) with BRAF V600
mutations
Hyman and colleagues [12] report the results of a basket-type study with the
same structure as the left-hand-side of Figure 2a. The treatment (T) was
Vemurafenib, the mutation (M) was BRAF V600. There were several cohorts
corresponding to different disease types (D):
• Colorectal cancer (CRC)
• Bile duct cancer
• Anaplastic thyroid cancer (ATC)
• Non-small cell lung cancer (NSCLC)
• Erdheim-Chester disease/Langerhans cell histiocytosis (ECD/LCH)
Figure 2.
A classification of master protocol designs by Stallard and colleagues [11]. Each square represents a cohort of
patients. (a) Single-arm cohorts. (b) Concurrent control arms.
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A Simon’s two-stage design [13] was used for each cohort independently to allow
for early futility stopping. Consequently, the cohort sizes ranged from 5 to 27.
Hobbs and colleagues [14], did a re-analysis of the data, and their findings are
reproduced in Figure 3. Looking at the response rate across cohorts, it appears that
there is more activity in NSCLC and ECD/LCH than in CRC. However, one can also
see a clear inverse relationship between response rate and number of prior thera-
pies, which muddies the water. This example highlights how difficult it can be to
interpret uncontrolled studies.
3.2 Example 2: FOCUS4
An example of a master protocol trial that does include concurrent control arms
is FOCUS4 [15], currently being run by the Medical Research Council Clinical Trials
Unit in London. It has an umbrella-type design like Figure 2b. The disease setting





A centralised molecular analysis is performed on each patients tumor. Based on
the results, patients are offered entry into an appropriate substudy, where they are
randomized to receive either an experimental treatment (T) targeted to their
mutation, or a control treatment.
Figure 3.
Results from a basket-type study of Vemuarafenib [12–13].
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The substudies will be analysed independently, as if they were separate trials.
The big advantage over independent studies is the increased efficiency from the
centralised molecular analysis, ensuring fewer screen failures. Complications may
arise when patients are eligible for more than one substudy, and this has to be
planned for in the protocol. Note also the inclusion of the Wild-type cohort in
FOCUS4. This maximizes the proportion of patients who undergo screening who
are given an option to go on a trial.
4. External control arms
Precision medicine is increasing the pressure on drug developers to find inno-
vative ways to demonstrate efficacy without requiring ever larger and lengthier
clinical trials. We have seen how operational efficiencies can be found in master
protocol trials. A related development is the use of ‘big data’—the bringing together
of historical RCT data, electronic health records, advanced statistical modeling, and
machine-learning—to produce a historical benchmark, or even a so-called ‘syn-
thetic control arm’, that might allow a single-arm study to take the place of an RCT
as a basis for seeking drug approval.
For this approach to be successful, the key use-case in oncology is a comparison
of overall survival (OS). It is typical for inference to focus on the (log) hazard ratio,
θ≔ log
λE tð Þ
λC tð Þ , (6)
where it is assumed that the hazard of death on the experimental arm, λE tð Þ, is
proportional to the hazard of death on the control arm, λC tð Þ, for all timepoints t.
Another way to describe λ tð Þ is that it is your risk of dying on day t given that you were
alive atmidnight.More stringent than proportional hazards is an assumption of constant
hazards, λj tð Þ ¼ λj for all t (j ¼ E,C). Although an over-simplification, this model is
often not a bad approximation to reality, and we will use it to compare operating
characteristics for a two-armRCT versus a single-arm trial with an external control arm.
4.1 Distribution of treatment effect estimators
The constant-hazards assumption allows us to express the log hazard ratio as the




¼ logmC � logmE: (7)
For a two-arm study with equal randomisation and D events, the estimate of the
log hazard ratio has the following (approximate) distribution:
θ̂ ¼ log m̂C � log m̂E � N θ, 4=Dð Þ: (8)
If we were to run a single-arm study instead, but keep the overall sample size the
same, i.e. put all patients who would have received the control treatment onto the
experimental arm, we could use the test statistic
θ̂
∗ ¼ logm ∗C � log m̂E � N θ þ logm ∗C � logmC, 1=D
 
(9)
where m ∗C is our best pre-trial estimate for the median OS on the control arm.
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4.2 Bias-variance trade-off
We can compare the precision of the two estimates in terms of their mean-
squared-errors,
mse θ̂





∗� � ¼ var θ̂ ∗
� �
þ bias θ̂ ∗
� �2
¼ 1=Dþ logm ∗C � logmC
�� ��2:
(11)





. However, as soon as
D>
3
logm ∗C � logmC
�� ��2 (12)
the bias will dominate, and the estimate from the two-arm trial will be more
precise.
4.3 NSCLC example
What is a typical value for ∣ logm ∗C � logmC∣? This depends on the context. The
FDA have published data from 14 large randomized control trials [16] in advanced
non-small-cell-lung cancer (NSCLC) conducted between 2003 and 2015. The
median survival on the control arm across the studies is shown in Figure 4. Three of
the studies were targeted towards patients with a particular biomarker. It is imme-
diately obvious that these three data points are different from the rest, and this
highlights the dangerous territory we are in. Nevertheless, if we focus on the 11
studies that did not use a targeted approach, the median overall survival ranged
from 7 to 13 months. Taking an average value, a sensible choice for logm ∗C is
log 9:5ð Þ. We could also think about the ‘true’ logmC for the current study belong-
ing to the same distribution as the 11 other studies, which we might approximate
with a normal distribution
logmC � N logm ∗C ¼ log 9:5ð Þ, σ2mC ¼ 0:03
� �
(13)





Plugging this into (12), the two-arm trial would be more precise than the single-arm
trial when D> 153.
4.4 Reducing the sample size
What if instead of moving patients from the control arm to the experimental
arm and keeping total sample size the same, we run a single-arm study with half
the number of patients, i.e. we keep the same sample size on the experimental
arm and replace the control arm with an historical benchmark? In this case, the
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mean-squared-error of the estimate from the two-arm trial will be lower than the
single-arm equivalent as soon as
D>
2
logm ∗C  logmC
 2,
(14)
where D is the number of events in the two-arm trial. For our lung cancer
example, this would mean as soon as D> 102.
4.5 More advanced methods
In the previous example we were using the average value from 11 previous
studies as a rather crude estimate of logm ∗C . Is it possible to improve the precision
using ‘big data’—bringing together historical RCT data, electronic health records,
advanced statistical modeling, and machine-learning?
We can look to a recent study by Carrigan and colleagues [17]. The group had
access to individual patient data from 9 RCTs in advanced NSCLC conducted
between 2011 and 2018, as well as electronic health records (EHR) from almost
50,000 patients. They used advanced regression and stratification techniques to
estimate treatment effect sizes, and their results are reproduced on the left hand
side of Figure 5. There is a high correlation (0.86) between the hazard ratio from
Figure 4.
Between-trial variability in median overall survival time from 14 phase 3 studies in advanced non-small-cell
lung cancer trials submitted to the FDA [16].
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lung cancer trials submitted to the FDA [16].
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the RCTs and the hazard ratio that would have been observed had the control arm
been replaced with electronic health record data. On the right hand side, the data
points have been transformed into an estimate of the bias ∣ logm ∗C � logmC∣,
assuming constant hazards. The mean value is 0.1 and according to (12) this means
that a two-arm trial would be more precise than a single-arm trial of the same total
sample size whenever D> 300. Similarly, using (14), a two-arm trial will be more
precise than a single-arm trial with half the sample size when D> 200.
To put these findings in some context, for a study with one-sided type-1 error of
α ¼ 0:025, 300 events would give 90% power when HR ¼ 0:69. Likewise, 100
events would give 90% power when HR ¼ 0:52.
5. Conclusions
Advances in pattern-recognition and prediction algorithms have the potential to
improve health outcomes, as well as making the drug development process more
efficient. Nevertheless, it is important to have a strong grasp of some limiting
factors, to avoiding spending time on futile endeavors.
The stratification of patient populations into ever finer subgroups is only likely
to prove useful when there exist potential treatments with very large differential
treatment effects. Marginal is not enough—it needs to be 100% more efficacious in
the target subgroup than in the non-target subgroup. Otherwise, a clinical trial in
the full population would have the same statistical power with far fewer patients
screened. This means that we need strong biological rationale and robust pre-
clinical evidence. In addition, it is essential that the diagnostic test has high sensi-
tivity and specificity. Otherwise, a large treatment effect in the true biomarker-
positive population would become diluted in the observed biomarker-positive popu-
lation.
In cases where there is a strong rationale for a targeted approach, recruitment
will be challenging. Master protocol trials can be an excellent option. They are an
efficient way to test novel agents, and they increase the chance that a patient
entering screening will be able to join a clinical trial.
Improvements in the quality of electronic health records, as well as better algo-
rithms to interrogate this data, are a positive development that can enhance our
Figure 5.
Correlation between RCT-derived and EHR-derived hazard ratios from nine studies in advanced non-small-
cell lung cancer [17]. On the right-hand-side, the results have been converted into an approximation of the bias
when estimating the median survival time on the control arm using EHR data.
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understanding of health outcomes, and help enormously with clinical trial design
and interpretation. Nevertheless, we should not forget the fundamental benefits of
concurrent control [18], and should remain realistic about the ability of synthetic
control arms to replace the real thing. We have seen that under favorable circum-
stances (highly prevalent disease, patient-level data from numerous high-quality
large RCTs, tens of thousands of electronic health records, well-defined and
accurately-measured primary endpoint, careful analysis), a single-arm study can
provide similar precision to a two-arm randomized comparison with sample size in
the low hundreds [17]. It is plausible, therefore, that for a new drug in this space
with a very large treatment effect, a single-arm study may provide convincing
evidence of efficacy. But one should expect this to be the exception, not the norm.
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Chapter 7
AI Enabled Precision Medicine: 
Patient Stratification, Drug 
Repurposing and Combination 
Therapies
Steve Gardner, Sayoni Das and Krystyna Taylor
Abstract
Access to huge patient populations with well-characterized datasets, coupled 
with novel analytical methods, enables the stratification of complex diseases into 
multiple distinct forms. Patients can be accurately placed into distinguishable sub-
groups that have different disease causes and influences. This offers huge promise 
for innovation in drug discovery, drug repurposing, and the delivery of more 
accurately personalized care to patients. Complex diseases such as cancer, dementia, 
and diabetes are caused by multiple genetic, epidemiological, and/or environmental 
factors. Understanding the detailed architecture of these diseases requires a new 
generation of analytical tools that can identify combinations of genomic and non-
genomic features (disease signatures) that accurately distinguish the disease sub-
groups. These sub-groups can be studied to find novel targets for drug discovery 
or repurposing, especially in the areas of unmet medical need and for selecting the 
best treatments available for an individual patient based on their personal genetic 
makeup, phenotype, and co-morbidities/co-prescriptions. This chapter describes 
new developments in combinatorial, multi-factorial analysis methods, and their 
application in patient stratification for complex diseases. Case studies are described 
in novel target discovery for a non-T2 asthma patient sub-group with distinct unmet 
medical need and in drug repurposing in a triple negative breast cancer population.
Keywords: precision medicine, genomics, patient stratification, target discovery, 
drug repurposing, therapy selection, clinical decision support, asthma,  
non-T2 asthma, cancer, triple negative breast cancer
1. Introduction
It is well-understood that the drugs available to and prescribed for patients, 
especially those with complex chronic diseases, are not always equally effective at 
treating their disease. In fact, many of the most widely prescribed drugs, includ-
ing expensive on-patent medications, benefit only a small proportion of patients 
to whom they are prescribed [1]. There are multiple reasons for this including 
misdiagnosis, genetic variations in drug response/resistance, different responses at 
disease stages, ethnicity biases in clinical trials [2], and inappropriate reimburse-
ment criteria for the disease.
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Drugs are often prescribed on the basis of a defined clinical pathway that is guided 
by the diagnostic label given to a patient’s disease in a ‘one size fits all’ approach. For 
highly heterogeneous diseases, this can seem like a largely trial and error basis before 
the right drug is found [3]. It can take months for patients to access a treatment that is 
effective and has a tolerable range of side effects. These delays not only waste drugs, 
they can increase the overall cost of treatment as a result of adverse events or worsen-
ing of the disease during the process of finding an effective prescription.
For example, it is notoriously difficult to select the right therapy and dose for 
patients newly diagnosed with depression. This is in part because depression is hard 
to diagnose precisely, due to it being multi-factorial, multi-genic with confounding 
situational influences and co-morbid with other conditions. As a result, depressive 
disorders are a huge societal burden affecting 6–7% of the workforce and costing 
the US economy $210 billion per year [4]. The failure to quickly access effective 
drugs requires multiple physician visits, resulting in lower quality of life and lost 
economic productivity for millions of patients. Many of the drugs that we do have 
are also poorly targeted ‘sledgehammers’ with widespread off-target effects affect-
ing cognitive function, weight gain, sleep, and sexual function.
As a result of these challenges, UnitedHealth recently announced a new policy 
to use precision medicine for depression patients [5] in an attempt to escape the 
historical ‘one size fits all’ approach to medicine. Precision medicine attempts to use 
more personal information about the patients and more detailed insights into the 
disease to match the right drugs to the right patient.
Some patients may not even have available therapeutic options as none of the 
existing drugs prescribed on the clinical pathway for a given disease may work for 
them. This can leave pockets of poorly treated patient sub-groups and high unmet 
medical need. Such unmet needs exist in cancer due to the idiopathic nature of 
somatic mutations, but also even in relatively prevalent diseases with germline 
genetic predispositions such as asthma, diabetes and schizophrenia.
There are two methods of addressing both of these causes of unmet medical 
need. The first way is to try to identify new drug targets for pockets of unmet 
medical need within a patient population. This is effectively the traditional drug 
discovery approach, although it can be significantly enhanced by new AI-enabled 
precision medicine technologies.
The second approach is to try to predictively match existing drugs with patients 
who we have reason to believe will benefit from them. This is appropriate when we 
can see that those drugs are active at targets that we know are modulating disease 
processes inside a particular patient sub-group. This approach is called drug repur-
posing (or repositioning). Until now, many of the current repurposing examples 
prescribed in the clinic have been discovered in a serendipitous manner, but the 
advent of more detailed patient datasets and higher resolution patient stratification 
analytics tools enables us to do this systematically for all patients with a specific 
disease.
In turn, the knowledge of which drugs are likely to work for which patient 
sub-groups enables principled, evidence-led therapy selection in a clinical setting. 
Based on an understanding of the combination of factors driving a specific patient’s 
disease, one or more drugs targeting those causative factors can be prescribed. 
This is better understood in oncology where mutational profiles have been used to 
evaluate the best therapeutic approach for specific tumours for many years. It also 
has application in other complex and chronic diseases whose aetiology, progression 
trajectory, phenotypes and therapy responses are mediated by multiple genetic and 
non-genetic factors.
These approaches, the tools and data that enable them, and the impacts that 
accurate patient stratification bring are discussed in this chapter.
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2. Patient stratification: the key to delivering precision medicine
Precision medicine—providing the right drug at the right time to the right 
patient—promises to deliver better medicines, improved patient outcomes and 
lower healthcare costs. It has the potential to benefit millions of patients and save 
global healthcare systems tens or even hundreds of billions of dollars per year 
through new, better targeted therapeutic options, more accurate prescription, 
reduced over-medication, and better compliance.
Accurate patient stratification drives better understanding of the factors under-
pinning disease risk, rate of progression and therapy response, and presents us 
with a new palette of opportunities to impact patient care. Clinical decision support 
systems are beginning to apply patient stratification insights to inform treatment 
choices at the point of care. By increasing the chance that patients will get the right 
drug or combination of drugs first time, such precision medicine tools can reduce 
the cost of delivering care at the same time as maximizing patient benefit.
Expensive medicines or drugs with more severe side-effects can be reserved for 
those patients for whom all other cheaper and safer options have proven ineffec-
tive. This enables a more nuanced and personalized approach to prescription than 
allowed by traditional blockbuster or ‘one-size fits all’ approaches and overcomes 
some of the issues associated with the limited clinical efficacy of expensive novel 
therapies.
As described above, two approaches can be taken to delivering precision medi-
cine. Either stratified disease sub-groups can be studied to find new targets for 
drug discovery, or the same detailed patient stratification information can be used 
to identify the best treatment (or set of treatments) from the existing formulary to 
apply to an individual patient given their genetic makeup, phenotype, co-morbidi-
ties and co-prescriptions.
Both approaches require a detailed understanding of the differential causes 
of diseases across a patient population. For monogenic diseases such as sickle cell 
anemia, Huntingdon’s disease or cystic fibrosis, this is relatively simple, being 
very largely determined by a single pathogenic mutation, or in some cases differ-
ent mutations in the same gene that have similar phenotypic effects. For complex, 
multi-factorial diseases such as cancer, dementia and diabetes this means finding 
combinations of features (disease signatures) that accurately describe disease sub-
groups rather than just finding single disease associated mutations in genes.
Revealing this level of detail requires a fundamental improvement in analytical 
tools. Disease population analytical methods such as Genome Wide Association 
Studies (GWAS) have attempted to find disease associated genes. They work by 
identifying single mutations (Single Nucleotide Polymorphisms or SNPs) that 
are over-represented in a case (disease) population compared to a control (non-
disease) population and summing these signals to predict which genes might be 
most disease associated.
GWAS have found some new targets for some diseases, but in general their 
impact on drug discovery has been somewhat disappointing. In particular, GWAS 
have not lived up to the initial expectations that they would fully reveal the inher-
ent complexity of multi-factorial diseases [6, 7]. Because they are designed only to 
find single SNP associations, GWAS cannot test the disease relevance of the huge 
number of potential combinations of SNPs, despite the fact that this is exactly 
what is driving differential disease risk, progression rates and therapy responses 
in patients. This has meant that GWAS can typically only explain a fraction of the 
observed phenotype variance and will only identify a portion of the targets that are 
relevant to a disease, particularly when these are most closely associated with one 
patient sub-group rather than the whole population.
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2. Patient stratification: the key to delivering precision medicine
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groups rather than just finding single disease associated mutations in genes.
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tools. Disease population analytical methods such as Genome Wide Association 
Studies (GWAS) have attempted to find disease associated genes. They work by 
identifying single mutations (Single Nucleotide Polymorphisms or SNPs) that 
are over-represented in a case (disease) population compared to a control (non-
disease) population and summing these signals to predict which genes might be 
most disease associated.
GWAS have found some new targets for some diseases, but in general their 
impact on drug discovery has been somewhat disappointing. In particular, GWAS 
have not lived up to the initial expectations that they would fully reveal the inher-
ent complexity of multi-factorial diseases [6, 7]. Because they are designed only to 
find single SNP associations, GWAS cannot test the disease relevance of the huge 
number of potential combinations of SNPs, despite the fact that this is exactly 
what is driving differential disease risk, progression rates and therapy responses 
in patients. This has meant that GWAS can typically only explain a fraction of the 
observed phenotype variance and will only identify a portion of the targets that are 
relevant to a disease, particularly when these are most closely associated with one 
patient sub-group rather than the whole population.
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A new generation of AI and multifactorial data analytics methods is now 
enabling us to start to untangle the complex combinatorial association signatures 
inherent in disease population datasets, properly characterizing disease sub-groups 
and identifying the different underlying factors causing and influencing their 
specific form of a disease.
One such tool, precisionlife MARKERS, is a massively scalable multi-omics 
association platform that enables the detection of high order epistatic interactions at a 
genome-wide study scale. It can find and statistically validate combinations of multiple 
(typically five or more) SNP genotypes (or other multi-omic features) that are found in 
many cases and relatively few controls, associating those combinations specifically with 
selected phenotypes, such as disease risk, progression rate and/or therapy response.
The insights generated provide a unique high-resolution insight into the archi-
tecture of complex diseases and evidence for the design and selection of therapy 
for individual patients. The importance of these tools to the delivery of precision 
medicine is described with example case studies in this chapter.
2.1 Combinatorial analysis tools for multi-factorial diseases
Precision medicine exploits (and is predicated on) the ability to identify more 
accurately which patients will respond to a specific drug or combination of drugs 
(and which patients will not). In cancer this principle is well understood even if the 
detailed associations between patient’s mutations and their disease/response status 
are still being established.
There are clear genetic targets, such as BRCA1, BRCA2 and PIK3CA in breast 
cancer, KRAS in colorectal cancer, or BRAF or HER2 in several different tumour 
types. These typically result in (relatively) large effect sizes often driven by muta-
tions in coding or direct gene expression control regions that result in significant 
loss of function in the targets. The causative principal is relatively clear in these 
cases, and patients with these types of cancers already have some personalized 
treatment options, and because the targets are identified, their diseases are the 
focus of even more detailed research.
However, outside of these coding region loss-of-function variants, other forms 
of cancer and other diseases, such as asthma, Alzheimer’s, ALS and autism, are 
even more multi-factorial and heterogeneous. They often involve multiple disease 
causing and disease modifying factors from the genome, epigenome, immune sys-
tem, epidemiological and environmental triggers, including diet and the patient’s 
microbiome. In these diseases, multiple different disease related factors usually 
outside of the direct coding regions of genes accumulate and interact to exert the 
final phenotypic effect.
A specific patient’s personal disease risks, rate of progression and responses to 
therapy vary enormously due to combinations of their mutations, predisposing 
phenotypic features and environmental influences. For these complex chronic 
diseases there are hundreds of features associated with different disease trajectories 
and therapy responses across the patient population.
The key to understanding diseases at a deeper level is to find combinations of 
these factors—disease signatures—that distinguish one patient sub-group from 
another. Using combinations of such factors provides a more granular way of 
stratifying patients, giving a higher resolution view of the disease. This enables 
novel, clinically relevant targets that were previously undetectable to be identified, 
providing a useful source of innovation for drug discovery/repurposing as well as 
informing therapy selection for individual patients (Figure 1).
The disease signatures can be used as patient stratification tools and form the 
basis of combinatorial risk prediction models as will be discussed later.
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2.2  Explaining mechanism of action and disease risk with combinatorial disease 
signatures
Knowing that a specific combination of SNPs/genes is strongly disease associ-
ated also helps to explain the metabolic context and the functional role those genes 
play in the disease. This information can be used to generate a minimally complex 
metabolic graph that connects the functions of all the genes contained in this 
network, as shown in Figure 2. This provides much more information about the 
context in which SNPs and genes occur than a standard GWAS study and enables 
focused validation of the metabolic role and disease relevance of the key targets.
Such signatures provide strong, testable hypotheses for the mechanism of action 
and also inform and accelerate the in vitro and in vivo target validation studies. 
This is a key contributor cited by AstraZeneca, GSK and AbbVie in improving their 
R&D productivity [8–10].
For the protective effect signature shown in Figure 2, it can be hypothesized that 
these genes all converge at a central signalling hub involving the insulin receptor 
(INSR), epidermal growth factor receptor (EGFR) and PI3K signalling cascade. 
Mutations in gene 6 appear to be modulating (blockading) the action of INSR, 
which is an important activator of PI3K, a key oncogene [11]. The PI3K/Akt signal-
ling pathway is involved in a variety of processes such as cell growth and survival 
Figure 1. 
Analysis of the disease associated SNPs in an 880 patient schizophrenia population (data provided by UK 
Biobank, combinatorial analysis performed by precisionlife MARKERS, visualization using R Shiny). 
The SNPs are clustered and coloured to show communities of patients that share combinations of disease 
co-associated SNPs. This graph therefore shows both the key patient sub-groups as well as the combination of 
SNPs (disease signatures) that are associated with their specific form of the disease.
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that are necessary for cancer progression [12]. If activation of PI3K is significantly 
reduced it would act to reduce oncogenesis, which would explain the lack of breast 
cancer in this sub-group even when their BRCA2 tumour suppression capabilities 
are compromised by mutation.
The protective effect disease signature shown in Figure 2 is just one of 3045 
disease signatures identified from a precisionlife MARKERS analysis of the 
(germline) genotypes of the BRCA2 positive population. Detailed patient strati-
fication can be achieved by merging all of the disease signatures found in a study. 
Overlaying shared SNPs from the disease signatures and then clustering them by 
the patients in which they co-occur reveals an unprecedented view of the disease 
architecture in the population under study. For the first time, this type of analysis 
shows in detail the disease sub-groups and the combinations of SNPs associated 
with their specific form of the disease.
Figure 3 shows a merged view of the 3045 disease signatures identified in the 
BRCA2 positive population described above. There are 762 unique SNPs in this set. 
Each circle on the graph below represents a single SNP with size proportional to its 
odds ratio (evaluated independently). Links connect SNPs that co-occur in cases 
and distance is inversely proportional to the number of shared cases. SNPs for the 
few (three) genes found by standard GWAS (FGFR2, CCDC170 and CCDC91) are 
shown coloured red, yellow or green. Novel disease associated SNPs that can only be 
identified using a combinatorial approach are shown in grey.
This type of multiple clustering within a single disease is consistent even within 
very highly genetically determined diseases. In several studies, multiple non-
overlapping patient sub-groups have been identified, including in bipolar disease 
[13] and diabetes [14].
Combinatorial analysis methods give novel, high-resolution insights into the 
disease architecture, enabling an understanding of how well a particular patient sub-
population maps to the targets of drugs approved for the disease. Patient sub-groups 
with all grey SNPs on this view are much less likely to be responsive to drugs acting at 
the targets whose SNPs are coloured. For a given patient, their specific combination 
of SNPs will in large part determine which drug or combination of drugs are likely 
to benefit them personally. This detailed stratification is therefore a key enabler of 
precision medicine and the selection of personalized treatment regimens.
Such stratification also enables systematic identification of the drug repurposing 
opportunities for a disease. SNPs associated with targets of on-market drugs approved 
for other diseases can be mapped onto the disease sub-populations to identify and 
prioritize repurposing targets. This application will be discussed later in the chapter.
Figure 2. 
Example of a 6 SNP disease signature associated with significantly reduced risk of developing breast cancer in 
a BRCA2 positive population. This disease signature occurs in 145 people who have not developed breast cancer 
by the age of 55 and zero early onset (<40 years) breast cancer patients in a 1600 patient population.
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2.3 Evolution of genomic and other patient data sources
The key requirement for combinatorial analysis (and patient stratification) 
is a high-resolution view of the causes of a disease and how these are distributed 
throughout the patient population. This clearly starts with a well-diagnosed patient 
(and matched control) population with detailed molecular, phenotypic and clinical 
data. Because most diseases are multi-factorial and heterogeneous we usually need 
hundreds or thousands of patients’ data in order to unravel the complex causes of 
disease. Such large high-quality patient datasets are beginning to become available 
with projects such as UK Biobank [15], disease charity projects such as Project MinE 
[16] in ALS, integrated hospital EMR systems and even pharmaceutical companies’ 
own clinical trials datasets.
Over the past 10 years, the evolution of clinical and research data capture has 
progressed rapidly, led by huge progress in DNA sequencing technologies. It is well-
known that the cost and accuracy of DNA sequencing has improved considerably 
more rapidly than Moore’s law for computing. At the same time other data capture 
technologies have also been improving rapidly. There is now often a vast quantity of 
patient-related data available that can also be analyzed alongside genomics data to 
better inform patient stratification and clinical decision making:
• Omics data, including:
 ○ Proteomic and metabolomic data including liquid biopsies
 ○ Epigenetic data
Figure 3. 
Multifactorial analysis finds multiple new mutations and targets associated with disease risk in BRCA2 positive 
breast cancer. SNPs are clustered by co-occurrence in patient cases—closer SNPs co-occur more frequently in 
cases. Yellow lines indicate that SNPs are in linkage disequilibrium.
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• Patient clinical data
 ○ Prescription, progression and response information
 ○ Patient records
 ○ Claims databases
 ○ Longitudinal studies
• Epidemiological and hyper-local datasets
 ○ Lifestyle, diet and exercise levels
 ○ Environmental data on weather, dust, pollution and other stressors
• Microbiomic and metagenomic data from the patient and their environment
• Biomedical imaging and AI-derived feature analysis
• Digital biomarkers, including:
 ○ Active sensor-derived data from ambulatory monitors, mobile, and wearable 
devices
 ○ Passive environmental monitoring systems
Given that diseases are influenced by some or all of the non-genomic factors 
described above it is clear that in order to predict and explain the various forms 
of such diseases, we must be able to include all of these dimensions of data in our 
analyses. Using precisionlife MARKERS this can be done either as input vari-
ables in the mining phases, e.g. to find genetic signatures specifically associated 
with high BMI, high drinking cohorts of breast cancer sufferers, or as cluster 
variables after the analysis to validate and/or explain the genetic signatures 
identified.
The protective effect signature observed in Figure 2 for example is known to be 
almost exclusively present in women of Hispanic ethnicity. In a standard GWAS, 
this type of population structure effect would have been deemed an artifact or 
confounder and eliminated using covariance methods. However, the protective 
effect is real and has a strong causative explanation, rather than just being a coinci-
dental observation. This has real clinical relevance when women with that signature 
are considering their therapeutic and surgical options after having undergone a 
BRCA test.
3. Novel target discovery and validation
Effective drug discovery requires an understanding of many aspects of the 
disease. It is highly advantageous to have:
• A defined unmet medical need with freedom to operate and a clear competitive 
positioning
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• A genetic explanation and testable hypothesis for the mechanism of action of 
the target
• Proof of differential expression of the target in disease related tissues
• Good chemical starting points with the right safety, bioavailability and off-
target effect profile
• Accurate patient stratification biomarkers
This is the 5Rs framework of drug discovery as described variously by 
AstraZeneca, GSK and AbbVie [8–10]. Following these criteria has been shown 
to improve the chance of successful development of a program from inception 
to Phase III by over four-fold. These are clearly useful guidelines and heuristics 
that we can use to apply to the selection of novel targets following identification 
of unmet medical needs and stratifying patients accordingly. An example of how 
we use our pipeline to identify novel targets is described below using data from an 
asthma population.
3.1 Stratifying an asthma patient population into two molecular phenotypes
Asthma is a debilitating disease that affects 1 in 13 people. 5.4 million people are 
currently receiving asthma treatment in the UK [17]. Asthma patients can be cat-
egorized into two molecular phenotypes: those with high T-helper cell type 2 (T2/
eosinophil) expression, which can result in an excessive inflammatory response, 
and those without (non-T2).
The aetiology of T2 asthma involves activation of the Th2 cells, which result 
in the release of cytokines such as IL-5 and IL-13. In turn, these cytokines recruit 
eosinophils to the affected tissue to counter the antigen(s) that triggered the Th2 
system. Patients with a T2 phenotype currently have a range of targeted biologic 
treatment options available to them.
However, non-T2 patients lack such targeted drugs and often have to rely on 
conventional symptomatic control therapies (such as bronchodilators and inhaled 
corticosteroids), which do little to combat the underlying disease pathology. These 
non-T2 patients make up approximately 30% of the asthma population [18], mean-
ing there is still a distinct clinical need for the development of novel targets for 
therapies that are targeted towards them.
While there have been many GWAS studies on asthma to date, prior studies have 
not focused on the genetic differences between T2 and non-T2 forms of asthma [19]. 
Our understanding of the genetics of T2 asthma are largely based on studies of the 
Th2-cytokine pathways.
Using precisionlife MARKERS with UK Biobank data, we performed a com-
parative study using a genotype dataset derived from UK Biobank to compare T2/
non-T2 asthma patient populations. We used a slightly modified version of the case 
selection criteria presented by Ferreira et al. [20]. While UK Biobank does not have 
data from sputum samples, blood eosinophil counts are considered a good indica-
tor of eosinophilia in the airways [21]. Using these criteria, we identified a total of 
42,205 total asthma cases. We randomly selected 90,034 age- and gender-matched 
subjects from the same database to serve as controls.
We selected a total of 15,071 cases with serum eosinophil counts of 0.15 (1500 
cells/mm3) or less as the non-T2 cohort, and a total of 7094 cases with serum 
eosinophil counts of 0.35 (3500 cells/mm3) or more as the T2 cohort. As some 
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data from sputum samples, blood eosinophil counts are considered a good indica-
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eosinophil counts of 0.35 (3500 cells/mm3) or more as the T2 cohort. As some 
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asthma cases did not have any eosinophil counts recorded, we excluded them from 
either group. In order to reduce errors due to misclassification, we also excluded 
a large group of cases with eosinophil counts between 0.15 and 0.35 which we 
considered to be moderate or borderline values.
Finally, we selected an age- and gender-matched control cohort of 21,688 sub-
jects without asthma or similar respiratory disease. After quality control filtering, 
the genotype dataset included 547,147 SNPs for each case and control subject.
Our aim was to identify significant genotype differences between T2 and non-T2 
asthma, to explain the observed difference in T2 phenotype and use this to develop 
novel targets specific for the non-T2 population. While UK Biobank does not have 
data from sputum samples, blood eosinophil counts are considered a good indica-
tor of eosinophilia in the airways [21]. Therefore, we used blood eosinophil counts 
from the UK Biobank database to separate asthma cases into T2 vs. non-T2 cohorts.
Using precisionlife MARKERS, we performed several studies comparing the T2 
cohort to the non-T2 cohort, and both cohorts independently to healthy controls. 
Firstly, we compared the lists of ‘critical’ SNPs with the lowest p-values from two of 
the studies: T2 vs. controls, and non-T2 vs. controls. We expected this comparison 
to identify three sets of critical SNP genotypes:
1. those that are significantly present in T2 asthma
2. those that are significantly present in non-T2 asthma
3. those that are common to both subtypes.
Figure 4 illustrates the numbers of critical SNP genotypes that are significant 
in each of these categories, indicating clear differences in SNPs between T2 and 
non-T2 cases.
The unique SNPs identified in the replication study (that is, those that show up in 
both cohorts as statistically significant minor alleles) follow a striking pattern. When 
prioritized by p-value, we see a large number of SNPs that relate to immune system 
disorders and asthma—which confirms our hypothesis that our analysis is finding 
biologically relevant high-order combinations of genotypic features.
We then mapped these SNPs into genes within +/− 1 KB and plotted the corre-
sponding genes in a network diagram to illustrate the genetic differentiation of the 
two subtypes of asthma at the level of genes (Figure 5).
Figure 4. 
Critical SNP genotypes that are significantly represented in T2 asthma (2064) vs. non-T2 asthma (1456) vs. 
those that are common to both subtypes (332).
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3.2  Using stratification insights to develop novel targets for non-T2 asthma 
patients
Next, we mapped the prominent SNP genotypes in T2 and non-T2 asthma 
to gene sets and performed a comparative pathway enrichment analysis (see 
Figure 6). As expected, the pathway enrichment analysis shows that T2 and non-T2 
asthma are quite different diseases that share a common symptomatology but little 
else. This is at odds with the clinical prescribing pathways in place for asthma cur-
rently and indicates the need for the development of novel drugs that are specific 
for each patient sub-group.
While many of the most significant genes we identified in the T2 asthma popula-
tion corresponded to classic T2-driven immune pathways, we identified a range of 
different non-immune pathways that were significant in the non-T2 cohort, includ-
ing metabolic and neuronal mechanisms.
Several of the most significant genes in the non-T2 population encode enzymes 
that are involved in key stages of fatty acid synthesis and oxidation pathways. 
Although all the genes we identified represent novel asthma targets, both of these 
pathways have been implicated in driving asthma pathogenesis [22, 23]. We also 
Figure 5. 
Cytoscape plot illustrating major genes involved in asthma disease architecture. Genes in red are prominently 
involved in T2 asthma, genes in green are prominently involved in non-T2 asthma, and genes in blue are 
involved in both subtypes.
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identified targets that are involved in the promotion of LDL oxidation. Increased 
oxidized LDLs (oxdLDLs) are hypothesized to increase bronchial inflammation 
through recruitment and degranulation of neutrophils [24], and inhibitors of this 
pathway are already of interest to several pharmaceutical companies as potential 
new asthma therapies.
Furthermore, we found a range of genes that modulate several different neuronal 
pathways, including regulation of GABAergic transmission, purinergic receptor activa-
tion and glutamate signalling. This implies that non-allergic asthma is driven by a vari-
ety of different mechanisms that are not directly related to the immune system. None 
of the current biologic treatment options address these non-immune mechanisms.
The clear differences between the T2 and non-T2 asthma cohorts hold signifi-
cant potential for better patient stratification, diagnosis and development of new 
treatment options. We have now identified over 20 novel genes that are significant 
only in the non-T2 population with strong, testable hypotheses for their mechanism 
of action. These represent promising opportunities for the development of person-
alized therapies for patients presenting with nonallergic asthma.
Figure 6. 
Pathway enrichment results for T2 (right) vs. non-T2 asthma (left) showing distinct genes and pathways 
associated with the two forms of asthma (calculated using the ClusterProfiler R package).
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4. Systematic drug repurposing
Healthcare is a huge and steadily rising cost for all major global economies. 
Decades of dedicated scientific endeavor and extensive industry investment in 
biopharmaceutical R&D have paid huge dividends in improving the health of 
nations. The associated costs are however significant and are becoming potentially 
unsustainable [25] due to changing demographics, reduced R&D productivity and 
increasing use of expensive new treatment modalities.
A new way of routinely identifying the most appropriate and cost-effective 
treatments for individual patients is needed. This would identify the best, most per-
sonalized therapies from both the existing formulary as well as innovative new drug 
options to improve outcomes and lower costs. This is the compelling proposition 
underpinning precision medicine, and it is being enabled in oncology and beyond 
by new developments in AI technology aimed at improving patient stratification, 
drug repurposing and therapy selection.
Precision medicine promises to deliver better medicines, improved patient 
outcomes, and lower healthcare costs [26]. Personalized therapies can reduce costs 
associated with the inefficiencies of the ‘one size fits all’ approach of healthcare 
systems such as trial-and error dosing, hospitalizations due to adverse drug reac-
tions, and reactive treatment [27]. However, developing novel targeted therapies 
for each patient sub-group is challenging. Robustly identifying disease causative 
mutations with druggable targets and developing the new medicines to target these 
is an expensive and time-consuming process that has proved difficult to scale, even 
with the advent of genomic medicine.
A more cost-effective approach can be to identify targets associated with the 
clinically relevant subgroups of patients with unmet medical needs and then search 
the current formulary to find the drugs that will be effective for each of them. This 
approach is called drug repurposing or repositioning.
4.1 Pharmacoeconomic pressures and healthcare costs
Over the last 70 years, improved vaccines, antibiotics, drugs and other health-
care interventions have delivered decades of profound positive change in lifespan, 
patient outcomes and socioeconomic productivity. But these benefits have come at 
a cost. In 2017, US healthcare spending was over $3.5 trillion—equivalent to $10,739 
per person or 18% of the country’s gross domestic product (GDP) [28]. This is 
expected to rise to almost $6 trillion (19.4% of GDP) by 2027 [29].
The world pharmaceutical market was worth $935 billion in 2017 [30]. 10% of 
the US healthcare budget is spent on prescription drugs [31]. This drug budget is 
increasing worldwide and is forecast to rise by an annual average of 6.1% in the US 
from 2020 to 2027. A key underlying driver of rising costs is the increase in chronic 
conditions, related to changes in lifestyle and an aging population [32]. Globally, 
33% of adults have multiple long-term diseases, rising to 75% in developed coun-
tries. Healthcare costs increase with each condition [33], and with age. Annual US 
treatment costs for an over-65 patient are five times higher than for under 18 s, 
and 2.5 times those for people aged 18–64 [34]. The number of over-65 s is set to 
increase significantly in the next 20 years.
At the same time R&D productivity in the pharma industry has been diminish-
ing for decades. In 2018, R&D returns declined to 1.9%, down from 10.1% in 2010 
[35]. Drug discovery is costly (at over $2.8B per marketed drug) [36] and lengthy—
it takes an average of 12 years to develop and market a new drug [37]. Even then, 
as noted above, many drugs benefit only a limited proportion of patients to whom 
they are prescribed [1].
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A secondary driver in the increase in drug spending is the growing emphasis in 
biopharmaceutical innovation away from small molecule drugs to more complex 
and expensive biologic drugs including targeted antibodies, cancer vaccines, 
checkpoint inhibitors, and cell and gene therapies. Since 2014, almost all the net 
growth in drug spending is accounted for by biologic medicines [38]. In 2017, while 
biologic drugs represented just 2% of all US prescriptions, they accounted for 37% 
of net drug spending.
There are good reasons underpinning this switch of emphasis—new biologic 
approaches have been revolutionary in offering new therapy options and more 
effective modalities for some extremely difficult to treat conditions, especially in 
oncology. Use of monoclonal antibodies also overcomes a lot of the issues associ-
ated with late-stage failure of small molecule compounds due to off-target effects, 
toxicity and bioavailability.
There is undoubtedly a subset of patients who will only benefit from these 
treatments and who should therefore have access to them, but the economics of their 
use can be challenging for widespread adoption by health systems [39]. High cost 
is a consistent attribute of biologic drugs, which on average cost $10,000–$30,000 
per patient per year. This is particularly true in the US where, unlike Europe, these 
drugs are regulated differently and have considerable protection with relatively little 
competition from generic versions, known as ‘biosimilars’ [40]. While potentially 
transformational for discrete patient sub-groups, this level of pricing for biologics 
does not always support their widespread use. This presents a challenge for all par-
ties—payers, providers, patients and even the pharma companies themselves in the 
longer run. Precision medicine is a key tool in ensuring that medicines are prescribed 
to those who can benefit from them, saving cost and improve patient treatment.
4.2 Using patient stratification to inform drug repurposing
As of 2018, over 1500 drugs have been approved [41, 42], including many safe 
and effective medicines that hit targets that play roles in multiple diseases. These 
can be used in other disease areas with a somewhat lower regulatory burden as they 
have already been safely prescribed (often for decades) in humans.
Traditionally, drug repurposing involves identifying a drug candidate that is 
proven safe in humans but that was either ineffective for its original indication, or 
that has been approved and launched in another disease area. Someone wishing to 
repurpose the drug would typically license it from the original inventor or company 
marketing the drug, reformulate it if necessary, and then take it through a short-
ened clinical trial in the new indication, before gaining approval and launch. This 
can be quicker and cheaper than de novo drug development. Repurposing can help 
identify therapies especially for areas of unmet medical need in complex disease 
such as asthma, ALS, dementia and breast cancer [43].
The detailed disease architecture views offered by the combinatorial approach 
used by precisionlife MARKERS take drug repurposing from a serendipitous exer-
cise, observing multiple metabolic roles or potential poly-pharmacology of specific 
targets, to a level where diseases can be systematic repurposed, identifying all of 
the available therapies for targets that are relevant to the various disease population 
sub-groups (Figure 7).
4.2.1 Identifying drug repurposing opportunities systematically in breast cancer
Breast cancer is a highly heterogeneous disease with significant variations in 
prognosis, treatment response across the patient population. It is currently the 
leading cause of cancer-related mortality in women [44], with approximately 1 in 
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8 women being diagnosed with the disease at some point in their lifetime [45]. 
Patients are currently classified into several different molecular subtypes, based 
on underlying disease mechanisms, hormone receptor status and tumour biol-
ogy. Common forms include ER, PR and HER2-positive and triple-negative breast 
cancer (TNBC).
Some of these have existing targeted therapies. Greater understanding of 
underlying HER2-positive disease mechanisms has led to the development of 
HER2-targeted therapies such as trastuzumab and lapatinib, generating significant 
improvements in patient survival as a result [46]. Notwithstanding these improve-
ments, up to 50% of HER2-positive breast cancer patients still go on to develop 
metastases.
However, although breast cancer treatment has a more personalized approach 
than some other diseases, subtypes of breast cancer patients—such as those with 
TNBC—do not respond to these targeted hormonal therapies. These may cor-
respond to more aggressive and harder to treat forms of the disease. Because of this 
there remains a significant need for more therapeutic options and greater person-
alization of treatment strategies in breast cancer therapy in order to continue to 
increase patient response rates and overall survival.
In order to investigate potential repurposing options for one key sub-group of 
patients who do not have as many therapeutic options, we wanted to stratify the 
breast cancer population and run a systematic repurposing study to identify all of 
Figure 7. 
Detailed disease architecture view of the SNPs (grey circles) and genes (blue circles) associated with ALS 
disease risk from a precisionlife MARKERS study of 8700 patients and 14,400 controls. This connects patient 
sub-groups with the genes/targets involved in their disease and the available drugs/development compounds 
known to be active against all of these targets (red triangles).
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the known active chemical compounds. Again, we used the UK Biobank to generate 
the study population (cases and controls). Unfortunately, the hormone receptor sta-
tus of the patients is not routinely available in the dataset, so tying these to disease 
phenotype at a very detailed level was not possible.
Genotype data of 547,197 SNPs from 11,088 breast-cancer cases and 22,176 
controls (1:2 case control ratio all women) was obtained from the UK Biobank 
(ICD10 code C50) [47]. An age-matched control set was created of randomly 
selected healthy females with no prior history of cancer. We ran the precisionlife 
MARKERS platform to identify disease associated signatures.
The results of the study are a series of SNPs, scored and ranked to select the most 
significant mutations. These are then mapped to genes and annotated using data 
from a wide range of publicly available data sources. Information on the functional 
role, pathways and expression levels for these genes is combined with information 
on active chemistry, druggability, on- and off-target effects, toxicity, bioavailability, 
as well as assays, models, scientific literature, IP filings and other sources.
A series of heuristics were then applied on the identified genes to find the targets 
and candidate drugs with the highest potential for repurposing on the basis of their 
correlation to disease, their existing disease indications, and other criteria such as 
expression in relevant (disease-related) tissues, acceptable safety profiles, delivery 
route, formulations and patent scope.
We found 175 risk-associated genes that are relevant to different patient sub-
populations. These genes were annotated and analyzed using the druggability 
heuristics discussed above. Using in silico tests, we identified 23 gene targets as high 
scoring repurposing candidates.
Different diseases may share common pathways, and drugs that affect genes 
in these pathways could therefore treat a variety of disease indications. Mapping 
existing drugs onto the genetic and metabolic signatures (Figure 8) indicates areas 
where there are already good clinical options, and also where off-label use of exist-
ing therapeutics with good safety and tolerability profiles, with acceptable routes of 
administration, could have potential. For a given patient, their specific combination 
of SNPs will in large part determine which drug or combination of drugs are likely 
to benefit them personally.
4.2.2 Our methodology identified two existing repurposed breast cancer drugs
Two of the targets we identified in our breast cancer study, P4HA2 and TGM2, 
which were both identified as having high repurposing potential, have already been 
investigated in the context of breast cancer and therefore serve as useful validation 
examples.
One of the highest scored genes identified in the analysis was P4HA2, whose 
protein product plays a role in collagen synthesis, catalyzing the formation of 
crucial 4-hydroxyproline residues that are involved in collagen helix formation and 
stabilization [48]. Collagen deposition in breast cancer increases cancer cell devel-
opment and growth [49]. Inhibiting P4HA2 may therefore prove beneficial in breast 
cancer by reducing collagen synthesis and deposition.
Even as well-known and ubiquitous a drug as aspirin decreases the expression of 
P4HA2, and thus lowering collagen deposition [50]. Aspirin is very well-studied [51], 
with a wealth of pharmacokinetic and toxicology data at high- and low-dose. It 
has a simple molecular structure (see Figure 9), meaning that it is notorious for 
interacting with a wide variety of biological targets. It was originally licensed as 
a non-selective COX-2 inhibitor [52], however it also modulates several different 
transcription factors and pathways implicated in cancer, including NF-κB, PIK3CA 
and AMPK and mTORC1 signalling [53].
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Aspirin reduces P4HA2 activity through two different mechanisms [50] and 
also enhances the levels of an miRNA called let-7 g, which binds and suppresses the 
expression of P4HA2. Additionally, the promoter of P4HA2 has three NF-κB bind-
ing sites and aspirin inhibits NF-κB expression, resulting in a concomitant decrease 
in P4HA2 activity. The benefits of this aspirin-induced reduction in collagen 
deposition were observed in a model of hepatocellular carcinoma, where inhibition 
of P4HA2 resulted in a reduction in tumour growth.
There is however conflicting evidence as to whether aspirin is effective in both 
reducing the risk of breast cancer and improving disease survival after diagnosis 
[53, 54]. A greater understanding of the mechanisms behind aspirin’s anti-tumour 
effect and stratification of the population into more clinically relevant subsets may 
indicate groups of patients who are more likely to respond to aspirin treatment. 
Our results identified a sub-group of patients with a gene signature that indicates 
aberrant P4HA2 expression for whom administration of aspirin is more likely to be 
effective.
TGM2 also scored highly for repurposing potential. TGM2 encodes an enzyme 
(transglutaminase 2, TG2) involved in post-translation modification of proteins, 
facilitating their crosslinking [55]. High TG2 expression has been associated with 
Figure 8. 
Graph of existing drug options for key targets identified as being relevant to disease sub-populations in a breast 
cancer population.
Figure 9. 
Molecular structures of aspirin (A), cystamine (B) and disulfiram (C).
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increased tumour growth and invasion in several different cancer types through the 
activation of PI3K/Akt and other cell survival pathways [56].
In breast cancer, TG2 is upregulated compared to its baseline in normal epithe-
lial tissue, and increasing expression is correlated with higher tumour stage [57]. It 
has also been shown that TG2 interacts with interleukin-6 (IL-6), facilitating IL-6 
mediated inflammation, tumour aggressiveness and metastasis in a mouse model 
of breast cancer [57]. Hence, repurposing a TG2 inhibitor in breast cancer could be 
therapeutically beneficial in a specific subtype of patients.
Cystamine is an allosteric inhibitor of TG2, causing the formation of a disulfide 
bond between two cysteine residues, diminishing TG2’s catalytic activity [58]. 
Moreover, although cystamine has not yet been trialled in breast cancer patients, an 
in vitro study has found that inhibiting TG2 expression resulted in reduced breast 
tumour growth compared to controls [59].
Unfortunately, trials in humans demonstrate that cystamine can cause a range 
of dose-limiting side effects [60]. Conversely, disulfiram, a drug approved for the 
treatment of chronic alcoholism, has a comparable molecular structure to cysta-
mine (see Figure 9). Palanski et al. demonstrated that disulfiram has the same 
activity as cystamine in vitro, with comparable inhibitory constants when assessed 
experimentally [61]. Disulfiram has a more favourable pharmacokinetic profile than 
cystamine; it can be administered orally with a maximum dose of 500 mg/day and 
is reasonably well tolerated in patients [62, 63].
Both targets identified from this study, TGM2 and P4HA2, have strong 
mechanistic links to breast cancer and are targeted by approved drugs with 
favourable pharmacokinetic and toxicity profiles. These two example targets 
demonstrate the potential of this approach to systematically identify repurpos-
ing candidates that have potential to be effective in specific sub-groups of breast 
cancer patients.
The analysis of multifactorial, multi-omic datasets using precisionlife 
MARKERS identifies disease associated combinations of features, provides an 
important improvement in analytical capability that will be central to the delivery 
all aspects of precision medicine. This will enable development of more detailed 
insights and personalized medicine strategies, with the potential to target spe-
cific sub-types of diseases with the greatest unmet need, such as triple negative 
breast cancer.
5. Combinatorial therapy design
Recognition of the need for more personalized prescription using all available 
information has driven huge interest in precision medicine, but progress has been 
slower outside of oncology [64]. The combination of large quantities of patient 
genotype, phenotype and clinical data and improved data analytics methods have 
the potential to usher in a new era of affordable precision medicine, lowering the 
cost of care and identifying the best drugs for individual patients, thereby giving 
them the best possible outcome. In a time of rising drug costs and squeezes on 
healthcare budgets, this step could be crucially important for the future affordabil-
ity of healthcare.
5.1 Personalized therapy selection
Repurposing drugs on an individual patient basis, through off-label prescrib-
ing, is already a route that can provide immediate access to effective drugs for 
patients with unmet needs. It is not without significant problematic issues, but 
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off-label prescribing already accounts for 20% of US out-patient prescriptions [65]. 
Including the examples shown below (Table 1) [66, 67].
More widespread delivery of precision medicine in the future could be achieved 
by having a principled and evidence led basis from which to make personalized sug-
gestions for an individual patient, and then studying the outcomes for patients and 
using these to refine future prescriptions [68]. This would need to be confirmed 
with appropriate biomarker tests (such as the combinatorial disease signatures 
described above) and subject to review as part of a personalized health plan by a 
comprehensive clinical team as is the current practice in oncology precision medi-
cine applications [69].
Payers and prescribers routinely collect such data over a sufficiently long time, 
and with appropriate controls, this can be used to identify a patient as a responder 
or non-responder to a particular treatment. Given the N-of-1 nature of the trials, 
the recommendations may also include off-label prescriptions, potentially including 
the full range of drugs available on the formulary, including generics. Recent studies 
have shown the efficacy and therapeutic benefits of choosing such non-standard 
drug options when guided by genomic insights, especially in diseases such as colon 
cancer [70, 71]. When available these may reduce the dosage of high toxic chemo-
therapy agents required while providing more targeted therapies that increase the 
effectiveness of treatment.
The key to maintaining effective oversight and control of such personalized 
interventions and deriving full benefit from them for future public health will be 
dependent on harmonizing their design and collection of their results. Aggregated 
results of many N-of-1 trials (with harmonized design and data capture) will offer 
an on-going information resource that can be used to identify how to better treat 
subsets of the population or even the population at large [1].
In the future, payers and prescribers will be able to use a clinical decision sup-
port tool based on the insights from a detailed combinatorial analysis of the disease 
architecture plus the results of the N-of-1 real world trials to prescribe existing 
drugs, either as approved or off-label, on a personalized basis to individual patients 
(see Figure 10). The additional therapeutic options from systematic repurposing, 
coupled with use of coordinated clinical decision support tools and structured 
N-of-1 trials will be designed to optimize the prescription of effective drugs, single 
or in combinations. This process could speed up the process of effective treatment 
for both the patient and the physician, cut costs, improve outcomes, and reduce 
side-effects.
Adding further datasets, such as known drug:drug, drug:disease and even 
drug:food interactions, and feeding back patient/clinician reported outcomes 
will further improve the personalization of recommendations for the patient, 
enabling the avoidance of predictable side-effects and adverse drug reaction 
with a patient’s other medications. It also present new opportunities to involve 
them as an active partner in the management of their own health, for example by 
providing personalized dietary advice that minimizes predictable adverse drug 
reactions [72].
Table 1. 
Examples of current common off-label prescriptions.
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6. Conclusions
Datasets are now being compiled in routine healthcare that give an unprecedent-
edly detailed and holistic view of patients. New AI and analytical tools are beginning 
to combine and analyze these data to improve diagnosis and the development and 
selection of therapies that are more closely targeted at specific patient sub-groups. 
These create opportunities to transform the delivery of medicine in the near future.
The combination of better access large quantities of high-quality multi-omic patient 
data, improved data analytics, systematic drug repurposing and N-of-1 trials have the 
potential to usher in a new era of affordable, personalized and precision medicine. This 
could lower the cost of care and identify the best drugs for individual patients, thereby 
giving them the best outcomes possible. In a time of rising drug costs and squeezes on 
healthcare budgets, this step could be crucially important for the future of healthcare.
The insights generated by multifactorial and multi-omic analysis of large disease 
populations are particularly enabling to:
• accelerate innovative drug discovery and repurposing projects
• find novel validated and stratified targets for complex diseases
• identify multi-omic biomarkers for patient stratification
• build better, more personalized combinatorial risk scores
• inform clinical decision support systems for precision medicine
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Toward the Clinic: Understanding 
Patient Perspectives on AI and 




The increasing application of AI-led systems for oncology drug development 
and patient care holds the potential to usher pronounced impacts for patients’ 
well-being. Beyond technical innovations and infrastructural adjustments, research 
suggests that realizing this potential also hinges upon patients’ trust and under-
standing. With the promise of precision oncology predicated on a data-driven 
approach, public and private survey studies indicate patients view the lack of 
clarity surrounding data privacy, security, and ownership as a growing concern. 
Assuming an in-depth, semi-structured interview protocol, this qualitative study 
examines cancer patients’ perceptions of the burgeoning development of AI-led 
systems for oncology as well as their perspectives on sharing health data (including 
genetic data) for drug development. This article seeks to provide greater insight 
into the legal and ethical challenges that surround the application of these tools and 
to explore patient-centered approaches to building the frameworks of trust and 
accountability crucial to transferring these advances to the clinic.
Keywords: AI, oncology drug development, health data-sharing, cancer patients
1. Introduction
Recent decades have witnessed major advances for AI systems, which has 
subsequently resulted in increased interest in applying AI-driven technologies for 
oncology drug development and cancer patient care. Beyond technical and infra-
structural adjustments, improvements, and innovations, recent studies suggest 
that realizing the potential of AI in healthcare and applying data-driven models 
to oncology drug development hinges in part upon the public’s—with especial 
regard to potential patients’ and users’—trust and understanding. As contingent to 
oncology drug development and research, the importance of the public’s capacity 
for trust extends to both the use of AI and data-sharing. Public and private survey 
studies indicate patients view the lack of clarity surrounding data privacy, security, 
and ownership as a growing concern. Exemplifying this, in September 2018, a 
KPMG survey of over 2000 Britons found that 51% of its participants were both 
worried about data privacy and unwilling to share personal data with U.K. organi-
zations for AI research and use [1]. In addition, the U.K.’s Academic Health Sciences 
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to oncology drug development hinges in part upon the public’s—with especial 
regard to potential patients’ and users’—trust and understanding. As contingent to 
oncology drug development and research, the importance of the public’s capacity 
for trust extends to both the use of AI and data-sharing. Public and private survey 
studies indicate patients view the lack of clarity surrounding data privacy, security, 
and ownership as a growing concern. Exemplifying this, in September 2018, a 
KPMG survey of over 2000 Britons found that 51% of its participants were both 
worried about data privacy and unwilling to share personal data with U.K. organi-
zations for AI research and use [1]. In addition, the U.K.’s Academic Health Sciences 
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Network, in conjunction with the Department of Health and Social Care, released a 
report delineating the results from a 2018 “state of the nation survey.” Similar to the 
findings of the KPMG survey, this report, titled “Accelerating Artificial Intelligence 
in Health and Care,” identified that, according to pioneers in the field, the “overall 
enablers” to realizing the potential of AI in health and care include an ‘ethical 
framework to build/preserve trust and transparency’ as well as “clarity around 
ownership of data” [2]. Likewise, when asked, “which of the following areas do 
you think will be the greatest problem for artificial intelligence,” the KPMG survey 
respondents’ top answer was “data privacy and security.”
As patients increasingly view the lack of clarity surrounding data privacy, secu-
rity, and ownership as a growing concern, the potential benefits of AI-led oncology 
drug development and oncology care systems must not be accepted as superseding 
their potential to enact social harm. As public and patient approval and participa-
tion contribute to the use and development of these systems is imperative to study 
patient perceptions of AI and AI-led oncology drug development endeavors and to 
heed and address public concerns. Accordingly, this chapter enlists and examines 
ethnographic, textual, and other qualitative data that the author has assembled 
in pursuing a broad examination of the legal, political, and ethical imperatives 
surrounding the development of AI-driven systems for healthcare and for oncol-
ogy, specifically. This chapter provides new evidence for understanding patient 
reception of the development and deployment of these systems as well as patients’ 
perceptions and willingness to participate in health-related AI development by 
sharing medical data, necessary to build these systems and advance their efficacy, 
with the public and private entities engaged in developing them. Rooted firmly in 
interview work produced utilizing an in-depth, semi-structured interview protocol 
this chapter offers insights into the legal and ethical quandaries that surround the 
application of these tools in order to ultimately explore and assess patient-centered 
approaches to building crucial frameworks of trust and accountability fundamental 
to transferring these advances into clinical settings for the betterment of patient 
outcomes.
This chapter opens by offering a contextual scaffolding to understanding the 
terms AI and machine learning. Subsequently, the author provides an introductory 
overview to understand how AI-led systems might be applied to clinical contexts 
and oncology setting, respectively. This is followed by a discussion of some practical 
considerations and challenges to AI-enabled healthcare applications. The author 
then provides an overview of the study’s methods and methodology to further con-
textualize the remaining discussion, which relies heavily upon the author’s original 
qualitative research. This leads to a discussion of patient perceptions, knowledge, 
and concerns regarding AI-driven systems for oncology, drug development, and 
medicine, more broadly. Immediately after, the author stages an exploration of 
patient perceptions and concerns regarding sharing their medical data to bolster AI 
and oncology drug development research. The final section of this chapter discusses 
further patient-centered recommendations and proposals for ensuring patient 
trust, participation, and safety pertinent to increasing the development and clinical 
use of AI systems for oncology.
2. Defining AI and machine learning
2.1 Defining AI systems and intelligence
Although conceptions of sentient, machinic animacies can be traced as far back 
as antiquity, the understanding of “AI” or “artificial intelligence” as a term and field 
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of study originated in 1956 following a conference organized at Dartmouth College 
by the American computer scientist, John McCarthy. McCarthy, who himself coined 
the term, is often hailed as a preeminent pioneer of AI McCarthy defined artificial 
intelligence as “the science and engineering of intelligent machines” [3]. The ensu-
ing decades saw the salad days of what the analytic philosopher John Haugeland 
names as “Good Old Fashioned AI” (GOFAI). Within the paradigm GOFAI, artifi-
cial intelligence essentially referred to “procedural, logic-based reasoning and the 
capacity to manipulate abstract symbolic representations” [4]. For instance, the 
commercial “expert systems” of the 1970s and 1980s are typically understood as 
exemplifying GOFAI. By 1969, however, data scientists began to seriously question 
the general viability of AI as well as the initial, florid promise that surrounded 
these systems. The deflation of these experts, coupled with considerable decreases 
in grant support and research output, led to an “AI winter,” which lasted approxi-
mately for the next 20 years until a renewed interest in machine learning techniques 
propelled AI research forward [5].
In contrast to GOFAI, the “intelligence” at stake in contemporary AI systems 
is typically understood to imbricate machine learning techniques. Intelligence, in 
the current paradigm, is thought to derive from systems’ abilities to detect patterns 
across vast datasets and predict outcomes based on probability statistics. In other 
words, today algorithmic systems are deemed AI provided they process and analyze 
vast amounts of data, beyond the scope of an individual human, in order to predict 
and automate certain activities. Critical to understanding AI’s consequences for 
epistemology and social practice, anthropologist of technology M.C. Elish stresses 
that “the datasets and models used in these systems are not objective representa-
tions of reality” as systems that utilize machine learning techniques “can only be 
thought to ‘know’ something in the sense that it can correlate certain relevant 
variables accurately” [4].
With some cognizance of the shifting valences the term accrued in decades 
since the 1950s, AI might be otherwise understood as “a characteristic or set of 
capabilities exhibited by a computer that resembles intelligent behavior” although, 
evidently, delimiting what might be understood as “intelligence” remains a crucial 
although unresolved and contested dimension in defining AI [6]. Some researchers 
consider artificial intelligence to be contingent on behavioral demarcations, osten-
sible when a “computer can sense and act appropriately in a dynamic environment” 
[6]. Others link intelligence to symbolic processing, exhibited, for instance, when a 
system can recognize and respond appropriately to speech [6].
2.2 Machine learning: “imposing a shape on data”
Given the breadth of the term’s inherent contestations, evolutions, and stub-
born fluidity, social researchers of technology such as Tim Hwang and M.C. Elish 
contend that definitions of artificial intelligence and intelligent systems might be 
appropriately understood as “moving targets.” Rather than possessing a static set 
of demarcations signaling intelligence, artificially intelligent systems are defined 
in relation to “existing beliefs, attitudes, and technology” [6]. They argue that the 
rhetorical power of “artificial intelligence” is found in its “slipperiness”: seemingly 
everyone has an idea of what AI is, and yet everyone’s notion is different [6]. In 
consequence, data scientists and engineers today tend to shy away from the term 
“artificial intelligence.” Indeed, the equivocality of “artificial intelligence” has siloed 
“AI” as a marketing term rather than a technical one [4].
Current research in artificial intelligence occurs primarily in the field of 
machine learning (ML). Although “machine learning” was coined in 1959, signifi-
cant interest in these techniques did not follow until the 1980s following further 
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machine learning (ML). Although “machine learning” was coined in 1959, signifi-
cant interest in these techniques did not follow until the 1980s following further 
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developments in techniques such as neural networks. Digital medicine researcher, 
Eric Topol argues that machine learning can be understood as “computers’ abil-
ity to learn without being explicitly programmed, with more than 50 different 
approaches like Random Forest, Bayesian networks, Support Vector machine uses”; 
they are “computer algorithms [that] learn from examples and experiences (data-
sets) rather than predefined, hard rules-based methods” [5]. Computer scientist 
Tom Mitchell has elaborated what that “learning” in the context of ML systems 
refers to. Mitchell writes: “A computer program is said to learn from experience E 
with respect to some class of tasks T and performance measure P if its performance 
at tasks in T, as measured by P, improves with experience E” [7].
Put differently, media and communications scholar Taina Bucher explains that 
although “algorithms are ‘trained’ on a corpus of data from which they may ‘learn’ 
to make certain kinds of decisions without human oversight…machines do not learn 
in the same sense that humans do.” Rather, Bucher argues, “the kind of learning 
machines do should be understood in a more functional sense” [8]. Citing legal 
scholar Harry Surden, Bucher explains that machine learning-driven systems are 
“capable of changing their behavior to enhance their performance on some task 
through experience” [8].
Machine learning is largely enabled by “proliferating data from which models 
may learn.” It follows that enormous datasets are paramount for developing effec-
tive ML systems. Machine learning techniques such as logistic regression models, 
k-nearest neighbors, and neural networks generally “pivot around ways of trans-
forming, constructing, or imposing some kind of shape on the data and using that 
shape to discover, decide, classify, rank, cluster, recommend, label, or predict what 
is happening or what will happen” [9]. Bucher underscores that what determines 
whether to use one technique over another “depends upon the domain (i.e., loan 
default prediction vs. image recognition), its demonstrated accuracy in classifica-
tion, and available computational resources, among other concerns” [8].
Machine learning systems are distinct from deterministic algorithms in that 
“given a particular input, a deterministic algorithm will always produce the same 
output by passing through the same sequence of steps” while an ML algorithmic 
system “will learn to predict outputs based on previous examples of relationships 
between input data and outputs” [8]. In other words, Bucher notes that “in contrast 
to the strict logical rules of traditional programming, machine learning is about 
writing programs that learn to solve problems by examples...using data to make 
models that have certain features” [8]. Feature engineering involves “extracting 
and selecting the most important aspects of machine learning” [8]. Signaling the 
constructed subjectivity of the knowledge produced by systems utilizing machine 
learning techniques, Bucher explains that “the understanding of data and what 
it represents, then, is not merely the matter of a machine that learns but also of 
humans who specify the states and outcomes in which they are interested in the first 
place” [8].
3. AI systems for oncology and oncology drug development
3.1 AI-enabled medical care
AI systems have been deployed in healthcare contexts since at least the 1970s 
following the development of computer-assisted clinical decision support tools, 
however the last decade is particularly thought to have been a watershed moment 
for the nexus of AI systems and healthcare. The advent of so-called big data analyt-
ics coupled with crucial advances in machine learning techniques (specifically, the 
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exponential development of new deep learning algorithms), has propelled both the 
development of, and a far-reaching rejuvenated interest in, applying these models 
for medical usage. This has compelled technologists, medical researchers, venture 
capitalists, and media pundits, among others, to question whether the contempo-
rary is witnessing the dawning of a new era of medicine. In the past several years 
alone, leading-edge advances in machine learning have enabled AI-driven systems 
to accurately identify heart rhythm abnormalities, predict suicides at a better 
rate than mental health professionals; to successfully interpret pathology slides 
of potential neoplastic tissues or medical scans with the same rate of accuracy 
(at times, even exceeding the rate of accuracy) of that of senior pathologists and 
radiologists; and to accurately diagnosis both a multitude of eye ailments such as 
diabetic retinopathy as well as some skin cancers at a similar rate to (and in some 
instances, better than) medical professionals [5]. Beyond these examples, other 
current efforts are directed at training AI systems to identify modifications in drug 
treatment protocols and to predict clinical outcomes.
3.2 AI-enabled cancer care
These celebrated developments, as well as a host of others, have led research-
ers in oncology-related fields to question how AI systems might be deployed 
to improve clinical outcomes for patients with cancer. Health researchers are 
emboldened by the promise that any piece of medical data able to be translated 
analytically such as “patterns, predictable outcomes, or pair associations” can 
be effectively evaluated by machines [10]. Currently, AI-based approaches to 
clinical trial design, pathology, and radiology are being studied for effectiveness 
with encouraging results. Under development are other promising applications of 
AI For example, data and medical scientists are endeavoring to integrate and ana-
lyze individuals’ multi-omics data (such as individuals’ genomes) using AI The 
ultimate goal of this cooperative research is to usher in a new standard of tailored 
or personalized medical care with the potential to improve clinical outcomes for 
patients with cancer. While some researchers and data scientists are pursuing the 
deployment of multi-omics data to improve early diagnosis in oncology, others 
are hoping AI-enabled approaches will aid in the continuing discovery of new and 
increasingly sensitive biomarkers for cancer care [10]. Healthcare professionals, 
researchers, and data scientists hope that, in the near future, complex biomarkers 
will constitute an improved basis for cancer prevention and diagnosis, offering 
patients the most optimal treatments based on the particular characteristics 
of their cancer, and aid medical professionals in determining the likelihood of 
 recurrence [11].
4. Practical considerations and challenges to AI-enabled healthcare
4.1 Contextualizing the hype: AI limitations
Accompanying the renewed interest in applying machine learning techniques 
to health data has been a buzz of exaggerated claims and overdrawn expectations 
regarding how quickly and comprehensively AI will transform modern medicine. 
Digital medicine researcher Eric Topol offers a partial list of the “outlandish expec-
tations” escorting the development AI-enabled healthcare. Some envision that soon 
these systems will “outperform doctors at all tasks; diagnose the undiagnosable; 
treat the untreatable; see the unseeable on scans and slides; predict the unpre-
dictable; classify the unclassifiable; eliminate workflow inefficiencies; eliminate 
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hospital admissions and readmissions; eliminate the surfeit of unnecessary jobs; 
result in 100% medical adherence; produce zero patient harm; and cure cancer” [5]. 
Instead, Topol and other medical researchers assume a more modest view: AI-driven 
systems will not serve as a panacea to all the aforementioned predicaments in 
modern healthcare but will instead gradually serve as an increasingly important tool 
in addressing these and other issues. Moreover, medical experts and technologists 
alike contend that the encouraging results AI-driven systems have garnered in fields 
like pathology and radiology, for example, should be taken neither as a justification 
for the outsourcing of pathologists and radiologists, nor point to the burgeoning 
obsolescence of medical specialists as a whole [10]. Rather, they stress that these 
initial successes should be understood as an “indication that their workload could 
be optimized and, importantly, the waiting time for patients to receive a diagnosis 
can be reduced” [10]. In this perspective, over time, the widespread adoption of 
AI systems in healthcare will result in a crucial leveling of the “medical knowledge 
landscape” [5]. As a consequence, some medical researchers believe that advances 
in AI and the eventual adoption of these systems within the realm of healthcare will 
herald unprecedented advantages to modern medical specialists by “restoring the 
gift of time” to health professionals allowing them to devote more clinical attention, 
emotional support, and guidance to patients [5].
4.2 Tempering visions of imminent medical revolutions
While in the past decade, the development of AI systems for use in the medical 
field has certainly progressed and led to feats that have garnered significant atten-
tion, these successes remain arguably limited and the progression of these systems 
decidedly gradual. Taking the field of narrow AI diagnostics as an example, recent 
systems have accurately diagnosed skin lesions and pathology slides in the realm of 
oncology. In cardiology, AI diagnostic systems have accurately interpreted echocar-
diographic images and electrocardiograms in diagnosing heart abnormalities [5]. 
Other AI diagnostic systems have successfully analyzed audio-wave forms to assist 
in diagnosing asthma, pneumonia, tuberculosis, and other lung ailments [5]. All of 
these successes, however, constitute narrow AI tools that, in reasonable estimations, 
would serve to aid rather than replace medical professionals. Demonstrably, one 
broad AI diagnostic system sits in recent memory of some oncologists as a stunning 
failure that highlights the limitations of AI-enabled healthcare at present. From its 
early inception, IBM’s AI-driven Watson supercomputer was hailed by the company 
as harnessing the power to revolutionize cancer care. Beginning in 2013, IBM initi-
ated partnerships with leading medical institutions renowned for their research in 
oncology such as the MD Anderson Cancer Center at the University of Texas, the 
Memorial Sloan-Kettering Cancer Center in New York, and the University of North 
Carolina’s Lineberger Comprehensive Cancer Center. IBM bought a multitude of 
competitor companies and spent millions in order to train Watson on crucial medi-
cal data including biomedical literature, patient histories and data, billing records, 
and medical histories. Although Watson had some success at the University North 
Carolina in identifying relevant clinical trials for patients and suggesting potential 
treatments based on its ability to ingest peer-reviewed biomedical literature, Watson 
was deemed a stunning failure and scrapped by MD Anderson in early 2016 follow-
ing missed deadlines, a series of fruitless pilot projects, and continuous changes to 
the types of cancer that would harness Watson’s focus. Watson’s problems at MD 
Anderson involved a limited ability to understand and suggest actionable insights 
from the medical data it ingested was made worse by fragmentary clinical data and a 
lack of evidentiary support in the studies it analyzed. Costing MD Anderson over 62 
million dollars before its collapse, investing in Watson proved a remarkable blunder 
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for the cancer research center [12]. A former manager at IBM asserts a further 
reason as to why the project failed miserably in its lofty efforts to transform oncol-
ogy. In his estimation, IBM “turned the marketing engine loose without controlling 
how to build and construct a product” [5]. Topol summarizes that while “there 
is certainly potential for computing to make a major difference [in medicine and 
oncology more broadly]... so far there has been minimal delivery on the promise.” 
Topol contends that the difficulty in assembly and aggregation of data has been 
underestimated, not just by Watson, but a myriad of tech companies venturing into 
healthcare [5]. The hype surrounding AI-enabled healthcare tools and indeed, the 
fortunes at stake, leads technology producers, marketers, commentators, investors, 
patients, and medical specialists to overestimate the speed of development and 
delivery of AI systems and, can result in ungrounded and uncritical conceptions of 
their potential to make significant, comprehensive impacts on medical care and of 
the liabilities these technologies can incur.
4.3  Defining standards and ensuring quality access to care in a context marked 
by enduring health inequities
Beyond a modest view for the rates of widespread AI development and deploy-
ment, potential of instantiations of AI-enabled healthcare also brings other critical 
considerations and challenges to the fore. One of the current challenges hamper-
ing AI-enabled approaches for routine use in clinical settings involves the lack of 
appropriate coherency regarding what constitutes standardization regarding these 
tools. The disparate development of tools utilizing machine learning techniques has 
produced a paradigm in which the same clinical question is addressed by separate 
systems developed in independent institutions. Validated on particular and dis-
tinct datasets or samples, these systems may produce different outputs, which can 
ultimately result in differing clinical recommendations and patient outcomes [10]. 
For example, pathologists can disagree whether a biopsy sample taken from a breast 
tissue is cancerous, which some studies suggest has contributed to an over-diagnosis 
of breast cancer. The subtle abnormalities exhibited by small, early-stage cancers 
are particularly difficult to diagnose. This issue extends beyond breast cancer 
to diagnosing melanomas, thyroid cancer, and prostate cancer. Existing clinical 
disagreement over what constitutes cancer may lead to cancer screening AI tools 
that mimic a tendency for over-diagnosis [13].
When applying an AI-driven tool in a clinical scenario, clinicians and other 
health professionals across institutions and national borders must have definitive 
assurances of scalable clinical standardization to deliver appropriate quality of 
care. Consequently, this requires international collaboration that must necessarily 
involve technology producers, clinical specialists, and regulatory bodies. Moreover, 
ensuring all patients have access to state of the art, AI-driven healthcare remains 
a significant challenge. Similar to other new technologies, experts predict that 
AI-enabled medical tools will be extremely costly for health institutions initially 
and will gradually decrease in expense over time. Given the potential of, for exam-
ple, more timely diagnosis and improved disease monitoring made possible by AI 
tools, patients being treated at medical centers able to afford AI resources are likely 
to experience better health outcomes than those at institutions without the financial 
means to invest in these expensive resources. In addition to possessing considerable 
economic resources, medical centers may also need to train health professionals in 
the workings and use of these tools, which presents another potential hurdle to the 
widespread deployment of these systems.
Furthermore, the U.S.-based research of both professor of medicine and clinical 
surgery at the University of Illinois, Robert A. Winn, and anthropologist Kadija 
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hospital admissions and readmissions; eliminate the surfeit of unnecessary jobs; 
result in 100% medical adherence; produce zero patient harm; and cure cancer” [5]. 
Instead, Topol and other medical researchers assume a more modest view: AI-driven 
systems will not serve as a panacea to all the aforementioned predicaments in 
modern healthcare but will instead gradually serve as an increasingly important tool 
in addressing these and other issues. Moreover, medical experts and technologists 
alike contend that the encouraging results AI-driven systems have garnered in fields 
like pathology and radiology, for example, should be taken neither as a justification 
for the outsourcing of pathologists and radiologists, nor point to the burgeoning 
obsolescence of medical specialists as a whole [10]. Rather, they stress that these 
initial successes should be understood as an “indication that their workload could 
be optimized and, importantly, the waiting time for patients to receive a diagnosis 
can be reduced” [10]. In this perspective, over time, the widespread adoption of 
AI systems in healthcare will result in a crucial leveling of the “medical knowledge 
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gift of time” to health professionals allowing them to devote more clinical attention, 
emotional support, and guidance to patients [5].
4.2 Tempering visions of imminent medical revolutions
While in the past decade, the development of AI systems for use in the medical 
field has certainly progressed and led to feats that have garnered significant atten-
tion, these successes remain arguably limited and the progression of these systems 
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systems have accurately diagnosed skin lesions and pathology slides in the realm of 
oncology. In cardiology, AI diagnostic systems have accurately interpreted echocar-
diographic images and electrocardiograms in diagnosing heart abnormalities [5]. 
Other AI diagnostic systems have successfully analyzed audio-wave forms to assist 
in diagnosing asthma, pneumonia, tuberculosis, and other lung ailments [5]. All of 
these successes, however, constitute narrow AI tools that, in reasonable estimations, 
would serve to aid rather than replace medical professionals. Demonstrably, one 
broad AI diagnostic system sits in recent memory of some oncologists as a stunning 
failure that highlights the limitations of AI-enabled healthcare at present. From its 
early inception, IBM’s AI-driven Watson supercomputer was hailed by the company 
as harnessing the power to revolutionize cancer care. Beginning in 2013, IBM initi-
ated partnerships with leading medical institutions renowned for their research in 
oncology such as the MD Anderson Cancer Center at the University of Texas, the 
Memorial Sloan-Kettering Cancer Center in New York, and the University of North 
Carolina’s Lineberger Comprehensive Cancer Center. IBM bought a multitude of 
competitor companies and spent millions in order to train Watson on crucial medi-
cal data including biomedical literature, patient histories and data, billing records, 
and medical histories. Although Watson had some success at the University North 
Carolina in identifying relevant clinical trials for patients and suggesting potential 
treatments based on its ability to ingest peer-reviewed biomedical literature, Watson 
was deemed a stunning failure and scrapped by MD Anderson in early 2016 follow-
ing missed deadlines, a series of fruitless pilot projects, and continuous changes to 
the types of cancer that would harness Watson’s focus. Watson’s problems at MD 
Anderson involved a limited ability to understand and suggest actionable insights 
from the medical data it ingested was made worse by fragmentary clinical data and a 
lack of evidentiary support in the studies it analyzed. Costing MD Anderson over 62 
million dollars before its collapse, investing in Watson proved a remarkable blunder 
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ensuring all patients have access to state of the art, AI-driven healthcare remains 
a significant challenge. Similar to other new technologies, experts predict that 
AI-enabled medical tools will be extremely costly for health institutions initially 
and will gradually decrease in expense over time. Given the potential of, for exam-
ple, more timely diagnosis and improved disease monitoring made possible by AI 
tools, patients being treated at medical centers able to afford AI resources are likely 
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Ferryman of the Data and Society Research Institute, enjoins them to contextualize 
AI-driven success stories in medicine—especially in the realm of cancer care—
against the backdrop of enduring health disparities in the United States. Although 
health expenditures in the U.S. are colossal with healthcare constituting more than 
18% of the United States’ gross domestic product (climbing more than 10 percent-
age points since 1975), increased healthcare spending has not corresponded to 
improved healthcare outcomes across population groups in the U.S. [5]. Ferryman 
and Winn stress the sobering fact that people of color continue to have dispropor-
tionately higher incidence and mortality rates for multiple cancers (among them: 
kidney, breast, cervical, and prostate cancer) as they pose the following question: 
“As big data comes to cancer care, how can we ensure that it is addressing issues 
of equity, and that these new technologies will not further entrench disparities in 
cancer?” [14]. Winn and Ferryman join other medical researchers in arguing that 
not only does a shift in increased usage of medical AI tools necessitate population-
representative data accessibility coupled with regulatory paradigms to ensure 
standardization and quality, but it also requires prioritizing healthcare equity, 
ethical health mandates, and inclusivity [15].
For example, Winn and Ferryman bring attention to how such a shift would 
impact the clinical responsibilities of health professionals. They reason that due 
to the nature of clinical care, clinicians must be able to assess, understand, and 
explain machine learning-driven systems to patients. Consequently this necessitates 
a certain level of transparency in how these systems are trained, developed, and 
produce outputs; these systems cannot be fully “black-boxed.” With the capacity of 
these technologies to refigure clinicians’ responsibilities, Winn and Ferryman echo 
a chorus of legal scholars who forewarn that a more robust integration of AI tools in 
clinical settings may incur both a transformation of the patient-doctor relationship 
as well as a reconceptualization of the regulations surrounding malpractice. Winn 
and Ferryman further contend that a shift in clinicians’ liabilities and obligations to 
demystify AI systems for patients may incur higher stakes for patients with “lim-
ited access to high quality clinical care, limited health literacy, earned mistrust of 
medical providers, and those individuals who may be exposed to interpersonal and 
institutional racism and discrimination in their healthcare encounters” [14]. They 
argue that it is critical that the potential ramifications for vulnerable patients due 
to the integration of AI technology in the clinic be not only acknowledged but also, 
consistently and intentionally managed. Together, these aforementioned challenges 
consist of only a small sampling of the issues that must be addressed before a suc-
cessful, widespread adoption of AI-driven medical tools can be undertaken.
5. Methods and methodology
This chapter is informed by and enlists textual, ethnographic, and other qualita-
tive data that the author has collected in undertaking a broad examination of the 
legal, political, and ethical imperatives surrounding the development of AI-driven 
systems for healthcare and for oncology, specifically. This study attends to patient 
reception of the development and deployment of these systems as well as patients’ 
perceptions and willingness to participate in health-related AI development by 
sharing medical data necessary to train and improve these systems with public and 
private entities engaged in developing them.
This analysis draws upon qualitative research methods including textual and 
content analysis of academic literature reviews, general audience media, and 
industry-oriented publications. This study was further augmented by an in-depth, 
semi-structured interview protocol. In addition to attending cancer patient 
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conferences, talks, and support groups, the author conducted interviews with 40 
relevant stakeholders. The approximately 15 hours of observation and 40 interviews 
were undertaken for the first 11 months of 2019. Interlocutors included cancer 
patients and their caregivers, cancer patient advocates, directors and specialists 
at cancer care nonprofits, technologists employed at firms developing AI tools for 
oncology, and clinicians. The interview corpus of this study includes 9 U.S. citizens, 
29 U.K. citizens, and 5 citizens from the European Union. Interviews were primarily 
conducted in cities located in Northern California in the U.S. as well as in London 
and Cambridgeshire in the U.K.
Among the interview corpus, 28 individuals are cancer patients who were 
actively undergoing treatment or who were in remission at the time of the inter-
view. Seven patients were in remission at the time the interviews were conducted 
and the remaining 21 patients are currently receiving treatment for their cancers. 
Twenty-four of the patients were born between 1939 and 1960.The four remaining 
patients were born after 1983, the youngest patient interviewed was born in 1990. 
The majority of the patients interviewed are retired from the workforce having had 
previous careers as secretaries, telecom and systems engineers, insurance salesmen, 
military logisticians, child-care providers, librarians, photographers, teachers, 
and small-business owners. At the time of the interviews, patients in the interview 
corpus who were in the workforce had employment as data scientists, teachers, 
lab technicians, and engineers. Those with employment were generally employed 
as part-time employees as a result of their continuing treatments. Other patients 
were stay-at-home parents and one patient is a doctoral student. When asked about 
socioeconomic status, most patients considered themselves to be middle-class. 
The patients in this interview corpus are of white, European descent although the 
interview corpus as a whole and the ethnographic work that supplements this study 
involved patients, advocates, and healthcare professionals from other ethnic and 
racial backgrounds. The patients interviewed possessed a multitude of different 
cancer diagnoses. Three of the patients interviewed had received a diagnosis of 
colorectal cancer; six had received a diagnosis of breast cancer; two had received a 
diagnosis of cervical cancer; six had received a diagnosis of bladder cancer; five had 
received a diagnosis of prostate cancer; seven had received lymphoma diagnoses; 
four had received a diagnosis of myeloma; and, one patient had received a diagnosis 
of skin cancer (several patients had developed multiple cancers).
Three individuals within this interview corpus are clinicians. Two of these 
clinicians are senior oncologists with extensive experience working at illustrious 
cancer research hospitals in the United Kingdom, Ireland, Italy, and the United 
States. The final clinician is completing their initial rotation-years as a pediatrician 
at a premiere research hospital on the west coast of the United States; this clinician 
previously earned a doctorate degree in medical anthropology. Their disserta-
tion research studied patient data-sharing and patient reception of self-tracking 
approaches to medical care. Seven interviews were conducted with data scientists, 
bioinformaticians, and start-up founders who work or previously worked at a U.K. 
and U.S.-based AI oncology-related start-up.
The remaining five interlocutors comprising this interview corpus are trained 
cancer patient advocates. One of these patient advocates is a U.K. citizen and the 
remaining four are U.S. citizens. All are based in California although three of them 
occasionally serve as advocates and patient ethicists for projects at renowned cancer 
research institutes in other U.S. states. One of these advocates is a licensed nurse 
practitioner with experience in global health consultancy; this advocate currently 
serves as the program director of a nonprofit cancer care center and clinic located in 
a Northern Californian metropolis. Another cancer patient advocate in this corpus 
has nearly three decades of experience and has earned several awards and accolades 
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conferences, talks, and support groups, the author conducted interviews with 40 
relevant stakeholders. The approximately 15 hours of observation and 40 interviews 
were undertaken for the first 11 months of 2019. Interlocutors included cancer 
patients and their caregivers, cancer patient advocates, directors and specialists 
at cancer care nonprofits, technologists employed at firms developing AI tools for 
oncology, and clinicians. The interview corpus of this study includes 9 U.S. citizens, 
29 U.K. citizens, and 5 citizens from the European Union. Interviews were primarily 
conducted in cities located in Northern California in the U.S. as well as in London 
and Cambridgeshire in the U.K.
Among the interview corpus, 28 individuals are cancer patients who were 
actively undergoing treatment or who were in remission at the time of the inter-
view. Seven patients were in remission at the time the interviews were conducted 
and the remaining 21 patients are currently receiving treatment for their cancers. 
Twenty-four of the patients were born between 1939 and 1960.The four remaining 
patients were born after 1983, the youngest patient interviewed was born in 1990. 
The majority of the patients interviewed are retired from the workforce having had 
previous careers as secretaries, telecom and systems engineers, insurance salesmen, 
military logisticians, child-care providers, librarians, photographers, teachers, 
and small-business owners. At the time of the interviews, patients in the interview 
corpus who were in the workforce had employment as data scientists, teachers, 
lab technicians, and engineers. Those with employment were generally employed 
as part-time employees as a result of their continuing treatments. Other patients 
were stay-at-home parents and one patient is a doctoral student. When asked about 
socioeconomic status, most patients considered themselves to be middle-class. 
The patients in this interview corpus are of white, European descent although the 
interview corpus as a whole and the ethnographic work that supplements this study 
involved patients, advocates, and healthcare professionals from other ethnic and 
racial backgrounds. The patients interviewed possessed a multitude of different 
cancer diagnoses. Three of the patients interviewed had received a diagnosis of 
colorectal cancer; six had received a diagnosis of breast cancer; two had received a 
diagnosis of cervical cancer; six had received a diagnosis of bladder cancer; five had 
received a diagnosis of prostate cancer; seven had received lymphoma diagnoses; 
four had received a diagnosis of myeloma; and, one patient had received a diagnosis 
of skin cancer (several patients had developed multiple cancers).
Three individuals within this interview corpus are clinicians. Two of these 
clinicians are senior oncologists with extensive experience working at illustrious 
cancer research hospitals in the United Kingdom, Ireland, Italy, and the United 
States. The final clinician is completing their initial rotation-years as a pediatrician 
at a premiere research hospital on the west coast of the United States; this clinician 
previously earned a doctorate degree in medical anthropology. Their disserta-
tion research studied patient data-sharing and patient reception of self-tracking 
approaches to medical care. Seven interviews were conducted with data scientists, 
bioinformaticians, and start-up founders who work or previously worked at a U.K. 
and U.S.-based AI oncology-related start-up.
The remaining five interlocutors comprising this interview corpus are trained 
cancer patient advocates. One of these patient advocates is a U.K. citizen and the 
remaining four are U.S. citizens. All are based in California although three of them 
occasionally serve as advocates and patient ethicists for projects at renowned cancer 
research institutes in other U.S. states. One of these advocates is a licensed nurse 
practitioner with experience in global health consultancy; this advocate currently 
serves as the program director of a nonprofit cancer care center and clinic located in 
a Northern Californian metropolis. Another cancer patient advocate in this corpus 
has nearly three decades of experience and has earned several awards and accolades 
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for her advocacy work. Previously, this advocate was employed as a patient advocate 
and advisor at an eminent national cancer support organization and is presently 
employed as a senior patient navigator with a focus on multicultural patient sup-
port at a California nonprofit that primarily caters to local, low-income women of 
color who have received cancer diagnoses although the organization remains open 
patients of all backgrounds. In her role, this advocate guides patients through treat-
ment, clinical trial options and hospital visits; assists patients with insurance forms 
and other medical paperwork; and provides patients with counseling and much 
needed psycho-social support. This advocate regularly serves on cancer patient 
advocate conference committees, counsels researchers seeking to work with cancer 
patients, and acts as a grant reviewer for emerging research ventures. The three 
remaining advocates have diverse employment histories in the fields of marketing, 
graphic design, emergency medicine, and nonprofit leadership. For nearly 15 years, 
these trained cancer survivor advocates with expertise in research and patient com-
munication have worked with national and local advocacy organizations serving on 
survivorship and research committees for various academic, nonprofit, and govern-
mental organizations. They frequently serve as research partners and advocates on 
scientific review committees and act as grant reviewers for emerging university-led 
research projects in the state of California. They also serve on clinical trials advisory 
committees as advocate observers, patient advisors, and stakeholder reviewers 
in partnership with state and national research bodies as well as national cancer 
research organizations including the National Institutes of Health, the American 
Cancer Society, the Department of Defense, and the Susan G. Komen Foundation. 
These advocates routinely volunteer at local nonprofits as helpline attendees and 
peer mentors to cancer patients currently undergoing treatment.
Coagulating and analyzing this qualitative data, this chapter offers insight into 
the perceptions and concerns some cancer patients (i.e., particularly those identify-
ing as middle class and of European descent), patient advocates, and clinicians 
abiding in the Home Counties of the U.K. and Northern Californian metropolises 
possess regarding both the deployment of AI systems for oncology as well as sharing 
health data with public and private entities for the purpose of developing these 
systems. Complementing the textual and ethnographic data, the interview work 
conducted enumerates popular dispositions toward biomedical technological devel-
opment for oncology within the socially stratified societies of the U.S. and the U.K. 
as well as refracts the particular exigencies of pursuing cancer treatments within the 
two nations’ contrasting healthcare systems.
Researchers studying the social and technical valences of AI continue to insist 
upon the foundational legitimacy and, indeed, the value of studying popular 
conceptions of machine learning-driven systems. Public perceptions contribute to 
the fashioning of the material and discursive realities these systems act upon and 
within and furthermore constitute collective contestations of the political realities, 
ethical liabilities, and financial viabilities immanent to the social production of 
these technological systems. Correspondingly, Monteescu and Elish contend that 
“When it comes to understanding the impact of AI, the social perceptions of a tech-
nology’s capabilities are equally important to technical definitions. Elsewhere we 
have observed that non-expert understandings of AI are often shaped by marketing 
rhetoric, which sometimes suggests capabilities that are not yet technically possible. 
For many developers of AI systems, this potential fuzziness is ‘not a bug but a fea-
ture,’ so to speak. The public perception of AI is often leveraged to drum up excite-
ment or stand in for a range of automated technologies that haven’t yet become fully 
actualized. The fluctuating understandings of AI will not be universally resolved, 
and so it is necessary to account for the consequences of AI as defined through both 
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technical definitions and social representations” [16]. Public trust, knowledge, 
and perception of health data-sharing and AI development and deployment will 
undoubtedly influence how governments, health organizations, and corporate 
entities continue to debate, contest, insist on, and invest in AI viability for medical 
usage. For this reason, public perceptions may also impact the material develop-
ment of these systems (e.g., via a collective willingness or unwillingness to use these 
systems for medical treatment or engage in health data-sharing for AI develop-
ment); the regulatory mandates and other frameworks of standardization, equity, 
and accountability pursued in their wake; the funding and long-term economic 
feasibility of these systems; and perhaps even the meaning of what medical care can 
or should constitute.
6.  Understanding patient perceptions of AI-driven systems for 
healthcare
This chapter presents an analytic overview of: the extent of knowledge a 
sample of U.S. and U.K. patients possess regarding AI systems for oncology and 
oncology-related drug development as well as healthcare, more broadly. Similar 
to other recent studies, the qualitative research that this discussion derives from 
indicates that general public audiences (inclusive of cancer patients) continue to 
possess varied notions of not only what constitutes AI, but also what capabilities 
these AI systems hold and the extent of proficiency with which they presently 
perform them. With varied (although certainly increasing) levels of sophistica-
tion, cancer patients (as evidenced in the interview sample) are questioning what 
potential ramifications patients should be aware of, and potentially concerned 
about, regarding the usage of AI systems for healthcare and oncology. They 
question what emotive and affective positions they should take with regard to 
AI Certainly, patients possess divergent understandings of both when and how 
this technology may impact or augment the standard of care within oncology 
that directs recommended treatment paths and contributes to patient outcomes. 
Nevertheless, many are attentive to the limitations of their current knowledge 
regarding these systems. In consequence, patients are questioning how they can 
stay informed, what constitutes trustworthy sources from which they can glean 
accurate and legible information, and what specific types of inquiries should they 
be attending to.
In order for healthcare technologies to be effectively responsive to patients’ 
needs, it is evident that institutions, persons, and entities involved in developing 
instruments that can affect cancer patients’ quality of care not only assess patients’ 
present knowledge and perceptions of emerging technology, but also heed and 
address their resultant questions and concerns. With a preponderant focus on ana-
lyzing the interview data the author has collected, this chapter assesses the express 
knowledge, perceptions, and suggestions a sample of U.S. and U.K. patients possess 
regarding AI systems for oncology and oncology drug development. Specifically, 
this chapter enumerates three primary analytical axes in attending to this dataset: 
cancer patients’ perception of AI systems for oncology; their willingness to contrib-
ute to the development of the efficacy of these systems and AI-drug development 
via medical data-sharing; the concerns they bear regarding both the deployment 
and integration of these systems as well as health data-sharing for the aforemen-
tioned purposes; and finally, the recommendations patients and relevant experts 
are proposing for building accountability measures to ensure both safe usage and 
improve patient trust.
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as well as refracts the particular exigencies of pursuing cancer treatments within the 
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actualized. The fluctuating understandings of AI will not be universally resolved, 
and so it is necessary to account for the consequences of AI as defined through both 
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technical definitions and social representations” [16]. Public trust, knowledge, 
and perception of health data-sharing and AI development and deployment will 
undoubtedly influence how governments, health organizations, and corporate 
entities continue to debate, contest, insist on, and invest in AI viability for medical 
usage. For this reason, public perceptions may also impact the material develop-
ment of these systems (e.g., via a collective willingness or unwillingness to use these 
systems for medical treatment or engage in health data-sharing for AI develop-
ment); the regulatory mandates and other frameworks of standardization, equity, 
and accountability pursued in their wake; the funding and long-term economic 
feasibility of these systems; and perhaps even the meaning of what medical care can 
or should constitute.
6.  Understanding patient perceptions of AI-driven systems for 
healthcare
This chapter presents an analytic overview of: the extent of knowledge a 
sample of U.S. and U.K. patients possess regarding AI systems for oncology and 
oncology-related drug development as well as healthcare, more broadly. Similar 
to other recent studies, the qualitative research that this discussion derives from 
indicates that general public audiences (inclusive of cancer patients) continue to 
possess varied notions of not only what constitutes AI, but also what capabilities 
these AI systems hold and the extent of proficiency with which they presently 
perform them. With varied (although certainly increasing) levels of sophistica-
tion, cancer patients (as evidenced in the interview sample) are questioning what 
potential ramifications patients should be aware of, and potentially concerned 
about, regarding the usage of AI systems for healthcare and oncology. They 
question what emotive and affective positions they should take with regard to 
AI Certainly, patients possess divergent understandings of both when and how 
this technology may impact or augment the standard of care within oncology 
that directs recommended treatment paths and contributes to patient outcomes. 
Nevertheless, many are attentive to the limitations of their current knowledge 
regarding these systems. In consequence, patients are questioning how they can 
stay informed, what constitutes trustworthy sources from which they can glean 
accurate and legible information, and what specific types of inquiries should they 
be attending to.
In order for healthcare technologies to be effectively responsive to patients’ 
needs, it is evident that institutions, persons, and entities involved in developing 
instruments that can affect cancer patients’ quality of care not only assess patients’ 
present knowledge and perceptions of emerging technology, but also heed and 
address their resultant questions and concerns. With a preponderant focus on ana-
lyzing the interview data the author has collected, this chapter assesses the express 
knowledge, perceptions, and suggestions a sample of U.S. and U.K. patients possess 
regarding AI systems for oncology and oncology drug development. Specifically, 
this chapter enumerates three primary analytical axes in attending to this dataset: 
cancer patients’ perception of AI systems for oncology; their willingness to contrib-
ute to the development of the efficacy of these systems and AI-drug development 
via medical data-sharing; the concerns they bear regarding both the deployment 
and integration of these systems as well as health data-sharing for the aforemen-
tioned purposes; and finally, the recommendations patients and relevant experts 
are proposing for building accountability measures to ensure both safe usage and 
improve patient trust.
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6.1 Patients’ expressed levels of knowledge
In characterizing the knowledge the patient interlocutors comprising the inter-
view corpus possessed at the time the interviews were conducted, it is principally 
important to register that the vast majority of these cancer patients had no formal 
or professional training in regards to these systems. While four of the patients 
offered examples demonstrating how they currently utilize or previously utilized 
machine learning systems in their employment, the remaining number (86% of 
the patient interlocutors) had no professional experience with these systems and 
learned about AI primarily through general audience media. All things considered, 
the interview data are largely representative then of not just modes of public 
perception but lay opinion. All of the patients, with the exception of one, registered 
having heard the term of AI and exhibited a capacity to grasp the foundations of its 
most basic principles. These interlocutors, moreover, often went on to demonstrate 
the applicability of AI tools or machine learning-driven systems within healthcare 
contexts. Furthermore, when offering examples, patient interlocutors chiefly cited 
examples from both oncology and general practitioner diagnostics. Those who 
demonstrated a familiarity of the application of machine learning systems to oncol-
ogy most frequently cited its current applicability to pathology, medical robotics, 
and multi-omics data-handling. Five patient interlocutors within the interview 
corpus related having previously prepared reports or presentations in which they 
offered an introductory overview of AI and AI applicability to oncology for either 
cancer patients and advocates, or otherwise general public audiences.
Unsurprisingly, the interviews exhibited a wide range of patient articulations 
of the foundational aspects of AI systems. For example, when asked what they 
knew about AI, one patient insisted that they knew “very little”; “I would assume 
it has something to do with algorithms. In [our support] group, we’ve talked about 
how there might be some algorithms that can be used for diagnostic tools for GP’s. 
To me, I don’t know if this is right, but AI has to do with data-handling. There’s so 
much data out in this world and we have to think about how are we going to make 
it useful.” After explaining that they first learned about the principles of AI from 
early science fiction novels (such as Isaac Asimov’s I, Robot), one patient defined 
AI in the following terms: “Well, I would say it is, basically, a computer that is 
capable of interpreting input, and making deductions from input that it is given. 
Obviously, the way it responds to that is being presumably programmed by a human 
being. But, I believe that computers, or at least AI, are capable of taking it beyond 
that, they’re capable of learning from the basic information they’re been given and 
building on that.” Another patient interlocutor explained: “Well, to my mind, AI 
is programming a computer of some sort to take various in-puts and to learn from 
them, basically. So if you got say, a visual system—cancers on an x-ray for example, 
you would have a system that you could teach. Say, put through a number positives 
or a number negatives of say a thousand scans and maybe a hundred of those are 
positive and you teach it to compare it to the negative ones and identify which ones 
are positive. Then you can leave it on its own to work by itself from that point on. 
Y’know once you are satisfied that it’s strike-rate is sufficient. You can leave it to 
its own devices. That’s how I kind of look at medical AI anyway. I also think AI is 
very much a black box, just from what I’ve seen on the telly. You set it going but you 
don’t necessarily understand how it’s doing it. [laughing]... Whether that’s true or 
not, I don’t know. But that’s my perception of it from the popular media I guess...I 
have no idea just how much AI is actually out there and performing at the moment, 
if you see what I mean. How far it’s come; how much use there is for it at present; 
whether it still remains a largely experimental field.” These three explanations offer 
a triangulation of the amount of knowledge and levels of coherency the majority of 
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the cancer patients interviewed expressed to the author. Many could give a rela-
tively clear articulation of how the elementary facets of machine learning or of how 
AI algorithms function. Typically, this sample of patients demonstrated that these 
systems function to process vast amounts of data, that with appropriate engineer-
ing and sufficient data training sets these algorithms can be “trained” to identify 
relevant variables as outputs, and that AI can be applied to medical data and have 
potential use for oncology.
Excluding the four patient interlocutors who have professional training in and 
experience with AI systems, patients related that they had arrived at their cur-
rent level of knowledge through general audience media. In particular, all of the 
remaining patient interlocutors cited two primary sources from which they derived 
knowledge regarding these systems. All related that they had learned about AI from 
journalistic sources and accounts they encountered via print media such as a local, 
national, international, or specialized newspapers (e.g., a business newspaper or 
magazine) and digital news platforms. Secondly, all related that they had gained 
an initial introduction to or a partial familiarity with the general principles of AI 
via speculative accounts found in genre fiction sources such as science fiction texts, 
films, and television series. Some indicated that accounts concerning AI in specula-
tive fiction or journalistic sources sparked a personal interest in these systems and 
their development; these patient interlocutors explained that they further bolstered 
their knowledge through nonfiction texts about AI development and applicability. 
Otherwise, patients related that they had further learned about AI via friends, 
spouses, or relatives who have professional involvement with AI Some reported 
having been informed by existing government reports (e.g., the U.K.’s 2018 House of 
Lords Report on Artificial Intelligence) that they were initially made aware of from 
journalistic sources. A small number of patient interlocutors indicated that they also 
learned about AI via their involvement in patient support groups or patient advo-
cacy work (including oncology-related conferences and involvement with medical 
research auditing).
6.2 Patients’ general perceptions of AI
Overwhelming, the cancer patients interviewed for this study held positive 
perceptions and opinions for the development of AI systems for oncology. With 
the exception of one patient interlocutor who admitted no knowledge and no 
opinions of these tools, the patient interlocutors comprising the interview corpus 
voiced hope for the relevancy and potential for AI development and application for 
medicine. Continuously, these patients insisted that as a “useful tool,” “able to catch 
things humans can’t,” AI systems would be a “step forward” inasmuch as they “will 
make things better” by “improv[ing] speed and quality of data analysis.” As one 
patient put it: “we’ve been waiting for a faster identification of things and this can 
only help.” Others noted with pronounced optimism that these tools may “reduce 
workloads” for medical professionals such as doctors and nurses. One patient 
mused that perhaps such systems could combat clinical biases and bigotry through 
objective and accurate data-handling; a view that has been critiqued by social 
researchers of technology as misguided. “Generally,” another patient concluded, “I 
think tech advances are a good thing.” Another interlocutor echoed this statement, 
adding: “It sounds great and I think it will give people confidence and perhaps a 
better chance at survival.”
Patients who possessed professional training or work experience in developing 
and deploying AI systems expressed similar hope and positivity about AI-enabled 
healthcare. One patient who works with AI tools as a lab technician within the 
context of drug development remarked that AI tools are “something in development 
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that can be really useful, especially for handling patient data and especially genom-
ics data... It’s really good for things that have a clear ‘yes’ or ‘no’ and beyond that 
there are always new improvements, new features to improve the algorithms with... 
If [AI tools for oncology] allow for the use of certain data like mutations and other 
genomics data, they could provide more confidence in the use of AI for cancer 
treatment predictions.” Two other patients, with tangential familiarity with AI 
systems given their respective professions as a statistician and systems engineer 
asserted that AI presented “a lot to be gained” and especially holds promise for the 
improvement of diagnostics. The systems engineer asserted his belief that, used 
in the arena of oncology, AI tools may “bring reliable indications for decisions that 
don’t get made or get lost in communication.”
Notably, many of the patient interlocutors interviewed characterized their 
perceptions of AI tools as thoroughly secondary and overshadowed by the cur-
rency and pervasiveness of popular teleological narratives of technology that cast 
technological development as both heroic and as “inevitable progress.” Concerning 
AI-enabled healthcare, patients frequently conceded: “It’s the way of the future.” 
In turn, some expressed that their conceptions of the inevitability of technological 
progression (in this instance, made manifest by AI tools for healthcare) encouraged 
feelings that “[The prospect of AI-enabled oncology] is exciting, but a little scary.” 
In other words, among declarations of the hope regarding the potential of AI, many 
patients voiced tepid fears in relation to offering their assessments of AI tools given 
their (and potentially others’) beliefs in the potential marginality of their own 
social locations—as, for instance, elders and, more broadly, as cancer patients. 
What would often begin as self-aware statements relating limited abilities to stay 
current with the seeming swiftness of many technological shifts and innovations, 
would in many interviews lead to remarks through which patients would minimize 
their relevancy and position to offer opinions, thoughts, or concerns about AI “Are 
we doomed?” one patient asked, “I don’t know. All I know is that [AI development] 
is unstoppable and frankly...you can’t put yesterday’s values on tomorrow.” Another 
insisted: “Everything is moving forward and does move forward. Why should this 
be any different? It’s how we live, and maybe we just need to get on and accept it.” 
Others voiced that regardless of the advancements in AI, they feel they are “too old” 
to “keep up” and described feeling as if they are suspended in a paradigm of being 
left behind with regard to their technological knowledge and savviness and have 
accepted this predicament as “their lot”: “Things move quickly and I’ve switched 
off.” In addition to age, patients pointed to their diagnosis and the rigorousness of 
their therapies as preventing them from seeing the future of AI development for 
oncology as pertinent to them. Patients interviewed in the middle of treatment 
cycles voiced a similar sentiment of being too sick to “keep up” or of not feeling 
capable of appropriately assessing how it would affect the future of oncology, let 
alone themselves and others. In fact, some patients asserted confidently: “[These 
tools] won’t affect me.”
Patients who were familiar with AI due to the nature of their professional 
employment admitted that while they firmly supported the technology’s use and 
development with great hope, in their view, these systems generally remain “under-
developed and under-utilized.” “Changes are happening,” these patients declared, 
“but slowly.” Likewise, one patient advocate related: “I’ve been hearing a lot about 
[AI tools for oncology] at conferences and it sounds wonderful but I haven’t seen it 
materialize yet in hospitals and clinics.”
In summary, some patients (often those with lay knowledge of AI systems) 
consider AI systems for oncology and medicine to be developing at a rapid rate 
and intertwine this conception of rapid technological development with a notion 
of “natural” and “inevitable” technological progression against which they would 
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unfavorably compare their age and health status as inversely related. In this view, 
their age and health status become barriers that immobilize their capacity to stay 
informed and interested in technological development. This logic perhaps serves as 
a basis for elaborating insecurities about whether they have an appropriate ability 
to speak lucidly or incisively about AI tools for oncology which, at times, results in a 
firm belief that they should not concern themselves with forming critical views and 
voicing judgments about the subject.
Beyond highlighting contrasting conceptions of the pace of AI development, 
patients framed their enthusiasm regarding AI systems for oncology with state-
ments conceding a general awareness that technological transition may produce 
vulnerabilities and risks for patients and medical staff. Despite widely expressed 
optimism, a majority of patients voiced that shifting to a greater use of AI tools for 
oncology and medicine may subject patients to additional risk for medical errors 
or mishaps. “There’s always room for errors and mistakes,” as one patient mused. 
“Errors,” another patient conceded, “are inevitable and it takes time to perfect 
technology. That’s progression. We learn by mistakes, sadly.” Further epitomizing 
this appraisal, a patient familiar with machine learning techniques explained: “If 
used for the benefit of mankind [sic], I am absolutely onboard for this tech. Bring 
it on. But forcing learning when the data isn’t there, isn’t the right thing to do.” In 
other words, despite an embrace of narratives of technological progression, patients 
voiced a desire for cautious progression of AI tools and emphasized the potential 
human costs of technological innovation and initial deployment.
Moreover, many patients indicated that they believe such tools may, in the 
future, produce some level of job insecurity for certain doctors and medical staff 
(e.g., radiologists, pathologists). Still, those who voiced this issue noted that they 
prioritized manifesting better health outcomes for patients over maintaining 
employment for medical professionals able to produce less satisfactory health 
outcomes. Others related that they believe that these tools will not encroach on 
the necessity of the roles of medical professionals or threaten their employment 
prospects but will instead produce “a major sea-change for the medical industry,” 
the consequence of which being that doctors and other medical staff will “need to 
be retrained or receive additional training.”
Finally, a small minority of patients experience the prospect of AI-enabled 
healthcare as shrouded in confusion and potential conspiracy. “I have concerns 
about it,” one patient admitted, “but only in a SciFi-horror film kind of way which 
is based on ignorance and a certain amount of misinformation.” Other patients 
related more earnest concerns about AI tools for healthcare regarding potential 
issues of developers’ nefarious intent, consolidated power, and misguided objec-
tives. One patient confessed these fears in the following manner: “In my way of 
understanding, ultimately, AI will be writing the software itself. And that’s where 
it goes out of control because from what I’ve seen, personally, and to the pres-
ent day, software engineers have a lot of power, a lot of power! And the people 
who write the software...they could conceal things, you get an unscrupulous one. 
Ninety-nine percent, I’m sure, are perfectly legitimate, but it only needs one or 
two unscrupulous ones who can put bugs in software. And it worries me that, as 
I say, ultimately, that software won’t be written by humans—the software itself 
will be interpreted and written by AI and I’m sure that’s ultimately where we’re 
going.” Other patients voiced wariness that there exists far too much control over 
the development and deployment of AI systems “in the hands of too few.” They 
stressed the need to democratize relations of power relating to how private enti-
ties and corporate structures consolidate the decision-making power over how 
and which issues are tackled with AI tools and consequently, how these tools are 
designed and implemented across sectors within and outside of medicine (e.g., the 
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unfavorably compare their age and health status as inversely related. In this view, 
their age and health status become barriers that immobilize their capacity to stay 
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related more earnest concerns about AI tools for healthcare regarding potential 
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tives. One patient confessed these fears in the following manner: “In my way of 
understanding, ultimately, AI will be writing the software itself. And that’s where 
it goes out of control because from what I’ve seen, personally, and to the pres-
ent day, software engineers have a lot of power, a lot of power! And the people 
who write the software...they could conceal things, you get an unscrupulous one. 
Ninety-nine percent, I’m sure, are perfectly legitimate, but it only needs one or 
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ties and corporate structures consolidate the decision-making power over how 
and which issues are tackled with AI tools and consequently, how these tools are 
designed and implemented across sectors within and outside of medicine (e.g., the 
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workings of financial services companies and investment banks or the political 
encroachment and monopolistic tendencies of tech mammoths such as Amazon, 
Google, and Facebook). Some patients’ portends remained vaguely sketched: “Like 
all tech, evil men get behind it and we see the bad side of everything...Insert Blade 
Runner quote here.”
In parallel, other patients declared that although they felt generally optimistic 
about the prospects of AI developments for healthcare, they underscored a desire 
for these technologies “to improve quality of life, not extend it.” One patient 
admitted, “I don’t want AI to cure cancer in order for people to live forever.” 
Evidently, one patient advocate insisted, “The promise of Big Data is confusing 
for patients.” Patient interlocutors with technical expertise and familiarity with 
AI systems expressed their bafflement over other patients’ and public figures’ 
confusions regarding these systems. One of these patients voiced his frustrations 
regarding the philosophical or imaginative fears some lay members of the public 
have: “I don’t understand why people think it’s some Doctor Who-Take-Over-the 
World syndrome!...most people in the last 30-40 years, would have used computing 
techniques of some sort to break down their spreadsheet or whatever. Conceptually, 
I don’t see a great difference between AI and that….I can’t wrap my head around 
why people think it’s some sort of SciFi, Doctor Who thing or, why they think it’s 
something that’s been invented last week by Amazon. It’s been around thirty years 
or so and the math has been around for one hundred years! And secondly, they’ve 
been doing it all their lives!” While this patient thought it might aid others without 
expertise to understand what he understood as the banalities of AI by drawing 
conceptual comparisons to more simple computing properties, another suggested 
confusions and conspiracy theories could be attributed to idiomatic decisions. He 
explained: “I feel, sort of working in that area, that we should stop talking about 
artificial intelligence and talk more about machine learning or statistical learning. 
Talk about something different from artificial intelligence because when people 
think about that they think of Arnold Schwarzenegger and The Terminator. In fact, 
statistical techniques, which are not strictly artificial intelligence, have been around 
for 30 years. There’s all sorts of techniques that we rely on that have been around 
for decades.” Together, their comments demonstrate the diverse range of general 
apperceptions of what these technologies might accomplish, how who develops and 
deploys these technologies may impact healthcare systems (including patients and 
medical professionals), and how popular depictions of and professional experience 
with AI tools contribute to contrasting notions and appraisals of their influence, 
application, and current state of development.
7.  Patient concerns regarding the development, integration, and 
deployment of AI tools in healthcare contexts
Despite varying levels of expertise and general knowledge, the patient inter-
locutors interviewed for this study expressed overlapping concerns regarding the 
development, integration, and deployment of AI tools for oncology and for use 
within healthcare contexts more broadly. Patients regularly articulated three core 
areas of concern regarding issues of regulatory oversight, development and training 
matters, as well as issues of standardization and integration. Together, these com-
mon concerns demonstrate how patients are ingesting existing reports of unin-
tended effects and social risks AI systems across different sectors have resulted in. 
Moreover, they exhibit how patients are envisioning and responding to the potential 
for AI technologies to produce instances of medical error and harm.
159
Toward the Clinic: Understanding Patient Perspectives on AI and Data-Sharing for AI-Driven…
DOI: http://dx.doi.org/10.5772/intechopen.92787
7.1 Patient concerns regarding the need for regulatory oversight
The fulcrum of patient interlocutors’ anxieties concern the need for regula-
tory oversight of AI tools. This issue materialized as a constant chorus for patients 
across nearly every interview. One mode in which this issue was raised was as a 
desire for a “human buffer” or a technical, medical expert between these systems 
and patients. Patients stressed that, beyond issues of efficacy, they were concerned 
that health providers might attempt to thoroughly replace “the human element 
of care” from medical contexts. “Regarding automation and AI techniques” one 
patient explained, “I think it is comforting to have a human around you. Or, to have 
a human be the bridge between robotics and the person, the impersonal screen and 
the person... I think personally it’s still nice to get some human element of care.” To 
ensure the retainment of this experience of care, patients enumerated preferences 
for trained medical experts to explain how these systems work, to remain available 
and present, and to oversee the results that these systems produce in real-time. 
Furthermore, patients fear the possibility of these systems to possess the power of 
executive decision-making. They instead stressed the need to limit the function of 
these systems to auxiliary tools that enable medical professionals and patients to 
make better-informed medical decisions. One patient elaborated: “As for [AI sys-
tems] making decisions, I don’t think it’s the way to go. I think it should be the way 
it’s done now, they give you all the options and the patient can make the decisions. 
Not the machine or anyone else.”
Even more frequently, patient interlocutors articulated the need for regulatory 
agencies and bodies to effectuate heightened oversight, greater legal accountability, 
and guaranteed quality control of these systems as a mandatory precondition to 
ensuring the prevention of medical error. In order to establish the responsible use of 
these systems within medical contexts, patients asserted that these systems cannot 
be introduced into clinical settings without appropriate regulatory safeguards. A 
patient interlocutor articulated this issue as such: “I don’t think it can just be done 
and introduced and used. I think safeguards have got to be put in place and moni-
tored. But who does that? I don’t know.” Other patients voiced misgivings concern-
ing the current lack of regulations because of the existing confusion of when robust 
regulatory schemes will be introduced and how they will operate. Particularly, 
patients are concerned with how regulatory schemes will be organized to arrange 
the necessary flexibility, international collaboration, and enforcement capacity to 
assure both the optimization of these systems and patient safety.
7.2 Patient concerns regarding the facets of AI development
In addition to concerns about the establishment of robust regulatory networks, 
patient interlocutors were also perturbed by unresolved several facets of current 
AI development. Foremost, given AI systems’ reliance on training datasets to 
improve the accuracy and efficiency of its outputs, patients stressed developers 
of AI medical tools are faced with crucial mandates regarding the assemblage of 
training datasets. Patient interlocutors stressed that ensuring regulatory usage and 
patient trust is fundamentally contingent upon developers’ abilities to guarantee 
the accuracy, completeness, and representativeness of their datasets. As one patient 
warned, “forcing learning when the data isn’t there, isn’t the right thing to do.” In 
questioning the potential for this technology to address health disparities or further 
entrench them, some patients raised concerns of how researchers and developers 
are grappling with the limitations of existing health data. Often these data are 
representative of only a small portion of world’s population. Patients fear that if AI 
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representative of only a small portion of world’s population. Patients fear that if AI 
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systems are trained on inadequate or unrepresentative data, these systems could 
potentially reify medical insights (as well as produce medicines and outcomes) 
with limited efficacy. Emphasizing the need to compile population-representative 
datasets, one patient disclosed: “My other concern with machine learning or AI, it’s 
sort of like that old saying for computers: ‘Garbage in, Garbage out’: to make sure 
you are getting the best training sets from African Americans and Asian Americans 
and Native Americans and not just Americans but all races [across different popula-
tions]... because that’s sort of the big picture. That is the problem with clinical trials 
in the U.S.—you get a bunch of white people! So racial diversity [is needed] and are 
you getting enough participants across all age groups?” To assemble representa-
tive, comprehensive, and accurate datasets, patients further asserted that health 
researchers and AI medical tool developers should be engaging in more collabora-
tive research rather than “working in silos” and aim to include multiple kinds of 
health data including multi-omics data and even non-biological or environmental 
data or multiple data points derived from multiple sources and perimeters. By 
the same token, patients were adamant that AI systems for medical use must be 
able to be updated to integrate new forms of health data. For example, one patient 
mused, that if an AI system functioned to predict health outcomes for patients 
with a certain cancer on a specific treatment protocol, it may run into issues if new 
therapies are discovered and become standard. Given this scenario, he explained, 
“the relevance of the model becomes less significant. So there are issues around 
that. The earlier you are in the interference of data—that is, the ability to learn out-
comes against base data is hugely, hugely relevant.” Correspondingly, patients were 
concerned about the abilities of AI models to be able to be responsive to additional 
information, changes and updates within health contexts. How will that be ensured, 
they asked? And how will the regulatory process account for this given that these 
systems should be retrained often?
Patients also questioned the efficacy of AI development given the relative homo-
geneity of developers. Some patient interlocutors questioned whether emerging 
AI-driven health technologies might only be fully responsive to and efficacious for 
the demographic groups resembling developers. These patients worry that as the tech 
industry is dominated by affluent to middle-class, cis-, white, male developers, the 
questions, issues, and systems developers are currently pursuing might bear the (un)
conscious markings of developers’ particular systemic privileges, interests, politics, 
desires, and bodies [17]. These patients reason that the needs, worldviews, and com-
mitments of those developing technological instruments will inevitably influence how 
these instruments will take shape in the world. Compounded by the troubling homo-
geneity of the tech industry, these patients foresee that these technologies have the 
potential to embody prejudices, unconscious blindspots, or inherent bias that could 
result in “unintended harm” that disproportionately affects the most vulnerable in 
society. Patients stressed the need for “diverse developing teams” who will hold “diver-
sity of viewpoints” and attend to their technologies’ capabilities to reinforce structural 
inequities and unjust psychological biases to produce harm for patients. Their com-
ments are heedful of the extent to which developers are concerned with constructing 
tools that function to oppose apathy, greed, and inequity. As one patient contended: 
“Your tech needs to include and account for everyone or you will create more barriers 
to quality care. It’s about making sure you don’t leave certain patients in the ‘Dark Age’ 
and giving all patients the right treatments for the strongest chance at survival.”
7.3 Patient concerns regarding health system integration and access
Furthermore, patients remain troubled by concerns regarding standardization, 
health system integration, and unequal access to leading-edge medical care. Some 
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patient interlocutors voiced doubts regarding the ability of their current health 
system to integrate and implement the use of these tools in a successful, rapid, and 
straightforward manner. As a result of predicaments stemming from its bureau-
cratic structure and mishaps related to its ability to securely manage health data, 
some U.K. patients held misgivings about the feasibility of the National Health 
Service to manage a transition to widespread, systematic use of cutting-edge, 
AI-driven medical tools. Comparatively, U.S. patients frequently voiced integration 
concerns relating to how the largely for-profit and privatized U.S. healthcare system 
results in unequal access to standard of care and even basic health services. As the 
healthcare landscape in the U.S. remains stunningly rife with inequities, patients 
fear a potential worsening of the existing unequal implementation and access to 
AI-driven systems for medical use. Accordingly, U.S. patients asked: what hospitals 
and medical centers have the resources to launch and integrate this technology for 
patients’ benefits? What patients will be denied access because of factors such as 
geographic location, healthcare provider, hospital availability, and insurance issues? 
How will this further entrench existing healthcare inequities? “While some patients 
might have access [to cutting-edge AI tools for oncology] through tertiary centers 
and university research hospitals, what’s happening at local clinics and hospitals?” 
one U.S. patient asked. “How will standardization play out?” she continued, “We 
have to make sure that people—that everybody—has access to it and that’s not the 
case here.” Another U.S. cancer patient advocate further elaborated: “Everyone 
is thinking it is promising and that it will come our way. My concern is that it is 
broadly accepted to be covered by public systems. We see a lot of disparities in terms 
of what public insurance like Medicare and Medicaid will cover versus what private 
insurance will cover. So my fear is that we are going to have two tiers.” Patient 
interlocutors comprising this interview corpus recognize that issues surrounding 
financial resources and incentives as well as individual health system’s bureaucratic 
and political structures will contribute to the ease or difficulty of systematic inte-
gration of AI tools for medicine. In turn, they reason that this may affect unequal 
access to the most efficacious care and thus, contribute to the further entrenchment 
of existing healthcare inequities.
8.  Understanding patient perceptions regarding data-sharing for AI and 
drug development research
Access to health datasets is a crucial factor in enabling oncology-specific drug 
development and AI systems research. This section examines patient responses and 
concerns regarding sharing their health data for these aforementioned purposes. 
Together, the comments of this sample of cancer patient interlocutors compose an 
opening through which to understand some patients’ perceptions, misconceptions, 
and misgivings regarding sharing their health data. Moreover, their responses 
exhibit variance in both existing knowledge of cancer patients and the extent to 
which they express a desire to be involved in the advancement of proposed AI 
systems for oncology and oncology drug development vis-a-vis data-sharing.
8.1 Data-sharing and research participation: concerns and caveats
Virtually all of the cancer patients interviewed for this study expressed both 
general enthusiasm and an overall willingness to be involved in oncology drug 
development and oncology AI tool advancement in some capacity. Furthermore, 
nearly 22% of the patients comprising the interview corpus indicated that they 
trust the regulatory schemes and ethical parameters that currently guide public and 
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drug development research
Access to health datasets is a crucial factor in enabling oncology-specific drug 
development and AI systems research. This section examines patient responses and 
concerns regarding sharing their health data for these aforementioned purposes. 
Together, the comments of this sample of cancer patient interlocutors compose an 
opening through which to understand some patients’ perceptions, misconceptions, 
and misgivings regarding sharing their health data. Moreover, their responses 
exhibit variance in both existing knowledge of cancer patients and the extent to 
which they express a desire to be involved in the advancement of proposed AI 
systems for oncology and oncology drug development vis-a-vis data-sharing.
8.1 Data-sharing and research participation: concerns and caveats
Virtually all of the cancer patients interviewed for this study expressed both 
general enthusiasm and an overall willingness to be involved in oncology drug 
development and oncology AI tool advancement in some capacity. Furthermore, 
nearly 22% of the patients comprising the interview corpus indicated that they 
trust the regulatory schemes and ethical parameters that currently guide public and 
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private entities involved in research enough to be willing to share their medical data 
for research purposes without any additional conditions or specific requests beyond 
these existing mandates. The potential for various issues pertaining to data security, 
storage, targeted surveillance, as well as risks of data re-identification and discrimi-
nation, did not inhibit these patients’ desire to contribute to oncology drug and AI 
development research. In their view, these potential complications did not present 
an undue risk to them given the existing frameworks of ethical and legal protections 
regarding research.
Nevertheless, the remaining portion of patient interlocutors held concerns and 
caveats potent enough to potentially prevent them from agreeing to participate in 
research. These patients presented a series of considerations that they specifically 
want corporate researchers to address in order for them to feel comfortable enough 
to agree to contribute health data for a private entities’ (e.g., pharmaceutical or 
biotech companies) efforts to conduct research regardless of their affiliations with 
medical research institutes or university research centers. Notably, however, when 
presented with a hypothetical scenario in which a university or medical research 
institute was conducting research without corporate collaboration (exclusive of 
funding) nearly all patients were willing to offer their medical data without any 
major caveats although a small number insisted that their willingness to share their 
data would be affected by corporate sponsorship in this scenario.
8.2 Concerns regarding data security and patient privacy
Most commonly, patient interlocutors declared that their primary concern with 
respect to sharing medical data for research purposes pertains to issues of data 
security and privacy. Despite current legal and ethical standards mandating the 
anonymization of medical data for research, patients voiced that keeping their data 
anonymized and their privacy secure remains their top priority and issue of con-
cern. Still, several of these patients admitted that if they were assured that their data 
would be kept anonymized and would be securely stored with respect to current 
industry and legal standards, they would be willing to participate in research. While 
a small number of patients expressed doubts as to whether their healthcare provider 
(i.e., the National Health Service) can effectively keep patients’ health data secure 
from hackers and data leaks, the majority of patients comprising this interview 
sample conceded that they had little to no knowledge of how their health data might 
be stored, kept secure, or circulated beyond their medical provider’s institution.
8.3  Lack of knowledge about legal mandates and fears of insurance 
complications
Many patients also disclosed that they were unsure of the dictates that ethical 
review boards and legal frameworks impose on researchers working with health 
data. While all of the U.S. patients interviewed were at least aware of the federal leg-
islation known as the Health Insurance Portability and Accountability Act or HIPPA 
(if not also other federal statutes such as GINA or relevant state laws), in contrast, 
U.K. patients, with the exception of those whose profession involves health data-
handling, disclosed that they typically unaware of U.K. statutes regarding health 
data protections to any degree of notable detail. Regardless of whether this igno-
rance stems from a lack of interest, from trust in the National Health Service to fully 
comply with the mandates of legal ordinances, or some other reason, both U.K. 
patients and U.S. patients alike indicated a concern that current legal frameworks 
are likely too lax in ensuring the protection of patients’ ability to access healthcare 
via private insurance. This was the second most frequently cited concern related to 
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health data-sharing and research participation across the interview corpus. “I am 
deeply concerned this data will make their way to insurance companies and affect 
premiums,” one patient asserted. In the event of a data breach or a scenario in which 
data mining allowed health insurance companies to have access to individuals’ 
health data subsequent to sharing their medical data for research purposes, patients 
questioned whether current law is robust enough to prohibit health insurance 
companies from obtaining their medical data for purposes of denying them cover-
age or limiting their access to coverage through higher fees for coverage based on 
data originally shared for research purposes.
8.4 Understanding other demands for securing consent
Beyond issues of data security, patients consistently related several other factors 
that would influence their decision to share medical data with a corporate entity for 
AI and drug development research related to oncology. Most frequently, patients 
expressed that they would be willing to share their data with companies for these 
purposes provided their research was explained to them in full and that they agreed 
with the ethical imperatives of the study and corporation more broadly. In this vein, 
patients were consistent in insisting that they wanted to know: (1) the research 
objectives of a potential study, (2) if the study posed any risks or potential for harm. 
To a slightly less degree patients asserted that they would also want to be informed 
about where their data would be stored once shared and who it would be handled 
by, who would own the data once it is shared for research, if their data to kept for 
future use or circulated for use in other studies, how the study was to be funded and 
executed, and how the corporate entity manages their profit motives with ethical 
mandates. Moreover, if provided with all this information, some patients explained 
that they would then only be willing to share their data if the company designed 
their research with the imperative to benefit as many cancer patients as possible. 
For instance, two patients related that if a pharmaceutical company was aiming to 
conduct research for a drug that would have only a minimal effect on patients’ well-
being and outcomes such as only be able to “prolong life for two months” based on 
“the need for profit” then they would not be interested in sharing their health data. 
“Big Pharma,” another patient emphasized, “is difficult to trust.” Others noted that 
they would want to gather more information about how the hypothetical company 
may or may not be engaged in depriving some patients of necessary treatments. 
One patient explained that if a company had a history of using patients’ data to help 
create drugs in order to then charge exorbitant prices that placed the drug out of 
reach for a majority of patients, they would not be willing to share their data to aid 
a company in their research. Still, two patients conceded that the future prospect 
of production of generics in this scenario would satisfy them enough to want to 
share their data. In addition, some patient interlocutors asserted their desire to 
be updated about the status of the research and its potential outcomes. Likewise, 
patients wanted to be assured that if researchers handling their data were to find 
something medically concerning or relevant to their future health status (e.g., a 
genetic predisposition for a disease) that they would be notified by the research 
body although some admitted that they were unsure as to how this would be accom-
plished given de-identification of the data.
8.5  Concerns regarding corporate ethics and the potential for targeted 
advertising
Moreover, patients insisted that additional regulatory safeguards are needed 
both in the U.S. and in the U.K. to protect patients participating in research not just 
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major caveats although a small number insisted that their willingness to share their 
data would be affected by corporate sponsorship in this scenario.
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respect to sharing medical data for research purposes pertains to issues of data 
security and privacy. Despite current legal and ethical standards mandating the 
anonymization of medical data for research, patients voiced that keeping their data 
anonymized and their privacy secure remains their top priority and issue of con-
cern. Still, several of these patients admitted that if they were assured that their data 
would be kept anonymized and would be securely stored with respect to current 
industry and legal standards, they would be willing to participate in research. While 
a small number of patients expressed doubts as to whether their healthcare provider 
(i.e., the National Health Service) can effectively keep patients’ health data secure 
from hackers and data leaks, the majority of patients comprising this interview 
sample conceded that they had little to no knowledge of how their health data might 
be stored, kept secure, or circulated beyond their medical provider’s institution.
8.3  Lack of knowledge about legal mandates and fears of insurance 
complications
Many patients also disclosed that they were unsure of the dictates that ethical 
review boards and legal frameworks impose on researchers working with health 
data. While all of the U.S. patients interviewed were at least aware of the federal leg-
islation known as the Health Insurance Portability and Accountability Act or HIPPA 
(if not also other federal statutes such as GINA or relevant state laws), in contrast, 
U.K. patients, with the exception of those whose profession involves health data-
handling, disclosed that they typically unaware of U.K. statutes regarding health 
data protections to any degree of notable detail. Regardless of whether this igno-
rance stems from a lack of interest, from trust in the National Health Service to fully 
comply with the mandates of legal ordinances, or some other reason, both U.K. 
patients and U.S. patients alike indicated a concern that current legal frameworks 
are likely too lax in ensuring the protection of patients’ ability to access healthcare 
via private insurance. This was the second most frequently cited concern related to 
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health data-sharing and research participation across the interview corpus. “I am 
deeply concerned this data will make their way to insurance companies and affect 
premiums,” one patient asserted. In the event of a data breach or a scenario in which 
data mining allowed health insurance companies to have access to individuals’ 
health data subsequent to sharing their medical data for research purposes, patients 
questioned whether current law is robust enough to prohibit health insurance 
companies from obtaining their medical data for purposes of denying them cover-
age or limiting their access to coverage through higher fees for coverage based on 
data originally shared for research purposes.
8.4 Understanding other demands for securing consent
Beyond issues of data security, patients consistently related several other factors 
that would influence their decision to share medical data with a corporate entity for 
AI and drug development research related to oncology. Most frequently, patients 
expressed that they would be willing to share their data with companies for these 
purposes provided their research was explained to them in full and that they agreed 
with the ethical imperatives of the study and corporation more broadly. In this vein, 
patients were consistent in insisting that they wanted to know: (1) the research 
objectives of a potential study, (2) if the study posed any risks or potential for harm. 
To a slightly less degree patients asserted that they would also want to be informed 
about where their data would be stored once shared and who it would be handled 
by, who would own the data once it is shared for research, if their data to kept for 
future use or circulated for use in other studies, how the study was to be funded and 
executed, and how the corporate entity manages their profit motives with ethical 
mandates. Moreover, if provided with all this information, some patients explained 
that they would then only be willing to share their data if the company designed 
their research with the imperative to benefit as many cancer patients as possible. 
For instance, two patients related that if a pharmaceutical company was aiming to 
conduct research for a drug that would have only a minimal effect on patients’ well-
being and outcomes such as only be able to “prolong life for two months” based on 
“the need for profit” then they would not be interested in sharing their health data. 
“Big Pharma,” another patient emphasized, “is difficult to trust.” Others noted that 
they would want to gather more information about how the hypothetical company 
may or may not be engaged in depriving some patients of necessary treatments. 
One patient explained that if a company had a history of using patients’ data to help 
create drugs in order to then charge exorbitant prices that placed the drug out of 
reach for a majority of patients, they would not be willing to share their data to aid 
a company in their research. Still, two patients conceded that the future prospect 
of production of generics in this scenario would satisfy them enough to want to 
share their data. In addition, some patient interlocutors asserted their desire to 
be updated about the status of the research and its potential outcomes. Likewise, 
patients wanted to be assured that if researchers handling their data were to find 
something medically concerning or relevant to their future health status (e.g., a 
genetic predisposition for a disease) that they would be notified by the research 
body although some admitted that they were unsure as to how this would be accom-
plished given de-identification of the data.
8.5  Concerns regarding corporate ethics and the potential for targeted 
advertising
Moreover, patients insisted that additional regulatory safeguards are needed 
both in the U.S. and in the U.K. to protect patients participating in research not just 
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from healthcare coverage issues, but also from the potential for corporate surveil-
lance and targeted advertising based on their medical data. Specifically, patients 
indicated that they believe that sharing their health data with entities beyond their 
healthcare provider and health insurer could potentially expose them to further 
and more intrusive corporate surveillance and targeted marketing. Although the 
inherent profit motives of private corporations admittedly troubled some patients, 
this factor and the potential of targeted marketing alone did not compel any patient 
interlocutors to declare that they would refuse to share their medical data based 
on these factors. Rather, patients related that they would take a “holistic” view of: 
the company, its research aims, the procedures and mechanisms of the study, and 
why and how a company might ask participants to transfer ownership of their data 
and further circulate it beyond the individual study. “Before I share my data,” one 
patient concluded, “I would really need to interrogate the company and its aims.”
Critically, patients widely differed in their insistence of how data security and 
related issues might be pertinent to their decision to participate in research for 
oncology drug development and AI One U.S.-based patient advocate who primar-
ily works with low-income cancer patients offered an explanation to suggest the 
variance with which patients stated these issues as relevant matters of concern. 
She contended that patients’ awareness of and inclinations to voice such concerns 
regarding data security and privacy are contingent upon their health status, 
resources, and level of education. She explained, “I don’t know how much patients 
know about the extent to which their health data is being shared. I don’t think I do 
either but to the extent that I do know...gosh, I think ‘Wow, I didn’t know that!’ So I 
don’t think most people know...Sometimes with advocates may be higher resourced 
or have come through [their treatments] and are now stable because in the thick of 
it I don’t hear patients being worried about [issues related to medical data-sharing] 
during the thick of treatment. Also, we have many clients who are less savvy about 
the system, and that is, lower resourced here, generally. So I haven’t heard a word 
about it. They are concerned with their personal privacy when it comes to their 
social security number, their immigration status, et cetera but as to whether they 
are concerned with their local CVS selling their data out? I don’t think they are 
concerned with that. I think that concern is a higher Maslow level than for instance, 
‘I’m in treatment and I gotta feed my family.’” In this advocate’s view, patients’ likeli-
hood to be concerned about the aforementioned issues of data ownership, security, 
data brokerage, threats to insurance coverage, and targeted corporate advertising 
necessitated a health status, insurance status, and an educational background that 
would allow them to consider such issues as sufficiently critical and indeed, the data 
collected by the author did not seem to dispute this view.
8.6  Genetic data-sharing: fears of discrimination and lack of knowledge  
and value
A smaller number of patients related they feared that in the event of a health 
data breach, or of medical data circulation subsequent to a private entity’s transfer-
ence of patient data to health data brokers following research participation, some 
individuals might be subjected to discrimination or stigma based on their health-
care status, data, or medical history. Patients were particularly concerned with 
discrimination and corporate surveillance with respect to genetic data. Although 
patients often insisted that they believed genomics “provides an additional path for 
predicting the cause of cancer,” that it will potentially “improve personalized treat-
ment,” and that “generally speaking, they see few negatives to [genomics] research,” 
many related that they remained apprehensive of what social effects the study of 
such data might entail and communicated fears related to the stigma of medical 
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genomics. For instance, some held fears of how genetic studies might embolden 
some researchers to take up “social genomics studies” reminiscent of the twentieth-
century eugenics and pseudoscientific approaches to genetics. In further explaining 
these qualms, patients cited the potential for discrimination related to genetic pre-
dispositions, STI or HIV/AIDS status, or mental health histories. As a result, a large 
portion of patients indicated that as legal protections against such ramifications 
are, by their estimations, weak or fail to account for contemporary use, patients 
may demand additional assurances from private entities engaged in health research 
that if they were to participate in research by sharing their medical data with them, 
their data would be secured to the highest possible standard and sufficiently de-
identified. As one patient explained, “As as it can be de-identified with confidence, 
then data leaks may be less harmful.” Some patients raised other concerns about the 
current lack of education regarding genomics and cancer patients, corporate actors, 
and oncologists possess. One patient contended: “I think the field is still early. I am 
concerned about commercial tests that may not be looking at the same genes and 
may give different results. Genetic counselors are a must!” Patients possessing these 
concerns were adamant that genetic data and genomics research needs to be coupled 
with educational initiatives and expert roles to explain results, consent procedures, 
and possible harm.
8.7 Issues of financial compensation, benefit-sharing, and medical inclusion
Finally, although most of the patients comprising the interview corpus were 
willing to share their health data for research without the prospect of financial com-
pensation or benefit-sharing possibilities, approximately 15% of the interviewees 
(both U.S. and U.K. patients) stressed that these issues would greatly influence their 
decision to share their health data with a private entity. This issue was particularly 
important for patients who were currently undergoing treatment. One patient, 
a mother in her early forties currently undergoing treatment for a rare cancer 
type, explained her interest in financial compensation and other benefit-sharing 
as well as how it would affect their decision to participate in private research: 
“Compensation is nice but I suppose if they can’t compensate and then can’t use the 
data, I would rather them be using the data if it’s going to be for the greater good 
and improving medicines and technology. I suppose it would be nice to know what 
they are working towards. So, in turn, they share: ‘This is what we are trying to 
achieve.’ But I sort of assume that if they use your data and have anonymized it by 
the time they do the study there’s really no way of them being able to come back and 
say, ‘This is what we’ve done with your data.’ In a case like with [the pharmaceutical 
company who makes a drug I need access to in order to attain a higher chance at 
survival], if they used your data to create a drug and then sell it for a sky-high price 
that you can’t afford, I think that’s wrong in a way. Why should they sell it at this 
sky-high price if they’ve used this data which has come to them as a free resource? 
Why is that fair? I suppose I’ve not really thought it through to that extent when I’ve 
given permission [before however] because I just think if this is research, it may 
possibly help me or help someone else in the future. [So] I probably would still want 
them to have the data. But maybe there should be other controls to stop them charg-
ing the Earth! Just making these drugs and saying, ‘these drugs are really amazing 
but you can’t have them because they are ridiculously expensive...We’ve made these 
drugs from your data which we have gathered and now we will sell them for ‘x’ 
amount.’ So yeah I suppose we would want some financial gain if you are going to be 
passing your information off to these companies...I would want the NHS [National 
Health Service] or say, Cancer Research UK, or someone like that just to use my data 
but maybe it is a bit different if you are talking about a big pharmaceutical company 
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or have come through [their treatments] and are now stable because in the thick of 
it I don’t hear patients being worried about [issues related to medical data-sharing] 
during the thick of treatment. Also, we have many clients who are less savvy about 
the system, and that is, lower resourced here, generally. So I haven’t heard a word 
about it. They are concerned with their personal privacy when it comes to their 
social security number, their immigration status, et cetera but as to whether they 
are concerned with their local CVS selling their data out? I don’t think they are 
concerned with that. I think that concern is a higher Maslow level than for instance, 
‘I’m in treatment and I gotta feed my family.’” In this advocate’s view, patients’ likeli-
hood to be concerned about the aforementioned issues of data ownership, security, 
data brokerage, threats to insurance coverage, and targeted corporate advertising 
necessitated a health status, insurance status, and an educational background that 
would allow them to consider such issues as sufficiently critical and indeed, the data 
collected by the author did not seem to dispute this view.
8.6  Genetic data-sharing: fears of discrimination and lack of knowledge  
and value
A smaller number of patients related they feared that in the event of a health 
data breach, or of medical data circulation subsequent to a private entity’s transfer-
ence of patient data to health data brokers following research participation, some 
individuals might be subjected to discrimination or stigma based on their health-
care status, data, or medical history. Patients were particularly concerned with 
discrimination and corporate surveillance with respect to genetic data. Although 
patients often insisted that they believed genomics “provides an additional path for 
predicting the cause of cancer,” that it will potentially “improve personalized treat-
ment,” and that “generally speaking, they see few negatives to [genomics] research,” 
many related that they remained apprehensive of what social effects the study of 
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genomics. For instance, some held fears of how genetic studies might embolden 
some researchers to take up “social genomics studies” reminiscent of the twentieth-
century eugenics and pseudoscientific approaches to genetics. In further explaining 
these qualms, patients cited the potential for discrimination related to genetic pre-
dispositions, STI or HIV/AIDS status, or mental health histories. As a result, a large 
portion of patients indicated that as legal protections against such ramifications 
are, by their estimations, weak or fail to account for contemporary use, patients 
may demand additional assurances from private entities engaged in health research 
that if they were to participate in research by sharing their medical data with them, 
their data would be secured to the highest possible standard and sufficiently de-
identified. As one patient explained, “As as it can be de-identified with confidence, 
then data leaks may be less harmful.” Some patients raised other concerns about the 
current lack of education regarding genomics and cancer patients, corporate actors, 
and oncologists possess. One patient contended: “I think the field is still early. I am 
concerned about commercial tests that may not be looking at the same genes and 
may give different results. Genetic counselors are a must!” Patients possessing these 
concerns were adamant that genetic data and genomics research needs to be coupled 
with educational initiatives and expert roles to explain results, consent procedures, 
and possible harm.
8.7 Issues of financial compensation, benefit-sharing, and medical inclusion
Finally, although most of the patients comprising the interview corpus were 
willing to share their health data for research without the prospect of financial com-
pensation or benefit-sharing possibilities, approximately 15% of the interviewees 
(both U.S. and U.K. patients) stressed that these issues would greatly influence their 
decision to share their health data with a private entity. This issue was particularly 
important for patients who were currently undergoing treatment. One patient, 
a mother in her early forties currently undergoing treatment for a rare cancer 
type, explained her interest in financial compensation and other benefit-sharing 
as well as how it would affect their decision to participate in private research: 
“Compensation is nice but I suppose if they can’t compensate and then can’t use the 
data, I would rather them be using the data if it’s going to be for the greater good 
and improving medicines and technology. I suppose it would be nice to know what 
they are working towards. So, in turn, they share: ‘This is what we are trying to 
achieve.’ But I sort of assume that if they use your data and have anonymized it by 
the time they do the study there’s really no way of them being able to come back and 
say, ‘This is what we’ve done with your data.’ In a case like with [the pharmaceutical 
company who makes a drug I need access to in order to attain a higher chance at 
survival], if they used your data to create a drug and then sell it for a sky-high price 
that you can’t afford, I think that’s wrong in a way. Why should they sell it at this 
sky-high price if they’ve used this data which has come to them as a free resource? 
Why is that fair? I suppose I’ve not really thought it through to that extent when I’ve 
given permission [before however] because I just think if this is research, it may 
possibly help me or help someone else in the future. [So] I probably would still want 
them to have the data. But maybe there should be other controls to stop them charg-
ing the Earth! Just making these drugs and saying, ‘these drugs are really amazing 
but you can’t have them because they are ridiculously expensive...We’ve made these 
drugs from your data which we have gathered and now we will sell them for ‘x’ 
amount.’ So yeah I suppose we would want some financial gain if you are going to be 
passing your information off to these companies...I would want the NHS [National 
Health Service] or say, Cancer Research UK, or someone like that just to use my data 
but maybe it is a bit different if you are talking about a big pharmaceutical company 
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that’s making billions of dollars or whatever...They can afford to compensate you...
and yeah there’s generics and I get that. I know that they will come out with gener-
ics for [the drug I need] eventually, but that’s too late for me. I need it now.” This 
patient interlocutor’s explanation of their conditions for medical data-sharing for 
research participation offers a sense of how patients currently undergoing treat-
ment are conceptualizing the issue of sharing their data and how they wish to 
benefit in the event of doing so.
In contrast to this patient’s understanding of the value of their medical data and 
sense of how it might be valuable for other actors, many patients expressed puzzle-
ment and apprehension with regard to how their data might hold future and current 
value. For example, one patient related: “My major concern is that there’s not 
enough knowledge to really benefit [for and as a patient currently undergoing treat-
ment] from shar[ing] this health data [including genetic data, with researchers]. I 
really wish it could accelerate and that we could use AI to guide the treatments but 
there’s not enough treatments out there to make a massive difference. I hope that 
it will progress soon...but today I don’t really know what you could do with this 
data that would impact your life in any way.” In addition to patients’ doubts that 
participating in research would have a significant impact on the health outcomes 
of current patients, other patients were confused as to how, in the event of a data 
breach, their health data information might be of value to others including hackers, 
government agencies, or corporate entities. “Why would someone want to hack 
into a researcher’s storage system and take my data” and “why would someone want 
to re-identify my data?,” some patients questioned. One patient insisted that this 
would have no bearing on a decision to participate in research: “But why someone 
want to do it? I don’t really see any reason. So no, it [is not and] wouldn’t be a worry 
for me.”
In addition to issues of financial compensation, some patients noted that issues 
of consent regarding medical data-sharing were of critical importance to influenc-
ing how likely they are to share their data with researchers for AI advancement 
and drug development. As several patients were insistent that medical inclusion of 
diverse populations in research must be a priority, some asserted that they would be 
unwilling to share their health data with researchers if they did not make the inter-
related issues of patient trust, efficacy, and medical inclusion key to their research. 
To this end, these patients wanted researchers to prioritize building relationships 
to recruit diverse populations for their studies, offer educational initiative to help 
equip potential participants with sufficient knowledge regarding what impacts and 
effects their participation might result in, and be committed to sharing resources 
and the benefits of “lower-resourced” populations. Only a demonstration of such 
commitments could impel these patients to want to share their data for research.
9.  Patient-centered approaches to building frameworks of trust and 
accountability
This section examines patient-centered recommendations and proposals for 
ensuring patient trust, participation, and safety pertinent to increasing the devel-
opment and clinical use of AI systems for oncology. Building on cancer patients’ 
concerns, this section highlights three major arenas for cultivating frameworks of 
trust and accountability crucial to advancing these systems and ushering them into 
clinical settings. Drawing from the qualitative data produced by this study in addi-
tion to the insights of other researchers, these three imperative arenas in need of 
reinforcement include: Building Knowledge and Redressing Consent and Resource 
Sharing; Addressing Health Inequities for AI Accountability; and, Promoting and 
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Establishing Additional Safeguards. Strengthening patient support, understanding, 
and participation in AI-related oncology drug development requires robust, varied 
responses to these three interrelated arenas of concern from a multitude of relevant 
actors. This section provides an overview that attempts to synthesize the attitudes, 
positions, and actions stakeholders can undertake to broadly ensure accountability, 
equity, and patient trust and participation with regard to these systems.
9.1  Navigating patient participation and trust: building knowledge, redressing 
consent, and sharing resources
Educational initiatives remain a critical aspect to earning trust and maintaining 
accountability within AI-oncology related research endeavors. Establishing truly 
informed consent requires equipping cancer patients, cancer patient advocates, and 
oncology care providers with the necessary knowledge to stay informed and alert 
about how these systems operate, how they are designed and trained, what ramifi-
cations might ensue as a result of their implementation. Cancer patient advocates 
are particularly vocal in stressing the importance of giving patients all necessary 
information required in order to understand what potential limitations or risks such 
systems may incur. They further assert the need for a collaborative approach to both 
building patient knowledge and to assessing how potential harms and complica-
tions are to be addressed. They believe that collaboratively produced and executed 
educational initiatives will foster support among the general patient populace for 
public and private investments in both AI development as well as for the infrastruc-
tural adjustments within their use may necessitate. Advocates and oncologists alike 
contend that patients often remain ignorant of the options for medical coverage and 
care available to them, particularly with respect to clinical trials and other forms of 
research involvement. This lack of education not only comprises one barrier to par-
ticipating in oncology-related research and drug development studies, but also may 
furthermore preclude patients from receiving the highest quality of care at their 
disposal. Additional knowledge regarding research endeavors and their potential 
benefits may encourage patients, many of whom profess to be open to engaging in 
research, to participate in AI-driven oncology drug development studies.
Indeed, many cancer patients, including the interlocutors who informed this 
study, actively assert their desire to learn more about the AI-driven systems that 
have the potential to considerably impact their treatment from trustworthy sources. 
Patient advocates reason that given the aforementioned demands on patients as 
well as the nature of clinical care, more advocates, researchers, and clinicians must 
be trained in how these systems operate and in how they might affect patients in 
order to equip them with the necessary expertise for helping patients navigate 
and assess the potential ramifications that these technologies may have on their 
treatment. Undeniably, more initiatives need to be established to educate patients 
in how machine learning-driven systems operate, what their levels of efficacy are, 
and what greater social effects they might precipitate. Such educational initiatives 
would serve as a crucial first step in assisting current, former, and future patients 
in understanding what crucial arenas can be acted upon to ensure that patients 
receive the quality of care they deserve. These arenas might include, for example, 
participating in relevant research or reinforcing support for policies that attempt 
to carve out how issues of liability will enfold in the face of medical error due to AI 
system usage. As stated earlier, such educational endeavors may hold higher stakes 
and greater challenges for patients with “limited access to high quality clinical care, 
limited health literacy, earned mistrust of medical providers, and those individuals 
who may be exposed to interpersonal and institutional racism and other discrimi-
nation in their healthcare encounters” [14].
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that’s making billions of dollars or whatever...They can afford to compensate you...
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Nevertheless, it remains important to consider how matters of securing consent 
and research participation extend far beyond merely bolstering educational initia-
tives for patients. For instance, too often issues pertaining to refusal of consent 
and slim participation are framed as the consequence of ingrained beliefs that 
stem from cultural beliefs rather than as rational stances toward the injustices of 
biomedical research from beget from the nexus of material inequities and historical 
oppressions. Against the myopia of cultural determinism, researchers of technology 
and medicine contend that patients’ (un)willingness to participate in research must 
be appropriately contextualized as complex responses to biomedicine in socially 
stratified societies. Ruha Benjamin frames such arguments in the following terms: 
“If we understand trust and distrust not simply as individual or cultural predisposi-
tions that are ‘held’ by some and not by others, but rather as outgrowths of social 
relationships that are produced through the allocation of material resources and 
symbolic power, then we see that techniques for cultivating relationships hinge on 
redistributing and refashioning those, respectively” [18].
Exemplifying the limitations engendered by material inequities, clinical trials fre-
quently fail to recruit people of color and other marginalized people. This fact holds 
further significance as research conducted by the U.S. Census Bureau predicts that 
the white population in the U.S. will fall below 50% by 2045. In conducting interview 
work, it was typical to hear patient advocates and medical professionals bemoan 
how clinical trials and other research endeavors struggled to recruit “diverse” 
patient groups for their studies. Beyond educational matters, advocates, clinicians, 
and cancer nonprofit directors frequently framed the issue of participation as one 
dominated by cultural inclinations (some groups are like ‘x’—‘x,’ in this case, being a 
list of static traits or stereotypes of racial groups) rather than as dispositions toward 
structural inequities. Through cogent research that examines how clinicians’ “‘ideas 
about [their patients’ ‘cultures’] contribute to health disparities,” anthropologist 
Khiara Bridges contends that “cultural stereotypes and beliefs in the way people 
from certain cultures ‘just are’ can be dangerous—and just as racist—as racism” [19]. 
Demonstrably, cultural determinism can result in deleterious health outcomes.
To combat this, Benjamin argues that it is necessary for medical researchers and 
health professionals to turn “away from a fixation with distrust and towards the 
problem of institutional trustworthiness” [18]. This logical turn refuses to heap 
blame, stigma, or tidy labels of ignorance upon marginalized populations whom 
medical researchers find it difficult to recruit for studies. Instead, it asks research-
ers to assume a self-reflexive approach to their work and recruitment efforts and 
compels them to question how their institution, research body, and associates 
can be accountable to marginalized populations possessing an earned distrust of 
medical intrusion whom researchers aim to include in medical studies. In advancing 
the logical turn from a narrow fixation on issues of patient distrust to the broader 
problem of institutional trustworthiness, health practitioners, tech developers, and 
medical researchers may begin to fruitfully rectify inequalities rather than repro-
duce stale, cultural deterministic, and circumlocutory narratives of why “subordi-
nate groups remain elusive to researchers” [19].
Ethicists and researchers similarly stress the need to rethink current regulations for 
securing consent for biomedical research. They advocate for a shift from the para-
digms of one-time consent to frameworks of accountability that attend to participants’ 
evolving concerns and adhere to ongoing commitments of responsible use of partici-
pant samples. They argue that as political surroundings, public opinion, the type of 
information collected, and the application of this data necessarily shifts, researchers 
must build responsive systems of consent. Consent practices, they argue, must not only 
integrate ongoing assessments of the risks and implications of their research but also 
frequent monitoring of patient attitudes, beliefs, and perspectives.
169
Toward the Clinic: Understanding Patient Perspectives on AI and Data-Sharing for AI-Driven…
DOI: http://dx.doi.org/10.5772/intechopen.92787
Ethicists assert that more needs to be done to guarantee reciprocity or ensure 
that participants, not just researchers and their affiliated institutions and fund-
ing bodies, are also benefiting from the research. This begins with a willingness 
to address historical injustices that have contributed to the mistrust that certain 
groups continue to hold with respect to biomedical research. For some, distributing 
broad benefits in genetics and genomics research involves making research and 
research instruments publicly available so that they are not tethered to the limited 
access that often characterizes commercial arrangements. Ethicists also explain 
that research organizations can engage in capacity-building in which more richly 
resourced research organizations collaborate and share resources with “lower 
resourced” organizations and community participants.
As ethicists continue to advocate for benefit-sharing in research through 
endeavors like capacity-building and commitments to engaging in open source 
and public domain initiatives, they also advocate for the redressal of the politics1 
of recruitment itself. As anthropologist Cori Hayden argues “scientific knowledge 
does not simply represent (in the sense of depict) ‘nature,’ but it also represents”... 
(in the political sense) the ‘social interests’ of the people and institutions that have 
become wrapped up in its production” [21]. Following Hayden’s affirmation of the 
“coproduction” of all scientific endeavors, Benjamin advocates for attending to 
“informed refusal” as “a necessary corollary to informed consent—one that extends 
the bioethical parameters of the latter into a broader social field concerned not only 
with what is right, but also with the political and social rights of those who engage 
technoscience as research subjects and tissue donors” [18]. Benjamin explains that 
“the notion of informed consent—although developed to protect the rights and 
autonomy of individuals to accept or refuse participation in research—implicitly 
links the transmission of information to the granting of permission; in conse-
quence, “the request to consent can be interpreted as guidance to consent” [18]. 
Juxtaposing “informed” and “refusal” thereby acts a signal of necessary humility 
that recalls individuals’ right to refuse participation and recognizes a paradigm in 
which refusal derives from an educated stance.
It is not enough to recognize that educational initiatives have the capacity to 
contribute to bolstering research endeavors. Rather, scholars of science and tech-
nology and medicine stress how “what matters is not only who is in the room and 
the intentions of those gathered, but also the structures of participation, modes 
of inclusion, and assumptions about what forms of knowledge and expression are 
valid and relevant” [18]. One U.S. based patient advocate incisively summarized 
these issues surrounding recruitment, knowledge-building, and participation.
“A researcher wants their research to be successful so they write their hypothesis 
and their aims to prove it. If a researcher has a skewed view about a group, I have 
seen that they write their study skewed that way. When researchers are doing some-
thing where they want to get groups in, I think they have to be honest first. A lot of 
the times the researchers don’t look like the community. So you can’t walk into the 
community and not be willing to hear their feelings. It’s important for communities 
of color to be in research. Part of that problem of not knowing how things affect 
African Americans, Asians, Latinos, and Native Americans is because they are not 
involved. But they also don’t have a reason to trust. So like I said to someone who 
was trying to conduct a research project, she said, ‘Well I don’t look like them’ and I 
said, ‘Then you say that.’ You don’t walk in there and pretend that the people looking 
1 Politics, invoked here, does not solely refer to the mechanisms of electoral issues concerning political 
candidates or parties. Rather, it extends to the “collective social activity”—“public and private, formal 
and informal, in all human groups, institutions and societies” which affects who gets what, when, and 
how [20].
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at you do not see that you are a white woman. You admit it. ‘I don’t look like you. I 
know that. And here’s where my heart lies. I want to hear what you are thinking’. 
Because at least then you look as though you are there for the right reason and you 
are not looking to skate around the elephant in the room. Because it is about build-
ing relationships. You want someone to participate in your study. You know that 
people of color need to participate and particularly now that they are talking about 
precision medicine and personalized care. If people of color don’t participate in that 
then what will they know about us? They won’t know anything. We will be in the 
dark age because we are not participating. Although someone came and talked to us 
and said ‘Getting people to participate in clinical trials even in the white commu-
nity is low. It’s lower with people of color.’ but there is something that you already 
know: tell the truth. [laughs] Say, ‘I want to do this research.’ But I feel like with 
researchers if it’s with people of color that you don’t know and that you have your 
implicit biased conceptions that were passed down or told to you, you don’t want 
to work with those groups. Like ‘Oh I don’t want to work with that group because 
they are this.’ When actually, you don’t know that. When actually you could make a 
difference and be noticed where others weren’t by stepping out and taking that risk 
because we already know as medicine is moving in this direction of personalized 
care, that other populations need to be considered. But you gotta be honest and you 
gotta figure out how to get them involved and getting them involved is sitting down 
and talking with them. Not saying ‘hey I want to do this research I am going to come 
into your community and I am going to use you and then I am going to disappear.’ 
But making a commitment to come back to the community and share what you 
learned. When I worked for American Cancer Society and was in San Francisco... I 
remember Black people [from the Bay View/Hunter’s Point neighborhood] talking 
about how many researchers showed up and came in, did a research study, got their 
data and took off and never came back. Well that group never wanted to see another 
researcher, ‘all they wanted to do was use us.’ You have to change it. And that, to 
me, means that you are willing to sit there and hear the difficult stuff...if there isn’t 
a hospital, if they have no way of getting the standard things needed, then how do 
you partner with other people?...So, researchers,...find out what is out there and 
available. Because there has to be a way to work around [institutional limitations 
like funding caps]. Saying ‘ok you are only going to fund this but I found these 
other community organizations and clinics, how can we work with them to try to 
bring the community you are working with back a solution?’ Instead of stopping 
and saying this is too hard and this is why I don’t work with this community. You 
problem solve.”
In addition to building patient knowledge concerning: medical technological 
advancements, research endeavors, the ramifications of technological interven-
tions, science and technology studies scholars, biotechnology researchers, and 
patient advocates maintain that health inequities must be robustly addressed. 
With regard to making health technologies inclusive rather than exclusionary, 
patient advocates advise developers and medical researchers to seek out and col-
laborate with communities of color and other socially marginalized groups. They 
encourage conducting research and creating tech that focuses on and addresses 
the needs of vulnerable groups. A crucial aspect of such a venture, they assert, 
involves: building relationships and collaborative problem solving with these 
interlocutors to ensure that needs of these groups (such as basic access to standard 
treatment options) as well as the analyst’s research goals are met. Patient advocates 
stress that those willing to be pioneering in this regard will be hailed as vanguards 
and more importantly, are more likely to be recognized by myriad patient groups 
as worthy of trust.
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9.2  Addressing and preventing the entrenchment of existing health inequities 
via AI tools
Amid the excitement for the potential medical insights machine learning and 
other AI systems might enable stands an increasingly emphatic chorus of experts 
urging both the developers of these systems and health specialists to ensure that 
these systems work to mitigate rather than entrench existing healthcare inequities.
Technology experts and critical algorithm studies scholars implore that we 
evaluate how these AI models—which increasingly manage and organize our lives—
are far from neutral or objective tools. Rather, as mathematician Cathy O’Neil 
asserts, we must soberly weigh how these instruments are demonstrably encoded 
with human prejudice, misunderstanding, and bias [22]. One reason for this lies in 
the fact that these systems and the insights they generate are fundamentally reliant 
on training data sets composed of existing reference data. Conveying the fallibility 
of the data-driven paradigm within a different sector, in 2018 Amazon reported 
that the company was forced to discontinue its AI hiring and recruitment system 
because it discriminated against women applicants. Amazon’s recruiting tool relied 
on resumes submitted to the company over the previous 10 years—the majority of 
which came from men. Accordingly, these reference data organized the algorithm 
to give preference to male applicants and to screen out women applicants vis-a-vis 
subtle cues in their resumes such as experience in a women’s organization or educa-
tion at a women’s college [23].
In another example beyond medicine, in 2016, investigative journalists uncov-
ered how predictive criminal risk assessment algorithms—software used by US 
courts to predict how likely a person is to commit a crime in the future and relay 
a recommendation for sentencing to a presiding judge—are prejudiced toward 
people of color as they consistently recommend stronger sentencing for Black and 
Latinx people [24]. Scholars, among them Ruha Benjamin and Safiya Noble, and 
investigative journalists such as Julia Angwin continue to scrutinize the ramifica-
tions of integrating AI systems across a multitude of disparate realms among them: 
housing, finance, news media, welfare eligibility, social media platforms, popular 
search engines, and healthcare. Their research confirms that AI systems possess the 
capacity to exacerbate existing social inequities.
As the preponderance of data-driven solutions becomes the norm for healthcare 
specifically, experts demand that we address how these tools can compound exist-
ing disparities in healthcare outcomes. One step toward this remediation, research-
ers assert, involves educating healthcare providers and developers to ensure they 
sufficiently comprehend how systemic inequities affect individual health. A robust 
understanding of the causes, consequences, and modes in which health inequities 
exist not only affords medical specialists and health tech developers a sense of what 
research and technological solution need to be prioritized to address injustices, 
but it can also coincide with a self-reflexive method of medical engagement. In 
other words, knowing how, why, and what health inequities exist, can allow one to 
approach health interventions with a heightened awareness of the imbrications and 
the potentially far-reaching implications of their actions and mediations. It would 
allow one a crucial frame of reference to question how their instruments and actions 
might be a catalyst for perpetuating social harm. Many argue that this knowledge is 
a necessary, fundamental, initial step toward remediating health injustice.
Dr. Tina K. Sacks, a medical sociologist who investigates how race and gender 
impact health outcomes and a proponent of this kind of knowledge building, advo-
cates for a structural approach to understanding health inequities. Sacks asserts: 
“Although the dominant paradigm in the United States emphasizes individual 
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at you do not see that you are a white woman. You admit it. ‘I don’t look like you. I 
know that. And here’s where my heart lies. I want to hear what you are thinking’. 
Because at least then you look as though you are there for the right reason and you 
are not looking to skate around the elephant in the room. Because it is about build-
ing relationships. You want someone to participate in your study. You know that 
people of color need to participate and particularly now that they are talking about 
precision medicine and personalized care. If people of color don’t participate in that 
then what will they know about us? They won’t know anything. We will be in the 
dark age because we are not participating. Although someone came and talked to us 
and said ‘Getting people to participate in clinical trials even in the white commu-
nity is low. It’s lower with people of color.’ but there is something that you already 
know: tell the truth. [laughs] Say, ‘I want to do this research.’ But I feel like with 
researchers if it’s with people of color that you don’t know and that you have your 
implicit biased conceptions that were passed down or told to you, you don’t want 
to work with those groups. Like ‘Oh I don’t want to work with that group because 
they are this.’ When actually, you don’t know that. When actually you could make a 
difference and be noticed where others weren’t by stepping out and taking that risk 
because we already know as medicine is moving in this direction of personalized 
care, that other populations need to be considered. But you gotta be honest and you 
gotta figure out how to get them involved and getting them involved is sitting down 
and talking with them. Not saying ‘hey I want to do this research I am going to come 
into your community and I am going to use you and then I am going to disappear.’ 
But making a commitment to come back to the community and share what you 
learned. When I worked for American Cancer Society and was in San Francisco... I 
remember Black people [from the Bay View/Hunter’s Point neighborhood] talking 
about how many researchers showed up and came in, did a research study, got their 
data and took off and never came back. Well that group never wanted to see another 
researcher, ‘all they wanted to do was use us.’ You have to change it. And that, to 
me, means that you are willing to sit there and hear the difficult stuff...if there isn’t 
a hospital, if they have no way of getting the standard things needed, then how do 
you partner with other people?...So, researchers,...find out what is out there and 
available. Because there has to be a way to work around [institutional limitations 
like funding caps]. Saying ‘ok you are only going to fund this but I found these 
other community organizations and clinics, how can we work with them to try to 
bring the community you are working with back a solution?’ Instead of stopping 
and saying this is too hard and this is why I don’t work with this community. You 
problem solve.”
In addition to building patient knowledge concerning: medical technological 
advancements, research endeavors, the ramifications of technological interven-
tions, science and technology studies scholars, biotechnology researchers, and 
patient advocates maintain that health inequities must be robustly addressed. 
With regard to making health technologies inclusive rather than exclusionary, 
patient advocates advise developers and medical researchers to seek out and col-
laborate with communities of color and other socially marginalized groups. They 
encourage conducting research and creating tech that focuses on and addresses 
the needs of vulnerable groups. A crucial aspect of such a venture, they assert, 
involves: building relationships and collaborative problem solving with these 
interlocutors to ensure that needs of these groups (such as basic access to standard 
treatment options) as well as the analyst’s research goals are met. Patient advocates 
stress that those willing to be pioneering in this regard will be hailed as vanguards 
and more importantly, are more likely to be recognized by myriad patient groups 
as worthy of trust.
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9.2  Addressing and preventing the entrenchment of existing health inequities 
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As the preponderance of data-driven solutions becomes the norm for healthcare 
specifically, experts demand that we address how these tools can compound exist-
ing disparities in healthcare outcomes. One step toward this remediation, research-
ers assert, involves educating healthcare providers and developers to ensure they 
sufficiently comprehend how systemic inequities affect individual health. A robust 
understanding of the causes, consequences, and modes in which health inequities 
exist not only affords medical specialists and health tech developers a sense of what 
research and technological solution need to be prioritized to address injustices, 
but it can also coincide with a self-reflexive method of medical engagement. In 
other words, knowing how, why, and what health inequities exist, can allow one to 
approach health interventions with a heightened awareness of the imbrications and 
the potentially far-reaching implications of their actions and mediations. It would 
allow one a crucial frame of reference to question how their instruments and actions 
might be a catalyst for perpetuating social harm. Many argue that this knowledge is 
a necessary, fundamental, initial step toward remediating health injustice.
Dr. Tina K. Sacks, a medical sociologist who investigates how race and gender 
impact health outcomes and a proponent of this kind of knowledge building, advo-
cates for a structural approach to understanding health inequities. Sacks asserts: 
“Although the dominant paradigm in the United States emphasizes individual 
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choice and responsibility, the empirical evidence indicates that our neighborhoods, 
schools, jobs, and other factors of day-to-day life shape individual and population 
health” [25]. Similarly, medical historian John Hoberman analyzes how the histori-
cal legacy of racialized thinking is reflected in the contemporary U.S. medical estab-
lishment by focusing on how physician racism contributes to health disparities. 
Hoberman’s research suggests that medical providers rely on false beliefs rooted in 
racial essentialism—such as the pernicious myth of so-called Black “hardiness”—to 
determine diagnosis and treatment for Black patients [25]. In addition to racial and 
gendered oppression, in the past several decades, researchers have demonstrated 
that health and well-being strongly correlate with socioeconomic status. Sacks 
summarizes: “One of the most important systemic inequalities is unequal access to 
income and wealth, which may lead to poor health behaviors, chronic conditions, 
and disease” [25].
The findings of the Institute of Medicine’s2 seminal study of the causes and 
ramifications of pervasive healthcare disparities in the US and the volume of 
research it prompted, found physician bias, whether conscious or unconscious, 
to be a crucial factor in the production of disproportionate healthcare outcomes. 
Subsequent empirical studies suggest that people of color and ethnic minorities, 
women, and other people who occupy vulnerable social positions are most suscep-
tible to the noxious consequences of bias and stereotyping. Sacks further flags that 
“numerous studies have documented that healthcare providers are unconsciously or 
unintentionally biased against members of marginalized groups, which ultimately 
leads to difference in treatment across multiple domains (i.e., speciality care, pain 
management, mental health services, etc.)” [25].
Myriad experts assert that it is imperative that we are cognizant and considerate 
of how social inequities are embedded into the health data upon which AI systems 
are built. Due to design and optimization constraints, training datasets primarily 
utilize the health data profiles of those who can afford and have access to long-
term, continuous healthcare as opposed to those who have limited access to care, 
discontinuous care, or fragmented records. Moreover, data gathered via clinical 
trials have long been known to be unrepresentative of the US population. Clinical 
trials routinely fail to recruit people of color and other marginalized people. 
Recently, investigative journalists at ProPublica reported that Black Americans, 
Native Americans, and other Americans of color are steeply under-represented in 
clinical trials for cancer drugs—even when the type of cancer disproportionately 
affects them [26]. This has translated to cancer treatments that are least effective 
for the population most afflicted by the disease. Critically, people of color continue 
to have disproportionately higher incidence and mortality rates for kidney, breast, 
prostate, and other cancers [14]. Likewise, AI tools designed to detect skin cancer 
have proven less adept at diagnosing skin cancer in Black and brown patients than 
white patients [5]. While people with fair skin have the highest incidence rates for 
skin cancer—the most prevalent human malignancy—the mortality rate for people 
with darker skin such as African Americans is considerably higher. Eric Topol 
contends that this is especially noteworthy for genomic studies driven by machine 
learning techniques: “First, people of European Ancestry compose most or all of the 
subjects in large cohort studies, which means that, second, they are of limited value 
to most people, as so much of genomics of disease and health is ancestry specific” 
[5]. Prioritizing health equity would not only result in more robust scientific and 
medical knowledge, but would also constitute a step toward engendering quality 
healthcare for all.
2 Now known as the National Academy of Medicine.
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Increasingly, health researchers such as Sacks and Jonathan Metzl propose 
efforts toward remediating health inequities that center on structural competency. 
They advocate for well-researched efforts at the institutional level that aim to 
address the enduring effects of historical oppression. For example, Sacks explains 
that structural competency involves moving beyond obfuscating framings of racism 
as a troubled American past or simply an individual failing of “bad” or “unedu-
cated” people. Instead, structural competency demands that we analyze how racism 
constitutes structural phenomenon embedded and reproduced in US institutions 
such as medical schools and healthcare settings [25].
Technology developers and data scientists, moreover, must also be involved in 
building structural competency across the institutions they navigate to produce 
more robust, just, and effective technological instruments. Data scientist Ben 
Green affirms that “by developing tools that inform, influence, impact important 
social or political decisions—who receives a job offer, what news people see, where 
police patrol—data scientists play an increasingly important role in constructing 
society” [20]. In consequence, Green argues that it is imperative that data scien-
tists move away from conceptions of technological instruments as simple tools 
that can “be designed to have good or bad outcomes” and instead recognize how 
the technologies they are developing “play a vital role in producing the social and 
political conditions of the human experience” [20]. By this logic, Green asserts that 
data scientists must also come to recognize themselves as political actors engaged 
in the “process of negotiating competing perspectives, goals, and values” rather 
than as neutral researchers merely coding away in their offices [20]. The decisions 
data scientists make and responsibilities they hold “cannot be reduced to a narrow 
professional ethics that lacks normative weight and supposes that, with some reflec-
tion, data scientists will make the ‘right’ decisions that lead to ‘good technology’” 
[20]. As “technology embeds politics and shapes social outcomes,” a position of 
neutrality remains an “unachievable goal” Green contends, as first, “it is impossible 
to engage in science and politics without being influenced by one’s background, 
values, and interests [20]. Second, striving to be neutral is not itself a politically 
neutral position—it is a fundamentally conservative one” as such a stance functions 
to maintain a radically inequitable status quo. Correspondingly, Green debunks the 
logic of the common tech refrain: “‘we shouldn’t let the perfect be in the enemy of 
the good’” [20]. Green highlights that data science lacks any theories or coherent 
discourse “regarding what ‘perfect’ and ‘good’ actually entail” and furthermore, 
“fails to articulate how data science should navigate the relationship” between 
the two notions; instead, such a claim “takes for granted that technology-centric, 
incremental reforms is an appropriate strategy for social progress” [20]. Green 
then points to the example of criminal risk assessment algorithms; “even if they can 
be designed not to have racial bias,” he argues, their deployment can “perpetuate 
injustice by hindering more systemic reforms of the criminal justice system” [20]. 
While recognizing that data science is capable of improving society, in Green’s 
assessment, a structurally competent approach demands that algorithmic and data 
science solutions be “evaluated against alternative reforms as just one of many 
options rather than evaluated merely against the status quo as the only possible 
reform” [20]. There should not be a starting presumption that machine learning (or 
any other type of reform provides an appropriate solution for every problem...data 
science reforms tend to (implicitly if not explicitly) assert that the precise means by 
which decisions are made is the only variable worth altering. There may be situ-
ations in which this assumption is correct, but it should not be made or accepted 
lightly, without interrogation and deliberation” [20].
Furthermore, patients and patient advocates recommend cultivating patient 
and health practitioner education in relation to developments in technology and 
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choice and responsibility, the empirical evidence indicates that our neighborhoods, 
schools, jobs, and other factors of day-to-day life shape individual and population 
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cal legacy of racialized thinking is reflected in the contemporary U.S. medical estab-
lishment by focusing on how physician racism contributes to health disparities. 
Hoberman’s research suggests that medical providers rely on false beliefs rooted in 
racial essentialism—such as the pernicious myth of so-called Black “hardiness”—to 
determine diagnosis and treatment for Black patients [25]. In addition to racial and 
gendered oppression, in the past several decades, researchers have demonstrated 
that health and well-being strongly correlate with socioeconomic status. Sacks 
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ramifications of pervasive healthcare disparities in the US and the volume of 
research it prompted, found physician bias, whether conscious or unconscious, 
to be a crucial factor in the production of disproportionate healthcare outcomes. 
Subsequent empirical studies suggest that people of color and ethnic minorities, 
women, and other people who occupy vulnerable social positions are most suscep-
tible to the noxious consequences of bias and stereotyping. Sacks further flags that 
“numerous studies have documented that healthcare providers are unconsciously or 
unintentionally biased against members of marginalized groups, which ultimately 
leads to difference in treatment across multiple domains (i.e., speciality care, pain 
management, mental health services, etc.)” [25].
Myriad experts assert that it is imperative that we are cognizant and considerate 
of how social inequities are embedded into the health data upon which AI systems 
are built. Due to design and optimization constraints, training datasets primarily 
utilize the health data profiles of those who can afford and have access to long-
term, continuous healthcare as opposed to those who have limited access to care, 
discontinuous care, or fragmented records. Moreover, data gathered via clinical 
trials have long been known to be unrepresentative of the US population. Clinical 
trials routinely fail to recruit people of color and other marginalized people. 
Recently, investigative journalists at ProPublica reported that Black Americans, 
Native Americans, and other Americans of color are steeply under-represented in 
clinical trials for cancer drugs—even when the type of cancer disproportionately 
affects them [26]. This has translated to cancer treatments that are least effective 
for the population most afflicted by the disease. Critically, people of color continue 
to have disproportionately higher incidence and mortality rates for kidney, breast, 
prostate, and other cancers [14]. Likewise, AI tools designed to detect skin cancer 
have proven less adept at diagnosing skin cancer in Black and brown patients than 
white patients [5]. While people with fair skin have the highest incidence rates for 
skin cancer—the most prevalent human malignancy—the mortality rate for people 
with darker skin such as African Americans is considerably higher. Eric Topol 
contends that this is especially noteworthy for genomic studies driven by machine 
learning techniques: “First, people of European Ancestry compose most or all of the 
subjects in large cohort studies, which means that, second, they are of limited value 
to most people, as so much of genomics of disease and health is ancestry specific” 
[5]. Prioritizing health equity would not only result in more robust scientific and 
medical knowledge, but would also constitute a step toward engendering quality 
healthcare for all.
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Increasingly, health researchers such as Sacks and Jonathan Metzl propose 
efforts toward remediating health inequities that center on structural competency. 
They advocate for well-researched efforts at the institutional level that aim to 
address the enduring effects of historical oppression. For example, Sacks explains 
that structural competency involves moving beyond obfuscating framings of racism 
as a troubled American past or simply an individual failing of “bad” or “unedu-
cated” people. Instead, structural competency demands that we analyze how racism 
constitutes structural phenomenon embedded and reproduced in US institutions 
such as medical schools and healthcare settings [25].
Technology developers and data scientists, moreover, must also be involved in 
building structural competency across the institutions they navigate to produce 
more robust, just, and effective technological instruments. Data scientist Ben 
Green affirms that “by developing tools that inform, influence, impact important 
social or political decisions—who receives a job offer, what news people see, where 
police patrol—data scientists play an increasingly important role in constructing 
society” [20]. In consequence, Green argues that it is imperative that data scien-
tists move away from conceptions of technological instruments as simple tools 
that can “be designed to have good or bad outcomes” and instead recognize how 
the technologies they are developing “play a vital role in producing the social and 
political conditions of the human experience” [20]. By this logic, Green asserts that 
data scientists must also come to recognize themselves as political actors engaged 
in the “process of negotiating competing perspectives, goals, and values” rather 
than as neutral researchers merely coding away in their offices [20]. The decisions 
data scientists make and responsibilities they hold “cannot be reduced to a narrow 
professional ethics that lacks normative weight and supposes that, with some reflec-
tion, data scientists will make the ‘right’ decisions that lead to ‘good technology’” 
[20]. As “technology embeds politics and shapes social outcomes,” a position of 
neutrality remains an “unachievable goal” Green contends, as first, “it is impossible 
to engage in science and politics without being influenced by one’s background, 
values, and interests [20]. Second, striving to be neutral is not itself a politically 
neutral position—it is a fundamentally conservative one” as such a stance functions 
to maintain a radically inequitable status quo. Correspondingly, Green debunks the 
logic of the common tech refrain: “‘we shouldn’t let the perfect be in the enemy of 
the good’” [20]. Green highlights that data science lacks any theories or coherent 
discourse “regarding what ‘perfect’ and ‘good’ actually entail” and furthermore, 
“fails to articulate how data science should navigate the relationship” between 
the two notions; instead, such a claim “takes for granted that technology-centric, 
incremental reforms is an appropriate strategy for social progress” [20]. Green 
then points to the example of criminal risk assessment algorithms; “even if they can 
be designed not to have racial bias,” he argues, their deployment can “perpetuate 
injustice by hindering more systemic reforms of the criminal justice system” [20]. 
While recognizing that data science is capable of improving society, in Green’s 
assessment, a structurally competent approach demands that algorithmic and data 
science solutions be “evaluated against alternative reforms as just one of many 
options rather than evaluated merely against the status quo as the only possible 
reform” [20]. There should not be a starting presumption that machine learning (or 
any other type of reform provides an appropriate solution for every problem...data 
science reforms tend to (implicitly if not explicitly) assert that the precise means by 
which decisions are made is the only variable worth altering. There may be situ-
ations in which this assumption is correct, but it should not be made or accepted 
lightly, without interrogation and deliberation” [20].
Furthermore, patients and patient advocates recommend cultivating patient 
and health practitioner education in relation to developments in technology and 
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healthcare as a significant step toward getting patients the right treatment involves 
informing them of their treatment options and of any potential consequences and 
side effects. This mandates that medical care providers be sufficiently educated to 
guide patients and that education materials are deliberately designed to be acces-
sible and easily comprehendible (e.g., offering treatment pamphlets in several 
languages rather than solely in the dominant language). For patient advocates, 
these three recommendations are critically imbricated in one another. One patient 
advocate succinctly questioned: “How am I supposed to educate a patient about a 
new treatment or drug they won’t have access to it?” Experts across the realms of 
healthcare and technology declare that prioritizing health equity necessitates that 
we create systems of accountability; educate ourselves on the causes and implica-
tions of health inequity; and set our aim ultimately at structural interventions.
9.3 Promoting and establishing additional safeguards
As previously discussed, patients, advocates, and other health professionals are 
deeply concerned that current legal parameters and regulatory schemes are not 
robust enough to protect them from the ill effects of potential misuse including 
health data breaches and medical data-mining. In addition to patients, legal schol-
ars, biomedical researchers, computer scientists, and genetic privacy experts are 
sounding the call for a legal overhaul of the statutes affording protections based on 
medical data-sharing and for genetic information, in particular.
Taking the example of genomics and genetics research in a U.S. context, legal 
experts reason that as genetic information is no longer adequately safeguarded 
by the protections of HIPAA and GINA, Congress and other legislative bodies 
may need to pass a broadly applicable, special-purpose genetic privacy law. These 
researchers also deem it necessary for US policymakers to address the issue of 
de-identified genetic data. Although legislatures could regulate DNA as personal 
identifying information in attempt to redress the legal loopholes of genetic gene-
alogy, LawSeq affiliates caution that such a law would not prevent individuals 
from adding their personal genomes to online databases for ancestry purposes. 
As a result, Joh and other legal scholars assert that state legislatures and attorneys 
general can and must act to set up guidelines concerning genetic surveillance and 
policing by law enforcement agencies while, in addition, Congress and the Federal 
Trade Commission could address the privacy and security issues of consumer 
genetic data [27]. Although legal experts do not necessarily advocate for stricter 
controls on genetic data within biomedical contexts, they do stress the need to 
regulate the practices of commercial genetic testing companies and data mining 
firms. Fortunately, many consumer testing companies are invested in preserving 
the trust of their customers. A few have formed an inter-market privacy coalition, 
re-committed to strengthening their consent clauses, and released public state-
ments declaring they are opposed to willingly cooperating with law enforcement 
[28]. Given that it is virtually impossible to ensure anonymity for genetic informa-
tion, researchers in medicine, law, and computer science also recommend establish-
ing restrictions on how genetic data are stored and repurposed. Some, like Yaniv 
Erlich, endorse the idea of attaching cryptographic signatures to genetic profiles 
and using blockchain technology to curb potential abuses. Others advocate for 
utilizing methods of obfuscation. One of these methods of obfuscation is referred 
to as “differential privacy” [29]. In this method, noise is introduced to portions of 
the genetic profile to prevent re-identification and repurposing of the data as well as 
to control access [29]. Nevertheless, the majority of experts across the fields of law, 
biomedical science, healthcare, and computer science are unanimous in asserting 
the urgency for stronger legislative protections.
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In addition to supporting more comprehensive regulatory and legal schemes for 
protecting patients’ data, patients also want to know how algorithmic systems for 
medical usage will be audited for safety. They are further concerned with how regu-
latory agencies will account for the fact and monitor AI systems for use in oncology 
context given these systems require regular updates. Will each update be monitored 
for safe use? How will these bodies guarantee standardization measures for these 
updates? Who will be responsible for potential instances of malfunction or medical 
error pertaining to these systems? Patients stressed that legislators, technologists, 
legal experts, and bioethicists must all be involved in producing answers to these 
queries and in establishing the necessary auditing agencies to assure enforcement 
and cooperation.
Still, patients offered yet another crucial safeguard that can be implemented 
across most university-related research institutes and research-driven corporate 
enterprises with relative ease: the involvement of patient advocates in overseeing 
studies. One patient advocate explained: “If I can throw in my two cents, I would 
encourage companies to involve patients and advocates sooner rather than later. 
And to set up a patient advisory board sooner rather than later even if they are still 
in development. Because they are going to give straight up advice and they are going 
to have knowledge and perspectives that researchers haven’t thought of. There’s no 
question they will. Researchers don’t know what they don’t know when it comes 
to working with patients. But if you bring them in sooner rather than later, they 
can learn as they go along.” As this patient advocate contends, patients, especially 
trained advocates, can offer incisive critiques and help guide researchers in reducing 
the potential for harm, irritating pragmatic issues, and major complications patients 
might encounter as a result of a study or product. Patient advocates can provide 
invaluable guidance and intellectual, sociological, and psychological insight into 
what issues are most pertinent and compelling to patients and how best researchers 
and research institutions can address their needs and concerns.
10. Conclusion
Researchers assert that AI systems can be understood as constitutive of collective 
contestations of the political realities, ethical liabilities, and financial viabilities 
immanent to their social production. Following this logic, studying the patient 
perceptions of AI and AI-led oncology drug development, listening to patient 
perspectives, and heeding their concerns constitutes a cooperative entry point to 
preventing harm, avoiding unnecessary risks, and building networks of public 
consent and approval.
This chapter examined: patient perceptions of AI-enabled healthcare and pres-
ent inclination to trust these tools to improve health outcomes; the extent to which 
they express a desire to be involved in the development of proposed AI systems 
vis-a-vis data-sharing based on their existing knowledge; the concerns and ques-
tions they bear regarding the integration and deployment of these technologies; the 
recommendations and suggestions they are proposing for ensuring patient trust; 
and finally, what patient-centered approaches to building frameworks of trust 
and accountability other researchers of medicine and algorithmic deployment are 
advancing. While this study found cancer patients hold an openness to participating 
in research and a general optimism for experimental endeavors related to improving 
patient outcomes that includes AI-led systems research and use, it also discovered 
that patients maintain a vast array of concerns that must be addressed to protect 
patients from a series of potential risks and existing avenues for medical harm and 
neglect. Specifically, this study discerned that cancer patients are troubled by: a 
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healthcare as a significant step toward getting patients the right treatment involves 
informing them of their treatment options and of any potential consequences and 
side effects. This mandates that medical care providers be sufficiently educated to 
guide patients and that education materials are deliberately designed to be acces-
sible and easily comprehendible (e.g., offering treatment pamphlets in several 
languages rather than solely in the dominant language). For patient advocates, 
these three recommendations are critically imbricated in one another. One patient 
advocate succinctly questioned: “How am I supposed to educate a patient about a 
new treatment or drug they won’t have access to it?” Experts across the realms of 
healthcare and technology declare that prioritizing health equity necessitates that 
we create systems of accountability; educate ourselves on the causes and implica-
tions of health inequity; and set our aim ultimately at structural interventions.
9.3 Promoting and establishing additional safeguards
As previously discussed, patients, advocates, and other health professionals are 
deeply concerned that current legal parameters and regulatory schemes are not 
robust enough to protect them from the ill effects of potential misuse including 
health data breaches and medical data-mining. In addition to patients, legal schol-
ars, biomedical researchers, computer scientists, and genetic privacy experts are 
sounding the call for a legal overhaul of the statutes affording protections based on 
medical data-sharing and for genetic information, in particular.
Taking the example of genomics and genetics research in a U.S. context, legal 
experts reason that as genetic information is no longer adequately safeguarded 
by the protections of HIPAA and GINA, Congress and other legislative bodies 
may need to pass a broadly applicable, special-purpose genetic privacy law. These 
researchers also deem it necessary for US policymakers to address the issue of 
de-identified genetic data. Although legislatures could regulate DNA as personal 
identifying information in attempt to redress the legal loopholes of genetic gene-
alogy, LawSeq affiliates caution that such a law would not prevent individuals 
from adding their personal genomes to online databases for ancestry purposes. 
As a result, Joh and other legal scholars assert that state legislatures and attorneys 
general can and must act to set up guidelines concerning genetic surveillance and 
policing by law enforcement agencies while, in addition, Congress and the Federal 
Trade Commission could address the privacy and security issues of consumer 
genetic data [27]. Although legal experts do not necessarily advocate for stricter 
controls on genetic data within biomedical contexts, they do stress the need to 
regulate the practices of commercial genetic testing companies and data mining 
firms. Fortunately, many consumer testing companies are invested in preserving 
the trust of their customers. A few have formed an inter-market privacy coalition, 
re-committed to strengthening their consent clauses, and released public state-
ments declaring they are opposed to willingly cooperating with law enforcement 
[28]. Given that it is virtually impossible to ensure anonymity for genetic informa-
tion, researchers in medicine, law, and computer science also recommend establish-
ing restrictions on how genetic data are stored and repurposed. Some, like Yaniv 
Erlich, endorse the idea of attaching cryptographic signatures to genetic profiles 
and using blockchain technology to curb potential abuses. Others advocate for 
utilizing methods of obfuscation. One of these methods of obfuscation is referred 
to as “differential privacy” [29]. In this method, noise is introduced to portions of 
the genetic profile to prevent re-identification and repurposing of the data as well as 
to control access [29]. Nevertheless, the majority of experts across the fields of law, 
biomedical science, healthcare, and computer science are unanimous in asserting 
the urgency for stronger legislative protections.
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In addition to supporting more comprehensive regulatory and legal schemes for 
protecting patients’ data, patients also want to know how algorithmic systems for 
medical usage will be audited for safety. They are further concerned with how regu-
latory agencies will account for the fact and monitor AI systems for use in oncology 
context given these systems require regular updates. Will each update be monitored 
for safe use? How will these bodies guarantee standardization measures for these 
updates? Who will be responsible for potential instances of malfunction or medical 
error pertaining to these systems? Patients stressed that legislators, technologists, 
legal experts, and bioethicists must all be involved in producing answers to these 
queries and in establishing the necessary auditing agencies to assure enforcement 
and cooperation.
Still, patients offered yet another crucial safeguard that can be implemented 
across most university-related research institutes and research-driven corporate 
enterprises with relative ease: the involvement of patient advocates in overseeing 
studies. One patient advocate explained: “If I can throw in my two cents, I would 
encourage companies to involve patients and advocates sooner rather than later. 
And to set up a patient advisory board sooner rather than later even if they are still 
in development. Because they are going to give straight up advice and they are going 
to have knowledge and perspectives that researchers haven’t thought of. There’s no 
question they will. Researchers don’t know what they don’t know when it comes 
to working with patients. But if you bring them in sooner rather than later, they 
can learn as they go along.” As this patient advocate contends, patients, especially 
trained advocates, can offer incisive critiques and help guide researchers in reducing 
the potential for harm, irritating pragmatic issues, and major complications patients 
might encounter as a result of a study or product. Patient advocates can provide 
invaluable guidance and intellectual, sociological, and psychological insight into 
what issues are most pertinent and compelling to patients and how best researchers 
and research institutions can address their needs and concerns.
10. Conclusion
Researchers assert that AI systems can be understood as constitutive of collective 
contestations of the political realities, ethical liabilities, and financial viabilities 
immanent to their social production. Following this logic, studying the patient 
perceptions of AI and AI-led oncology drug development, listening to patient 
perspectives, and heeding their concerns constitutes a cooperative entry point to 
preventing harm, avoiding unnecessary risks, and building networks of public 
consent and approval.
This chapter examined: patient perceptions of AI-enabled healthcare and pres-
ent inclination to trust these tools to improve health outcomes; the extent to which 
they express a desire to be involved in the development of proposed AI systems 
vis-a-vis data-sharing based on their existing knowledge; the concerns and ques-
tions they bear regarding the integration and deployment of these technologies; the 
recommendations and suggestions they are proposing for ensuring patient trust; 
and finally, what patient-centered approaches to building frameworks of trust 
and accountability other researchers of medicine and algorithmic deployment are 
advancing. While this study found cancer patients hold an openness to participating 
in research and a general optimism for experimental endeavors related to improving 
patient outcomes that includes AI-led systems research and use, it also discovered 
that patients maintain a vast array of concerns that must be addressed to protect 
patients from a series of potential risks and existing avenues for medical harm and 
neglect. Specifically, this study discerned that cancer patients are troubled by: a 
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lack of clarity and protections surrounding medical data usage, the potential for 
emerging technologies to exacerbate existing healthcare inequities, and anemic 
approaches to resource-sharing, consent procedures, and educational initiatives to 
bolster research participation and patient trust.
Still, this qualitative study maintains limitations in its scope and aims, its dis-
coveries and discussion. Further research, including quantitative research, may of 
course aid in parsing out the complexities of understanding cancer patients’ varied 
responses to relevant oncology-specific, technological developments. In particular, 
this study could be bolstered by additional comparative, cross-cultural research 
regarding the distinctions between U.S. and U.K. patients and how their contrast-
ing medical care systems may affect their healthcare experiences and impact their 
positions toward burgeoning medical technologies.
Patient approval and participation are not only imperative to developing and 
improving AI-systems given the need for vast amounts of patients’ medical data 
but also to ensuring the use and future widespread adoption of these tools which 
possess the potential to improve patient outcomes. It is crucial to attend to patients’ 
concerns, establish stronger frameworks for ensuring patient trust, and implement 
accountability infrastructures.
Thanks
I am truly grateful to the patients, their relatives, clinicians, nurses, and non-
profit directors and employees who granted me interviews. Thank you for your 
presence, trust, time and for sharing your experiences, perceptions, and concerns 
with formidable heaps of honesty and vulnerability.
I also extend my deepest thanks to Geoffroy Dubourg Felonneau for his support, 
to Belle Taylor for her patience and editing efforts, and to the CCG team for a fruit-
ful year and welcoming environment.
© 2020 The Author(s). Licensee IntechOpen. Distributed under the terms of the Creative 
Commons Attribution - NonCommercial 4.0 License (https://creativecommons.org/
licenses/by-nc/4.0/), which permits use, distribution and reproduction for  
non-commercial purposes, provided the original is properly cited. 
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responses to relevant oncology-specific, technological developments. In particular, 
this study could be bolstered by additional comparative, cross-cultural research 
regarding the distinctions between U.S. and U.K. patients and how their contrast-
ing medical care systems may affect their healthcare experiences and impact their 
positions toward burgeoning medical technologies.
Patient approval and participation are not only imperative to developing and 
improving AI-systems given the need for vast amounts of patients’ medical data 
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